Cancer gene mutation detection in circulating cell-free DNA in blood by Kikuchi, Hugh
 warwick.ac.uk/lib-publications  
 
 
 
 
 
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/104207 
 
Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 
 
 
 
 
 
 
 
 
 
 
 
Cancer gene mutation 
detection in circulating 
cell-free DNA in blood 
 
 
 
 
by 
 
Hugh Kikuchi BSc MPhil 
 
  
 
 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of 
Doctor of Philosophy in Medical Sciences 
 
Division of Biomedical Sciences, Warwick Medical School, University of Warwick 
 
April 2018 
 
  
  
2 
 
Table of Contents 
Table of Contents ........................................................................................................... 2 
Abbreviations ........................................................................................................................... 7 
List of Figures ......................................................................................................................... 13 
List of Tables .......................................................................................................................... 17 
Acknowledgements ................................................................................................................ 23 
Declaration ............................................................................................................................. 26 
List of Publications ................................................................................................................. 28 
Abstract .................................................................................................................................. 30 
Chapter One - Introduction ........................................................................................... 32 
1.1 LUNG CANCER .................................................................................................................. 33 
1.1.1 Diagnosis of Lung Cancer in the UK .............................................................................. 34 
1.1.2 Treatment of Lung Cancer ............................................................................................ 37 
1.2 INTRODUCTION TO COLORECTAL CANCER ...................................................................... 38 
1.2.1 Diagnosis of Colorectal Cancer ..................................................................................... 40 
1.2.2 Treatment of Colorectal cancer .................................................................................... 41 
1.3 GENETIC BASIS OF CRC AND NSCLC ................................................................................. 41 
1.3.1 EGFR .............................................................................................................................. 42 
1.3.2 KRAS .............................................................................................................................. 44 
1.3.3 Other significant genes in the EGFR/ KRAS pathway .................................................... 46 
1.4 NICE GUIDELINES FOR EGFR TESTING IN NSCLC .............................................................. 49 
1.5 NICE GUIDELINES FOR KRAS TESTING IN COLORECTAL CANCER ..................................... 57 
1.6 LIMITATIONS OF EXISTING PROTOCOLS .......................................................................... 57 
1.7 INTRODUCTION TO CELL FREE DNA ................................................................................. 58 
1.8 STUDIES OF EGFR MUTATION DETECTION ...................................................................... 62 
1.8.1 Studies Investigating Alternative Tissue Sample Types or Sample Processing 
Methods ................................................................................................................................. 64 
1.8.2 Studies of EGFR Mutation Detection Techniques ......................................................... 69 
1.8.3 Studies of EGFR Mutant Detection using Blood/ cfDNA ............................................... 74 
1.8.4 Recent Validations of EGFR testing Methods ............................................................... 76 
1.9 SUMMARY ........................................................................................................................ 81 
1.10 HYPOTHESIS/ RESEARCH QUESTIONS ............................................................................ 83 
1.11 PROJECT AIMS ................................................................................................................ 83 
1.12 JUSTIFICATION OF RESEARCH DESIGN ........................................................................... 84 
A1 CHAPTER ONE APPENDIX .................................................................................................. 85 
LITERATURE SEARCH .............................................................................................................. 85 
3 
 
A1.1 Search One- To identify articles related to EGFR detection from tissue ....................... 85 
A1.2 Search Two- To identify articles related to EGFR detection from blood/ cfDNA .......... 85 
A1.3 Search Three- To identify articles performing direct comparisons of techniques ........ 86 
A1.4 Search Four- To identify articles specifically investigation Cell Free/ Circulating Tumour 
DNA ........................................................................................................................................ 86 
A1.5 Search Five- To identify recent validation studies to update literature search ............ 86 
A1.6 Literature Results ........................................................................................................... 88 
Chapter Two – Detection of EGFR and KRAS mutants using the novel GeneFirst™ PNA PCR 
assay ........................................................................................................................... 92 
2.1 INTRODUCTION ................................................................................................................ 93 
2.1.1 AIMS .............................................................................................................................. 99 
2.2 METHODS ....................................................................................................................... 100 
2.2.1 Equipment ................................................................................................................... 100 
2.2.2 Kits ............................................................................................................................... 100 
2.2.3 Pathology Department Extracted DNA Samples ......................................................... 101 
2.2.4 Lung Cancer (NSCLC) Extracted DNA samples ............................................................ 101 
2.2.5 CRC Extracted DNA samples ....................................................................................... 102 
2.2.6 UHCW Pathology Department Mutation Results ....................................................... 103 
2.2.6.1 Qiagen Therascreen EGFR RGQ PCR ........................................................................ 103 
2.2.6.2 Life Technologies KRAS castPCR™ ............................................................................ 103 
2.2.7 Quantification of DNA by the Qubit platform ............................................................. 105 
2.2.8 GeneFirst PCR .............................................................................................................. 106 
2.2.8.1 GeneFirst EGFR Kit ................................................................................................... 106 
2.2.8.2 GeneFirst KRAS Kit ................................................................................................... 109 
2.2.8.3 Next Generation Sequencing of Tissue DNA ............................................................ 112 
2.3 RESULTS.......................................................................................................................... 115 
GENEFIRST EGFR ASSAY ....................................................................................................... 115 
2.3.1 GF EGFR Assay Version 1 ............................................................................................. 115 
2.3.2 GF EGFR Assay Version 2 ............................................................................................. 118 
2.3.3 GF EGFR Assay Version 3 ............................................................................................. 122 
2.3.4 GF EGFR Assay Version 4 ............................................................................................. 125 
2.3.5 GF EGFR Assay Version 5 ............................................................................................. 127 
GENEFIRST KRAS ASSAY ....................................................................................................... 132 
2.3.6 GF KRAS Assay Version 1 ............................................................................................. 132 
2.3.7 GF KRAS Assay Version 2 ............................................................................................. 135 
4 
 
2.3.8 GF KRAS Assay Version 3 ............................................................................................. 138 
2.3.9 GF KRAS Assay Version 4 ............................................................................................. 140 
2.3.10 GF KRAS Assay Version 5 ........................................................................................... 143 
2.3.11 Confirmatory Testing using Next Generation Sequencing........................................ 148 
2.3.12 GF EGFR/ KRAS Assays and cfDNA ............................................................................ 151 
2.3 DISCUSSION .................................................................................................................... 153 
2.3.1 GeneFirst EGFR PCR assay development using Tissue ................................................ 153 
2.3.2 GeneFirst KRAS PCR assay development using Tissue ................................................ 155 
2.3.3 NGS application ........................................................................................................... 158 
2.3.4 Conclusion ................................................................................................................... 159 
A2 CHAPTER TWO APPENDIX ............................................................................................... 161 
A2.1 GeneFirst EGFR raw data versions 1-5 ......................................................................... 161 
A2.2 GeneFirst KRAS raw data versions 1-5 ......................................................................... 167 
A2.3 NGS Supplemental Data .............................................................................................. 173 
Chapter Three – Optimisation and Validation of Cancer Gene Mutation Detection in tissue 
using TaqMan Array ................................................................................................... 174 
3.1 INTRODUCTION .............................................................................................................. 175 
3.1.1 Aims ............................................................................................................................ 178 
3.2 METHODS ....................................................................................................................... 179 
3.2.1 Equipment ................................................................................................................... 179 
3.2.2 Kits and Reagents ........................................................................................................ 179 
3.2.3 Design of REB Arrays ................................................................................................... 180 
3.2.4 Patients and Samples .................................................................................................. 182 
3.2.5 DNA Extraction ............................................................................................................ 182 
3.2.6 TaqMan Arrays ............................................................................................................ 183 
3.2.7 Data Analysis ............................................................................................................... 184 
3.3 RESULTS.......................................................................................................................... 186 
3.3.1 Setting Analysis Thresholds ........................................................................................ 186 
3.3.2 Optimisation of sample loading .................................................................................. 193 
3.3.3 Parallel testing of Pathology Department Diagnostic Samples .................................. 199 
3.3.4 Parallel testing: EGFR .................................................................................................. 199 
3.3.5 Parallel testing: KRAS/ NRAS ....................................................................................... 201 
3.3.6 Parallel testing: BRAF .................................................................................................. 203 
3.3.7 Sensitivity and Specificity ............................................................................................ 205 
3.3.8 Prospective testing of plasma cfDNA .......................................................................... 207 
5 
 
3.4 DISCUSSION .................................................................................................................... 210 
A3 CHAPTER THREE APPENDIX ............................................................................................ 215 
Chapter Four – Automated isolation of circulating cell free DNA from blood plasma in 
lung cancer ................................................................................................................ 216 
4.1 INTRODUCTION .............................................................................................................. 217 
4.1.1 Aims ............................................................................................................................ 220 
4.2 METHODS ....................................................................................................................... 221 
4.2.1 Equipment ................................................................................................................... 221 
4.2.2 Kits ............................................................................................................................... 222 
4.2.3 Cell Free DNA Analysis ................................................................................................ 223 
4.2.3.1 Patients and Samples ............................................................................................... 224 
4.2.3.2 Plasma Separation ................................................................................................... 224 
4.2.3.3 DNA Extraction from Plasma .................................................................................... 225 
4.2.4 DNA quantification ...................................................................................................... 226 
4.2.5 Ion Torrent Next Generation Sequencing of Plasma DNA .......................................... 227 
4.2.6 TaqMan Array PCR Assay ............................................................................................ 228 
4.2.7 Statistical Analysis ....................................................................................................... 228 
4.3 RESULTS.......................................................................................................................... 229 
4.3.1 DNA quantity ............................................................................................................... 229 
4.3.2 NGS Library quality: Quantitation EZ1 vs Maxwell ..................................................... 233 
4.3.3 NGS Data Quality ........................................................................................................ 234 
4.3.4 NGS Variant Detection ................................................................................................ 241 
4.3.5 NGS Hotspot Detection ............................................................................................... 242 
4.3.6 Performance of cfDNA in TaqMan Array Assay .......................................................... 244 
4.3.7 Disease Stage versus cfDNA Levels in Plasma ............................................................. 245 
4.4 DISCUSSION .................................................................................................................... 247 
Chapter Five – Discussion ........................................................................................... 253 
5.1 INTRODUCTION .............................................................................................................. 254 
5.2 SINGLE GENE TESTING ................................................................................................... 254 
5.3 MULTIPLE GENE TESTING ............................................................................................... 257 
5.4 CELL FREE DNA ............................................................................................................... 259 
5.5 OUTCOMES FROM WORK PERFORMED IN THIS PROJECT ............................................. 262 
5.6 LIMTATIONS OF THE PROJECT ....................................................................................... 263 
5.6.1 GeneFirst Assays ......................................................................................................... 263 
5.6.2 TaqMan Array ............................................................................................................. 264 
5.6.3 Plasma Samples ........................................................................................................... 265 
6 
 
5.7 DEVELOPMENTS IN THIS FIELD ...................................................................................... 266 
5.8 FUTURE WORK AND CONCLUSION ................................................................................ 269 
REFERENCES ............................................................................................................... 273 
 
 
  
7 
 
Abbreviations 
  
% Percent 
ΔCt Delta Cycle threshold 
AKT Alternative name for PKB (Protein Kinase B) 
ALK Anaplastic Lymphoma Kinase 
ARMS Amplification Refractory Mutation System 
ATC Anaplastic Thyroid Carcinoma  
BAL Bronchoalveolar lavage  
BEAMing Beads Emulsion Amplification Magnetics 
Bi-PASA Bidirectional PCR Amplification of Specific Alleles 
bp Base Pair 
BRAF v-Raf murine sarcoma viral oncogene homolog B 
BRISQ Biospecimen reporting for improved study quality 
castPCR Competitive allele-specific Polymerase Chain Reaction, also referred to as CAST 
CD340 Cluster of Differentiation 340 
CE-IVD CE marked- In Vitro Diagnostic 
CE-SSCA Capillary Electrophoresis Single-Strand Conformation analysis 
cfDNA  Circulating/ Cell Free Deoxyribonucleic Acid 
CNG Copy Number Gain 
CNV Copy Number Variation 
COLD-PCR Co-amplification at Lower Denaturation temperature-PCR 
COSMIC Catalogue of Somatic Mutations in Cancer, online database 
CoV Coefficient of Variance 
CR Conserved Regions  
C-Raf RAF proto-oncogene serine/threonine-protein kinase 
8 
 
CRC Colorectal Cancer 
CRUK Cancer Research UK 
Ct Cycle Threshold 
CT Computed Tomography 
CTC Circulating Tumour DNA 
ctDNA Circulating Tumour Cell 
dH2O Distilled and autoclaved water 
DLBCL Diffuse Large B-Cell Lymphoma  
DNA Deoxyribonucleic Acid 
dPCR Digital Polymerase Chain Reaction 
dsDNA Double Stranded Deoxyribonucleic Acid 
EBUS Endobronchial ultrasound 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Rector 
EQA External Quality Assessment 
ErbB2 Alternative name for HER2 
ErbB3 Alternative name for HER3 
EUS Endoscopic ultrasound 
FDA Food and Drug Administration 
FFPE Formulin Fixed Parafin Embedded 
FFPET Formulin Fixed Parafin Embedded Tumour 
FNA Fine Needle Aspiration 
FRET-PCR Fluorescence Resonance Energy Transfer PCR 
g Gravity 
9 
 
gDNA Genomic Deoxyribonucleic Acid 
GDP Guanosine diphosphate 
GF GeneFirst 
GTP Guanosine-5'-triphosphate 
HE Hematoxylin and Eosin 
HER Human Epidermal Growth Factor Receptor 
HER 3 Human Epidermal Growth Factor Receptor 3 
HER2/neu Human Epidermal Growth Factor Receptor 2/ proto-oncogene neu 
HRM High Resolution Melt 
HVR Hypervariable Region  
IHC Immunohistochemistry  
IL Interleukin 
KRAS Kirsten Rat Sarcoma viral oncogene homolog  
LBC Liquid Based Cytology  
LCM Laser Capture Microdissection 
LINE-1  Long interspersed nuclear elements 1 
LNA Linked Nucleic Acid 
LoD Limit of Detection 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization Time Of Flight 
MAP MIDI Activated Pyrophosphorolysis 
MAPK Mitogen-Activated Protein Kinase 
MDT Multidisciplinary Team 
ME-PCR Mutant Enriched Polymerase Chain Reaction 
MET MET Proto-Oncogene, Receptor Tyrosine Kinase, also referred to as c-MET 
MGB Minor Groove Binder 
10 
 
MIDI Micro-Insertions, Deletions, Indels 
miRNA Micro Ribonucleic Acid 
MM Master Mix 
MPE Malignant Pleural Effusion  
MRI Magnetic Resonance Imaging 
MS Mass Spectrometry 
n Number 
NAEDI National Awareness and Early Diagnosis Initiative  
ng  Nanogram 
NGS Next Generation Sequencing 
NHS National Health Service 
NICE National Institute of Health and Care Excellent 
NPA Negative Percent Agreement 
NPC Nasopharyngeal Carcinoma  
NPV Negative Predictive Value 
NRAS Neuroblastoma RAS viral oncogene homolog 
NSCLC Non-Small Cell Lung Cancer 
NTC No Template Control 
p Probability 
P. Page 
PAP-A Pyrophosphorolysis-Activated Polymerisation Allele specific amplification 
PBMC Peripheral Blood Mononuclear Cell 
PCR Polymerase Chain Reaction 
PE Pleural Effusion  
PET-CT Positron Emission Tomography- Computed Tomography 
11 
 
PFS Progression Free Survival 
PGM Personal Genome Machine (NGS Instrument) 
PI3K Phosphatidylinositol-3-Kinase 
PIK3CG Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 
pM Picomolar 
PNA Peptide Nucleic Acid 
PPA Positive Percent Agreement 
PPV Positive Predictive Value 
PTEN Phosphatase and tensin homolog 
Q-PCR Quantitative Polymerase Chain Reaction 
RFLP Restriction Fragment Length Polymorphism 
RGQ RotorGene ™ Q (PCR Instrument) 
RNA Ribonucleic Acid 
RPO Residual Polyp of Origin 
RT-PCR Real Time Polymerase Chain Reaction 
SAP Shrimp Alkaline Phosphatase 
SD Stable Disease 
SNP Single Nucleotide Polymorphism 
SOP Standard Operating Procedure 
SSCP Single Strand Conformation Polymorphism  
SSLC Small Cell Lung Cancer 
STAT Signal Transducer and Activator of Transcription 
TA TaqMan Array 
Tam-Seq Tagged-amplicon deep Sequencing  
TBNA Transbronchial Needle Aspiration 
12 
 
TGFα Transforming Growth Factor Alpha 
TKI Tyrosine Kinase Inhibitor 
TLDA TaqMan Low Density Array (original name for TaqMan Array) 
TP53 Tumor Protein p53, also known as P53 
UHCW University Hospital Coventry and Warwickshire 
UK United Kingdom 
UKLS UK Lung Cancer Screening Trial  
µl Microlitre 
UV Ultraviolet 
VEGF-A Vascular Endothelial Growth Factor A 
WGS Whole Genome Sequencing 
WT Wild-type 
  
 
 
  
13 
 
List of Figures 
 
Figure 1.2  Page 40  Diagram of benign to CRC transformation. 
Figure 1.3  Page 42 Summary of the EGFR and KRAS signalling pathway. 
Figure 1.3.3  Page 47 Diagram of RAS functional domains and isoforms. 
Figure 1.4.4  Page 54 The chemistry of pyrosequencing technology.  
Figure 1.4.6.  Page 55 Diagram demonstrating the principle of Single Strand 
Confirmation Polymorphism (SSCP) Analysis.  
Figure 1.4.7.  Page 57 Diagram showing the melt curves from HRM analysis.  
Figure 1.8.2.1  Page 74 Diagram of the Bi-PASA reaction. 
Figure 1.8.2.2  Page 75 Diagram of the SNaPshot® kit chemistry.  
Figure 2.1.1  Page 95 ARMS primers. 
Figure2.1.2 Page 96 The mechanism of the Scorpion Primer Probe. 
Figure 2.1.3:  Page 97 Diagram of a PNA molecule and a PNA/ DNA duplex. 
Figure 2.2.6.1  Page 103 Mutations tested by Qiagen Therascreen EGFR RGQ PCR Kit. 
Figure 2.2.6.2 Page 104 Mutations tested by Life Technologies BRAF KRAS castPCR 
assay. 
Figure 2.2.7  Page 105 Qubit 2.0 Nucleic Acid Analyser Instrument. 
Figure 2.2.8.2 Page 112 Additional analysis algorithm for GF KRAS PCR version 5. 
Figure 2.2.8.3.2 Page 114 Ion Chef Instrument and Ion Torrent Personal Genome 
Machine (PGM). 
Figure 2.3.3  Page 124 Agarose gel image of GF EGFR version 3 assay PCR products.  
Figure 2.3.10.1 Page 147 EGFR and KRAS Endogenous Control performance. 
Figure A2.1  Page 166 Amplification plot showing the ROX channel from the no 
template control experiment with GF EGFR assay version 3. 
14 
 
Figure A2.2.1  Page 172 Amplification plot showing the ROX channel from the no 
template control experiment with GF KRAS assay version 3. 
Figure A2.2.2  Page 172 Amplification plot showing the FAM channel from the no 
template control experiment with GF KRAS assay version 3. 
Figure 3.2.6  Page 184 Diagram of the TaqMan Array card. 
Figure 3.3.2.1  Page 195 Amplification plots from TaqMan Array runs at varying 
gDNA concentrations. 
Figure 3.3.2.2  Page 196 Amplification plots from TaqMan Array runs at varying 
gDNA concentrations. 
Figure 3.3.2.3  Page 196 Performance of TA control assays (_rf) at varying DNA 
inputs. 
Figure 3.3.2.4  Page 197 Summary chart of mean Ct from all control assays (_rf) at 
varying DNA inputs. 
Figure 3.3.2.5  Page 197 Performance of TA mutant target assays (_mu) at varying 
DNA inputs. 
Figure 4.2.1.1  Page 222 Promega Maxwell and Qiagen EZ1 DNA Extraction 
Instruments. 
Figure 4.2.1.2  Page 222 Nanodrop spectrophotometer instrument. 
Figure 4.3.1.1 Page 230 DNA isolation from plasma, using platforms Qiagen EZ1 and 
Promega Maxwell. Measurements by Nanodrop. 
Figure 4.3.1.2 Page 230 DNA isolation from plasma, using platforms Qiagen EZ1 and 
Promega Maxwell. Measurements by Qubit. 
Figure 4.3.1.3 Page 231 Graph showing the cfDNA recovery from plasma separated 
at varying storage times. Measurements from Qubit instrument. 
15 
 
Figure 4.3.1.4 Page 232 Graph showing the cfDNA recovery from plasma separated 
at varying storage times. EZ1 platform only. Measurements from Qubit 
instrument. 
Figure 4.3.1.5 Page 232 Graph showing the cfDNA recovery from plasma separated 
at varying storage times. Maxwell platform only. Measurements from Qubit 
instrument. 
Figure 4.3.2 Page 234 Graph showing NGS library quantification values, arranged 
in ascending order from Maxwell extracts. 
Figure 4.3.3.1 Page 235 Graph showing EDTA blood storage time against mean read 
length from NGS analysis. 
Figure 4.3.3.2 Page 236 Graph showing EDTA blood storage time against mean read 
length from NGS analysis. EZ1 platform only. 
Figure 4.3.3.3 Page 236 Graph showing EDTA blood storage time against mean read 
length from NGS analysis. Maxwell platform only. 
Figure 4.3.3.4 Page 238 Graph showing EDTA blood storage time against mean 
number of reads from NGS analysis. 
Figure 4.3.3.5 Page 239 Graph showing EDTA blood storage time against mean 
number of reads from NGS analysis. EZ1 Platform only. 
Figure 4.3.3.6 Page 239 Graph showing EDTA blood storage time against mean 
number of reads from NGS analysis. Maxwell Platform only. 
Figure 4.3.3.7 Page 240 Graph correlating read length against coverage from NGS 
analysis. Samples are grouped by extraction method. 
Figure 4.3.4 Page 242 Graph showing the number of variants detected in each 
cfDNA sample, arranged in ascending order (based on Maxwell extract 
variant detection).  
Figure 4.3.5 Page 243 Graph of hotspot mutations detected in cfDNA libraries. 
16 
 
Figure 4.3.7 Page 246 Graph showing cfDNA concentration against patient disease 
stage. 
  
17 
 
List of Tables 
 
Table A1.6.1  Page 90 Articles selected after literature search and filtering. Part 1. 
Table A1.6.2  Page 91 Articles selected after literature search and filtering. Part 2. 
Table A1.6.3  Page 92 Articles selected after literature search and filtering. Part 3. 
Table 2.2.6.1  Page 103 Mutations tested by Qiagen Therascreen EGFR RGQ PCR Kit. 
Table 2.2.8.1.1 Page 106 EGFR mutations detected by the GeneFirst assays. 
Table 2.2.8.1.2  Page 107 Reaction compositions of the GeneFirst EGFR PCR kits. 
Table 2.2.8.1.3 Page 108 Cycling conditions of the GeneFirst EGFR PCR kits. 
Table 2.2.8.2.1 Page 109 KRAS mutations detected by the GeneFirst assays. 
Table 2.2.8.2.2  Page 110 Reaction composition of the GeneFirst KRAS PCR kits. 
Table 2.2.8.2.3 Page 111 Cycling conditions of the GeneFirst KRAS PCR kits. 
Table 2.2.8.3.1 Page 113 The European OncoNetwork 22-gene NGS panel. 
Table 2.3.1.1 Page 116 Summary table showing the concordance % and discrepancy 
% of the GeneFirst EGFR PCR assay version 1. 
Table 2.3.1.2 Page 117 Endogenous control results from samples tested with EGFR 
assay version 1. 
Table 2.3.2.1 Page 119 Summary table showing the concordance % and discrepancy 
% of the GeneFirst EGFR PCR assay version 2. 
Table 2.3.2.2 Page 120 Limit of Detection (LOD) experiments using mutant samples 
diluted to varying degrees with WT samples. 
Table 2.3.2.4  Page 121 Endogenous control results from samples tested with EGFR 
assay version 2. 
Table 2.3.3.1 Page 122 Summary table showing the concordance % and discrepancy 
% of the GeneFirst EGFR PCR assay version 3. 
18 
 
Table 2.3.3.2 Page 124  Endogenous control results from samples tested with EGFR 
assay version 3. 
Table 2.3.4.1 Page 126 Summary table showing the concordance % and discrepancy 
% of the GeneFirst EGFR PCR assay version 4. 
Table 2.3.4.2 Page 126 Endogenous control results from samples tested using EGFR 
assay version 4. 
Table 2.3.5.1 Page 128 Summary table showing the concordance % and discrepancy 
% of the GeneFirst EGFR PCR assay version 5. 
Table 2.3.5.2 Page 129 Complete analysis of PCR results from all GF EGFRv5 master 
mixes. 
Table 2.3.5.3 Page 130 Summary of GF EGFR version 5 data. 
Table 2.3.5.4  Page 130 Endogenous control results from samples tested using the 
EGFR version 5 assay. 
Table 2.3.5.5 Page 131 Summary table showing the concordance % and discrepancy 
% of all the samples tested with the GeneFirst EGFR PCR assay versions 1- 5. 
Table 2.3.6.1 Page 133 Summary table showing the concordance % and discrepancy 
% of the GeneFirst KRAS PCR assay version 1. 
Table 2.3.6.3 Page 134 Endogenous control results from samples tested using the 
KRAS assay version 1. 
Table 2.3.7.1 Page 136 Summary table showing the concordance % and discrepancy 
% of the GeneFirst KRAS PCR assay version 2. 
Table 2.3.7.2 Page 136 Limit of Detection (LoD) experiments using mutant samples 
diluted to varying degrees with WT samples. 
Table 2.3.7.3  Page 137 Endogenous control results from samples tested using the 
KRAS assay version 2. 
19 
 
Table 2.3.8.2 Page 139 Summary table showing the concordance % and discrepancy 
% of the GeneFirst KRAS PCR assay version 3. 
Table 2.3.8.3 Page 140 Endogenous control results from samples tested using the 
KRAS assay version 3. 
Table 2.3.9.2 Page 141 Summary table showing the concordance % and discrepancy 
% of the GeneFirst KRAS PCR assay version 4. 
Table 2.3.9.3 Page 142 Endogenous control results from samples tested using the 
KRAS assay version 4. 
Table 2.3.10.1 Page 143 Summary table showing the concordance % and discrepancy 
% of the GeneFirst KRAS PCR assay version 5. 
Table 2.3.10.2 Page 144 Analysis of PCR results from all GF KRASv5 master mixes.  
Table 2.3.10.3  Page 145 Endogenous control results from samples tested using the 
KRAS assay version 5. 
Table 2.3.10.4 Page 146 Summary of GF KRAS version 5 data. 
Table 2.3.10.5 Page 147 Summary table showing the overall concordance % and 
discrepancy % of the GeneFirst KRAS PCR assay versions 1-5. 
Table 2.3.11.1 Page 149 Hotspot mutations detected in samples from the GeneFirst 
EGFR and KRAS assays. 
Table 2.3.11.2 Page 149 Mutation detection results from five assays: Therascreen, 
GeneFirst EGFR PCR, castPCR, GeneFirst KRAS PCR and Ion Torrent NGS. 
Table 2.3.12.1  Page 151 Endogenous control results from plasma samples tested on 
EGFR assay version 3. 
Table 2.3.12.2  Page 151 Endogenous control results from plasma samples tested on 
KRAS assay version 3. 
Table 2.3.12.3  Page 152 cfDNA samples analysed with GF PCR and NGS. 
20 
 
Table A2.1.1 Page 161 Anonymised Pathology samples tested using the GeneFirst 
EGFR PCR assay version 1. 
Table A2.1.2:  Page 162 Anonymised Pathology samples tested using the GeneFirst 
EGFR PCR assay version 2.  
Table A2.1.3 Page 163 Anonymised Pathology samples tested using the GeneFirst 
EGFR PCR assay version 3. 
Table A2.1.4 Page 164 Anonymised Pathology samples tested using the GeneFirst 
EGFR PCR assay version 4. 
Table A2.1.5 Page 165 Anonymised Pathology samples tested using the GeneFirst 
EGFR PCR assay version 5. 
Table A2.1.6  Page 166 Experiments running no template controls in the GF EGFR 
assay version 3. 
Table A2.2.1 Page 167 Anonymised Pathology samples tested using the GeneFirst 
KRAS PCR assay version 1. 
Table A2.2.2 Page 168 Anonymised Pathology samples tested using the GeneFirst 
KRAS PCR assay version 2. 
Table A2.2.3 Page 169 Anonymised Pathology samples tested using the GeneFirst 
KRAS PCR assay version 3. 
Table A2.2.4 Page 170 Anonymised Pathology samples tested using the GeneFirst 
KRAS PCR assay version 4. 
Table A2.2.5  Page 171 Anonymised Pathology samples tested using the GeneFirst 
KRAS PCR assay version 5. 
Table A2.2.6  Page 171 Experiments running no template controls in the GF KRAS 
assay version 3. 
Table A2.3  Page 173 All NGS hotspot data detected in tissue DNA samples that 
were tested using the GeneFirst EGFR or KRAS assays. 
21 
 
Table 3.2.3  Page 181 Reference (suffix _rf) and Mutant (suffix _mu) assays 
included in the TA assay plate lay out. 
Table 3.3.1.1  Page 187 TaqMan Array control assay performance with a selection of 
samples at varying DNA concentrations. 
Table 3.3.1.2  Page 189 TaqMan Array mutant target assay performance with a 
selection of samples at varying DNA concentrations. 
Table 3.3.1.3  Page 190 TaqMan Array control assay performance with a selection of 
samples at varying DNA concentrations. 
Table 3.3.1.4  Page 192 TaqMan Array control assay performance with a selection of 
samples at varying DNA concentrations.  
Table 3.3.2.1  Page 194 Data from increasing DNA input. 
Table 3.3.4.1  Page 200 Results of NSCLC validation samples, including Therascreen 
and TaqMan Array results. 
Table 3.3.4.2  Page 201 NSCLC samples giving discrepant results (Therascreen vs 
TaqMan Array) and associated NGS results. 
Table 3.3.5.1  Page 202 Results of colorectal validation samples, including castPCR 
and TaqMan Array results. 
Table 3.3.5.2  Page 203 Colorectal samples giving discrepant results (castPCR vs 
TaqMan Array) and associated NGS results. 
Table 3.3.6.1  Page 204 Results of Melanoma validation samples, including TaqMan 
Array and NGS results. 
Table 3.3.6.2  Page 204 Colorectal samples giving discrepant results (castPCR vs 
TaqMan Array) and associated NGS results. 
Table 3.3.7.1 Page 205 Validation summary of lung samples tested using the 
TaqMan Array assay. 
22 
 
Table 3.3.7.2  Page 206 Validation summary of colorectal samples tested using the 
TaqMan Array assay. 
Table 3.3.7.3  Page 206 Validation summary of melanoma samples tested using the 
TaqMan Array assay. 
Table 3.3.7.4  Page 207 Validation summary of Melanoma samples tested using the 
TaqMan Array assay. 
Table 3.3.8  Page 208 TA results for control and mutant assays using prospective 
cfDNA samples. 
Table A3 Page 215 Costings estimate for new TaqMan Array assay compared to 
the currently in use test (Qiagen Therascreen). 
Table 4.2.3.1 Page 225 Samples and clinical details, n= 40. N.B. PL012 and PL017 
excluded due to technical reasons. 
Table 4.3.5 Page 244 Hotspots detected from cfDNA samples. 
Table 4.3.6 Page 245 Results from TaqMan Array analysis of paired cfDNA 
samples (positive for mutations on NGS). 
  
23 
 
Acknowledgements 
 
The work presented in this thesis would not be possible without the assistance of a very 
broad range of people and institutions, who I would like to acknowledge and thank here. 
 
My academic supervisor Prof Ian Cree, whose knowledge and experience are unmatched in 
the field of molecular pathology and has been a constant source of advice, guidance, support 
and encouragement throughout the project. My second academic supervisor, Dr Anne 
Reiman, whose expertise in molecular genetics was invaluable to my supervision, and also 
delivered a vast majority of my training in the laboratory, gave me the skills to complete this 
project. My additional supervisor, Prof Dimitris Grammatopoulos, who took over as primary 
supervisor at the end of the project, was critical to facilitating the completion of the project 
at Warwick Medical School. 
 
All laboratory work included in this thesis was performed in the Pathology Department at 
University Hospital Coventry and Warwickshire, so I would like to give my heartfelt thanks to 
all the staff in the Pathology Department who accommodated me using their laboratory 
space during their busy diagnostic schedules. In particular I would like to thank the staff of 
the molecular laboratory who were always so accommodating and supportive: Jenifer Nyoni, 
Andrew Whitehead, Zandra Woodward, Monika Dutt, Ranveer Chaven, Harriet Pegden, 
Sarah Clark (extra thanks for proof reading draft 3 of the thesis manuscript), Steve Hamilton 
and Conor Cairns. The molecular laboratory manager, Tina Wotherspoon, was extremely 
supportive of our research work and has been instrumental in our assay validations and the 
constructing of business cases for ongoing work in the department. The clinical scientists: 
Katie Jones, Megan Goddard, Samantha Horridge and Lisa Hodges, were very supportive and 
I’d like to thank them for their interest and assistance. In particular, I’d like to thank Lisa 
24 
 
Hodges for her continued support and for proof reading the second draft of my thesis 
manuscript. 
 
The Arden Tissue Bank was instrumental in obtaining FFPE tissue samples used in this project. 
I would to thank Sean James the tissue bank manager for his continued support and 
assistance, as well as the other staff, Andrew White and Adrian Fisk.  
 
The Blood Sciences laboratory of the UHCW Pathology Department was essential for 
obtaining EDTA blood samples for this project. I would like to thank the Senior BMA, Julie 
Evans, as well as Mark Huntley and Carl Young for the huge amount of assistance they gave 
me in terms of understanding the systems in Blood Sciences and how to most efficiently 
collect the samples. 
 
I would like to thank David Snead (consultant histopathologist) for his support, clinical 
expertise, insight and interest in our work during this project. Also in Histopathology I’d like 
to thank Peter Smith (clinical scientist) and Dr William Anderson for their assistance in 
collecting tissue samples and compiling clinical data. Finally from Pathology, I would like to 
thank the Deputy Department Head, Dr Judith Timms, who was very supportive throughout 
the project and was instrumental in bringing our developments into diagnostic use. 
 
Outside of the Pathology Department, I’m very grateful to the clinical staff at UHCW who 
were instrumental to facilitating the collection of clinical samples for use in this research 
project. From the lung clinic, I’d like to thank Dr Judith Drought for her active assistance in 
triaging blood samples to Pathology specifically for research use. From the nursing teams, I 
would like to thank Lindsay Fitzpatrick, Sam Thomas and Dawn Beaty from the lung nursing 
team for their support, interest and assistance in identifying appropriate clinical samples for 
25 
 
inclusion in this project. Without the support of the clinical staff this project would not have 
been anywhere near as complete. 
 
This work involved a number of outside collaborators from Industry. At GeneFirst, I would 
like to thank CEO Guoliang Fu for initial funding of the project and supply of reagents, as well 
as senior scientist Michal Bilski for his advice and assistance during the early development 
phase of this project. At Promega, I would like to thank Fiona Marshall for collaborating with 
us in the development of the circulating DNA extraction kit, for supplying us with prototype 
kits, and for continued technical support and advice. At Thermo Fisher Scientific, I would like 
to thank: Marco Rijnen and Freddie Sharkey from the clinical team for their support of our 
work; Chris Maddren, Daniel Dancer, Ashley Page and Kicki Bergefall for technical support; 
Rachel Holding and Charlie Fuller for arranging discounts on consumables; and finally 
particular thanks go to Andy Gaze as our engineer for all the installation, technical support, 
troubleshooting and servicing of our sequencing instruments, without whom we’d have 
(occasionally) been in real trouble! 
 
Beyond the areas of academia and industry, I would like to thank my family and friends who 
have been utterly critical in supporting me during this degree, and without whom the 
decision to return to study as a mature student would have been significantly harder. To my 
fellow students at Warwick Medical School (too numerous to individually name), thank you 
for the support and interest, and for helping me balance work and life. 
 
Finally I’d thank my parents Greer and Koyu Kikuchi, and my brothers Ian and Tom, for their 
unwavering support during this very challenging phase of my career, getting to the end 
wouldn’t have been possible without them. 
  
26 
 
Declaration 
 
This thesis is submitted to the University of Warwick in support of my application for the 
degree of Doctor of Philosophy. I, Hugh Kikuchi, declare that it has been composed by myself 
and has not been submitted in any previous application for any degree and all the research 
has been undertaken in accordance with University safety policy and Guidelines on Ethical 
Practice. 
 
I am aware of University regulations governing plagiarism and I declare that this document 
is all my own work except where I have stated otherwise.  
 
The presented work, including data generation and data analysis, was carried out by the 
author except in the cases outlined below: 
 
 Tissue sample collection and processing. Tissue samples were collected by UHCW 
surgical teams as part of their routine delivery of treatment to lung and colorectal 
cancer patients. Tissue samples were processed and fixed by biomedical scientists in 
the histopathology laboratory in the UHCW Pathology department. Routine testing 
of clinical samples for genetic markers was performed by biomedical scientists in the 
molecular laboratory, the results of which were used to select samples for testing 
during this project. 
 
 Blood sample collection. Blood samples were collected by phlebotomists in the 
UHCW Phlebotomy Department. These samples were triaged to the Blood Sciences 
27 
 
laboratory (specimen reception) in the UHCW Pathology department, where they 
were processed and stored by biomedical scientists and biomedical assistants. 
 
 Prospective testing of cfDNA samples using the validated TaqMan Array assay in 
UHCW Pathology was performed by BMS staff as part of the routine workflow. The 
data from these tests are shown in table 3.3.8. 
 
 Statistical analysis and selected figures (Chapter 4). Statistical analysis of data 
generated in this chapter was analysed by Katherine Lloyd, the statistics expert in 
our research group. Katherine wrote the methods text describing the analysis done 
(chapter four methods) and also produced the following figures: 4.3.1.1- 5; 4.3.2; 
4.3.3.1- 7; 4.3.7. 
  
28 
 
List of Publications 
 
Parts of this thesis have been published by the author. The findings from chapter three 
were published in the journal Pathogenesis with the following details: 
 
Authors: Hugh Kikuchi 1,2, Anne Reiman 1,2, Jenifer Nyoni 1, Katherine Lloyd 3, Richard 
Savage 4, Tina Wotherspoon 1, Lisa Berry 1, David Snead 1,2, Ian A. Cree 
1,5,6,*Corresponding Author 
Institutions: 1. Department of Pathology – Coventry and Warwickshire Pathology 
Services (CWPS), University Hospitals Coventry and Warwickshire, Coventry 
CV2 2DX, UK 
2. Warwick Medical School, University of Warwick, University Hospitals 
Coventry and Warwickshire, Coventry CV2 2DX, UK 
3. MOAC DTC, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, 
UK 
4. Systems Biology Centre, University of Warwick, Gibbet Hill Road, 
Coventry CV4 7AL, UK 
5. Institute of Ophthalmology, University College London, Bath Street, 
London EC1V 9EL, UK 
6. Centre for Technology Enabled Health Research (CTEHR), Faculty of 
Health & Life Sciences, Coventry University, Coventry CV1 5FB, UK 
Article Title: Development and validation of a TaqMan Array for cancer mutation 
analysis 
Journal details: Pathogenesis 3 (2016), 1-8. 
  
29 
 
 
Authors: Lesley Uttley, BSc; Helen Buckley Woods, BSc; Hugh Kikuchi, BSc; Anne 
Reiman, PhD; Susan Harnan, PhD; Becky L Whiteman, BSc; Sian Taylor 
Phillips, PhD; Michael Messenger, PhD; Angela Cox, BA, PhD; Dawn Teare, 
BSc, MSc, PhD; Orla Sheils; Jacqui Shaw; Ian A Cree, MBChB, PhD, FRCPath;* 
* Corresponding author 
Article Title: The evidence base for circulating tumour DNA blood-based biomarkers for 
the early detection of cancer 
Journal details: BMC Cancer 2017 17: 697 
 
 
 
  
30 
 
Abstract  
 
Background: Lung cancer is the most common cause of cancer death worldwide and is 
estimated to account for more than 1,380,000 deaths per year. Lung cancer can be separated 
into two major histological types: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung 
Cancer (NSCLC), accounting for approximately 15% and 85% of cases respectively. Epidermal 
Growth Factor Receptor (EGFR) is a tyrosine-kinase receptor.  In NSCLC EGFR overexpression 
is found in over 80% of cases, and EGFR copy number gain (CNG) or amplification is found in 
nearly 60% of them. Tumours with EGFR mutations can be treated using anti-EGFR drugs; 
however currently genetic analysis has to be performed on tissue which is obtained by 
biopsy. 
 
Aims: This project aims to investigate alternative methods of obtaining tumour DNA 
for genetic analysis, to potentially improve or support the current diagnostic process. 
This project will investigate both new testing methods (molecular assays) and new 
sources of tumour DNA (cell free DNA from plasma). 
 
Methods: A number of methods were employed during this project. Initially EGFR and KRAS 
mutation detection was attempted using a novel Peptide Nucleic Acid Polymerase Chain 
Reaction (PNA-PCR) assay devised by GeneFirst Ltd (Oxford, UK). The second approach 
utilised custom designed TaqMan Array 384 well plate assays for the detection of EGFR, 
KRAS, NRAS and BRAF mutations. 40 clinical EDTA blood samples were obtained for the 
investigation of the use cfDNA for oncogenic mutation detection. Plasma DNA extracted 
using two automated platforms (Qiagen EZ1 and Promega Maxwell). The extracted DNA was 
analysed using the Ion Torrent Next Generation Sequencing (NGS) platform. 
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Results: The GeneFirst novel PNA PCR assays appeared to tolerate low concentration FFPE 
DNA samples but had a very high false positive rate and the endogenous control assay failed 
regularly (0- 33.3% failure rate over different assay versions). The TaqMan Array assay was 
very successful at detecting EGFR, KRAS, NRAS and BRAF mutations from FFPE tissue, 
displaying 97.62% and 94.74% concordance with previously used diagnostic assays (Qiagen 
Therascreen EGFR RGQ PCR and Thermo Fisher KRAS castPCR). For the automated isolation 
of cfDNA, the Promega Maxwell instrument gave consistently superior results to the Qiagen 
EZ1. CfDNA was successfully used to detect oncogenic mutations using both PCR and NGS 
assays. 
 
Conclusion: This project has utilised a number of approaches in order to investigate new 
approaches for the detection of clinically actionable oncogenic mutations, both in FFPE tissue 
(obtained through surgery or biopsy) and the relatively new cfDNA analyte. Two PCR 
techniques were compared using DNA from FFPE tissue, and the TaqMan Array assay was 
shown to be vastly superior. The TaqMan Array was subsequently adopted as the primary 
diagnostic assay in UHCW Pathology. CfDNA (despite the limited number of samples) showed 
great potential as an alternative for tissue for detection actionable cancer mutations. The 
Ion Torrent Next Generation Sequencing system proved to be the most sensitive and 
powerful technique of the ones utilised here, and will prove an invaluable asset for future 
development of this work. 
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Chapter One - Introduction 
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1.1 LUNG CANCER 
 
Lung cancer is the most common cause of cancer death worldwide and it is estimated to 
account for more than 1,380,000 deaths a year (Ferlay et al., 2010). In the UK the National 
Health Service records 39,000 new diagnoses and 35,000 deaths annually (NICE, 2011b). 
Amongst these cases a large proportion, approximately 90% (Subramanian & Govindan, 
2007), are smoking related, however there is still a significant proportion of lung cancer 
patients who are never smokers. This ratio between smokers and former/non-smokers varies 
greatly internationally. Gender is also a consideration, as amongst male and female groups 
of lung cancer patients the proportion of smokers varies. The 90% figure given previous 
generally applies to North America and Europe, where smoking levels are relatively high. In 
other areas of world such as Asia, where smoking levels are lower and environmental hazards 
are more common, they have a much higher proportion of lung cancer patients who have 
never smoked. For example levels of smoking amongst female lung cancer sufferers in Korea 
and Hong Kong were previous recorded as 25% (Lee et al., 2000) and 56% (Toh et al., 2004) 
respectively- far lower than the North American and European levels. Therefore although 
efforts to reduce tobacco use would have a dramatic effect on lung cancer prevalence, there 
is still a significant cohort of lung cancers amongst non-smoking patients. 
 
Lung cancer can be separated into two major histological types: Small Cell Lung Cancer (SCLC) 
and Non-Small Cell Lung Cancer (NSCLC). SCLC accounts for approximately 13% of lung cancer 
worldwide (Woolf et al., 2016). In SCLC the cancer cells contain dense neurosecretory 
granules. SCLC may have an endocrine or paraneoplastic syndrome association (Rosti et al., 
2006), and these cancers are often associated with the larger airways (Leslie, 2011). As the 
name suggests, the tumour cells in SCLC are much smaller than normal cells, with very little 
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cytoplasm. Some suggest that the reduced cytoplasm is caused by damage to the control 
mechanisms within the cell that regulate its size (Leslie, 2011). 
 
The other histological type is Non-Small Cell Lung Cancer (NSCLC). This is the more common 
type of lung cancer, accounting for approximately 85% of cases worldwide (Ettinger et al., 
2010). In England and Wales NSCLC accounts for 72% (NICE, 2012) of lung cancer cases. 
NSCLC can be further classified into three subtypes: adenocarcinoma, squamous-cell lung 
carcinoma and large-cell lung carcinoma (Pikor et al., 2013). Adenocarcinoma is the most 
common form, making up 40% of all lung cancers. Whilst it is often associated with smoking, 
adenocarcinoma is also the most common form of lung cancer amongst never-smokers 
(defined as those who have smoked fewer than 100 cigarettes in their life time). Squamous 
cell carcinoma accounts for approximately 30% of lung cancers and typically occurs in the 
larger airways. Large cell carcinoma makes up about 9% of lung cancers. They are 
characterised by large cancer cells, with large and conspicuous nuclei and excess cytoplasm, 
and may show keratinisation in some cells. 
 
 
1.1.1 Diagnosis of Lung Cancer in the UK 
 
Early diagnosis is a critical factor in patient prognosis, as the chances of progression-free 
survival (PFS), stable disease (SD), remission and recovery are maximised if diagnosis is 
confirmed early and treatment started as soon as possible. As the stage at diagnosis 
increases, the likelihood of a favourable outcome for the patient reduces dramatically. The 
challenge for healthcare services is to rapidly test and diagnose those with early symptoms. 
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In 2008 the National Awareness and Early Diagnosis Initiative (NAEDI) was launched by the 
Department of Health in collaboration with Cancer Research UK (Richards, 2009) to better 
inform the public about the symptoms of various cancers including lung, so those showing 
symptoms can present themselves to their doctors as early as possible. A recent strategy for 
early detection is the UK Lung Cancer Screening Trial (UKLS) which has offered low-dose CT 
screening to individuals considered at high risk of developing lung cancer (Field et al., 2016). 
In total 1994 individuals were scanned by low-dose CT (computed tomography), resulting in 
42 (2.1%) new diagnoses of lung cancer. This trial proposes that routine screening of high 
risk individuals may be an efficient means of detecting early disease and cost effective in 
terms of treatment. In addition to awareness and early diagnosis, supporting smoking 
cessation is another key healthcare priority. The NHS Stop Smoking Services were established 
in 1999 (Dobbie et al., 2015) to support those trying to stop smoking. 
 
Some of the symptoms of lung cancer can often be confused with other less severe 
conditions, and this may contribute towards late diagnosis in many patients. The main 
symptom of lung cancer is haemoptysis, but this is not always the first symptom and thus 
not a reliable symptom for early diagnosis. Haemoptysis can be experienced with or without 
any of the following other unexplained or persistent symptoms (i.e. lasting longer than three 
weeks): cough, chest or shoulder pain, dyspnoea, weight loss, chest signs, hoarseness, finger 
clubbing, cervical/ supraclavicular lymphadenopathy and any features of metastasis (for 
example in brain, bone, liver or skin) (NICE, 2012). 
 
Upon presenting with any of these symptoms, a suspected lung cancer patient will be 
referred for a chest x-ray. If this test suggests lung cancer then the patient will be referred 
36 
 
onto a lung cancer multidisciplinary team (MDT), and will be offered a contrast-enhanced 
Computed Tomography (CT) scan of the chest, liver and adrenals. This is often followed up 
with a spirometry to assess fitness for definitive treatment (NICE, 2017). Diagnosis requires 
biopsy, which is also important for staging of the disease by histology and cytology. At this 
stage the techniques that can be used for confirmation and investigation of the disease 
depend greatly on the size and location of the lesion. Obtaining tissue may require 
bronchoscopy, endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration or 
biopsy, endoscopic ultrasound (EUS)-guided fine needle aspiration  or biopsy and non-
ultrasound-guided transbronchial needle aspiration (NICE, 2011b). If surgery is considered, 
then Positron-Emission Tomography (PET) is often used to stage patients more accurately. 
 
If biopsy is possible, the collected tissue is fixed in 10% neutral buffered formalin (4% 
formaldehyde) and embedded in paraffin wax, producing a Formalin Fixed Paraffin 
Embedded (FFPE) block of tissue (Cree et al., 2014). Sections of the tumour block are 
mounted onto microscope slides and are analysed by a histopathologist to classify the 
tumour and confirm the histology. For patients who are eligible for EGFR mutational analysis 
the neoplastic cell content of the sample must be evaluated, and macrodissection may be 
performed on the FFPE sample (Cree et al., 2014). This is done to increase the proportion of 
neoplastic cells in the analysis sample.  This material is then used perform mutation testing. 
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1.1.2 Treatment of Lung Cancer 
 
Patients with a confirmed diagnosis of lung cancer are offered a number of treatments, 
depending on many factors such as the age and general health of the patient, the stage of 
the disease and the mutation status of their cancer. Treatment options include: 
chemotherapy, targeted molecular therapy, immunotherapy, radiotherapy, surgery. As the 
disease stage increases the treatment options become limited. Radiotherapy and surgery are 
often not recommended or impossible from stage III onwards as the disease has spread too 
far to be effectively targeted, or the patient is too ill to consider them.  
 
Currently there is a large range of chemotherapy agents available to clinicians for lung cancer 
treatment. Guidelines for which compounds to use are complex, and as a result choices of 
chemotherapy regimen can vary from patient to patient. Standard first line chemotherapy 
for NSCLC involves a single third generation drug (docetaxel, gemcitabine, paclitaxel or 
vinorelbine) in combination with a platinum drug, such as carboplatin or cisplatin (NICE, 
2011b). The treatment may be changed to monotherapy depending on the patients’ 
tolerance of the combination treatment. For patients with EGFR mutation positive NSCLC, 
then the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are recommended for first 
line treatment, with newer EGFR inhibitors reserved for relapse or de novo T790M mutation 
(NICE, 2011b). For Patients with EGFR mutation negative NSCLC, pemetrexed in combination 
with cisplatin is the recommended first line chemotherapy for adenocarcinomas. For SCLC 
cisplatin or carboplatin are often given either as a monotherapy or in combination with 
etoposide (Kalemkerian et al., 2013).  The advent of immunotherapy with anti-PDL1 antibody 
drugs is changing the outlook for lung cancer patients (Lee & Chow, 2014) and may even 
reach front line consideration.  The patient’s tolerance of the treatment chosen, incidence 
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and extent of side effects and the tumour response must be closely monitored, and 
treatment adjusted accordingly if necessary. 
 
 
1.2 INTRODUCTION TO COLORECTAL CANCER 
 
Colorectal cancer (CRC) is the second most common form of cancer in women and third most 
common cancer in men worldwide (El Zoghbi & Cummings, 2016), making CRC the third most 
common cancer and the fourth most common cause of cancer death worldwide (Favoriti et 
al., 2016). In the UK every year there are approximately 40,000 new cases (41,112 cases 
2013, Cancer Research UK) and approximately 16,000 deaths (16,187 cases 2012, Cancer 
Research UK). There are a number of lifestyle risk factors associated with developing CRC 
including: high BMI, lack of physical activity, red/ processed meat consumption, alcohol 
intake and smoking (Johnson et al., 2013). There is considerable variation in the rates of CRC 
globally, with approximately 55% of cases occurring in the more economically developed 
countries (Ferlay et al., 2015). This is mostly likely due to associated lifestyle factors. 
 
Despite the high prevalence of CRC, it also one of the most preventable cancers due to the 
fact it largely arises from benign lesions (either tubular adenomas or serrated polyps) which 
later develop into cancers (Grady & Markowitz, 2015). It can take many years for benign 
adenomas or polyps to become CRC, which provides a considerably larger diagnostic window 
than many other types of cancer. Therefore one important challenge for CRC prevention is 
to maximise awareness of symptoms so patients present themselves to their healthcare 
services during this benign period.  Large adenomas and cancers tend to bleed intermittently, 
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so that fecal occult blood testing is the basis of increasingly successful screening programmes 
for CRC (HQO, 2009). 
 
The transformation of a benign polyp to colorectal cancer has been studied extensively. A 
summary  of the process is shown in figure 1.2.1, adapted from (Fearon & Vogelstein, 1990). 
There are a number of genetic alterations that occur during the transformation of a benign 
polyp into a cancerous lesion. The exact sequence and genes involved varies from case to 
case, which highlights the need for genetic analysis of tumour DNA during clinical 
management. Typically the original benign lesion is engulfed by the transformed tumour, 
however in a small proportion of cases part of the original lesion remains, referred to as the 
residual polyp of origin (RPO). A logical question in this situation is: are tumours that still 
contain the original polyp (CRC RPO+) biologically, genetically or clinically different to 
tumours where there is no residual polyp (CRC RPO-)? This raises the concern that current 
models (based on CRC RPO- tumours) is not an accurate representation of benign to CRC 
transformation. In a recent study by Druliner et al. (Druliner et al., 2016) 10 RPO+ colorectal 
cancer samples (CRC RPO +) were obtained and analysed by whole genome sequencing 
(WGS) and RNA sequencing, and compared to a panel of CRC RPO- tumours. Their analysis 
revealed that CRC RPO+ tumours are indistinguishable from CRC RPO- tumours. This shows 
that current models of CRC transformation are representative of both tumour types. 
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Figure 1.2 Diagram of the major steps involved in benign to CRC transformation, adapted from (Fearon & 
Vogelstein, 1990). Horizontal arrows show disease progression, vertical arrows and text boxes show the genes 
typically involved with each stage of disease progression. 
 
 
1.2.1 Diagnosis of Colorectal Cancer 
 
The four main symptoms of colorectal cancer are abdominal pain, change in bowel habits, 
loose stools and blood in stools. Upon presentation, investigation will consist of a number of 
different techniques, including: colonoscopy, sigmoidoscopy with barium enema, CT 
colonography, or flexible sigmoidoscopy with barium enema (NICE, 2011a). The investigative 
method used depends on the health of the patient and location of the tumour. If a tumour 
is identified by either colonoscopy or sigmoidoscopy this will be followed by biopsy for 
histological classification and genetic analysis. Methods for staging the disease after 
diagnosis include: contrast-enhanced CT of the chest, abdomen and pelvis; magnetic 
resonance imaging (MRI); and endorectal ultrasound (NICE, 2011a).  
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1.2.2 Treatment of Colorectal cancer 
 
For non-metastatic/ local disease, treatment options include chemotherapy (e.g. 
capecitabine and oxaliplatin), radiotherapy, chemoradiotherapy and surgery (either 
laparoscopic or open resection). In the event of colonic obstruction, other measures may 
need to be employed such as applying colonic stents. The exact choice of treatment is 
typically decided on a case by case basis by the local MDT. 
 
For metastatic disease, treatment frequently involves combination chemotherapy such as 
oxaliplatin and irinotecan in combination with fluoropyrimidines, or capecitabine and tegafur 
with uracil (NICE, 2011a). Surgery is considered where possible. Biological agents are also 
used to treat advanced CRC, including Bevacizumab (VEGF-A inhibitor) or Cetuximab (EGFR 
inhibitor). Sometimes these agents are combined with chemotherapy agents like oxaliplatin. 
Another consideration for metastatic disease are secondary tumours, which need to be 
assessed my MRI or PET-CT and treated as decided by the local MDT. 
 
 
1.3 GENETIC BASIS OF CRC AND NSCLC 
 
Mutations in the EGFR-RAS pathway are common to both CRC and NSCLC, though they differ 
in the genes most commonly affected, and in the consequences for patients. 
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Figure 1.3 Summary of the EGFR and KRAS signalling pathway. Upon activation by its ligand, EGFR initiates a 
signalling cascade resulting in gene expression in the nucleus, driving the cell towards proliferation, survival and 
migration. 
 
 
1.3.1 EGFR 
 
Epidermal Growth Factor Receptor (EGFR) is a tyrosine-kinase receptor from the Human 
Epidermal Growth Factor Receptor (HER) family of receptors. EGFR is sometimes 
alternatively referred to as ErbB-1 or HER1. It is a cell surface receptor protein that is 
constitutively activated by a range of ligands including EGF and TGFα. The HER family of 
tyrosine-kinase receptors are involved in a number of cellular processes including 
development, proliferation and survival; all of which are essential for normal cell function, 
but are also significant in the development of cancer (Jardines et al., 1993). 
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The other members of the HER family are HER2 (also called CD340, HER2/neu or ErbB2), 
HER3 (ErbB3) and HER4 (ErbB4). HER2 is similar to EGFR (HER1) as it can heterodimerise with 
any of the other HER family proteins. In contrast to other HER family proteins, HER2 has no 
ligand, but heterodimerises with other HER proteins to form active complexes. Amplification 
of the ERBB2 gene are found in 15-30% of breast cancers (Mitri et al., 2012). HER3 lacks signal 
transduction capability in a homodimer, but forms active complexes with other HER proteins. 
HER4 is a single-pass type I transmembrane protein, activated by heparin-binding EGF-like 
growth factor, betacellulin and neuregulins (NCBI, 2017). 
 
Upon ligand binding EGFR dimerises to form either a homodimer (with another EGFR 
molecule) or a heterodimer with a related receptor from the HER family (HER2, HER3 or 
HER4). After dimerisation EGFR autophosporylates tyrosine residues which cause the 
activation of two main downstream signalling pathways: RAS/MAPK and PI3K/ AKT 
(Koudelakova et al., 2013). These pathways lead to the cellular processes involved in 
proliferation and survival (Arteaga, 2003). In normal tissue, these pathways would be 
activated in the normal regulated manner i.e. cells responding to a biological stimulus. In 
cancer however, EGFR has often been found to contain activation mutations or to have an 
increased copy number. In NSCLC EGFR overexpression is found in over 80% of cases, and 
EGFR copy number gain (CNG) or amplification is found in nearly 60% of them (Koudelakova 
et al., 2013). Increased EGFR activation was previously considered a poor prognostic marker 
(Hirsch et al., 2003), however a later meta-analysis did not confirm the prognostic 
significance of EGFR overexpression (Nakamura et al., 2006). 
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The most clinically useful aspect of determining the mutational status of EGFR in NSCLC is in 
assessing how well a patient will respond to tyrosine-kinase inhibitors therapy. The key 
activating mutations that occur in EGFR are exon 21 L858R and exon 19 deletions, which 
account for approximately 90% of pathogenic mutations (Sholl et al., 2010). Other 
pathogenic mutations are exon 20 insertions and the (also exon 20) T790M anti-EGFR 
resistance mutation (Sharma et al., 2007). Being able to detect these specific activating and 
resistance mutations give clinically actionable information for patient management. 
Conversely in CRC, KRAS mutations have been found to confer resistance to anti-EGFR 
therapy (Tan & Du, 2012). 
 
 
1.3.2 KRAS 
 
Kirsten Rat Sarcoma viral oncogene homolog (KRAS, also known as V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog) is a gene located on human chromosome 12 and encodes 
the KRAS protein (McGrath et al., 1983). The KRAS protein is a GTPase and thus performs a 
major role in cell processes such as cell growth, apoptosis and differentiation (Shields et al., 
2000). KRAS acts as a molecular on/ off switch, in its GTP-bound form it is active, inducing 
multiple signalling pathways, and in its GDP-bound form it is inactive. It forms an essential 
step in many signal transduction pathways downstream of cytokines such as EGF, including 
C-Raf (Li et al., 2000), PIK3CG (Rubio et al., 1999), MAPK (Vojtek & Der, 1998) and STAT 
(Vojtek & Der, 1998). The RAS genes were first discovered during the 1960s through research 
into cancer-causing retroviruses in animals. Experiments using mouse leukaemia viruses 
resulted in the identification of rat sarcoma genes, and later investigations in the early 1980s 
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using human cancer cell lines identified human homologs of the rat KRAS genes (Pulciani et 
al., 1982). 
 
The fact that KRAS was rapidly identified as an oncogene reflects its significant role in many 
human cancers. Activating KRAS mutations are known to occur in many human malignancies, 
including approximately 90% of pancreatic cancers, approximately 30% of lung cancers, 
approximately 60% of thyroid, and approximately 43% colorectal carcinomas (Shackelford et 
al., 2012). KRAS is downstream of EGFR, and once EGFR becomes activated GTP bound KRAS 
will activate its wide range of downstream effectors. Mutations causing constitutive 
activation of KRAS are all point mutations and occur in codons 12 and 13 of exon 2, codon 61 
of exon 3, and 117 and 146 of exon 4 (Rajalingam et al., 2007; Cree, 2016b; Cree, 2016a; 
Sorich et al., 2015). Constitutive activation of KRAS means that all its downstream signalling 
pathways remain active, giving rise to uncontrolled cell growth and replication, resulting in 
malignancy. 
 
In NSCLC, KRAS mutation most commonly occurs in adenocarcinomas. As yet there has been 
no clear relationship established between KRAS mutation and smoking history, unlike EGFR 
mutations which tend to be more common in non-smokers. As KRAS is downstream of EGFR, 
activating mutations in KRAS have been shown to result in resistance to anti-EGFR therapy 
(Shackelford et al., 2012). No RAS mutation dependent therapeutics have yet entered 
practice.  Therefore KRAS testing in NSCLC is useful to ensure patients are being treated with 
the most appropriate regimen and to avoid unnecessary ALK (Anaplastic Lymphoma Kinase) 
testing. At present the prognostic value of KRAS status is not fully understood, however early 
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detection of KRAS mutations would still be extremely valuable for early diagnosis and patient 
management. 
 
 
1.3.3 Other significant genes in the EGFR/ KRAS pathway 
 
Neuroblastoma RAS viral oncogene homolog (NRAS), like KRAS, is a member of the RAS gene 
family. The RAS family are group of GTPases that are involved in a number of pathways 
regulating cell proliferation, differentiation and apoptosis (Prior & Hancock, 2012). All cells 
contain three RAS isoforms: KRAS, NRAS and HRAS (Harvey Rat Sarcoma Virus). NRAS was 
first discovered in 1982 by scientists led by Robin Weiss at the Institute of Cancer Research 
(Marshall et al., 1982).  
 
The three RAS isoforms share a high degree of sequence homology: 100% homology for a 
majority of the sequence, with the C-terminal 23-24 amino acids making up the 
hypervariable region (HVR). This HVR has been shown to be important for the RAS protein 
membrane interactions and localisation within the cell (Prior & Hancock, 2012) and thus is 
the most likely explanation for functional and localisation differences between the various 
isoforms. Figure 1.3.3 shows a diagram of the RAS protein and the degree of homology 
between the different isoforms across the domains. 
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Figure 1.3.3 Diagram of RAS functional domains and differences between isoforms. HVR is post-translationally 
modified to enable membrane interactions and differential localisation. Asterisks indicate oncogenic mutation 
sites and codons 12, 13 and 61. Adapted from (Prior & Hancock, 2012). 
 
 
In the context of cancer, the contribution of NRAS is analogous to the mechanism of KRAS 
(described earlier). NRAS is most commonly found to be mutated in melanoma, where 20% 
of cases carry activating mutations in NRAS (Milagre et al., 2010). It was the first oncogene 
to be identified in melanoma in 1984 (Albino et al., 1984). By comparison, NRAS mutations 
are generally found at low abundance in lung and colon cancers. This may be due to NRAS 
being overexpressed in melanocytes compared to the other isoforms, and therefore it is 
more susceptible to mutation in this tissue type. Clinically the presence of an activating NRAS 
mutation is associated with a poorer prognosis (Devitt et al., 2011). Interestingly there is 
some evidence that the presence of an NRAS mutation may have some correlation with a 
better treatment response to high dose IL(interleukin)-2 compared to those with wild-type 
NRAS (Fedorenko et al., 2013). At present there are no treatments that specifically target 
NRAS, although are a number are in development. Current clinical trials are largely focused 
on inhibiting the downstream pathways mitogen-activated protein kinase (MAPK) and 
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phosphatidylinositol-3-kinase (PI3K), aiming to attenuate the upregulation caused by the 
NRAS mutation (Russo et al., 2014). 
 
The final gene which will be described in this section is BRAF, also known as proto-oncogene 
B-Raf or v-Raf murine sarcoma viral oncogene homolog B. It is a member of the Raf family of 
signal transduction protein kinases (NCBI, 2016) which are involved in directing cell growth. 
The BRAF protein consists of 766 amino acids, separated into three domains which are 
referred to as Conserved Regions (CR) 1-3. Each region is functionally different, with CR1, 
CR2 and CR3 containing the Ras-GTP binding domain, serine-rich hinge region and protein 
kinase domains respectively (Daum et al., 1994) (Cutler et al., 1998). BRAF mutations are the 
most commonly identified in melanoma, accounting for approximately 50% of cases (Davies 
et al., 2002).  
 
Over 90% of cutaneous melanoma samples with BRAF mutations contain a substitution of 
valine to glutamic acid at codon 600, p.V600E (Davies et al., 2002). The high frequency and 
consistency of mutations in BRAF make it an attractive target for therapy. At present there 
are two main inhibitors used for treating BRAF positive melanoma in clinical trials: 
vemurafenib (Zelboraf) and dabrafenib (Tafinlar) (Wood & Luke, 2016). They were shown to 
be effective at treating BRAF positive melanoma, although there are a number of side effects 
associated with the toxicity. Another issue with these compounds is they often caused the 
patients to develop squamous cell carcinomas of the skin (potentially due to paradoxical 
hyper-activation of the MAPK pathway in wild-type cells), so combination therapy (an anti-
BRAF inhibitor combined with a MEK inhibitor) is likely to be further investigated as the 
optimal treatment regimen (Carlos et al., 2015). Vemurafenib and dabrafenib are currently 
offered as treatments for BRAF positive advanced stage melanoma in the UK. 
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As with EGFR and KRAS described earlier, NRAS and BRAF are very important targets for 
characterising patient tumours and identifying the most appropriate treatment option. 
Whilst NRAS and BRAF are not the primary focus of this investigation, detection of these 
genes will be included at certain phases in order to demonstrate that devising accurate 
molecular techniques can be easily expanded or customised to be appropriate for a wider 
clinical context.  
 
 
1.4 NICE GUIDELINES FOR EGFR TESTING IN NSCLC 
 
The National Institute for Health and Care Excellence (NICE) is a UK based organisation that 
works to create universal comprehensive guidelines and regulations for many aspects of 
Medicine and Science, with an aim to maximise patient safety and therapeutic effectiveness. 
Whilst it primarily provides guidance for UK government bodies, the National Health Service 
and UK Pharmaceutical companies, it also has a large influence internationally. In the UK a 
majority of healthcare practices design their best practice guidelines to NICE regulations 
(https://www.nice.org.uk/). 
 
NICE has produced comprehensive guidelines for treatment of lung cancer (described earlier) 
and also for the use of EGFR mutation detection in NSCLC. Clinical trials have shown that lung 
cancer patients who are positive for EGFR activation mutations respond better to tyrosine 
kinase inhibitor therapy compared to treatment with standard chemotherapy (Hagiwara & 
Kobayashi, 2013). Therefore it is logical that all patients with NSCLC be tested for EGFR 
mutations (key pathogenic mutations described in section 1.3.1), as this will have a 
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significant influence on clinical management choices made by their attending physician, 
ultimately leading to an improved outcome from more appropriate therapy. 
 
The procedure for testing for EGFR mutations in NSCLC in UK diagnostic laboratories is not 
standardised, and there is some variation in the methods used. The methods for testing for 
EGFR mutations can be divided into two key types: targeted mutant detection and mutation 
screening. With targeted methods, only known mutations are analysed, whereas with 
mutation screening all known and novel variants are screened for. Many laboratories use 
both of these types of method for EGFR mutant detection. NICE has evaluated many tests 
currently in diagnostic use in NHS laboratories. Each is summarised in sections 1.4.1 – 1.4.8. 
 
1.4.1 Qiagen™ Therascreen EGFR RGQ PCR Kit 
 
This is a real-time PCR assay that detects 29 EGFR mutations (for full list, see section 2.2.6.1). 
The test first requires DNA to be extracted from FFPE samples using the QIAamp DNA FFPE 
Tissue Kit, and then a control assay needs to be performed to quantify the total extracted 
DNA. The Therascreen PCR can then be performed to detect EGFR mutants in the sample. To 
detect the mutant, the Therascreen PCR uses two technologies: Amplification Refractory 
Mutation System (ARMS) for specific amplification of the mutants; and Scorpions for 
detection of the amplified regions. For diagrams of the Scorpion-ARMS technology, see 
section 2.1. 
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1.4.2 Roche Molecular Systems Cobas® EGFR Mutation Testing Kit 
 
This is another real-time PCR assay for EGFR mutations, able to detect 41 different variants. 
Like Therascreen, the DNA needs to be extracted from the clinical sample using a specific kit, 
the Cobas® DNA Sample Preparation Kit. The extracted DNA can then be analysed using the 
Cobas® EGFR assay. The PCR uses complimentary primer pairs and fluorescently labelled 
probes to detect the mutations. The assay is run using the Cobas® z480 analyser which 
automates amplification and detection, and the software provides the laboratory with 
automated test result reporting. 
 
1.4.3 Sanger Sequencing 
 
This method of analysis allows all mutation types to be detected, both known and novel. 
Sanger sequencing is a very commonly used technique for disease mutant detection, 
however there is considerable variation in the way the procedures are performed. Typically, 
DNA will be extracted from the clinical sample and PCR used to amplify the region of interest, 
in this case, various regions of exons 19-21 of the EGFR gene. The amplified fragments will 
then be cleaned up and sequenced using multiple primers in both directions to ensure 
adequate sequence coverage and accuracy. A dye terminator cycle sequencing reaction will 
be used to rebuild the amplified fragments incorporating dideoxynucleotides labelled with 
fluorescent dyes for sequence determination, and the library of fragments will be analysed 
using capillary sequencing. The data from this sequencing will be analysed using various 
software packages to align all the sequence reads and create a consensus for all sequenced 
regions. Mutations will be identified by comparing the sample consensus with known data 
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of wild-type and mutant sequences. The advantage of this technique is that it can detect 
novel mutants; however the disadvantage of this technique is sensitivity in the context of a 
mixed sample- Sanger sequencing only works well when the tumour DNA makes up at least 
25% of the total sample, though this can be improved by careful PCR design: product sizes of 
<150 bp to take account of DNA fragmentation in FFPE samples (Young et al., 2013). 
 
1.4.4 Pyrosequencing 
 
Pyrosequencing assays are designed to detect specific mutations, and in many labs are used 
alongside fragment length analysis to identify deletions and insertions. Pyrosequencing 
works by detecting the release of pyrophosphate molecules upon the incorporation of a 
specific nucleotide. A typical pyrosequencing protocol is similar to Sanger sequencing: DNA 
is extracted from the clinical sample and amplified by PCR. The PCR amplicons are then 
cleaned up and used as the template for the pyrosequencing reactions. This method is more 
sensitive than Sanger sequencing- the minimum level of tumour DNA in a wild-type sample 
is 5% (NICE, 2012). An example of one of the pyrosequencing assays available for EGFR 
mutant detection is the Qiagen Therascreen EGFR Pyro Kit (Qiagen, 2011).  
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Figure 1.4.4 Diagram representing the chemistry of pyrosequencing technology. With each incorporation of a 
dNTP molecule, a pyrophosphate molecule is released, which in turn is catalysed by the sulphurylase enzyme to 
release ATP. The ATP is used as substrate by the luciferase enzyme to generate luciferin and light emission, which 
is detected by a camera. The strength of the light signal is proportional to amount of ATP present. Adapted from 
(Ahmadian et al., 2006). 
 
 
1.4.5 Fragment Length Analysis 
 
Fragment Length Analysis is a technique that distinguishes DNA fragments based on their 
length, therefore it is best employed for the detection of deletions and insertion events, as 
substitutions will have no effect on fragment size (Ellison et al., 2013). Extracted DNA 
samples are extracted, amplified by PCR and fluorescent dyes are incorporated. The 
Direction of synthesis 
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amplicons are then combined with mixed size standards and analysed by electrophoresis. 
The fluorescence intensity is used to establish the fragment size and detect any insertions or 
deletions. In some cases, fragment length analysis has been shown to be more effective at 
detecting exon 19 deletions than direct sequencing (Pan et al., 2005). 
 
1.4.6 Single Strand Conformation Polymorphism Analysis 
 
Single Strand Conformation Polymorphism (SSCP) Analysis is a screening method that 
distinguishes sequence variations by changes in electrophoretic mobility differences. 
Extracted DNA is extracted and amplified by PCR. The amplicons are then denatured into 
single stranded DNA molecules. In single stranded form the DNA will spontaneously undergo 
three-dimensional folding that will create a unique structure depending on the nucleotide 
sequence. Single stranded molecules of differing nucleotide sequence will fold differently, 
and these differences in folding configuration can be assessed by gel electrophoresis (NICE, 
2012).  
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Figure 1.4.6. Diagram demonstrating the principle of Single Strand Confirmation Polymorphism (SSCP) Analysis. 
Adapted from (ThermoFisher, 2016). Mutant and wild-type single stranded amplicons will three dimensionally 
fold in a unique conformation which can be distinguished by gel electrophoresis. 
 
1.4.7 High Resolution Melt Analysis 
 
High Resolution Melt (Dubsky et al.) Analysis is a fast and cost effective screening method 
for all types of mutations in double stranded DNA e.g. polymorphisms and epigenetic 
changes. The method works by analysing the temperature at which different DNA molecules 
separate as temperature increases and can be combined with COLD-PCR (Co-amplification 
at Lower Denaturation temperature-PCR) and careful primer design to produce highly 
specific assays still in clinical diagnostic use (Pichler et al., 2009). Intercalating fluorescent 
dyes are incorporated into amplified DNA fragments in a PCR step before HRM analysis. The 
dyes fluoresce strongly when incorporated into double stranded DNA. During the HRM 
analysis, the increasing temperature causes strands to separate and fluorescence to drop 
suddenly. By analysing known wild-type samples alongside unknown or mutant samples, the 
difference in temperature at which fluorescence drops can identify mutant alleles. This 
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technique can also distinguish heterozygous or homozygous mutants in the analysed 
amplicons (Pasay et al., 2008). 
 
 
Figure 1.4.7. Diagram showing the melt curves from HRM analysis. The amplicon containing the mutant gives a 
different melt curve to the amplicon containing the wild-type, which is demonstrated by the change in 
fluorescence signal. Adapted from (Willmore-Payne et al., 2006). 
 
 
1.4.8 Next Generation Sequencing 
 
Next Generation Sequencing (NGS) is a relatively new technique, having recently 
revolutionised genetic analysis options available to molecular researchers. It has by far the 
broadest and deepest coverage of all the techniques described, but comes with some 
significant drawbacks. These drawbacks can be summarised as turnaround time and cost. 
Although NGS platforms vary, generally the library preparation can be very laborious, taking 
several days to complete before the actual sequence analysis can be run. Related to 
turnaround time is also the time and skill required for analysis, despite the fact that a lot of 
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the alignment and variant calling is done automatically, the final analysis can still be very 
involved, and some expertise is required for the initial setting up of the analysis parameters 
that the automated systems follow. Cost is also a major issue. The equipment, reagents and 
consumables for NGS are very expensive, and often only a limited number of patient samples 
can be analysed in any given run. There are multiplex options available to researchers using 
NGS systems; however the cost per patient still remains high (Cree et al., 2014) . 
 
 
1.5 NICE GUIDELINES FOR KRAS TESTING IN COLORECTAL CANCER 
 
At present NICE does not offer specific guidance on methods for KRAS mutation detection in 
metastatic CRC. A project to evaluate available methods and produce KRAS testing guidance 
began in 2012, however on 11th September 2014 the project was discontinued (NICE, 2015). 
The aims of the discontinued project have been combined into a current evaluation of 
cetuximab and panitumumab (NICE, 2016). 
 
 
1.6 LIMITATIONS OF EXISTING PROTOCOLS 
 
The limitations of existing protocols and detection techniques can be separated into three 
categories: firstly the stage at which biological material is available for sampling and testing; 
secondly the quality and purity of the DNA extracted and analysed once the material is 
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available; and thirdly the individual assay variability in terms of sensitivity, specificity, limit 
of detection and scope of mutations they can detect, as well as their associated cost.  
 
In the case of sample collection, due to the non-specific nature of early and mid-stage lung 
cancer symptoms, investigation and diagnosis do not usually occur until the disease has 
significantly advanced, thus reducing the patient’s favourable prognosis once treatment has 
begun. Coupled with this the difficulties associated with sample collection make early stage 
high tumour content samples very difficult to obtain. 
 
Sample quality i.e. the proportion of tumour cells collected for analysis, is highly variable 
between sample types and can be a major obstacle for mutation detection with some assays. 
Many molecular assays have high sensitivity and specificity, but may not be able to detect 
mutant populations in a highly heterogeneous sample. Furthermore certain preservatives, 
whilst effectively protecting genetic material from degradation, can also cause some 
alteration to the DNA which can create problems in molecular assays downstream.  
 
 
1.7 INTRODUCTION TO CELL FREE DNA 
 
Cell Free or Circulating Free DNA (cfDNA) is defined as DNA that has been released from lysed 
cells. Genetic material is then free to circulate throughout various bodily fluids e.g. blood, 
pleural effusion, semen and amniotic fluid. The process of releasing DNA occurs naturally 
during normal bodily processes i.e. apoptosis/necrosis of redundant or dying cells, and is 
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usually rapidly removed from the blood by the kidneys and liver, as well as being metabolised 
by plasma nucleases such as DNase1. An alternative mechanism for the release of cfDNA is 
the shedding of intact cells from tissues, which then go on to lyse and release their DNA 
content into the surrounding environment. As a result of these natural processes (apoptosis/ 
necrosis and cell shedding) it is normal for cell free DNA to be detectable in healthy 
individuals. In a normal healthy subject, cfDNA levels have been recorded as being between 
0 and 100ng/ml blood with an average of 30 ng/ml (Anker & Stroun, 2000).  
 
Cell Free DNA is a relatively new marker in molecular diagnostics. The presence of elevated 
levels of cfDNA in the serum/ plasma of cancer patients was first demonstrated in 1977 (Leon 
et al., 1977), however it is only recently started to be regarded as a potentially useful 
diagnostic and prognostic tool. In the context of a cancer patient, the patient’s tumour 
contains a much higher proportion of apoptotic or necrotic cells than normal tissue, and thus 
mutated tumour cell DNA will be shed into the blood stream, in addition to the background 
cfDNA released by normal processes. Several studies have quantified higher levels of cfDNA 
in cancer patients (Shapiro et al., 1983). In addition others have proposed that an increased 
level of cfDNA in a patient’s blood could by itself be used as a diagnostic marker for cancer 
(Gormally et al., 2007).  
 
The use of cfDNA as a tool for genetic analysis poses a number of technical challenges. Firstly, 
once the DNA has been released from the protective environment of the cell and nucleus, 
the DNA is often severely fragmented, with individual molecules rarely being larger than a 
few hundred base pairs. This makes cfDNA potentially unsuitable for detecting and 
sequencing large intact gene fragments. This issue may have been recently solved by 
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Forshew et al. (Forshew et al., 2012) who developed a tagged-amplicon deep sequencing 
(TAm-Seq) method that allowed the full gene analysis of TP53 in plasma samples from 
ovarian cancer patients. This recent development shows yet more potential for the use of 
cfDNA for non-invasive molecular analysis of clinical samples. 
 
Secondly, in the case of mutant DNA (e.g. from cancer cells) the total extract of cfDNA from 
the bodily fluid will contain a heterogeneous mixture of both wild-type tissue DNA and 
(usually) a much smaller proportion of mutated DNA. This characteristic of cfDNA has been 
a major technical challenge to investigators seeking to use cfDNA as a diagnostic or 
prognostic tool, as many technologies require both high concentrations of DNA and a high 
proportion of mutants in order to detect them, such as conventional Sanger sequencing. In 
a successful detection assay, the sample must either be enriched for the mutant/ target DNA, 
and the wild-type DNA removed or suppressed in such a manner so that it does not interfere 
with the detection of the mutant template. 
 
A key consideration when planning to analyse cfDNA is the sample type that the cfDNA will 
be isolated from. As described earlier cfDNA can be isolated from a number of bodily fluids, 
however they are not all equivalent in terms of the quality of DNA that can be obtained from 
them. In the diagnostic setting, whole blood is readily collected, from which serum or plasma 
can be derived, so these two sample types are the primary choices as sources of cfDNA for 
molecular analysis. The study by Lee et al. in 2001 (Lee et al., 2001) analysed cell free DNA 
isolation from plasma and serum, as a source of DNA for detecting post-transfusion 
chimerism. The findings showed that serum typically contains more cfDNA than plasma, 
however it is largely genomic DNA from cell lysis during the clotting process (Lee et al., 2001). 
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This strongly suggests plasma is far more appropriate for isolating circulating tumour DNA. 
Another study the following year by Thijssen et al. (Thijssen et al., 2002) compared cfDNA 
levels in serum and plasma samples from colorectal cancer patients. Like the paper by Lee et 
al. they found higher cfDNA levels in serum, and serum cfDNA levels were significantly 
associated with metastasis, whereas plasma DNA levels were predictive for recurrences 
(Thijssen et al., 2002). Due to the significant amount of genomic DNA in serum, cfDNA from 
plasma is considered to be more reflective of the amount and composition of cfDNA in vivo. 
A number of articles and studies utilised cfDNA from both serum and plasma (Xue et al., 
2009; Gormally et al., 2007; Aung et al., 2010; Board et al., 2010; Ghorbian & Ardekani, 2012) 
but did not necessarily compare the relative quality of the cfDNA derived from the two 
sources. Some studies comparing cfDNA from serum and plasma gave varied results, with 
some studies finding results from the two samples types were comparable (Morgan et al., 
2012) whereas others found plasma to be a better source of cfDNA (Park et al., 2012). In 
recent articles related to cancer research plasma cfDNA is used most frequently (Zhao et al., 
2013; Gonzalez-Cao et al., 2015; Karachaliou et al., 2015).  
 
Beyond cancer, cfDNA has been identified as potentially useful in a number of other contexts. 
In prenatal testing, cfDNA is being employed for the detection of multiple foetal genetic 
conditions such as trisomy 21 (Simpson, 2013). In transplantation, donor DNA from donor 
organs has been detected in recipient blood (Sigdel et al., 2013). CfDNA has been found to 
have applications in autoimmune disorders such as Systemic Lupus Erythematosis (SLE) 
(Galeazzi et al., 2003) and Rheumatoid Arthritis (Yan et al., 2006). Increased cfDNA levels 
have also been described in patients with sepsis (Martins et al., 2000) and has also been 
reported to occur during strenuous exercise (Breitbach et al., 2012). This range of fields 
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shows that the study of cell free DNA has a broad range of applications, and development of 
assays utilising this biological marker may have great clinical utility. 
 
 
1.8 STUDIES OF EGFR MUTATION DETECTION 
 
In order to assess the status of research into EGFR testing methods at the time of this 
project’s commencement a literature search was performed. 25 articles were identified and 
collected by the multiple searches and filtering steps described in the Methods. A summary 
of all these articles can be found in tables A1.6.1 and A1.6.2 (chapter one appendix). These 
studies varied greatly in terms of the techniques they analysed, sample types they used, 
number of samples involved, and the study design. All of the articles were investigating EGFR 
mutation detection methods, using molecular techniques and a majority used clinical 
samples to assess the properties of the various methods employed. 
 
A wide range of techniques were covered within these articles. Direct sequencing was the 
most used technique, featuring in sixteen studies, often as a comparator method (Angulo et 
al., 2012; Betz et al., 2011; Borras et al., 2011; Buttitta et al., 2013; Dahse et al., 2008a; Hu 
et al., 2012; Kamel-Reid et al., 2012; Liu et al., 2013a; Lopez-Rios et al., 2013; Sriram et al., 
2011; Su et al., 2011; Young et al., 2013) but as the primary method in four cases (Billah et 
al., 2011; Kimura et al., 2006; Smouse et al., 2009; Malapelle et al., 2012). Qiagen 
Therascreen EGFR assay was also frequently used, being used in five studies (Allegrini et al., 
2012; Angulo et al., 2012; Kamel-Reid et al., 2012; Lopez-Rios et al., 2013; Yuan et al., 2012). 
Fragment size analysis assays (Betz et al., 2011; Kamel-Reid et al., 2012; Su et al., 2011; Young 
et al., 2013) and High Resolution Melt assays (Borras et al., 2011; Do et al., 2008; Hu et al., 
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2012; Sriram et al., 2011) were the joint next most popular technique type investigated, each 
being used in four studies each. Immunohistochemistry (IHC) was used in two studies 
(Angulo et al., 2012; Liu et al., 2013a). IHC was not the primary type of technique this review 
focuses on, many other publications using only IHC-related techniques were excluded, 
however in these two papers other molecular techniques were also being used, and thus the 
studies were included in collected literature. Pyrosequencing was used in two studies (Borras 
et al., 2011; Young et al., 2013). NGS was used in only one study (Buttitta et al., 2013). 
 
The sample types used in these studies was also very varied. A majority of studies based their 
investigations on FFPE tumour samples (either blocks, smears or microscope slide mounted 
sections), however many other sample types were used, including: Endobronchial 
ultrasound-guided Fine-Needle Aspirate (EBUS FNA) (Billah et al., 2011), Computed-
Tomography guided FNA (CT FNA) (Billah et al., 2011), Ultrasound-guided superficial FNA 
(Billah et al., 2011), Bronchoalveolar lavage (BAL) (Buttitta et al., 2013), serum/ plasma 
samples (Hu et al., 2012; Liu et al., 2013a; Sriram et al., 2011; Yuan et al., 2012), cell lines, 
Malignant Pleural Effusion (MPE) (Kimura et al., 2006; Liu et al., 2013a), Endobronchial 
ultrasound guided transbronchial needle aspiration (EBUS TBNA) (Schmid-Bindert et al., 
2013), and commercially available DNA standards (Young et al., 2013). The numbers of 
samples used in the studies varied greatly, the lowest was 25 (Yuan et al., 2012) ranging up 
to 586 (Sriram et al., 2011). 
 
The variety of assays, sample types and numbers of samples encompassed by these articles 
gave the dataset a considerable amount of depth and scale, with many contrasting studies. 
Conversely however this very heterogeneous dataset also generated a very variable set of 
study outcomes. In particular, the studies varied greatly in their aims and study design. 
Therefore, the degree of equivalence between the studies reviewed was hard to assess. 
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Some articles described validations of in-house or novel techniques, whilst others used only 
one technique to analyse different sample types, and others encompassed multiple centres 
and multiple techniques with a set panel of samples. As a result, many of the studies 
quantified or qualified their findings using very different measures. Some studies used 
Positive Predictive Values (PPV) and Negative Predictive Values (NPV), whilst others used 
sensitivity and specificity, Limit of Detection (LoD) or qualitative measures i.e. mutations 
detected/ not detected. Some included technical details such as the amount of genomic DNA 
required to perform the various assays, whilst others did not. This heterogeneity in the 
dataset has provided a large amount of information, however it also means direct 
comparisons of some studies is impossible. 
 
Despite the highly varied nature of the articles reviewed, the investigations could be 
matched together in terms of their study approach. Based on these criteria, the studies could 
be grouped together into three subsets: studies investigating different tissue sample types 
for EGFR mutation detection; studies investigating different EGFR mutation detection 
techniques; and studies investigating EGFR mutation detection using Blood or cfDNA. 
 
 
1.8.1 Studies Investigating Alternative Tissue Sample Types or Sample 
Processing Methods 
 
Many studies investigated alternative sample types that can be used to obtain tumour DNA 
for EGFR mutation detection. This is a logical approach to improving mutation detection as 
there are many detection assays available that can achieve high accuracy, and finding a new 
sample type without having to develop a new assay could prove to be a very cost-efficient 
and labour-efficient means of improving EGFR mutant detection. 
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The best established sample type for EGFR mutation analysis is FFPE tumour material 
collected by biopsy. As a result, many studies focused on FFPE samples, or used FFPE as a 
comparator specimen to compare other sample types to. A total of seven studies (Allegrini 
et al., 2012; Betz et al., 2011; Hu et al., 2012; Liu et al., 2013a; Malapelle et al., 2012; Schmid-
Bindert et al., 2013; Smouse et al., 2009; Sriram et al., 2011) included FFPE tumour samples 
in their investigations. Four studies focused on other sample types resulting in cytological 
preparations, including Fine-Needle Aspirates (FNA), Bronchoalveolar Lavage (BAL) and 
Malignant Pleural Effusion (MPE) (Billah et al., 2011; Buttitta et al., 2013; Kimura et al., 2006; 
Liu et al., 2013a). Studies focusing primarily on FFPE samples will be examined first. 
 
Allegrini et al. (Allegrini et al., 2012) used Qiagen Therascreen to test a range of cytological 
samples including fine needle aspirates (FNA), pleural effusion (PE) or ascitic fluid, and 
samples from bronchial washing and brushing. This range of samples provided an interesting 
comparison as the samples are fixed by a number of different methods (ethanol 73.1%, 
Duboscq-Brasil 16.7%, formalin 9.3%). They analysed the sample types for the entire Qiagen 
Therascreen panel of EGFR mutations. 85.2% of samples were successfully amplified, 
detecting EGFR mutations in 23.9%. Amongst the samples detected positive for EGFR 
mutations, 41% contained less than 200 cancer cells and 18.2% contained less than 50% 
neoplastic cells. They concluded that cytological samples were a suitable source of genetic 
material for EGFR mutation analysis. 
 
Betz et al. (Betz et al., 2011) compared cytological smears against FFPE tumour samples using 
direct sequencing and PCR-based fragment analysis to analyse the mutation status. Their 
assays examine KRAS codons 12, 13 and 61, and EGFR exon 19 deletions and L858R. 
Interestingly their data showed that cytological smears actually improved mutation 
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detection over FFPE samples. In dilution experiments EGFR mutations were detectable at 
10% (proportion of tumour to wild-type), and KRAS mutations were detectable at 5%. 
 
Hu et al. (Hu et al., 2012) used both multiple sample types and detection methods. They 
examined three sample types: FFPE tumour samples, frozen tumour samples and serum; and 
used High Resolution Melting analysis and direct sequencing (as a comparator) for mutation 
detection. Using these two techniques they analysed EGFR exons 18-21. FFPE tumour 
samples proved to be the best sample type for mutation detection, as this sample type gave 
the most positive results (55.67%), followed by frozen tumour samples (51.06%) and serum 
(46.81%). Compared to direct sequencing, the sensitivity and specificity of the HRM assay 
was 91.97% and 100% respectively. 
 
The study by Smouse et al. (Smouse et al., 2009) aimed to compare the use of FFPE surgical 
tumour samples against cytology cell blocks for mutation detection. They used only direct 
sequencing as their analysis method, examining EGFR exons 18-21. The study found that 
90.9% of the 263 sample analysed were suitable for sequencing. EGFR mutations were 
detected in 28% of FFPE samples and 58% of cytology samples; however cytology samples 
made up only 5% of the total samples examined in the study. The group concluded that 
cytological samples were a suitable substitute for tumour samples, giving comparable 
sensitivity. 
 
Schmid-Bindert et al. (Schmid-Bindert et al., 2013) performed a slightly different study to the 
articles reviewed so far, as they focused on RNA yield for a number of applications, but also 
included EGFR mutational analysis and thus the study was included in this review. They used 
the TaqMan MGB Real Time PCR assay to detect EGFR mutations (exons 19- 21) in three 
sample types including: endobronchial biopsy, endobronchial ultrasound-guided 
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transbronchial needle aspirate (EBUS TBNA) and Computed Tomography-guided core biopsy. 
All three of these sample types were additionally split into two: one aliquot was FFPE 
preserved, whilst the other was stored in RNAlater until extraction. EGFR mutations were 
detected in 24.8% of samples tested, with EBUS TBNA giving the highest proportion of 
positive samples (31.3%). All samples came from patients with confirmed NSCLC, however 
the EGFR status had not been previously investigated, so interpretation of these EGFR results 
are unclear. 
 
Malapelle et al. (Malapelle et al., 2012) performed another slightly different study. Their 
investigation examined the use Liquid Based Cytology (LBC) samples like some other studies, 
but they also analysed effect of a specialist sample processing technique: Laser Capture 
Microdissection (LCM) of Papanicolaou-stained cells. Direct sequencing was used to analyse 
the mutation status of EGFR (exon 19 deletions) and KRAS (codon 12), and the results were 
compared in samples with and without the use of LCM during sample preparation. The 
results showed that the use of LCM increased EGFR and KRAS mutation detection from 21% 
to 40% by concentrating the neoplastic cell DNA, suggesting insufficient sensitivity of their 
mutation analysis in standard cytological preparations. 
 
Other studies focusing on sample type for optimising mutations detection used non-FFPE 
tumour material for their investigations. Billah et al. (Billah et al., 2011) used direct 
sequencing as their analysis method and analysed a range of cytological samples including: 
endobronchial ultrasound-guided fine-needle aspirates (EBUS FNA), computed-tomography 
guided fine-needle aspirates (CT FNA), body fluid, ultrasound guided superficial FNA and 
other cytological specimens. Using direct sequencing they analysed EGFR exons 18- 21 and 
KRAS codons 12, 13 and 61. Sample insufficiency was generally low (6.2% overall) ranging 
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from 3.6% to 33% across the sample types. EBUS samples gave the lowest insufficiency rates. 
EGFR and KRAS mutations were detected in 19.4% and 23.6% of samples respectively. 
 
Bronchoalveolar Lavage and Pleural Effusion were the focus of a study by Buttita et al. 
(Buttitta et al., 2013). Samples were previously characterised and grouped as mutant or wild-
type. This was the only study to use Next Generation Sequencing (Roche 454) for analysis of 
EGFR (exons 19-21). Direct sequencing was used a comparator. This early NGS method 
proved to be extremely sensitive, achieving high coverage of the sequencing targets, and 
very high sensitivity detecting mutant DNA in a 1:10000 dilution with wild-type. In the 
mutant positive group of samples, NGS detected mutations in 81% of samples, against only 
16% detected by Sanger sequencing. In the wild-type group, 42% of samples were identified 
as positive by NGS. This study showed NGS to be vastly superior to direct sequencing in terms 
of sensitivity. 
 
Kimura et al. (Kimura et al., 2006) also focused on pleural effusion as the primary sample 
type, as this is a common complication in lung cancer. They extracted the cell free fraction 
of pleural effusion for analysis, using direct sequencing for mutation detection. EGFR 
mutants were detected in 25.6% of samples. No comparator method was used, as the main 
focus of the paper was examining the response to gefitinib in EGFR mutant positive patients. 
However, the principle of EGFR mutant detection from cell free pleural effusion was 
demonstrated. 
 
Liu et al. 2013 (Liu et al., 2013b) performed a comparison of three EGFR mutant detection 
methodologies: the ADx ARMS kit, Sanger sequencing and mutant-specific 
Immunohistochemistry; using four different sample types: tumour tissue, malignant pleural 
effusion (MPE) cell block, MPE supernatant and plasma. The three techniques analysed EGFR 
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exon19 deletions and L858R mutants. Compared to direct sequencing ARMS had a sensitivity 
and specificity of 81.8% and 100% respectively. Comparing plasma against tissue, ARMS had 
a sensitivity and specificity of 67.5% and 100%. This investigation showed that tumour tissue 
was the best source of tumour DNA for mutational analysis, but that that other sample types 
were also suitable for performing EGFR mutations detection. 
 
1.8.2 Studies of EGFR Mutation Detection Techniques 
 
EGFR testing in NSCLC has been the focus of research for many groups over the last four 
years, and as a result there have been a number of recent publications comparing and 
contrasting the range of detection methods available. This approach can be very complex as 
assays vary greatly in terms of their sensitivity and specificity, and the range of mutations 
they can detect. Sanger sequencing was regularly employed in these studies, being the 
historical ‘gold standard’ for mutant detection, and many targeted or screening assays were 
compared against direct sequencing. Interestingly there were also a mixture of commercially 
available kits used as well as novel and in-house methods. 
 
Qiagen Therascreen again featured heavily in these studies, being a widely available and 
widely used commercial kit for EGFR mutation detection. Angulo et al. (Angulo et al., 2012) 
used Qiagen Therascreen and IHC to analyse EGFR in FFPE samples, with direct sequencing 
as a comparator method. They looked only at exon 19 deletion and L858R. Their results 
showed that Therascreen was more sensitive and specific than the IHC assay, compared to 
direct sequencing. Therascreen demonstrated a sensitivity and specificity of 100% (for the 
two mutations analysed), whereas the IHC assay sensitivity and specificity were 71.4% and 
100% respectively. Additionally the Therascreen assay demonstrated a LoD of 5%. The LOD 
of the IHC assay was not assessed. 
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Lopez-Rios et al. 2013 (Lopez-Rios et al., 2013) compared the COBAS EGFR mutation test 
against Sanger sequencing and Qiagen Therascreen EGFR kit, all using formalin fixed paraffin 
embedded tumour samples (FFPET). The COBAS assay is designed for a much wider range of 
mutations that Therascreen, detecting 41 mutations across EGFR exons 18- 21, whereas 
Therascreen only detects 29 mutations across the same regions. Testing of all their samples 
using both kits gave COBAS assay a Positive Percent Agreement (PPA) of 98.9% and a 
Negative Percent Agreement (NPA) of 100% compared to Therascreen. The COBAS PPA and 
NPA compared to sequencing was 98.8% and 79.3% respectively. They concluded that the 
COBAS and Therascreen assays were highly reproducible to each other, were far more 
sensitive than conventional Sanger sequencing. Furthermore COBAS required the least DNA 
input of all three assays. 
 
Two studies, Kamel-Reid et al. (Kamel-Reid et al., 2012) and Young et al. (Young et al., 2013) 
performed larger investigations incorporating multiple testing centres and a larger array of 
techniques. Kamel-Reid et al. prepared mixtures of EGFR mutant and wild-type cell lines 
ranging from 0.1- 50%, which were then distributed along with FFPE tumour slides to each 
of the five Canadian centres involved in the study. The techniques used by the five centres 
for analysis of EGFR exon 19 deletions and L858R included PCR and fragment analysis, FRET-
PCR (Fluorescence Resonance Energy Transfer PCR), RFLP (Restriction Fragment Length 
Polymorphism), Qiagen Therascreen and direct sequencing. Impressively all centres achieved 
a 1% LoD, some being able to detect the 0.1% standard using Qiagen Therascreen. For the 
FFPE samples, the centres achieved a concordance of 87%. 
 
A similar investigation was carried out by Young et al. (Young et al., 2013) in the UK. 11 
different centres were sent a panel of 15 samples of cell line mixtures of varying mutation 
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loads (0- 15%) and tasked with assessing the EGFR gene for exon 19 deletions and L858R 
mutations. Seven different methods were used to assess the samples received, including: 
pyrosequencing, COLD-PCR (Co-amplification at Lower Denaturation temperature-PCR), 
Sanger Sequencing, CE-SSCA (Capillary Electrophoresis Single-Strand Conformation Analysis), 
ARMS (Amplification Refractory Mutation System), Qiagen Therascreen, Fragment size 
analysis. Results showed that all techniques were able to detect exon 19 deletions at ≥5% 
and L858R at ≥7.5%. COBAS EGFR assay and fragment size analysis (in 3/6 labs) were able to 
detect exon 19 deletions at 1%. Qiagen Therascreen, ARMS, CE-SSCA and COLD-PCR/ 
pyrosequencing were able to detect L858R at 1%. Sanger sequencing was found to be least 
sensitive method used by the 11 centres involved. 
 
High Resolution Melting analysis featured in multiple studies (Borras et al., 2011; Do et al., 
2008; Sriram et al., 2011), most likely because it is a fast and cost effective test in comparison 
to sequencing and commercial PCR methods. Borras et al. (Borras et al., 2011) carried out a 
study of three oncogenes (EGFR, KRAS and BRAF) using HRM and pyrosequencing (KRAS 
only), with direct sequencing as the comparator method. The two techniques were tested 
using FFPE samples from lung and colorectal cancer patients, targeting five mutations in 
EGFR, six mutations in KRAS, and one in BRAF (see table A1.6.1, chapter one appendix). HRM 
detected 100% of mutations in EGFR, KRAS and BRAF, and demonstrated a LoD of 2.5%. 
Pyrosequencing detected 100% of KRAS mutations with higher sensitivity than Sanger 
sequencing. The study showed HRM to be an effective technique for mutant detection, 
however as it cannot distinguish between different types of mutant, sequencing will often 
be required as an additional confirmatory test. 
 
Sriram et al. (Sriram et al., 2011) used HRM and Mutant Enriched (ME) PCR (also known as 
PCR clamping) for detection of EGFR exon 19 deletions and L858R mutants, using direct 
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sequencing as the comparator method. This study involved the largest number of samples 
of the articles reviewed here: it tested 522 fresh frozen surgically resected tumour samples. 
It was also one of the few to analyse serum or plasma: 64 of the surgical samples also had 
matched serum samples, bringing the total number of samples tested to 586. HRM proved 
to be the slightly more accurate of the two techniques, demonstrating 100% sensitivity and 
specificity, whilst ME-PCR demonstrated 100% sensitivity and 99% specificity. However, ME-
PCR showed better performance with serum than HRM, detecting 50% of mutants in 
matched sera, whilst HRM only detected 33%. This study clearly illustrated that techniques 
need to be carefully selected based on the sample types being analysed. 
 
Do et al. (Do et al., 2008) also compared HRM against direct sequencing using FFPE samples. 
The HRM assay was tested using a range of input gDNA concentrations from 1-100 ng. HRM 
was used to analyse both EGFR and KRAS mutations. For EGFR the HRM technique 
demonstrated a sensitivity of 100% and a specificity of 88-93% on different exons due to the 
occurrence of false positives. For KRAS HRM demonstrated a sensitivity and specificity of 
100%. For both genes the HRM could detect mutants with an input DNA concentration of 1 
ng.  
 
Two novel techniques that did not feature in other articles were Bidirectional PCR 
Amplification of Specific Alleles (Bi-PASA, Dahse et al. (Dahse et al., 2008b; Dahse et al., 
2008a)) and SNaPShot®, a multiplex PCR system (ThermoFisher, 2012) and a Triplex Sizing 
Assay were employed by Su et al. (Su et al., 2011). In the study by Dahse et al., they designed 
a novel Bi-PASA assay for exon 19 deletions and a novel allele specific PCR to detect L858R 
mutations in FFPE adenocarcinoma samples. Direct sequencing was employed as a 
comparator method. In serial dilution experiments the LoD was 12.5% for Bi-PASA and 25% 
for the allele specific PCR. This shows a much higher LoD (i.e. poorer analytical sensitivity) 
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than many other assays assessed in these studies. When testing the adenocarcinoma 
samples, the assays correctly identified three positive samples. 
 
 
Figure 1.8.2.1 Diagram of the Bi-PASA reaction, in this example covering the EGFR exon 19 deletion. Outer primers 
P and Q flank the mutation site and are always amplified as a reaction control. Inner primers A and B determine 
the wild-type or mutant status. Primer A is complementary to the wild-type, therefore fragment AQ is only 
generated by the wild-type. Primer B is complementary to the mutant (deletion), therefore fragment BP is only 
generated by the mutant. Adapted from (Dahse et al., 2008a). 
 
 
SNaPShot® and a Triplex Sizing Assay were used by Su et al. (Su et al., 2011) for the analysis 
of multiple cell line and FFPE adenocarcinoma samples. Direct sequencing was used as a 
comparator. The SNaPShot® technique was able to analyse a broad range of mutations: a 
total of 38 mutations across eight genes (EGFR, BRAF, KRAS, NRAS, PI3KCA, MEK1, AKT1 and 
PTEN). The Triples Sizing Assay was used to detect EGFR exon 19 deletions and exon 20 
insertions, and HER2 exon 20 insertions. Both assays performed well and detected 100% of 
mutants in known mutant samples. Both also demonstrated very low LoD: they were able to 
detect mutations at 1.56%.  
 
Wild-type 
Fragment 
(AQ) 
Mutant 
Fragment 
(PB) 
Control 
Fragment 
(PQ) 
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Figure 1.8.2.2 Diagram of the SNaPshot® kit chemistry. Annealing primers bind upstream of the mutation site. 
Labelled ddNTPs bind to the mutation site which can then be identified by electrophoresis and fluorescence 
detection. From Life Technologies product brochure (ThermoFisher, 2012). 
 
 
1.8.3 Studies of EGFR Mutant Detection using Blood/ cfDNA 
 
Several PCR based assays have been developed in recent years specifically designed to detect 
mutations in a small amount of cfDNA with a significant background of wild-type DNA. Whilst 
there are a range of studies being conducted in this field, relatively few are focusing on EGFR 
mutation detection in NSCLC. 
 
Taniguchi et al. (Taniguchi et al., 2011) used BEAMing (Beads Emulsion Amplification 
Magnetics) to detect EGFR mutations in plasma samples from 44 patients. In total 32 (72.7%) 
out of 44 patient samples were detected as positive for EGFR mutations. The properties of 
BEAMing also allow quantification of mutant alleles within the heterogeneous (in terms of 
tumour and normal tissue-derived DNA) blood DNA samples. The data showed that mutant 
alleles constituted between 0.1- 1% of the total DNA isolated. The study suggested that the 
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sensitivity of BEAMing, and its ability to give a quantitative measure of allele frequency make 
it a promising tool for tumour mutant detection, and may also prove useful for disease 
progression monitoring. 
 
Punnose et al. (Punnoose et al., 2012) performed a study focusing on Circulating Tumour 
Cells (CTC) and Circulating Tumour DNA (ctDNA) in trial of Pertuzamab and Erlotinib. A total 
of 41 patients were included in the study, 25 of which also had plasma samples. CTCs were 
measured using the Cell Search™ platform. EGFR mutations were assessed using the Qiagen 
DXS EGFR assay. In addition, five other genes were analysed: KRAS, BRAF, NRAS, AKT1 and 
PI3KCA. CtDNA was found to be superior for detecting EGFR mutations in comparison to CTC. 
The EGFR and KRAS results from ctDNA were completely concordant with matched tumour 
samples. CtDNA also detected new mutations post-treatment which were not detected using 
CTCs, demonstrating the potential use ctDNA for disease monitoring. 
 
The study by Chen et al. (Chen et al., 2009) employed MAP (MIDI (micro-insertions, deletions, 
indels) Activated Pyrophosphorolysis) to detect EGFR mutations in the DNA extracted from 
blood and tissue from lung and breast tumours. MAP was developed by the research group, 
by modifying an existing technique called Pyrophosphorolysis-Activated Polymerisation 
Allele specific amplification (PAP-A). PAP-A is an ultra-sensitive method for detecting rare 
DNA mutations. It works by using allele specific primers that are blocked at their 3’ end by a 
dideoxy molecule (Chen et al., 2009). When a mutant allele is present, the blocked primer 
binds to the mutant DNA, at which point pyrophosphorolysis removes the 3’ block and allows 
extension to occur. Chen et al. modified this technique from PAP-A (just described) to MAP 
by increasing the number of wild-type sequence mismatches in the allele specific primers, 
increasing sensitivity. They then applied their modified technique to detecting common EGFR 
mutations in a limited number of clinical samples (4 normal lung tissue, 6 breast cancer 
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patient plasma and 10 healthy blood samples) and screening a large number of control DNA 
samples (6400). Using this approach, no EGFR mutations were detected in the healthy tissue 
and blood samples, or in the breast cancer patient plasma samples. However, TP53 
mutations that were detected at diagnosis were undetectable after treatment in four of the 
six women, suggesting clinical remission. MAP detected no EGFR mutations in the large 
cohort of control DNA samples, suggesting that somatic EGFR mutation is extremely rare. 
 
Kim et al. (Kim et al., 2013) performed a study that aimed to assess EGFR mutation detection 
from plasma cfDNA using Peptide Nucleic Acid (PNA)-mediated PCR clamping in the form of 
the commercially available PNAClamp ™ EGFR Mutation Detection Kit (PANAGENE Inc., 
Korea). Plasma samples from 60 patients across 11 centres were tested. All patients showed 
a partial response to gefitinib therapy. Forty (66.7%) of the 60 patients had previous EGFR 
mutation results (Kim et al., 2013), of which 35 were positive. After testing the plasma 
samples, 10 cases gave positive results for EGFR mutations. EGFR mutations were no longer 
detectable after two months of treatment. The data from this study shows that this particular 
technique is not sufficiently sensitive to detect EGFR mutations in cfDNA compared with 
matched tissue samples. 
 
 
1.8.4 Recent Validations of EGFR testing Methods 
 
The three previous sections (1.8.1- 3) give an overview of the literature covering various 
aspects of EGFR mutation detection up to late 2014 when this project was in its early stages. 
Since 2014, there have been a number of publications describing validation studies of new 
diagnostic methods based on many of the techniques previously described. From 2015 to 
present there are six publications in particular that present interesting studies, some of 
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which were diagnostic validations. Of the six studies: three used PCR based techniques 
(Vliegen et al., 2015; Malapelle et al., 2016; Zhang et al., 2015b) , one used pyrosequencing 
(Xie et al., 2015), one used NGS (Fujita et al., 2015), and one used MALDI-TOF (Matrix-
Assisted Laser Desorption/Ionization Time Of Flight) (Su et al., 2016).  
 
Vliegen et al. (Vliegen et al., 2015) validated a combined locked nucleic acid (LNA) PCR/ 
Sanger sequencing assay for the detection of EGFR exon 18 mutations (G719A/S/C) and exon 
19 deletions in DNA extracted from FFPE tissues samples. This assay consisted of two steps. 
First the extracted DNA samples were amplified using the LNA PCR assay. The LNA molecules 
blocked amplification of the wild-type sequences, therefore enriching the amplicons for the 
mutant alleles (if present). The amplified products were then sequenced using conventional 
Sanger sequencing. The results from the LNA/ Sanger assay were compared retrospectively 
to the original diagnostic results using Fragment Length Analysis and The Qiagen Therascreen 
EGFR assay. The LNA/ Sanger assay demonstrated a high degree of concordance with the 
Therascreen results, 100% of samples tested on both techniques gave the same results. The 
assay also displayed a high level of sensitivity with a LoD of 3.13% tumour cell content. The 
study concluded that the LNA/ Sanger assay achieved equivalent accuracy, whilst being 25-
50% cheaper than the Therascreen assay. The disadvantage however was that the LNA/ 
Sanger assay required more hands on time, and in its present form does not cover all the 
most common EGFR mutations. 
 
The study by Malapelle et al. (Malapelle et al., 2016) aimed to address the problem of the 
difficulties encountered when attempting to detect EGFR mutations from cytological smear 
samples which are small samples and thus contain a very low number of tumour cells (and 
therefore a low concentration of tumour DNA). Their approached involved the use of a digital 
PCR (dPCR) technique, designed to detect EGFR exon 19 deletions and the L858R mutation. 
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The dPCR assay only required 2 ng of input DNA, and can detect mutation rates at 0.1% 
(Zhang et al., 2015a) so therefore should be well suited to low DNA concentration samples. 
The results from this study showed the dPCR technique to be sensitive and accurate. The 
dPCR was tested down to 1% in LoD assays and a majority (19/20) of cytology samples tested 
gave the same results as previous testing. In one case the dPCR detected an additional L858R 
mutation which was not detected by the previously used assays (Fragment Length Analysis 
and TaqMan PCR). The additional mutant was confirmed by cloning and sequencing. This 
study demonstrated that dPCR is a suitable technique for the detection of EGFR mutants, 
and offers a considerable advantage in terms of low DNA requirement and robustness with 
low DNA concentration/ quality samples. In a previous study, this group reported that 16.2% 
of the cytological samples received for analysis had to be rejected due to insufficient 
cellularity (Malapelle et al., 2013). The improved sensitivity of dPCR may reduce this rejection 
rate, as well as reduce the service turnaround time and assay failure rate. 
 
Zhang et al (Zhang et al., 2015b) performed a study using the SNaPshot® technique to detect 
oncogenic mutations in a number of genes including EGFR, KRAS and BRAF, as well as KIT and 
PIK3CA. This article is slightly different to others reviewed here, as the clinical context of this 
article is nasopharyngeal carcinoma (NPC), however this does not impact on the technical 
aspects of mutation detection assays. Also EGFR is considered to be an important mutation 
in NPC, with up to an 80% prevalence of EGFR overexpression in NPC primary biopsies (Pan 
et al., 2008). EGFR mutations however are rare in NPC, at 0-1% prevalence (Lee et al., 2006). 
70 fresh frozen tissue samples from NPC patients were extracted and analysed using the 
SNaPshot® assay. The result of mutation detection from these samples was compared to 
clinicopathologic data. Of the 70 samples, 12 (17.1%) tested positive for the presence for 
hotspot mutations in at least one of the five oncogenes analysed (3 in EGFR). These results 
were consistent with the findings of a previous study (Jiang et al., 2014). The SNaPshot® assay 
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passed all assay controls, however there was no comparator method used to compare the 
mutation results against. No correlation was found between the mutation status and the 
clinicopathologic data for each patient.  
 
Xie et al. (Xie et al., 2015) performed a large study, using pyrosequencing to analyse FFPE 
tissue samples from NSCLC and CRC patients. In the total the study analysed 494 and 1099 
tissue samples for NSCLC and CRC respectively. Extracts from cell lines were also used to 
perform LoD experiments. The pyrosequencing technique demonstrated the ability to detect 
2% mutant alleles in the wild-type background. Sanger sequencing was used to confirm the 
results from the LoD experiments with cell lines. In the NSCLC samples, the pyrosequencing 
detected EGFR mutations in 176 of 494 (35.6%). In the 1099 CRC samples, 437 samples 
contained mutations (39.8%). Sanger sequencing was used to confirm the results generated 
by the pyrosequencing. These results show a very high prevalence of EGFR and KRAS 
mutations amongst NSCLC and CRC patients, and that pyrosequencing appears to be a 
sensitive and accurate means of detecting mutations in FFPE tissue. However the study 
reported that in samples tested using both Sanger sequencing and pyrosequencing, 
pyrosequencing detected more mutations, which is most likely due to the relatively low 
sensitivity of direct sequencing. As a result the pyrosequencing technique used in routine 
clinical service at the author’s resident hospital. 
 
The study by Fujita et al. (Fujita et al., 2015) was a validation study of Next Generation 
Sequencing assay for the detection of oncogenic mutations from FFPE tissue biopsy samples 
from NSCLC patients. The NGS assay ran on the Ion Torrent platform, utilising the Ion 
AmpliSeq™ Cancer Hotspot Panel version 2, which is designed to analyse 50 cancer hotspot 
genes, including EGFR and KRAS. 21 tissue samples were analysed using the Ion Torrent 
assay. A cycleave PCR assay (Yatabe et al., 2006) and Sanger sequencing were used to verify 
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the results. Comparison of the results showed the mutations detected by the NGS platform 
matched the results from the other assays in all cases. In addition, in one case a low 
frequency T790M mutation was identified in 53 of 900 reads (5.9%) for that amplicon, 
possibly demonstrating the emergence of a resistant subpopulation in that patients tumour. 
This subpopulation would not be detectable by Sanger sequencing and may not have been 
detectable by the cycleave PCR assay. This study showed the NGS assay for the accurate, 
sensitive and practical for use in the clinical setting, especially when there is limited material 
for molecular analysis. 
 
The final study in this section is by Su et al. (Su et al., 2016) and is slightly unusual compared 
to the other studies as the main mutation detection technique used was matrix-assisted-
laser-desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) rather than 
PCR or sequencing. This article is an interesting contrast to other approaches, but still 
requires the extraction and amplification of DNA and thus has a molecular biology 
component similar to other studies. Briefly, the procedure involved extraction of the sample 
DNA, amplification of the target region, treatment with SAP (shrimp alkaline phosphatase), 
single nucleotide extension with mutation specific probe, then MALDI-TOF MS analysis. The 
technique was tested and optimised using mutant and wild-type cell lines, achieving a LoD 
of 1%. Analytical sensitivity and specificity were tested with a panel of clinical samples. 
Sanger sequencing was used as the comparator method. The test achieved 100% analytical 
sensitivity and specificity, so the technique went into routine use. In the course of the period 
covered by the study, 8147 lung adenocarcinoma samples were tested with this technique, 
of the failure rate was only 0.1% (n= 5). This study shows an interesting alternative approach 
to EGFR mutation detection. The only technical issue presented was that the technique 
occasionally detect positive mutants in their wild-type PBMC (peripheral blood mononuclear 
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cell) DNA which was attributed to background signal, which highlights the need to establish 
accurate thresholds for clinical diagnostic use. 
 
 
1.9 SUMMARY 
 
From the review of literature presented in section 1.8 it is very clear that there has been 
considerable interest in finding the most efficient methods for performing EGFR mutation 
analysis on clinical samples. This interest ranges from investigation of new sample types to 
use with existing mutation detection methods, to developing novel methods for EGFR 
mutant detection to address the short comings of existing methodologies. It is clear that 
Sanger sequencing, although for a long time considered the “gold standard” for mutant 
characterisation in tumour tissue, is gradually becoming obsolete in comparison with NGS 
technologies, as these have vastly superior coverage and sensitivity. At the time of initial 
literature searching (2013/14) Sanger sequencing was considered the “gold standard” for 
mutation detection/ sequence determination. By contrast NGS was less widely adopted, 
possibly due to the cost and hands on time. In later validation studies of 2015/16 (section 
1.8.4) Sanger sequencing was still used in a number of cases, however NGS is very likely to 
supersede this method soon as speed and cost reduce.  
 
Real time PCR assays offer a much cheaper and quicker alternative to NGS for EGFR mutation 
detection, though limited in mutation coverage. Several techniques and kits using real time 
PCR technology have been examined here, and have shown to demonstrate high sensitivity, 
specificity and reproducibility in the studies analysed. Real time PCR also represents a 
considerable cost saving over more advanced techniques, and can be performed on 
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machinery that is widely available and affordable. The weaknesses of these approaches are 
that they lack the sensitivity and range of mutations that other techniques can achieve.  The 
majority of studies use Therascreen or COBAS, and these have also been used as comparators 
in a number of studies.  
 
FFPE tissue is still the main sample type employed by diagnostic centres for EGFR mutation 
analysis, as DNA yields are consistently the highest from this sample type. Although the use 
of cfDNA as a source of tumour DNA has previously been limited, work is expanding in this 
field, and the COBAS (Roche) cfDNA test has recently been approved by the Food and Drug 
Administration (FDA) (Roche, 2016) and has been used in a number of studies (Weber et al., 
2014b; Weber et al., 2014a; Mok et al., 2015) . 
 
This introduction chapter has described the clinical and biological background of lung and 
colorectal cancer, and the essential need for rapid and accurate means of performing genetic 
testing on patient tumour samples. The current range of detection techniques have been 
described in detail, along with some of the newer techniques and approaches that have 
recently appeared in the literature. The clear underlying problem remains the reliance on 
tissue which contributes to a significant delay in terms of time between diagnosis and genetic 
characterisation. This project aims to address these problems, by investigating new methods 
and new sources of tumour DNA. 
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1.10 HYPOTHESIS/ RESEARCH QUESTIONS 
 
I suggest that detection of mutations in circulating free DNA in the blood plasma of NSCLC 
cancer patients is likely to overcome some of the limitations imposed by reliance on tissue 
in three areas: 
 
(1) Known heterogeneity of mutations within tumours. 
(2) Lack of tissue availability from patients. 
(3) Development of new mutations during tumour progression.   
 
1.11 PROJECT AIMS 
 
 To compare the new and prototype PCR technology with existing methods for the 
detection of EGFR mutations in blood and formalin-fixed paraffin embedded (FFPE) 
tumour samples. 
 To determine the relative accuracy of new and existing technology for the detection of 
KRAS and EGFR mutations in plasma. 
 To investigate the stability of cfDNA in EDTA Blood over varying storage times, and the 
effect of storage time on downstream applications. 
 To develop and validate NGS and PCR solutions for blood mutation analysis in lung 
cancer. 
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1.12 JUSTIFICATION OF RESEARCH DESIGN 
 
The research project design was initially based on parallel testing of the novel GeneFirst 
technology against current standard methods for EGFR mutation detection in NSCLC 
samples. The two key variables in the study are firstly; the type of molecular assay employed, 
and two; the sample type used to obtain the analyte DNA. 
 
The Pathology Department at University Hospital Coventry and Warwickshire NHS Trust 
(UHCW) is an ideal location for performing this type of research. The laboratories and 
equipment are all run and maintained to UK Accreditation Service (UKAS) ISO15189 
standards, and thus all investigations and evaluations carried out by this project were run to 
the same standards, and could provide data for analytical and clinical validation to permit 
rapid introduction of the resulting assay methods to clinical practice. The Department also 
regularly processes tissue samples for EGFR and KRAS mutation analysis, and therefore is a 
good source of reference and comparison material for this project. 
 
Beyond the Pathology Department, UHCW runs a wide variety of clinical services, including 
regular lung clinics for the treatment and investigation of patients with thoracic conditions. 
Amongst these patients there were a significant cohort of lung cancer suffers who were 
undergoing routine blood testing at various points during their treatment. These samples 
proved to be a good source of plasma for cfDNA extraction and analysis, using standard 
phlebotomy and processing methods. 
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A1 CHAPTER ONE APPENDIX 
 
LITERATURE SEARCH 
 
The MEDLINE database was searched using the search tool within the EndNote X7 software 
on 24th November 2013 to identify original study articles that analysed the currently available 
methods for detecting EGFR mutations in samples from NSCLC patients. Due to the nature 
of this review, multiple searches were performed in order to capture all relevant articles 
relating to all the topics within the scope of the article. The details of searches and terms 
used are given below:  
 
 
A1.1 Search One- To identify articles related to EGFR detection from tissue 
 
(Any field) mutation detection methods lung 
[AND] (Title) EGFR mutation lung method* 
[OR] (Any field) EGFR mutation testing lung 
[OR] (Title) EGFR mutation cytology 
 
 
A1.2 Search Two- To identify articles related to EGFR detection from blood/ 
cfDNA 
 
(Any field) mutation detection method* lung cell circulating free DNA 
[AND] (Title) EGFR mutation lung method* blood 
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[OR] (Any field) EGFR mutation testing lung cell circulating free DNA 
[OR] (Title) EGFR mutation blood 
 
 
A1.3 Search Three- To identify articles performing direct comparisons of 
techniques 
 
(Any field) mutation detection methods lung comparison 
[AND] (Title) EGFR mutation lung method* 
[OR] (Any field) EGFR mutation testing lung comparison 
[OR] (Title) EGFR mutation cytology 
 
 
A1.4 Search Four- To identify articles specifically investigation Cell Free/ 
Circulating Tumour DNA 
 
(Any field) mutation detection method* lung cell free DNA 
[AND] (Title) EGFR mutation lung method* 
[OR] (Any field) EGFR mutation lung circulating tumour DNA 
[OR] (Title) EGFR mutation circulating tumour DNA 
 
 
A1.5 Search Five- To identify recent validation studies to update literature 
search 
 
(Any field) EGFR mutation detection validation 
[AND] (Year) 2015 
87 
 
[OR] (Year) 2016 
 
 
Search results from both searches were filtered by the following criteria: 
 English Language 
 Non-review article* 
 Non-clinical 
 Techniques assessed were molecular i.e. designed around the extraction and/ or 
amplification of DNA. 
 Study performed using a minimum of 20 samples. 
 
* Review articles were not automatically excluded, but were used as sources for identifying 
original studies. They were not used as primary sources of information. 
 
Articles that did not meet these criteria were excluded. Search 1 initially yielded 246 articles 
which were reduced to 90 after filtering. Search 2 initially yielded 244 articles which were 
reduced to 106 after filtering. Search 3 initially yielded 32 articles, reduced to 9 after filtering. 
Search 4 produced 18 articles, reduced to 7 after filtering. Search 5 generated 21 Due to the 
similar terminology in all four searches; there was some duplication of a proportion of the 
resultant articles. However, doing multiple searches ensured that specific articles were not 
missed by the individual search algorithms.  
 
 
 
88 
 
A1.6 Literature Results 
 
The abstracts from then articles identified by the five searches were then reviewed for 
relevance to this study and any that were still not directly relevant to the search criteria were 
also excluded. To exclude duplicates, the four lists of articles generated by the initial 
searches, filtering and abstract analysis were combined into a single list and all duplicated 
entries excluded. After review of the abstracts the numbers of relevant articles from the 
MEDLINE searches were filtered to 35 full text articles. These articles were reviewed and ten 
full text articles were identified as irrelevant and excluded. This gave a final citation list of 25 
articles. 
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Table A1.6.1 Articles selected after literature search and filtering. Part 1 of 3 (9 articles), results divided in three 
for ease of reading. Parts 2 and 3 of table shown in table A1.6.2 and A1.6.3. 
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Table A1.6.2 Articles selected after literature search and filtering. Part 2 of 3 (8 articles), results divided in three 
for ease of reading. Parts 1 and 3 of table shown in table A1.6.1 and A1.6.3. 
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 b
e
in
g 
ac
h
ie
ve
d
 in
 s
o
m
e
 
lo
ca
ti
o
n
s,
 a
n
d
 d
e
te
ct
e
d
 c
e
ll
 li
n
e
 D
N
A
 
w
it
h
 1
00
%
 s
p
e
ci
fi
ci
ty
. O
n
 t
u
m
o
u
r 
sa
m
p
le
s 
th
e
 s
it
e
s 
ac
h
ie
ve
d
 8
7%
 
co
n
co
rd
an
ce
, h
o
w
e
ve
r 
p
o
o
re
r 
sa
m
p
le
 
q
u
al
it
y 
re
su
lt
e
d
 in
 s
o
m
e
 d
is
co
rd
an
t 
re
su
lt
s.
4 
o
f 
th
e
 5
 s
it
e
s 
u
se
d
 in
 h
o
u
se
 
d
e
te
ct
io
n
 m
e
th
o
d
s,
 o
n
ly
 o
n
e
 
u
se
d
 a
 c
o
m
m
e
rc
ia
l k
it
 
(T
h
e
ra
sc
re
e
n
).
K
im
u
ra
 e
t 
a
l. 
20
06
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g
N
o
n
e
P
le
u
ra
l E
ff
u
si
o
n
 f
ro
m
 N
SC
LC
 
p
at
ie
n
ts
EG
FR
 E
xo
n
s 
18
- 
21
.
43
N
o
t 
st
at
e
d
A
ll
 s
am
p
le
s 
w
e
re
 s
u
ff
ic
ie
n
t 
fo
r 
an
al
ys
is
 b
y 
se
q
u
e
n
ci
n
g,
 a
n
d
 E
G
FR
 
m
u
ta
ti
o
n
s 
w
e
re
 d
e
te
ct
e
d
 in
 2
5.
6%
 o
f 
sa
m
p
le
s.
Se
n
si
ti
vi
ty
 a
n
d
 S
p
e
ci
fi
ci
ty
 c
o
u
ld
 
n
o
t 
b
e
 d
e
te
rm
in
e
d
 a
s 
se
q
u
e
n
ci
n
g 
d
at
a 
fr
o
m
 t
u
m
o
u
r 
as
 
n
o
t 
av
ai
la
b
le
 f
o
r 
th
e
se
 p
at
ie
n
ts
.
Li
u
 e
t 
a
l.
 2
01
3
A
d
x-
A
R
M
S 
ki
t 
an
d
 IH
C
.
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g
Tu
m
o
u
r 
ti
ss
u
e
, M
P
E 
ce
ll
 b
lo
ck
, 
M
P
E 
su
p
e
rn
at
an
t 
an
d
 p
la
sm
a.
EG
FR
 E
xo
n
 1
9 
D
e
le
ti
o
n
s 
an
d
 L
85
8R
.
86
 s
e
ts
 o
f 
m
at
ch
e
d
 
sa
m
p
le
s
N
o
t 
st
at
e
d
C
o
m
p
ar
e
d
 t
o
 A
R
M
S,
 t
h
e
 s
e
n
si
ti
vi
ty
 
an
d
 s
p
e
ci
fi
ci
ty
 o
g 
se
q
u
e
n
ci
n
g 
fo
r 
EG
FR
 
m
u
ta
n
t 
d
e
te
ct
io
n
 w
as
 8
1.
8%
 a
n
d
 
10
0%
. C
o
m
p
ar
e
d
 t
o
 t
u
m
o
u
r 
ti
ss
u
e
, t
h
e
 
se
n
si
ti
vi
ty
 a
n
d
 s
p
e
ci
fi
ci
ty
 o
f 
p
la
sm
a 
u
si
n
g 
A
R
M
S 
w
as
 6
7.
5%
 a
n
d
 1
00
%
.
W
h
il
st
 t
u
m
o
u
r 
is
 t
h
e
 o
p
ti
m
al
 
m
at
e
ri
al
 f
o
r 
m
u
ta
ti
o
n
 d
e
te
ct
io
n
, 
M
P
E 
ce
ll
 b
lo
ck
, M
P
E 
su
p
e
rn
at
an
t 
an
d
 p
la
sm
a 
p
ro
ve
d
 t
o
 b
e
 
su
it
ab
le
 a
lt
e
rn
at
iv
e
s.
Lo
p
e
z-
R
io
s 
et
 
a
l.
 2
01
3
C
O
B
A
S 
EG
FR
 M
u
ta
ti
o
n
 T
e
st
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g 
an
d
 
Q
ia
ge
n
 T
h
e
ra
sc
re
e
n
FF
P
E 
tu
m
o
u
r 
sa
m
p
le
s
C
O
B
A
S:
 4
1 
m
u
ta
ti
o
n
s 
in
 E
G
FR
 e
xo
n
s 
18
, 
19
, 2
0 
an
d
 2
1;
 T
h
e
ra
sc
re
e
n
: 2
9 
m
u
ta
ti
o
n
s 
in
 E
G
FR
 e
xo
n
s 
18
, 1
9,
 2
0 
an
d
 2
1;
 
Se
q
u
e
n
ci
n
g:
 m
u
ta
ti
o
n
 s
cr
e
e
n
in
g 
in
 E
G
FR
 
e
xo
n
s 
18
, 1
9,
 2
0 
an
d
 2
1.
12
4
Te
st
 t
o
ta
ls
 (
n
o
t 
p
e
r 
w
e
ll
):
 C
O
B
A
S 
15
0n
g,
 
Th
e
ra
sc
re
e
n
 8
00
n
g,
 
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g 
60
0n
g.
Th
e
 C
O
B
A
S 
te
st
 d
is
p
la
ye
d
 a
 P
P
A
 o
f 
98
.9
%
, N
P
A
 o
f 
10
0%
 a
n
d
 O
P
A
 9
9.
2%
 
co
m
p
ar
e
d
 t
o
 T
h
e
ra
sc
re
e
n
 a
n
d
 
Se
q
u
e
n
ci
n
g.
Th
e
ra
sc
re
e
n
 a
n
d
 C
O
B
A
S 
te
st
s 
ar
e
 h
ig
h
ly
 c
o
n
co
rd
an
t.
 T
h
e
 
C
O
B
A
S 
te
st
 r
e
q
u
ir
e
s 
th
e
 le
as
t 
am
o
u
n
t 
o
f 
gD
N
A
 o
f 
th
e
 t
h
re
e
 
te
st
s.
M
al
ap
e
ll
e
 e
t 
a
l.
 2
01
2
D
ir
e
ct
 s
e
q
u
e
n
ci
n
g 
w
it
h
 la
se
r 
ca
p
tu
re
 m
ic
ro
d
is
se
ct
io
n
 (
LC
M
)
D
ir
e
ct
 s
e
q
u
e
n
ci
n
g 
w
it
h
o
u
t 
la
se
r 
ca
p
tu
re
 
m
ic
ro
d
is
se
ct
io
n
 (
LC
M
)
C
e
ll
 li
n
e
s,
 a
n
d
 li
q
u
id
 b
as
e
d
 
cy
to
lo
gy
 (
LB
C
) 
sa
m
p
le
s.
EG
FR
 a
n
d
 K
R
A
S
2 
ce
ll
 li
n
e
s 
 
(P
C
-9
 a
n
d
 
H
19
75
),
an
d
 4
2 
cl
in
ic
al
 L
B
C
 
sa
m
p
le
s
N
o
t 
st
at
e
d
U
se
 o
f 
LC
M
 in
cr
e
as
e
d
 E
G
FR
 a
n
d
 K
R
A
S 
m
u
ta
n
t 
d
e
te
ct
io
n
t 
fr
o
m
 2
1%
 t
o
 4
0%
.
LC
M
 s
ig
n
if
ic
an
tl
y 
in
cr
e
as
e
s 
se
q
u
e
n
ci
n
g 
se
n
si
ti
vi
ty
 f
ro
m
 L
B
C
 
sa
m
p
le
s.
Sc
h
m
id
-
B
in
d
e
rt
 e
t 
a
l.
 
20
13
Ta
q
m
an
 M
G
B
 r
e
al
 t
im
e
 P
C
R
 a
ss
ay
C
o
m
p
ar
e
d
 d
if
fe
re
n
t 
sa
m
p
le
 
ty
p
e
s 
u
si
n
g 
a 
co
m
m
o
n
 
m
u
ta
ti
o
n
 d
e
te
ct
io
n
 m
e
th
o
d
Fo
rc
e
p
 b
io
p
sy
, E
n
d
o
b
ro
n
ch
ia
l 
u
lt
ra
so
u
n
d
 g
u
id
e
d
 
tr
an
sb
ro
n
ch
ia
l n
e
e
d
le
 
as
p
ir
at
io
n
 (
EB
U
S 
TB
N
A
),
 a
n
d
 C
T-
gu
id
e
d
 c
o
re
 b
io
p
sy
. S
am
p
le
s 
w
e
re
 s
p
li
t 
in
 t
w
o
: o
n
e
 w
as
 F
FP
E 
p
re
se
rv
e
d
, t
h
e
 o
th
e
r 
w
as
 
st
o
re
d
 in
 R
N
A
la
te
r 
u
n
ti
l 
e
xt
ra
ct
io
n
.
EG
FR
 E
xo
n
s 
19
 a
n
d
 2
1.
10
1
N
o
t 
st
at
e
d
EG
FR
 m
u
ta
ti
o
n
s 
 w
e
re
 d
e
te
ct
in
g 
in
 2
5 
o
f 
th
e
 1
01
 s
am
p
le
s 
te
st
e
d
.
Th
e
 r
e
su
lt
s 
sh
o
w
e
d
 t
h
at
 a
ll
 
th
re
e
 s
am
p
le
s 
w
e
re
 s
u
it
ab
le
 f
o
r 
u
se
 f
o
r 
m
o
le
cu
la
r 
an
al
ys
is
.
Sm
o
u
se
 e
t 
a
l.
 
20
09
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g
C
o
m
p
ar
e
d
 d
if
fe
re
n
t 
sa
m
p
le
 
ty
p
e
s 
u
si
n
g 
a 
co
m
m
o
n
 
m
u
ta
ti
o
n
 d
e
te
ct
io
n
 m
e
th
o
d
FF
P
E 
tu
m
o
u
r 
sa
m
p
le
s 
an
d
 
cy
to
lo
gy
 c
e
ll
 b
lo
ck
s
EG
FR
 E
xo
n
s 
18
-2
4
26
3
N
o
t 
st
at
e
d
23
9 
(9
0.
9%
) 
sa
m
p
le
s 
w
e
re
 s
u
ff
ic
ie
n
t 
fo
r 
an
al
ys
is
. S
u
rg
ic
al
 s
am
p
le
s 
yi
e
ld
e
d
 
lo
w
e
r 
in
su
ff
ic
ie
n
cy
 r
at
e
s 
th
an
 
cy
to
lo
gy
 s
am
p
le
s 
(7
.4
%
 a
n
d
 3
3%
).
 
EG
FR
 m
u
ta
ti
o
n
s 
w
e
re
 d
e
te
ct
e
d
 a
t 
27
.8
%
 a
n
d
 5
8%
 o
f 
su
rg
ic
al
 a
n
d
 
cy
to
lo
gy
 s
am
p
le
s.
M
u
ta
ti
o
n
s 
w
e
re
 d
e
te
ct
ab
le
 in
 
sa
m
p
le
 w
it
h
 2
5%
 o
r 
h
ig
h
e
r 
tu
m
o
u
r 
ce
ll
u
la
ri
ty
.
Sr
ir
am
 e
t 
a
l.
 
20
11
M
u
ta
n
t-
En
ri
ch
e
d
 P
C
R
 (
M
E 
P
C
R
) 
an
d
 H
ig
h
 R
e
so
lu
ti
o
n
 M
e
lt
 (
H
R
M
) 
an
al
ys
is
.
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g
Fr
e
sh
 f
ro
ze
n
 s
u
rg
ic
al
ly
 r
e
se
ct
e
d
 
tu
m
o
u
r 
sa
m
p
le
s,
 a
n
d
 a
 li
m
it
e
d
 
n
u
m
b
e
r 
o
f 
m
at
ch
e
d
 s
e
ru
m
 
sa
m
p
le
s.
 E
G
FR
 m
u
ta
n
t 
ce
ll
 li
n
e
s 
(H
16
50
 a
n
d
 H
19
75
) 
an
d
 E
G
FR
 
W
T 
h
u
m
an
 g
D
N
A
 w
e
re
 a
ls
o
 
u
se
d
.
EG
FR
 E
xo
n
 1
9 
D
e
le
ti
o
n
s 
an
d
 L
85
8R
.
52
2 
tu
m
o
u
r 
sa
m
p
le
s,
 6
4 
o
f 
w
h
ic
h
 h
ad
 
m
at
ch
e
d
 
se
ru
m
 
sa
m
p
le
s
N
o
t 
st
at
e
d
EG
FR
 m
u
ta
ti
o
n
s 
w
e
re
 d
e
te
ct
e
d
 in
 5
%
 
o
f 
tu
m
o
u
r 
sa
m
p
le
s.
 M
E-
P
C
R
 d
is
p
la
ye
d
 
10
0%
 s
e
n
si
ti
vi
ty
 a
n
d
 9
9%
 s
p
e
ci
fi
ci
ty
; 
H
R
M
 d
is
p
la
ye
d
 1
00
%
 s
e
n
si
ti
iv
ty
 a
n
d
 
sp
e
ci
fi
ci
ty
. I
n
 s
e
ru
m
, M
E-
P
C
R
 
d
e
te
ct
e
d
 5
0%
 o
f 
m
u
ta
n
ts
, H
R
M
 
d
e
te
ct
e
d
 3
3%
.
Li
m
it
e
d
 d
e
te
ct
io
n
 o
f 
o
n
ly
 t
w
o
 
m
u
ta
ti
o
n
s.
91 
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A
u
th
o
rs
M
u
ta
ti
o
n
 T
e
st
in
g 
M
e
th
o
d
(s
)
C
o
m
p
ar
at
o
r 
M
e
th
o
d
(s
)
Sa
m
p
le
 t
yp
e
(s
)
M
u
ta
ti
o
n
s 
A
ss
e
se
d
N
u
m
b
e
r 
o
f 
sa
m
p
le
s
D
N
A
 in
p
u
t 
re
q
u
ir
e
d
Fi
n
d
in
gs
C
o
m
m
e
n
ts
Su
 e
t 
a
l.
 2
01
1
SN
aP
sh
o
t 
m
u
lt
ip
le
x 
P
C
R
 a
ss
ay
 
(L
if
e
 T
e
ch
n
o
lo
gi
e
s)
; a
n
d
 T
ri
p
le
x 
Si
zi
n
g 
A
ss
ay
D
ir
e
ct
 S
e
q
u
e
n
ci
n
g
C
e
ll
 li
n
e
s 
an
d
 F
FP
E
SN
aP
sh
o
t 
as
se
ss
e
d
 3
8 
p
o
in
t 
m
u
ta
ti
o
n
s 
in
 e
ig
h
t 
ge
n
e
s:
 E
G
FR
, K
R
A
S,
 B
R
A
F,
 N
R
A
S,
 
P
IK
3C
A
, M
EK
1,
 A
K
T1
 a
n
d
 P
TE
N
).
 T
ri
p
le
x 
Si
zi
n
g 
A
ss
ay
 a
ss
e
ss
e
d
 E
G
FR
 E
xo
n
 1
9 
D
e
le
ti
o
n
s,
 E
G
FR
 E
xo
n
 2
0 
in
se
rt
io
n
s 
an
d
 
H
ER
2 
Ex
o
n
 2
0 
in
se
rt
io
n
s.
35
 lu
n
g 
ca
n
ce
r 
ce
ll
 
li
n
e
s,
 3
4 
h
e
ad
 
an
d
 n
e
ck
 c
e
ll
 
li
n
e
s,
 7
3 
lu
n
g 
ad
e
n
o
ca
rc
in
o
m
as
.
SN
aP
sh
o
t,
 n
o
t 
st
at
e
d
. 
Tr
ip
le
x 
Si
zi
n
g 
A
ss
ay
 1
n
g.
B
o
th
 a
ss
ay
s 
id
e
n
ti
fi
e
d
 1
00
%
 o
f 
kn
o
w
n
 
m
u
ta
n
t 
sa
m
p
le
s.
 S
N
aP
sh
o
t 
co
u
ld
 
d
e
tc
t 
m
u
ta
n
ts
 a
ll
e
ll
e
s 
fr
o
m
 1
2.
5%
 t
o
 
1.
56
%
 in
 a
 W
T 
b
ac
kg
ro
u
n
d
. L
85
8R
 w
as
 
d
e
te
ct
e
d
 a
t 
1.
09
%
. T
ri
p
le
x 
Si
zi
n
g 
A
ss
ay
 c
o
u
ld
 d
e
te
ct
 m
u
ta
n
ts
 a
t 
6.
25
%
 
to
 1
.5
6%
 in
 a
 W
T 
b
ac
kg
ro
u
n
d
.
SN
aP
sh
o
t 
is
 li
m
te
d
 t
o
 k
n
o
w
n
 
SN
P
s 
o
n
ly
, a
n
d
 t
h
e
 T
ri
p
le
x 
Si
zi
n
g 
A
ss
ay
 c
an
 o
n
ly
 d
e
te
ct
 d
e
le
ti
o
n
s 
o
r 
in
se
rt
io
n
s.
Yo
u
n
g 
et
 a
l. 
20
13
Se
ve
n
 d
if
fe
re
n
t 
m
e
th
o
d
s 
fr
o
m
 1
1 
d
if
fe
re
n
t 
ce
n
tr
e
s 
w
e
re
 a
ss
e
ss
e
d
, 
in
cl
u
d
in
g:
 p
yr
o
se
q
u
e
n
ci
n
g,
 C
O
LD
-
P
C
R
, S
an
ge
r 
Se
q
u
e
n
ci
n
g,
 C
E-
SS
C
A
, A
R
M
S,
 Q
ia
ge
n
 
Th
e
ra
sc
re
e
n
, F
ra
gm
e
n
t 
si
ze
 
an
al
ys
is
.
N
/A
H
19
75
 c
e
ll
 li
n
e
 (
L8
58
R
 c
o
n
tr
o
l)
, 
an
d
 g
e
n
o
m
ic
 D
N
A
 r
e
fe
re
n
ce
 
st
an
d
ar
d
 f
o
r 
Ex
o
n
 1
9 
D
e
le
ti
o
n
s 
(H
o
ri
zo
n
 D
ia
gn
o
st
ic
s,
 U
K
)
EG
FR
 E
xo
n
 1
9 
D
e
le
ti
o
n
 a
n
d
 L
85
8R
.
15
 s
am
p
le
s 
fo
r 
e
ac
h
 o
f 
th
e
 1
1 
p
ar
ti
ci
p
at
in
g 
ce
n
tr
e
s.
N
o
t 
st
at
e
d
A
ll
 c
e
n
tr
e
s 
co
u
ld
 d
e
te
ct
 m
u
ta
n
t 
sa
m
p
le
s 
at
 7
.5
%
, a
n
d
 5
%
 w
as
 a
ch
ie
ve
d
 
b
y 
al
l b
u
t 
o
n
e
 c
e
n
tr
e
. T
h
e
 m
o
st
 
se
n
si
tv
e
 t
e
ch
n
iq
u
e
s 
w
e
re
 
Th
e
ra
sc
re
e
n
, A
R
M
S,
 C
E-
SS
C
A
 a
n
d
 
C
O
LD
-P
C
R
, d
e
te
ct
in
g 
th
e
 m
u
ta
n
ts
 a
t 
1%
.
Sa
n
ge
r 
Se
q
u
e
n
ci
n
g 
w
as
 t
h
e
 le
as
t 
se
n
si
ti
ve
 m
e
th
o
d
. N
o
 f
al
se
 
p
o
si
ti
ve
s 
w
e
re
 r
e
p
o
rt
e
d
.
Yu
an
 e
t 
a
l.
 
20
12
D
xs
 E
G
FR
 M
u
ta
ti
o
n
 K
it
C
o
m
p
ar
e
d
 t
h
e
ir
 M
o
d
if
ie
d
 
P
h
e
n
o
l C
h
lo
ro
fo
rm
 (
M
P
C
) 
e
xt
ra
ct
io
n
 m
e
th
o
d
 w
it
h
 
Q
ia
ge
n
 Q
IA
m
p
 M
in
El
u
te
 
V
ir
u
s 
Sp
in
 K
it
ED
TA
 p
la
sm
a
EG
FR
 E
xo
n
 1
9 
D
e
le
ti
o
n
s
25
N
o
t 
st
at
e
d
R
e
su
lt
s 
w
e
re
 1
00
%
 c
o
n
co
rd
an
t 
w
it
h
 
p
re
vi
o
u
s 
se
q
u
e
n
ci
n
g 
re
su
lt
s.
 H
o
w
e
ve
r 
o
n
ly
 1
/2
5 
sa
m
p
le
s 
w
as
 a
 c
o
n
fi
rm
e
d
 
EG
FR
 m
u
ta
n
t,
 o
th
e
rs
 w
e
re
 a
ll
 
co
n
fi
rm
e
d
 w
il
d
-t
yp
e
.
M
P
C
 m
e
th
o
d
 y
ie
ld
e
d
 C
FD
N
A
 o
f 
h
ig
h
e
r 
co
n
ce
n
tr
at
io
n
 a
n
d
 lo
w
e
r 
fr
ag
m
e
n
ta
ti
o
n
, a
n
d
 g
av
e
 a
 
st
ro
n
ge
r 
C
T 
in
 m
u
ta
n
t 
d
e
te
ct
io
n
 
as
sa
y.
D
ah
se
 e
t 
a
l. 
20
08
B
id
ir
e
ct
io
n
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Chapter Two – Detection 
of EGFR and KRAS mutants 
using the novel GeneFirst™ 
PNA PCR assay 
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2.1 INTRODUCTION 
 
Prior to 1983, the study of DNA was a relatively crude field in its infancy. In order to isolate 
enough DNA for analysis, DNA was extracted in relatively high quantities from cells, as there 
was no way of amplifying the DNA from a small sample. As a result, most DNA research was 
performed using cell lines or tissue samples, as smaller samples would not yield sufficient 
DNA for analysis. In 1983 Kary Mullis developed Polymerase Chain Reaction (Mullis et al., 
1986), also known as PCR, a technique which would go on to  revolutionise molecular biology. 
Kary Mullis went on to receive the Nobel Prize for Chemistry in 1993 for his work on PCR. 
This technique involves manipulation of the properties of DNA and the enzyme DNA 
polymerase, and by cyclically changing the temperature of a mixture of template DNA, DNA 
polymerase enzyme and primers (short DNA oligonucleotides complementary to the genetic 
region of interest) the original DNA sample can be amplified by many orders of magnitude. 
This incredible tool gave scientists the ability to analyse very small samples of DNA, and since 
its invention PCR has been applied in a broad range of applications including: forensics, 
genetics, microbiology, and diagnostic medicine. 
 
As with many molecular biology techniques, PCR has developed through many generations 
since its initial invention, and now there are many different types of PCR designed for 
different applications. Probably the most significant evolution of the technique is what is 
commonly referred to as real-time or quantitative PCR (RT or Q-PCR). The first version of 
PCR, whilst revolutionary, was a qualitative technique, impossible to accurately quantify, and 
vulnerable to reduced sensitivity and specificity under certain circumstances, including the 
presence of inhibitors. 
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Q-PCR was developed in the early 1990s (Holland et al., 1991) (Higuchi et al., 1993), and 
works on the same basic principle as standard PCR, but with the addition of a fluorescent 
intercalating dye SYBR green™ which could be detected in real time (Woo et al., 1998). As 
the technique developed fluorescently tagged molecular probes were introduced as a more 
specific alternative to SYBR green. These probes are similar to primers (short DNA 
oligonucleotides complementary to a specific target DNA sequence) but they additionally 
have a fluorescent “reporter” dye molecule bound to the oligonucleotide. Typically the 
probes also possess a “quencher”, an inhibitor molecule that chemically prevents the 
fluorescent dye from activating. As the probe is incorporated into the synthesised DNA 
molecule (during PCR) the quencher is removed resulting in activation of the reporter dye 
molecule, giving a detectable fluorescent signal (typically under stimulation with UV light or 
a laser). This evolution of the PCR method gives far greater specificity and accuracy, because 
the PCR amplification is not measured simply by the amount of DNA amplified but by the 
fluorescent signal generated by amplification of the specific target region. As a result, the 
measured amplification is less prone to contamination or false-positives/ negatives, and thus 
the assay has improved sensitivity and specificity compared to standard PCR. An additional 
advantage of this technique is it can be quantitative with inclusion of a panel of standards 
run alongside the samples.  
 
The next evolution of PCR has involved the addition of specific inhibitors to further increase 
PCR specificity. This has particular significance in the field cancer gene mutation detection 
from clinical samples. With a clinical sample, for example from a biopsy of a suspected 
cancerous legion, there will be a high degree of heterogeneity in the tissue recovered. With 
any given tumour sample, the percentage of neoplastic cells within the tumour tissue may 
be anywhere between 1 and 100%, meaning the DNA extracted from such a sample will be 
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similarly heterogeneous. With standard PCR or Q-PCR, it is very likely that the wild-type DNA 
will outcompete the mutated DNA during amplification, giving a false negative result. 
 
To counter this, new molecular tools have been developed to suppress the amplification of 
wild-type DNA sequences. Examples include: Scorpions (Thelwell et al., 2000), Peptide 
Nucleic Acids (Nielsen & Egholm, 1999) and Locked Nucleic Acids (Kumar et al., 1998). These 
molecules function in a number of different ways, but essentially they all work to suppress 
the amplification of the wild-type DNA sequences, resulting in the only amplification being 
from the minority mutant DNA population in the mixed sample. A number of commercial 
assays utilising this technology are available (see Introduction) two of which (Qiagen 
Therascreen and Life Technologies castPCR) are in use at UHCW Pathology Department for 
the detection of cancer mutations as part of their diagnostic service. The Scorpion-ARMS 
technology incorporated into the Qiagen assay is shown in figures 2.1.1 and 2.1.2 below. 
 
 
Figure 2.1.1 ARMS primers are designed to match the target mutant DNA sequence. They will not hybridise to 
the wild-type DNA sequence, and thus Taq polymerase will not extend the DNA strand. From (Berninger, 2010). 
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Figure 2.1.2 Diagram showing the mechanism of the Scorpion Primer Probe. Step 1) The Scorpion primer binds 
upstream of the target DNA region. Step 2) The Scorpion primer is extended by DNA polymerase. The copied 
region is complementary to the distal end of the Scorpion prime. The blocking group (black) stops DNA 
polymerase from copying the probe region. Step 3). The newly extended Scorpion primer is denatured by 
increasing temperature. Step 4) As the PCR reaction cools the extended Scorpion primer rearranges and 
hybridises to itself. The fluorophore is now no longer in close proximity to the quencher and subsequently begins 
to fluoresce. Any un-extended Scorpions re-anneal and are quenched. Adapted from (Berninger, 2010). 
 
Peptide Nucleic Acids (PNA) were developed by Nielson and Egholm in 1999 (Nielsen & 
Egholm, 1999). The name PNA is a misnomer, as technically these molecules are not nucleic 
acids, but simulate their binding properties.  PNA have a very simple structure, with their 
main obvious difference to nucleic acid is that they do not possess a pentose ring or 
phosphate groups. Figure 2.1.3 shows the structure of a PNA molecule and a PNA/ DNA 
complex. The backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by 
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amide bonds (Nielsen & Egholm, 1999). The bases (A, T, G, C) are attached to the glycine 
backbone by methyl carbonyl linkages. 
 
 
Figure 2.1.3: Right: PNA molecule. Left: PNA/ DNA duplex. From (Nielsen & Egholm, 1999) 
 
The glycine backbone of the PNA molecule means that the PNA backbone has a neutral 
charge, contrasting with DNA, which is negatively charged. As a result of this there is less 
repulsion between the binding molecules and therefore PNA binds DNA with a higher affinity 
than DNA/ DNA complexes (Egholm et al., 1993). Similar data has also been found for PNA/ 
RNA complexes (Jensen et al., 1997). This higher affinity binding is particular advantageous 
when using PNA as an inhibitor of DNA replication or transcription. PNA also bind DNA with 
a greater specificity than DNA/DNA, which has an obvious advantage in terms of assay design 
for specific targets. Mismatched bases in a PNA/DNA duplex are more destabilising 
compared to an equivalent DNA/DNA duplex (Nielsen & Egholm, 1999), so this reduces the 
chance of false positive results from a partially bound PNA oligomers.  
 
GeneFirst Ltd. (Oxford, UK) developed novel PCR based assays for the detection of EGFR and 
KRAS mutations from Cell Free DNA. The assays were designed to detect 11 EGFR mutations 
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and 7 KRAS mutations with the DNA making up less than 1% of the total DNA sample with 
wild-type DNA as the majority template. The PCR methods used Peptide Nucleic Acids (PNA) 
to block the non-specific amplification of the wild-type DNA, so only the mutant DNA is 
amplified and detected by the assay. Mutant allele amplification is enhanced by the use of 
Locked Nucleic Acid (LNA) oligonucleotides that bind to the mutant alleles and chemically 
stabilise oligonucleotide binding. 
 
This technology represented a potential step forward in EGFR mutant detection, as it was 
predicted to be sufficiently sensitive to detect mutations in cfDNA. Collecting a blood sample 
is a relatively non-invasive procedure, and can be done at the very earliest stage once lung 
cancer investigation has begun. Thus if the test is successful, tailored treatment can begin 
immediately without the need for biopsies which may not be obtainable from the patient 
due to the site of the tumour or co-morbidity. 
 
As a first stage in this investigation, the prototype versions were tested using tissue, as this 
is the current standard method for detecting cancer mutations. If their effectiveness using 
tissue could be proven, then this is a fair validation of their performance, and it would then 
be logical to then move on to testing cfDNA. Another consideration is sample availability. 
Patient plasma samples taken for research were scarce and of limited volume, hence 
decisions about how to best use them had to be carefully considered. Beginning testing of 
these prototype assays with cfDNA would risk wasting precious cfDNA samples until the 
assay conditions are not yet fully optimised. 
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2.1.1 AIMS 
 
 To compare the GeneFirst technology with the existing methods (Qiagen Therascreen 
EGFR RGQ PCR assay and Thermo Fisher KRAS castPCR assay) for the detection of EGFR 
mutations in blood, cytology and formalin-fixed paraffin embedded (FFPE) tumour 
samples. These existing methods (specified above) will be considered the “gold 
standard” for mutation detection in this phase of the project. 
 
 To determine the accuracy of the GeneFirst technology for the detection of KRAS and 
EGFR mutations in plasma versus tissue. 
 
 To determine the compatibility of the GeneFirst assays for use with cell free DNA. 
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2.2 METHODS 
 
2.2.1 Equipment 
 
Bench top centrifuge compatible with 1.5ml micro-centrifuge tubes (up to 15500 x g) 
Bench top centrifuge compatible with 96 well PCR plates (up to 1600g) 
Bench top centrifuge compatible with 0.2 ml PCR strip tubes 
Bench top centrifuge compatible with Ion Torrent sequencing chips (314v2, 316v2 and 
318v2) 
Heat block capable of heating 1.5ml tubes to 70C 
Promega Maxwell Automated Extraction Instrument 
Laminar Flow safety cabinet with UV decontamination feature 
Qubit 2.0 Nucleic Acid Analyser 
Life Technologies ViiA 7 Dx Real Time PCR instrument with Fast 96 well block 
Life Technologies Ion Chef instrument (see figure 2.2.8.3.2) 
Life Technologies Ion Torrent PGM instrument (see figure 2.2.8.3.2) 
Gel Electrophoresis Apparatus and UV imaging equipment 
Millipore water purification system 
 
 
2.2.2 Kits 
 
GeneFirst EGFR PCR kit (prototype, versions 1-5) 
GeneFirst KRAS PCR kit (prototype, versions 1-5) 
Qubit dsDNA High Sensitivity reagent kit 
Promega Maxwell FFPE DNA Kit 
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Promega Maxwell Circulating DNA Kit (prototype) 
Life Technologies Ion AmpliSeq™ Colon and Lung Panel 
Life Technologies Ion AmpliSeq™ Library Kit 2.0 
Life Technologies Ion Express Barcode 1-16 Kit 
Life Technologies Ion Express Barcode 17- 32 Kit 
Life Technologies Ion Torrent PGM Sequencing 200 Kit 
Life Technologies Ion PGM IC 200 Kit 
Life Technologies Oncomine™ Solid Tumour DNA Kit 
 
 
2.2.3 Pathology Department Extracted DNA Samples 
 
Previously extracted DNA samples were collected from UHCW Pathology Department. These 
samples were processed as part of the Department’s routine diagnostic services (EGFR and 
KRAS testing for lung and colorectal cancer, SOP MM RA 19 and SOP MM RA 20).  
 
 
2.2.4 Lung Cancer (NSCLC) Extracted DNA samples 
 
FFPE tissue sample were processed for DNA extraction according to the Pathology 
Department SOP (SOP MM WI 12). Briefly, thin sections from FFPE tumour samples were 
mounted on microscope slides, stained with Hematoxylin and Eosin (HE) and examined by a 
histopathologist. The histopathologist confirmed the type of cancer and staged the disease. 
Samples from patients with confirmed NSCLC and requested for EGFR mutation analysis were 
transferred to the Pathology department molecular team. Here the FFPE sections were 
scraped from the slides and extracted using the Qiagen EZ1 automated extraction platform 
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according the manufacturer’s instructions (Qiagen EZ1 DSP Virus 2.0 kit). DNA samples were 
eluted in 60 µl elution volumes and stored at -20C until ready for molecular analysis. 
 
 
2.2.5 CRC Extracted DNA samples 
 
FFPE tissue sample were processed for DNA extraction according to the Pathology 
Department SOP (SOP MM RA 20). Briefly, thin sections from FFPE tumour samples were 
mounted on microscope slides, stained with Hematoxylin and Eosin (HE) and examined by a 
histopathologist. The histopathologist confirmed the type of cancer, staged the disease and 
marked areas of the slide with high tumour content. Samples from patients with confirmed 
NSCLC and requested for KRAS mutation analysis were transferred to the Pathology 
department molecular team. Here the marked slide from the histopathologist was used to 
manually micro-dissect high tumour content sections from the original FFPE tumour block 
using a disposable 1 mm skin punch. These punched FFPE sections were incubated in lysis 
buffer at 70 C for up to 4 hours to dissolve the paraffin and lyse the cellular material. The 
lysate was then extracted using the Promega Maxwell automated extraction platform using 
the Maxwell FFPE Extraction kit according to manufacturer’s instructions. DNA samples were 
eluted in 60 µl elution volumes and stored at -20 C until ready for molecular analysis. 
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2.2.6 UHCW Pathology Department Mutation Results 
 
2.2.6.1 Qiagen Therascreen EGFR RGQ PCR 
 
The UHCW Pathology Department uses the Qiagen Therascreen EGFR RGQ PCR assay (Qiagen 
Ltd, Manchester, UK) for detection of EGFR mutations in tumour tissue samples. This assay 
detects a total of 29 mutations across EGFR exons 19 to 21, see figure 2.2.6.1. The 
Therascreen assay requires the preparation of eight master mixes (seven mutation detection 
assays and one control assay), giving a total DNA requirement of 80 ng.  The assays were run 
in a Qiagen RotorGene QPCR instrument according to the manufacturer’s instructions, and 
analysed according to manufacturer’s instructions. 
 
Table 2.2.6.1 Mutations tested by Qiagen Therascreen EGFR RGQ PCR Kit, information from Kit Handbook. 
 
 
 
2.2.6.2 Life Technologies KRAS castPCR™ 
 
The UHCW Pathology Department uses an in house KRAS castPCR assay based around a 
custom plate design, validated and performed as recently reported (Bolton et al., 2015), 
Qiagen Therascreen EGFR RGQ PCR Kit 
Mutations detectable against a background of wild-type genomic DNA
19 Deletions in exon 19 (detects mutations but does no distinguish between them)
T790M
L858R
L861Q
G719X (detects G719S, G719A and G719C but does not distinguish between them)
S768I
3 insertions in exon 20 (detects mutations but does no distinguish between them)
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using standard operating procedures. 50 ng of gDNA is required per reaction and up to 6 
samples can be run per plate. The castPCR assay format is a predesigned 96-well plate in 
which the wells are preloaded with the primers and probes for mutation and control assays 
(16 in total), therefore the only reagents that need to be prepared are PCR master mix and 
gDNA from each of the samples to be analysed. Every sample and control must be analysed 
by all 16 assays (20 µl per reaction), and therefore the PCR master mix and gDNA are 
combined and diluted with nuclease free dH2O to achieve the correct concentration and 
volume. The plates run in a Life Technologies ViiA7 instrument (Thermo Fisher Scientific) 
according to manufacturer’s instructions. The mutations that are detectable by the KRAS 
castPCR assay are shown in figure 2.2.6.2. 
 
 
Figure 2.2.6.2: Exert from Life Technologies BRAF KRAS castPCR Kit Handbook showing mutant targets included 
in the assay. 
 
 
Surplus DNA extracts from diagnostic samples which were tested using either the Qiagen 
Therascreen EGFR assay or the Life Technologies KRAS in-house castPCR assay were selected 
for parallel testing with the prototype GeneFirst EGFR and KRAS MMD PCR assays. 
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2.2.7 Quantification of DNA by the Qubit platform 
 
UHCW Pathology Department SOPs include DNA quantification steps using the Nanodrop 
spectrophotometer instrument, which is standard method used in the department. For 
Nanodrop protocol see chapter four methods (section 4.2.4). Extracted DNA samples were 
analysed immediately by BMS staff after extraction where possible. If not possible they were 
stored at -20˚C until ready to be quantified. 
 
As earlier quantification data (from Nanodrop) for the diagnostic DNA extracts was typically 
not straightforward to recover (as it did not constitute part of the diagnostic report), all 
samples were re-quantified using the Qubit 2.0 Nucleic Acid Analyser platform and the Qubit 
High Sensitivity dsDNA kit. The Qubit High Sensitivity dsDNA reagent was diluted 1/200 in 
Qubit High Sensitivity dsDNA buffer to create the working buffer. 199 µl of Qubit working 
buffer was added to 1 µl of an extracted DNA sample in a 0.5 ml optical Qubit tube. After 
brief mixing and centrifuging the tube (containing the working buffer and sample) was 
loaded into the Qubit instrument and measured according to manufacturer’s instructions. 
The DNA quantification measurement was given in ng/ µl. 
 
 
Figure 2.2.7 Qubit 2.0 Nucleic Acid Analyser Instrument. 
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2.2.8 GeneFirst PCR 
 
Extracted DNA samples (from multiple sources, as described above) were analysed for 
mutations in EGFR and KRAS using the novel GeneFirst EGFR and KRAS mutation detection 
assays. 
 
2.2.8.1 GeneFirst EGFR Kit 
 
The assay kit was composed of an enzyme master mix and a series of primer-probe mixtures 
for the detection of specific mutations. The range of mutations that the assay could detect 
expanded over the course of the various assay versions produced by GeneFirst. A table 
showing the assay versions and the mutations they were designed to detect is shown below. 
 
 
Table 2.2.8.1.1: Table showing the range of EGFR mutations detected by versions 1- 5 of the GeneFirst assay. 
 
EGFR
MASTER MIX Version 1 Version 2 Version 3 Version 4 Version 5
19 deletions in 
exon 19
T790M (exon 20) T790M (exon 20) T790M (exon 20) T790M (exon 20)
T790M, L858R L861Q (exon 21) L861Q (exon 21) L861Q (exon 21) G719C (exon 18)
n/a G719C (exon 18) G719C (exon 18) G719C (exon 18) L861Q (exon 21)
n/a G719S (exon 18) G719S (exon 18) G719S (exon 18) G719S (exon 18)
n/a G719A (exon 18) G719A (exon 18) G719A (exon 18) G719A (exon 18)
n/a
2307_2308ins9 
(exon 20)
2307_2308ins9 
(exon 20)
2307_2308ins9 
(exon 20)
2307_2308ins9 
(exon 20)
n/a
2310_2311insGGT 
(exon 20)
2310_2311insGGT 
(exon 20)
2310_2311insGGT 
(exon 20)
2310_2311insGGT 
(exon 20)
n/a
2319_2320ins CAC 
(exon 20)
2319_2320ins CAC 
(exon 20)
2319_2320ins CAC 
(exon 20)
2319_2320ins CAC 
(exon 20)
n/a S768I (exon 20) S768I (exon 20) S768I (exon 20) S768I (exon 20)
n/a L858R (exon 21) L858R (exon 21) L858R (exon 21) L858R (exon 21)
n/a
19 exon 19 
deletions
19 exon 19 
deletions
19 exon 19 
deletions
19 exon 19 
deletions
D
Target Mutations
A
B
C
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Amplification reactions were set up, typically comprising of 10 µl enzyme mix, 8 µl primer-
probe mix and 2 µl gDNA (1-50ng) or 2 µl dH2O (for no template control), total reaction 
volume 20 µl. The exact composition of the reactions varied as the kits were updated by 
GeneFirst. Table 2.2.8.1.2 below shows the reaction compositions over the course of version 
1 to 5 of the EGFR kit. 
 
 
Table 2.2.8.1.2: Reaction compositions over all five versions of the GeneFirst EGFR PCR kit. 
 
 
 
PCR Reactions were run according to manufacturer’s instructions using the Life Technologies 
ViiA7 Real Time PCR platform in 96 well plates (Microamp® Optical 96 well plates). Cycling 
conditions also varied as the kit was updated; table 2.2.8.1.3 shows the cycling conditions 
for version 1 to 5. 
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Table 2.2.8.1.3: Cycling conditions for versions 1- 5 of the GeneFirst EGFR PCR kit. 
 
 
GENEFIRST EGFR ASSAY
Assay Version Cycles Temperature
Duration of 
Cycles
Data Collection
1 95C 9 min
95C 6 sec
52°C 30 sec
72°C 15 sec
93°C 6 sec
56°C 35 sec FAM, VIC, CY5, ROX
60°C 30 sec
50°C 2 min
95°C 9 min
95°C 4 sec
50°C 30 sec
72°C 20 sec
93°C 6 sec
54°C 30 sec FAM, VIC, ROX
60°C 30 sec
50°C 2 min
95°C 8 min
95°C 6 sec
62°C 45 sec
90°C 6 sec
52°C 30 sec
63°C 15 sec
90°C 6 sec
56°C 35 sec FAM, VIC, ROX
60°C 15 sec
1 95°C 3 min
95°C 4 sec
52°C 25 sec
72°C 15 sec
91°C 5 sec
56°C 35 sec FAM, VIC, ROX
60°C 20 sec
50°C 2 min
95°C 3 min
95°C 4 sec
63°C 30 sec
95°C 4 sec
52°C 30 sec
72°C 20 sec
93°C 6 sec
56°C 30 sec FAM, VIC, ROX
60°C 30 sec
10
45
4
10
40
1
1
10
40
3
50
2
1
12
9
5
10
40
1
10
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2.2.8.2 GeneFirst KRAS Kit 
 
The assay kit was composed of an enzyme master mix and a series of primer-probe mixtures 
for the detection of specific mutations. The range of mutations that the assay could detect 
expanded over the course of the various assay version produced by GeneFirst. A table 
showing the assay versions and the mutations they were designed to detect is shown below. 
 
Table 2.2.8.2.1: Table showing the range of KRAS mutations detected by versions 1- 5 of the GeneFirst assay. 
 
 
 
Amplification reactions were set up, typically comprising of 12.5 µl enzyme mix, 8.5 µl 
primer-probe mix and 2 µl gDNA (1-50ng) and 2µl dH2O (4 µl for no template control), total 
reaction volume 25 µl. Reactions were thermo-cycled according to manufacturer’s 
instructions using the Life Technologies ViiA7 Real Time PCR platform. Tables 5 and 6 below 
show the reaction mix compositions and modifications to the cycling conditions for version 
1 to 3 of the KRAS kit. 
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Table 2.2.8.2.2: Reaction composition for version 1-5 of the GeneFirst KRAS PCR Kit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5
REAGENTS (µl)
Taq Mix 10 12.5 10 10 8
KRAS Mix (A, 
B)
5 8.5 8 8 6
dH2O 0-5 3 0 0 to 20 µl
gDNA 1-5 2 2 2 1-6
KRAS Assay Version:
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Table 2.2.8.2.3: Cycling conditions for versions 1- 5 of the GeneFirst KRAS PCR kit. 
 
GENEFIRST KRAS ASSAY
Assay Version Cycles Temperature
Duration of 
Cycles
Data Collection
1 95C 9 min
95C 9 sec
51°C 30 sec
72°C 15 sec
93°C 6 sec
55°C 35 sec FAM, VIC, ROX
60°C 30 sec
50°C 2 min
95°C 3 min
95°C 4 sec
50°C 30 sec
72°C 20 sec
93°C 6 sec
54°C 30 sec FAM, VIC, ROX
60°C 30 sec
50°C 2 min
95°C 8 min
95°C 6 sec
62°C 45 sec
90°C 6 sec
52°C 30 sec
63°C 15 sec
90°C 6 sec
56°C 35 sec FAM, VIC, ROX
60°C 15 sec
50°C 2 min
95°C 8 min
95°C 6 sec
62°C 45 sec
90°C 6 sec
52°C 30 sec
63°C 15 sec
90°C 6 sec
56°C 35 sec FAM, VIC, ROX
60°C 15 sec
50°C 2 min
95°C 3 min
95°C 4 sec
63°C 30 sec
95°C 4 sec
52°C 30 sec
72°C 20 sec
93°C 6 sec
56°C 30 sec FAM, VIC, ROX
60°C 30 sec
50
2
1
3
12
9
40
1
10
40
1
10
5
1
10
10
40
4
1
12
9
40
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Figure 2.2.8.2: Additional analysis algorithm for interpretation of GF KRAS PCR version 5 results. (From 
GeneFirst kit insert) 
 
 
2.2.8.3 Next Generation Sequencing of Tissue DNA 
 
Libraries were prepared from extracted clinical samples using the Life Technologies Ion 
Torrent AmpliSeq™ 200 library kit, according to the manufacturer’s guidelines. Just 10ng of 
template gDNA was used per sample for each of the library preparations. Target regions were 
amplified using the European OncoNetwork Colon and Lung Cancer 22-gene panel which is 
commercially available as the Ion AmpliSeq™ Colon and Lung Panel (ThermoFisher). Figure 
2.2.8.3.1 below gives an overview of the Colon and Lung Panel primer pool.  
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Table 2.2.8.3.1: Specifications of European OncoNetwork 22-gene panel, included in Ion AmpliSeq™ Colon and 
Lung Cancer Panel (from Thermo Fisher OncoNetwork panel booklet). This NGS panel was later included in the 
CE-IVD Oncomine Solid Tumour DNA kit for NGS library preparation. 
 
 
 
The amplified products from each sample were ligated with separate Ion Express barcode 
sequences to enable simple differentiation of the samples by the Ion Torrent platform. The 
libraries were then purified and quantified using The Ion AmpliSeq™ Q-PCR method. 
Quantified libraries were then combined into solutions of equal concentration (three 
samples/ libraries at a time). These were then further processed and loaded onto the Ion 
PGM 314 chips using the Ion Chef platform. The loaded chips were then sequenced using the 
Ion Torrent PGM Instrument. Sequence analysis parameters were set up in advance and 
performed automatically by the Ion Torrent Server running Variant Caller software. Data 
from each library provided a comprehensive output of all mutations detected, included 
known and novel. 
 
Sequencing was performed as previously described (Tops et al., 2015), with the following 
changes to accommodate Ion Chef loading of the Ion Torrent 316 or 314 chips. Stored or 
newly extracted DNA was checked for content and quality using a Qubit 2.0 Fluorometer. 10 
ng of gDNA from each of the samples chosen for NGS analysis was combined with the 
Ampliseq™ reagents and primer pool for the OncoNetwork 22 gene panel (Tops et al., 2015) 
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and amplified for 22 cycles. After initial amplification the amplified products are partially 
digested before Ion Express Adapters and Barcode sequences are ligated to the library 
fragments. Following barcoding the libraries are cleaned up using a magnetic bead method. 
The cleaned up products are then quantified by the AmpliSeq™ Q-PCR method. Once the 
libraries have been successfully quantified they are combined and diluted to 50 pM. For Ion 
Torrent 314 chips, 3 libraries were combined per chip. These library pools were then loaded 
into the Ion Chef instrument for further library preparation and chip loading. The loaded 314 
chips were then run on the Ion Torrent PGM instrument according to manufacturer’s 
instructions. The Variant Caller plugin (including in the provided Ion Suite software) was used 
to analyse the aligned sequence data for the identification of hotspot mutations and novel 
variants. 
 
 
 
Figure 2.2.8.3.2 (Left) Life Technologies Ion Chef Instrument. (Right) Ion Torrent Personal Genome Machine 
(PGM). 
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2.3 RESULTS 
 
Over the course of the project, the GeneFirst EGFR and KRAS PNA/ LNA PCR assay went 
through several developmental versions (five for both the EGFR and KRAS kits), based on 
data and feedback from the project. All versions of the assays were tested from October 
2013 to December 2014 using pre-extracted nucleic acid samples obtained from the 
Pathology Department, UHCW. The samples were all FFPE diagnostic tissue samples from 
lung and colorectal cancer patients, unless otherwise stated. Tables 2.8.1.2, 2.8.1.3, 2.8.2.2 
and 2.8.2.3 in the Methods section shows how the PCR protocol and cycling conditions 
changed with each new version of the assay. 
 
GENEFIRST EGFR ASSAY 
 
A total of 142 tissue sample analyses were performed using various versions of the GeneFirst 
EGFR PCR assay. Since the beginning of the project, the EGFR assay progressed through five 
successive versions. All samples used to test the GeneFirst EGFR Assay were DNA samples 
extracted from tissue. 
 
2.3.1 GF EGFR Assay Version 1 
 
The first version of the assay provided single tube amplification and detection of three 
significant EGFR mutations, using three different fluorescent dyes (FAM, VIC and Cy5). The 
assay also featured an endogenous control for monitor reaction efficiency, which used the 
ROX dye reporter. 
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Table 2.3.1.1 show a summary of the samples tested using the EGFR version 1 assay, and the 
percentage concordance between the currently used Qiagen Therascreen EGFR assay and 
the prototype GeneFirst EGFR assay. The percentage concordance for mutant positive 
samples and wild-type (WT) samples was 68.8% and 60% respectively. 
 
 
Table 2.3.1.1: Summary table showing the concordance % and discrepancy % of the GeneFirst EGFR PCR assay 
version 1.  
 
 
 
Whilst a majority (66.7%) of sample results agreed with the original Therascreen results, 
overall the level of discrepancy was 33.3%, a significant level, and not suitable for diagnostic 
use. The most frequent discrepancy encountered was the occurrence of false positives, 
where mutant samples would give positive results for unexpected mutations, or where WT 
samples would give a positive result. For more results of individual samples run, see chapter 
two appendix, table A2.1.1. 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 11 5 16 68.8
WT 3 2 5 60.0
Totals 14 7 21
Concordance % 66.7
Discrepancy % 33.3
GeneFirst EGFR v1
Th
er
as
cr
ee
n
Sample Concordance %
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l
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Table 2.3.1.2 Endogenous control results from samples tested with EGFR assay version 1. The Mutation Type field 
refers to the results determined by previous testing with the Qiagen Therascreen assay. ROX = ROX reporter 
signal, NTC = No template control, WT = Wild-type. 
 
 
 
Table 2.3.1.2 shows the performance of the endogenous control assay (ROX fluorophore) in 
GF EGFR assay version 1. Of 25 samples, five have given incorrect results, a failure rate of 
20%. All NTC (no template controls) gave a negative signal. 
 
 
ROX
Study ID Mutation type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Assay 
Pass/ Fail
Comments
EGFRv1 01 Exon 19 Del 7.8 30.189 POS PASS
EGFRv1 02 Exon 19 Del 16.0 36.170 POS PASS
EGFRv1 03 Exon 19 Del 16.8 NEG FAIL Endogenous control fail
EGFRv1 04 Exon 19 Del 11.2 NEG FAIL Endogenous control fail
NTC 0.0 NEG PASS
EGFRv1 05 L858R 25.6 32.480 POS PASS
EGFRv1 06 L858R 15.8 NEG FAIL Endogenous control fail
EGFRv1 07 L858R 16.8 NEG FAIL Endogenous control fail
NTC 0.0 NEG PASS
EGFRv1 08 T790M 33.4 23.994 POS PASS
EGFRv1 09 T790M 18.4 29.418 POS PASS
EGFRv1 10 WT 12.0 32.495 POS PASS
EGFRv1 11 WT 9.0 28.436 POS PASS
EGFRv1 12 WT 25.2 29.318 POS PASS
EGFRv1 13 WT 6.0 29.114 POS PASS
EGFRv1 15 T790M + L858R 16.8 31.982 POS PASS
EGFRv1 16 T790M 34.0 29.212 POS PASS
EGFRv1 18 T790M 30.0 30.740 POS PASS
NTC NEG PASS
EGFRv1 17 Exon 19 Del 52.6 30.328 POS PASS
EGFRv1 20 Exon 19 Del 2.5 30.803 POS PASS
NTC NEG PASS
EGFRv1 19 L861Q 1.6 35.811 POS PASS
EGFRv1 21 S768I 13.5 NEG FAIL Endogenous control fail
EGFRv1 14 WT 34.6 30.163 POS PASS
 PCR Pass: 20
PCR Fail: 5
Failure rate: 20.0%
PCR VALIDATION
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2.3.2 GF EGFR Assay Version 2 
 
The second version of the assay expanded the assay's range dramatically. By using four 
separate master mixes, the assay was now able to identify more mutations, see Methods 
table 2.8.1.1. This also meant the assay was more complicated to set up, had a much higher 
volume requirement from the samples and reduced the number of samples that could be 
analysed per 96 well plate. As each sample had to be run in duplicate over four master mixes, 
therefore each sample took up eight wells in the plate, and needed sufficient DNA for all 
reactions to occur optimally. This also posed a significant problem in terms of sourcing 
adequate volumes of sample material. The samples obtained from the Pathology were all 
previously extracted and tested, resulting in the available volumes varying greatly. The 
average remaining volume of the previously tested Pathology lab samples was between 15- 
20 µl, although there was often far less than this remaining. As the EGFR assay required a 
total 16 µl per sample, the limited volumes available made it sometimes impossible to fully 
test many samples. 
 
Table 2.3.2.1 shows the percentage concordance between the currently used Qiagen 
Therascreen EGFR assay and the prototype GeneFirst EGFR assay. The percentage 
concordance for mutant positive samples and wild-type samples was 46.2% and 74.1% 
respectively. A table of the individual samples tested using version of the GeneFirst EGFR 
assay is included in the chapter 2 appendix (table A2.1.2). 
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Table 2.3.2.1: Summary table showing the concordance % and discrepancy % of the GeneFirst EGFR PCR assay 
version 2. WT= Wild-type. 
 
 
 
Overall the more complicated version 2 of the assay achieved a lower % concordance than 
the previous version, 60.4% for version 2 compared to 66.6% in version 1. 
 
 
 
 
 
 
 
 
 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 12 14 26 46.2
WT 20 7 27 74.1
Totals 32 21 53
Concordance % 60.4
Discrepancy % 39.6T
o
ta
l
GeneFirst EGFR v2 Sample Concordance %
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Table 2.3.2.2: Limit Of Detection (LOD) experiments using mutant samples diluted to varying degrees with WT 
samples. The Mutation Type field refers to the results determined by previous testing with the Qiagen 
Therascreen assay. For each reaction mix: green +/- symbols indicate true results, red +/- symbols indicate false 
results. 
 
 
 
In addition to the standard mutation testing, Limit of Detection (LoD) experiments were 
carried out, see table 2.3.2.2. Here a positive sample was diluted using WT samples. These 
diluted samples were run on the assay to assess the Limit of Detection. The version 2 EGFR 
assay achieved a 0.5 ng LoD for sample 48, and 1.5 ng for sample 52, showing a good level of 
sensitivity.  However, the assay also produced a number of false positives in one of master 
mixes for sample 48 (master mix A), and for sample 52 the undiluted sample was not 
detected. 
 
To summarise, version 2 of the EGFR assay showed a promising LoD sensitivity, but still a 
poor specificity owing to a high level of false positives. 
 
 
Study ID Mutation type Dilution DNA (ng)
Result 
(Reaction 
Mix A)
Result 
(Reaction 
Mix D)
Limit of 
Detection
1 15 + +
1/10 1.5 + +
1/20 1 + +
1/50 0.5 - +
1 30 - -
1/10 3 + -
1/20 1.5 + -
1/50 0.6 - -
EGFRv2 48 L858R 0.5 ng
EGFRv2 52 T790M 1.5 ng
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Table 2.3.2.4 Endogenous control results from samples tested with EGFR assay version 2. The Mutation Type 
field refers to the results determined by previous testing with the Qiagen Therascreen assay. NTC = No template 
control, WT = Wild-type. 
 
 
 
Table 2.3.2.4 shows the performance of the ROX endogenous control assay for all individual 
samples tested with the GF EGFR assay version 2. All samples gave the expected results 
(samples ROX positive, NTC ROX negative).  
 
 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Controls 
Pos/ Neg
Assay 
Pass/ Fail
Study ID
Mutation 
type
DNA (ng, 
total)
Controls 
Pos/ Neg
Assay 
Pass/ Fail
EGFRv2 10 T790M 18.40 POS PASS EGFRv2 31 WT 0.52 POS PASS
EGFRv2 14 T790M 16.40 POS PASS EGFRv2 32 WT 73.92 POS PASS
EGFRv2 12 L861Q 25.20 POS PASS EGFRv2 33 WT 22.56 POS PASS
EGFRv2 09 WT 25.60 POS PASS EGFRv2 34 WT 4.14 POS PASS
EGFRv2 51 L858R 16.80 POS PASS EGFRv2 35 WT 9.86 POS PASS
EGFRv2 16 L858R 9.00 POS PASS NTC NEG PASS
EGFRv2 08 WT 7.80 POS PASS EGFRv2 36 WT 0.36 POS PASS
EGFRv2 01 Exon 19 Del 16.00 POS PASS EGFRv2 37 Exon 19 Del 0.43 POS PASS
EGFRv2 02 Exon 19 Del 16.80 POS PASS EGFRv2 38 Exon 19 Del 1.64 POS PASS
EGFRv2 03 Exon 19 Del 16.80 POS PASS EGFRv2 39 G719X 1.06 POS PASS
NTC NEG PASS NTC NEG PASS
EGFRv2 13 T790M 80.00 POS PASS EGFRv2 40 WT 2.34 POS PASS
EGFRv2 11 T790M 80.00 POS PASS EGFRv2 41 WT 17.68 POS PASS
EGFRv2 06 T790M 18.40 POS PASS EGFRv2 42 WT 1.39 POS PASS
EGFRv2 07 T790M 18.40 POS PASS EGFRv2 43 WT 37.40 POS PASS
EGFRv2 50 L858R 25.60 POS PASS EGFRv2 44 WT 25.90 POS PASS
EGFRv2 05 L858R 16.80 POS PASS EGFRv2 45 WT 23.00 POS PASS
NTC NEG PASS EGFRv2 47 WT 31.40 POS PASS
EGFRv2 17 Exon 19 Del 56.96 POS PASS NTC NEG PASS
EGFRv2 18 S768I 13.80 POS PASS EGFRv2 46 WT 30.00 POS PASS
EGFRv2 19 WT 34.60 POS PASS NTC NEG PASS
EGFRv2 20 L858R 15.80 POS PASS EGFRv2 49 L858R 2.80 POS PASS
EGFRv2 21 WT 12.00 POS PASS EGFRv2 04 L858R 1.50 POS PASS
EGFRv2 22 WT 0.48 POS PASS EGFRv2 48 L858R 1.00 POS PASS
EGFRv2 23 WT 0.40 POS PASS EGFRv2 15 L858R 0.50 POS PASS
EGFRv2 24 WT 0.40 POS PASS NTC NEG PASS
EGFRv2 25 WT 15.32 POS PASS EGFRv2 55 T790M 30.00 POS PASS
EGFRv2 26 WT 0.32 POS PASS EGFRv2 52 T790M 3.00 POS PASS
EGFRv2 27 WT 18.00 POS PASS EGFRv2 53 T790M 1.50 POS PASS
NTC NEG PASS EGFRv2 54 T790M 0.60 POS PASS
EGFRv2 28 WT 2.90 POS PASS  PCR Pass: 63
EGFRv2 29 WT 39.20 POS PASS PCR Fail: 0
EGFRv2 30 WT 2.88 POS PASS Failure rate: 0.0%
PCR VALIDATION PCR VALIDATION
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2.3.3 GF EGFR Assay Version 3 
 
Version 3 of the EGFR assay retained the same expanded panel of mutations and four master 
mix format. Where possible, samples that had been previously tested on version 2 were re-
tested on version 3, although this was not possible in a number of cases due to the very low 
volume of original sample. There was also a severely limited input of new samples, due to 
the generally low occurrence of EGFR positive samples processed by the Pathology 
Department. There was also a period where the Pathology Department temporarily 
suspended its EGFR testing service, which resulted in a complete absence of new samples 
during this period. 
 
Table 2.3.3.1: Summary table showing the concordance % and discrepancy % of the GeneFirst EGFR PCR assay 
version 3. WT= Wild-type. 
 
 
 
Table 2.3.3.1 shows the levels of concordance and discrepancy in version 3 of the assay to 
be 39.1% and 60.9% respectively. Compared to version 2 this represents a 21.3% reduction 
in concordance with the original Therascreen results. For the individual concordant and 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 5 11 16 31.3
WT 4 3 7 57.1
Totals 9 14 23
Concordance % 39.1
Discrepancy % 60.9T
o
ta
l
GeneFirst EGFR v3 Sample Concordance %
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discrepant sample results tested by version 3 of the EGFR assay, see chapter two appendix, 
table A2.1.3. 
 
In addition to the low concordance with Therascreen, another problem with the GeneFirst 
EGFR assay appeared in version 3. In many analysis runs, the No Template Control (NTC) 
negative control samples started giving a positive signal for the endogenous control (ROX 
channel). This was initially considered to be accidental user contamination; however 
successive repeats and reactions prepared with only master mix (i.e. reagents only, no DNA 
or nuclease free water) continued to produce this endogenous control positive signal. 
Examples of these experiments are shown in chapter two appendix, section A2.1 table A2.1.6 
and figure A2.1. 
 
To further investigate this phenomenon the PCR products from the no template control 
experiments were run on an agarose gel and examined under UV to assess the presence of 
primer dimers or additional amplicons. Figure 2.3.3 shows the gel image from this analysis, 
there is no evidence of primer dimers or amplicons, suggesting that the signals detected in 
the ROX channel may be due to technical reasons associated with the ROX probe. 
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Figure 2.3.3 Image of GF EGFR version 3 assay PCR products run on a 2% agarose gel, visualised under UV. The 
loading wells are located towards the top of the image, above to the 1000 bp ladder position. There is no evidence 
of primer dimers or amplicons on the gel. 
 
Table 2.3.3.2 Endogenous control results from samples tested with EGFR assay version 3. Ct values from failed 
assays are highlighted in red. Cells containing anomalous Ct values from reactions where no template was loaded 
are given a black border. ROX A = ROX reporter signal in master mix A, ROX B = ROX reporter signal in master mix 
B, ROX C = ROX reporter signal in master mix C, ROX D = ROX reporter signal in master mix D, NTC = No template 
control, WT = Wild-type. 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct 
Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay 
Pass/ Fail
EGFRv3 01 T790M 60.0 24.447 POS 28.650 POS 26.799 POS 33.274 POS FAIL
EGFRv3 02 T790M 36.8 20.186 POS 22.001 POS 19.317 POS 20.538 POS FAIL
EGFRv3 03 T790M 18.4 23.493 POS 28.560 POS 27.294 POS 27.982 POS FAIL
EGFRv3 04 L858R 5.6 21.690 POS 22.663 POS 20.723 POS 25.888 POS PASS
EGFRv3 05 Exon 19 Del 113.9 24.932 POS 25.520 POS 23.605 POS 24.894 POS PASS
EGFRv3 07 T790M 78.5 23.036 POS 23.281 POS 21.714 POS 22.860 POS PASS
EGFRv3 06 T790M 26.2 23.148 POS 23.892 POS 21.595 POS 23.401 POS PASS
EGFRv3 10 WT 10.0 29.009 POS 29.328 POS 26.388 POS 28.136 POS PASS
EGFRv3 08 WT 149.6 27.130 POS 27.096 POS 24.678 POS 24.805 POS PASS
EGFRv3 09 WT 74.8 24.813 POS 24.921 POS 23.063 POS 24.461 POS PASS
NTC - 0.0 34.240 POS 30.036 POS 27.992 POS 29.199 POS FAIL
EGFRv3 11 WT 207.2 35.255 POS 35.672 POS 35.183 POS 38.240 POS PASS
EGFRv3 12 WT 51.8 26.392 POS 27.146 POS 23.619 POS 27.247 POS FAIL
EGFRv3 13 Exon 19 Del 0.9 27.652 POS 28.320 POS 30.154 POS 27.278 POS PASS
EGFRv3 14 WT 69.2 27.787 POS 28.284 POS 30.979 POS 29.106 POS PASS
EGFRv3 15 L858R 16.8 28.108 POS 29.497 POS 27.319 POS 27.026 POS PASS
EGFRv3 16 WT 0.6 28.226 POS 29.567 POS 26.735 POS 29.208 POS FAIL
EGFRv3 22 Exon 19 Del 1.7 24.157 POS 23.661 POS 23.181 POS 25.761 POS PASS
EGFRv3 23 L861Q 60.8 24.095 POS 22.743 POS 21.010 POS 22.895 POS PASS
EGFRv3 24 L858R 16.2 25.160 POS 25.153 POS 23.504 POS 35.112 POS PASS
EGFRv3 25 L861Q 0.9 29.923 POS 29.469 POS 32.514 POS 29.910 POS PASS
EGFRv3 26 Exon 19 Del 18.2 24.120 POS 24.460 POS 22.697 POS 27.985 POS PASS
NTC - 0.0 31.221 POS 30.389 POS 28.150 POS POS FAIL
NTC - 0.0 29.802 POS NEG 31.689 POS 29.680 POS FAIL
EGFRv3 27 L861Q 60.8 24.113 POS 22.617 POS 27.248 POS 27.705 POS PASS
EGFRv3 28 L861Q 0.9 31.556 POS 29.056 POS 28.673 POS 29.838 POS PASS
NTC - 0.0 30.716 POS 29.824 POS 28.719 POS 32.390 POS FAIL
 PCR Pass: 18
PCR Fail: 9
Failure rate: 33.3%
ROX A ROX B ROX C ROX D
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Table 2.3.3.2 shows the results from the ROX endogenous control assay for all samples tested 
with GF EGFR assay version 3. 9/18 samples failed the control assay in at least one master 
mix. The strangest results are those where no template was added (cells given a black 
border), as these would be expected to be negative. 
 
 
2.3.4 GF EGFR Assay Version 4 
 
Version 4 of the EGFR assay saw a minor improvement in concordance with the Therascreen 
results. Overall concordance was 46.67% which is a higher level of concordance than was 
achieved by version 3 (39.12%), however less samples were available for testing in version 4 
(23 samples for version 3, 15 samples for version 4). The results for the individual samples 
tested can be found in table A2.1.4 (chapter two appendix). 
 
Table 2.3.4.1 shows a breakdown of concordance across the mutant and wild-type samples 
tested. The assay gave 100% concordance with the wild-type samples tested, however only 
two samples were tested. The recurring problem of false positives/ discrepant results with 
mutant samples from previous versions of the assay were also present in this version: 8 of 
13 mutant samples gave discrepant results compared to the original Therascreen results. 
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Table 2.3.4.1: Summary table showing the concordance % and discrepancy % of the GeneFirst EGFR PCR assay 
version 4. WT = Wild-type. 
 
 
 
Table 2.3.4.2 Endogenous control results from samples tested using EGFR assay version 4. Anomalous Ct values 
are highlighted in red. ROX A = ROX reporter signal in master mix A, ROX B = ROX reporter signal in master mix B, 
ROX C = ROX reporter signal in master mix C, ROX D = ROX reporter signal in master mix D, NTC = No template 
control, WT = Wild-type. 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 5 8 13 38.5
WT 2 0 2 100.0
Totals 7 8 15
Concordance % 46.7
Discrepancy % 53.3T
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GeneFirst EGFR v4 Sample Concordance %
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Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
EGFRv4 14 Exon 19 Del 57.0 19.831 POS 19.702 POS 18.486 POS 18.643 POS PASS
EGFRv4 02 T790M 78.5 17.395 POS 17.309 POS 18.557 POS 17.336 POS PASS
EGFRv4 03 Exon 19 Del 1.7 22.789 POS 22.314 POS 20.506 POS 20.236 POS PASS
EGFRv4 04 WT 35.6 21.595 POS 21.207 POS 20.252 POS 20.446 POS PASS
EGFRv4 05 T790M 17.5 18.669 POS 18.435 POS 17.422 POS 18.061 POS PASS
EGFRv4 06 L858R 33.6 22.201 POS 21.722 POS 20.234 POS 20.625 POS PASS
EGFRv4 07 L858R 2.6 18.764 POS 19.072 POS 17.842 POS 18.491 POS PASS
EGFRv4 08 L858R 1.3 19.160 POS 19.187 POS 17.898 POS 19.160 POS PASS
EGFRv4 09 L858R 0.5 19.162 POS 18.942 POS 17.996 POS 19.144 POS PASS
NTC 0.0 21.906 POS 21.865 POS 20.648 POS 20.559 POS FAIL
NTC 0.0 22.430 POS 21.692 POS 20.556 POS 20.680 POS FAIL
NTC 0.0 22.178 POS 21.766 POS 20.885 POS 20.693 POS FAIL
EGFRv4 10 Exon 19 Del 32.2 24.345 POS 27.789 POS 25.152 POS 26.784 POS PASS
EGFRv4 11 Exon 19 Del 11.2 24.005 POS 28.999 POS 25.936 POS 27.874 POS PASS
EGFRv4 12 Exon 19 Del 16.8 24.010 POS 29.503 POS 26.360 POS 28.560 POS PASS
EGFRv4 13 L858R 31.6 24.134 POS 29.316 POS 26.196 POS 28.800 POS PASS
EGFRv4 01 Exon 19 Del 13.4 22.885 POS 25.216 POS 22.221 POS 23.619 POS PASS
EGFRv4 15 WT 30.6 23.859 POS 27.863 POS 22.899 POS 23.564 POS PASS
NTC 0.0 24.278 POS 32.091 POS 26.994 POS 31.514 POS FAIL
NTC 0.0 23.602 POS 32.112 POS 26.228 POS 30.334 POS FAIL
 PCR Pass: 15
PCR Fail: 5
Failure rate: 25.0%
ROX A ROX B ROX C ROX D
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Table 2.3.4.2 shows the results of the ROX endogenous control from the GF EGFR assay 
version 4. In this set of samples all the NTCs failed the ROX endogenous control assay, 
including two ‘blank’ samples (reactions prepared without addition of water as a substitute 
for sample i.e. taq mix and primer/ probe mix only). This strongly suggests an issue with one 
or both of the assays reagents. All samples gave positive signals in the endogenous control 
assay. Unlike the testing of the previous assay version, all samples had sufficient volume to 
test all master mixes, however the validity of these results cannot be assessed due to the 
positive signals given by the NTCs. 
 
 
2.3.5 GF EGFR Assay Version 5 
 
Version 5 was the final version of the EGFR assay made available by GeneFirst for this project. 
30 samples were tested, 11 wild-types and 19 mutants. Unfortunately all the samples panel 
either contained very low remaining sample volume (after routine testing by the Pathology 
department) or were of low DNA concentration. 12 samples (11 wild-type and 1 mutant) 
contained DNA concentrations that were below the level which could be accurately 
quantified by the Qubit instrument. The results for the individual samples tested with this 
final version of the assay can be found in table A2.1.5 (chapter two appendix). Some samples 
are indicated with “Unknown (low)” in the DNA loading field of the table.  
 
Overall concordance with the original Therascreen results for this version of the assay was 
26.67%. This is a reduction of 20% compared to version 4. A breakdown of the results are 
shown in table 2.3.5.1. Despite this being the most recent version of the assay, the 
performance of the assay was poorer than the previous two versions. Again, the persistent 
issue of false positive/ discrepant results were a feature of the version 5 dataset. Only 2 of 
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17 (10.5%) mutant samples and 6 of 11 (55%) wild-type samples matched the original 
Therascreen results.  
 
 
Table 2.3.5.1: Summary table showing the concordance % and discrepancy % of the GeneFirst EGFR PCR assay 
version 5. WT = Wild-type. 
 
 
 
To accurately assess the performance of version 5 of the EGFR assay, the data was reanalysed 
to examine the results given by each of the assays four separate reaction master mixes. The 
EGFR assay consisted of four master mixes, with each mix using two reporter fluorophores 
(VIC and FAM, linked to mutant target probes) therefore it was possible to generate eight 
signals per sample. From our dataset of 30 samples, it is therefore possible to have up to 
generate 240 PCR signals across the eight reactions. The results from all four master mixes 
are shown in table 2.3.5.2. In total there were 125 signals detected, of which 41 (32.8%) were 
either false positives or false negatives. Of the individual master mixes, the data suggests 
that master mix C performed the best, with only 5 false results, whereas master mix D 
performed the worst, with 19 false results. 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 2 17 19 10.5
WT 6 5 11 54.5
Totals 8 22 30
Concordance % 26.7
Discrepancy % 73.3T
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Table 2.3.5.2: Complete analysis of PCR results from all GF EGFRv5 master mixes. Designations ‘True Positive’, 
‘True Negative’, ‘False Positive’ and ‘False Negative’ are assigned based on the original Therascreen results. 
 
 
 
The data from table 2.2.5.2 was used to calculate the sensitivity and specificity of the version 
5 assay. The results of these calculations are shown in table 3.2.5.3. The GF EGFR version 5 
assay achieved a sensitivity and specificity of 68.2% and 67.0% respectively.  
 
 
 
 
 
 
 
A B C D
True 
Pos
True 
Neg
False 
Pos
False 
Neg
EGFRv5 09 Exon 19 Del FALSE POS TRUE NEG TRUE NEG TRUE POS 1 2 1 0
EGFRv5 01 Exon 20 Ins TRUE NEG TRUE NEG TRUE POS FALSE POS 1 2 1 0
EGFRv5 02 L861Q and G719X FALSE NEG TRUE POS x2 TRUE NEG FALSE POS 2 1 1 1
EGFRv5 03 Exon 19 Del TRUE NEG TRUE NEG TRUE NEG TRUE POS 1 3 0 0
EGFRv5 04 T790M FALSE NEG FALSE POS TRUE NEG FALSE POS 0 1 2 1
EGFRv5 05 L861Q TRUE NEG
TRUE POS, FALSE 
POS
TRUE NEG FALSE POS 1 2 2 0
EGFRv5 06 L858R TRUE NEG FALSE POS FALSE POS FALSE NEG 0 1 2 1
EGFRv5 07 T790M FALSE NEG FALSE POS TRUE NEG FALSE POS 0 1 2 1
EGFRv5 08 S768I TRUE NEG TRUE NEG TRUE POS FALSE POS 1 2 1 0
EGFRv5 18 Exon 19 Del TRUE NEG TRUE NEG TRUE NEG TRUE POS 1 3 0 0
EGFRv5 10 Exon 20 Ins TRUE NEG TRUE NEG TRUE POS FALSE POS x2 1 2 2 0
EGFRv5 11 L861Q and G719X
FALSE POS, 
FALSE NEG
TRUE POS x2 TRUE NEG FALSE POS 2 1 2 1
EGFRv5 12 Exon 19 Del TRUE NEG FALSE POS TRUE NEG TRUE POS 1 2 1 0
EGFRv5 13 T790M FALSE NEG TRUE NEG TRUE NEG FALSE POS 0 2 1 1
EGFRv5 14 L861Q TRUE NEG TRUE POS TRUE NEG FALSE POS 1 2 1 0
EGFRv5 15 L858R FALSE POS FALSE POS TRUE NEG FALSE POS 0 1 3 0
EGFRv5 16 T790M TRUE POS TRUE NEG TRUE NEG FALSE POS 1 2 1 0
EGFRv5 17 S768I TRUE NEG TRUE NEG TRUE POS FALSE POS 1 2 1 0
EGFRv5 21 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
EGFRv5 22 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
EGFRv5 23 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
EGFRv5 19 WT FALSE POS TRUE NEG TRUE NEG FALSE POS 0 2 2 0
EGFRv5 20 Del TRUE NEG TRUE NEG TRUE NEG FALSE NEG 0 3 0 1
EGFRv5 24 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
EGFRv5 29 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
EGFRv5 25 WT TRUE NEG FALSE POS FALSE POS TRUE NEG 0 2 2 0
EGFRv5 26 WT TRUE NEG TRUE NEG FALSE POS FALSE POS 0 2 2 0
EGFRv5 27 WT TRUE NEG FALSE POS FALSE POS FALSE POS 0 1 3 0
EGFRv5 28 WT TRUE NEG TRUE NEG FALSE POS TRUE NEG 0 3 1 0
EGFRv5 30 WT TRUE NEG TRUE NEG TRUE NEG TRUE NEG 0 4 0 0
TRUE 22 25 23 12
FALSE 9 7 5 19
ResultGF EGFRv5 PCR Master Mix
Study ID
Mutation 
type
Totals: 15 69 34 7
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Table 2.3.5.3: Summary of GF EGFR version 5 data. 
 
  
GeneFirst EGFR Assay version 5
Test Mutant Present Mutant absent
Positive True Positive 15 False Positive 34
Negative False Negative 7 True Negative 69
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
68.2%
67.0%
30.6%
90.8%
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Table 2.3.5.4 Endogenous control results from samples tested using the EGFR version 5 assay. Samples with DNA 
concentrations below the lower quantifiable range were designated ‘unknown’. ROX A = ROX reporter signal in 
master mix A, ROX B = ROX reporter signal in master mix B, ROX C = ROX reporter signal in master mix C, ROX D 
= ROX reporter signal in master mix D, NTC = No template control, WT = Wild-type. 
 
 
 
Table 2.3.5.4 shows the results for the endogenous control assay for all samples tested using 
the GF EGFR assay version 5. In total 9/ 25 samples failed the endogenous control in at least 
one master mix, resulting in a failure rate of 26.5%. Of the NTCs, only 1/4 failed which showed 
an improvement on the results from version 4 of the assay.  
 
By the end of the investigation, 142 FFPE tissue samples had been tested using the five 
versions of the GF EGFR assays. A summary of the testing is shown in table 2.3.5.5. Overall 
Study ID Mutation type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
EGFRv5 01 Exon 19 Del 30 23.134 POS 28.003 POS 25.352 POS 24.045 POS PASS
EGFRv5 02 Exon 20 Ins 30 21.175 POS 25.900 POS 22.624 POS 23.324 POS PASS
EGFRv5 03 L861Q and G719X 30 NEG 31.618 POS 26.254 POS 28.079 POS FAIL
EGFRv5 04 Exon 19 Del 30 21.406 POS 26.556 POS 23.608 POS 25.294 POS PASS
EGFRv5 05 T790M 30 22.427 POS 27.174 POS 22.891 POS 23.724 POS PASS
EGFRv5 06 L861Q 30 22.427 POS 27.211 POS 23.094 POS 25.043 POS PASS
EGFRv5 07 L858R 30 NEG NEG 35.664 POS NEG FAIL
EGFRv5 08 T790M 30 22.169 POS 27.137 POS 23.467 POS 24.119 POS PASS
EGFRv5 09 S768I 30 23.633 POS 29.029 POS 25.153 POS 25.799 POS PASS
NTC 0 NEG NEG NEG NEG PASS
EGFRv5 10 Exon 19 Del 15 22.997 POS 27.510 POS 24.121 POS 24.274 POS PASS
EGFRv5 11 Exon 20 Ins 15 21.364 POS 25.800 POS 22.607 POS 23.523 POS PASS
EGFRv5 12 L861Q and G719X 15 21.782 POS 27.274 POS 23.397 POS 24.312 POS PASS
EGFRv5 13 Exon 19 Del 15 22.673 POS 27.365 POS 24.074 POS 24.663 POS PASS
EGFRv5 14 T790M 15 20.775 POS 25.400 POS 22.101 POS 23.096 POS PASS
EGFRv5 15 L861Q 15 22.766 POS 27.961 POS 23.937 POS 24.853 POS PASS
EGFRv5 16 L858R 15 26.743 POS 39.233 POS 27.878 POS 36.766 POS PASS
EGFRv5 17 T790M 15 20.693 POS 25.101 POS 21.914 POS 22.526 POS PASS
EGFRv5 18 S768I 15 22.614 POS 27.341 POS 23.800 POS 24.778 POS PASS
NTC 0 NEG NEG NEG NEG PASS
EGFRv5 19 WT Unknown 23.298 POS 29.563 POS NEG NEG FAIL
EGFRv5 20 WT Unknown 24.694 POS NEG NEG NEG FAIL
EGFRv5 21 WT Unknown 27.948 POS NEG 17.898 POS 20.483 POS FAIL
EGFRv5 22 WT Unknown 16.599 POS 22.002 POS 18.245 POS 18.875 POS PASS
EGFRv5 23 Del Unknown 16.897 POS 22.018 POS NEG NEG FAIL
EGFRv5 24 WT Unknown 25.133 POS NEG NEG NEG FAIL
NTC 0 NEG NEG 39.173 POS NEG FAIL
EGFRv5 25 WT Unknown 17.268 POS 23.712 POS 18.924 POS 22.147 POS PASS
EGFRv5 26 WT Unknown 22.769 POS 34.479 POS 28.061 POS NEG PASS
EGFRv5 27 WT Unknown 20.868 POS 28.288 POS 22.299 POS 26.968 POS PASS
EGFRv5 28 WT Unknown 22.383 POS 33.795 POS 28.589 POS 33.378 POS PASS
EGFRv5 29 WT Unknown 23.426 POS NEG 30.235 POS 38.301 POS PASS
EGFRv5 30 WT Unknown 27.161 POS NEG NEG NEG FAIL
NTC 0 NEG NEG NEG NEG PASS
 PCR Pass: 25
PCR Fail: 9
Failure rate: 26.5%
ROX A ROX B ROX C ROX D
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49.3% of results matched the original Therascreen results. The assays generally worked 
better with wild-type samples, which were concordant with the original results in 67.3% of 
cases, whereas only 38.9% of mutant samples matched the original results. The relatively 
low sensitivity and specificity of the GF EGFR assays is reflected in the relatively low level of 
concordance seen in this phase of the project. 
 
 
Table 2.3.5.5: Summary table showing the concordance % and discrepancy % of all the samples tested with the 
GeneFirst EGFR PCR assay versions 1- 5. WT = Wild-type. 
 
 
 
GENEFIRST KRAS ASSAY 
 
2.3.6 GF KRAS Assay Version 1 
 
Unlike version 1 of the EGFR assay, version 1 of the KRAS assay started by utilising multiple 
master mixes for mutant detection. The assay was designed to detect a total of eight KRAS 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 35 55 90 38.9
WT 35 17 52 67.3
Totals 70 72 142
Concordance % 49.3
Discrepancy % 50.7
GeneFirst EGFR v1 - 5 Sample Concordance %
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mutants using two master mixes. The mutations could not be distinguished, so a positive 
result on a particular master mix indicated that a mutation was present, but did not specify 
the exact type of mutation. All samples used to test the GeneFirst KRAS Assay were DNA 
samples extracted from tissue. The mutation detection results of the individual samples 
tested can be found in table A2.2.1 (appendix). 
 
Table 2.3.6.1 shows a summary of the assays performance. Version 1 of the KRAS assay 
achieved 88.9% concordance with the original KRAS castPCR results, and 11.1% discrepancy. 
This performance is significantly better than the performance of version 1 of the EGFR assay. 
All wild-type samples were correctly identified, although only three such samples were 
tested with KRAS version 1. 
 
 
Table 2.3.6.1: Summary table showing the concordance % and discrepancy % of the GeneFirst KRAS PCR assay 
version 1. WT = Wild-type. 
 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 13 2 15 86.7
WT 6 0 6 100.0
Totals 19 2 21
Concordance % 90.5
Discrepancy % 9.5T
o
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GeneFirst KRAS v1 Sample Concordance %
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Table 2.3.6.3 Endogenous control results from samples tested using the KRAS assay version 1. N.B. Not all samples 
analysed using both master mixes (see “PCR MM” column for the master mixes used). MM = Master Mix, NTC = 
No template control, WT = Wild-type. 
 
 
 
Table 2.3.6.3 shows the ROX endogenous control results for the GF KRAS assay version 1. All 
6/6 NTC samples gave a positive signal in the ROX channel, despite there being no template 
DNA included in any of these reactions. This strongly suggests some form of technical error 
occurring in one or more of the PCR reagents. Due to these results, testing of this version of 
the assay was suspended. 
 
Study ID
Mutation 
type
PCR MM
DNA (ng, 
total)
ROX Ct 
(Mean)
Control Pos/ 
Neg
Assay Pass/ 
Fail
Comments
KRASv1 01 G12A A 30.0 27.480 POS PASS
KRASv1 02 G12A A 30.0 38.177 POS PASS
KRASv1 03 WT A 30.0 31.139 POS PASS
KRASv1 04 G12A A 30.0 33.404 POS PASS
NTC A 0.0 20.110 POS FAIL NTC ROX positive
KRASv1 08 G12A A 15.0 13.548 POS PASS
KRASv1 09 G12D A 15.0 23.656 POS PASS
KRASv1 10 G12A A 15.0 21.449 POS PASS
KRASv1 11 WT A 15.0 39.682 POS PASS
NTC A 0.0 20.469 POS FAIL NTC ROX positive
KRASv1 12 G12A A 7.5 25.088 POS PASS
KRASv1 13 G12D A 7.5 29.343 POS PASS
KRASv1 14 G12A A 7.5 29.145 POS PASS
KRASv1 15 WT A 7.5 42.462 POS PASS
NTC A 0.0 20.469 POS FAIL NTC ROX positive
KRASv1 05 WT B 30.0 NEG FAIL Endogenous control fail
KRASv1 06 G12C B 30.0 39.276 POS PASS
KRASv1 07 G12V B 30.0 19.388 POS PASS
NTC B 0.0 22.871 POS FAIL NTC ROX positive
KRASv1 16 G12C B 15.0 31.276 POS PASS
KRASv1 17 G12V B 15.0 26.656 POS PASS
KRASv1 18 WT B 15.0 25.421 POS PASS
NTC B 0.0 11.160 POS FAIL NTC ROX positive
KRASv1 19 G12C B 7.5 33.603 POS PASS
KRASv1 20 G12V B 7.5 28.944 POS PASS
KRASv1 21 WT B 7.5 9.370 POS PASS
NTC B 0.0 11.160 POS FAIL NTC ROX positive
 PCR Pass: 20
PCR Fail: 7
Failure rate: 25.9%
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2.3.7 GF KRAS Assay Version 2 
 
Version 2 of the GeneFirst KRAS assay did not expand its capabilities to detect new 
mutations, but the master mixes were redesigned so the mutations were redistributed (see 
chapter two methods table 2.2.8.2). Table A2.2.2 (appendix) shows all the concordant and 
discrepant samples tested using version 2. Here more wild-type samples were tested to 
validate the specificity of the assay. 
 
Table 2.3.7.1 shows a summary of the assays performance. Version 2 of the KRAS assay 
achieved 63.3% concordance with the original KRAS castPCR results, and 36.7% discrepancy. 
Version 2 performed significantly worse than version 1. All wild-type samples were correctly 
identified, displaying 100% concordance with the original KRAS castPCR results. All the 
discrepant samples came from the mutant samples, either due to the mutations not being 
detected or additional unexpected mutations would be present. 
 
To test the LoD of the KRAS version 2 assay, positive samples were diluted in the same 
manner as the EGFR LoD experiments (see section 2.3.2.2). Serial dilutions were prepared, 
reaching 1% at the low end. The KRAS version 2 assay performed well, detecting both 
mutants at 0.6 ng of DNA input. Unfortunately there were also some false positive signals 
detected in the other KRAS PCR master mix, see table 2.3.7.2. 
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Table 2.3.7.1: Summary table showing the concordance % and discrepancy % of the GeneFirst KRAS PCR assay 
version 2. WT = Wild-type. 
 
 
 
Table 2.3.7.2: Limit Of Detection (LoD) experiments using mutant samples diluted to varying degrees with WT 
samples. For each reaction mix: green +/- symbols indicate true results, red +/- symbols indicate false results. 
 
 
 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 16 12 28 57.1
WT 11 0 11 100.0
Totals 27 12 39
Concordance % 69.2
Discrepancy % 30.8T
o
ta
l
GeneFirst KRAS v2 Sample Concordance %
C
A
ST
Sample Name Mutation type Dilution
DNA (ng, 
total)
Result 
(Reaction 
Mix A)
Result 
(Reaction 
Mix D)
Limit of 
Detection
1 31.4 + -
1/10 3.0 + -
1/20 1.5 + +
1/50 0.6 + -
1 27.0 - +
1/10 3.0 - +
1/20 1.5 - +
1/50 0.6 + +
KRASv2 30 G12V 0.6 ng
KRASv2 43 G13D 0.6 ng
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Table 2.3.7.3 Endogenous control results from samples tested using the KRAS assay version 2. N.B. Samples 
KRASv2 03, 05, 06, 08, 10 were not analysed on both master mixes, therefore corresponding cells without data 
are indicated with 'N/A' (Not Applicable). ROX A = ROX reporter signal in master mix A, ROX B = ROX reporter 
signal in master mix B, NTC = No template control, WT = Wild-type. 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
Comments
KRASv2 21 G12V 30.0 19.870 POS 21.395 POS PASS
KRASv2 07 G12C 30.0 20.219 POS 20.759 POS PASS
KRASv2 11 G12V 30.0 20.664 POS 20.785 POS PASS
KRASv2 02 WT 30.0 20.468 POS 21.307 POS PASS
KRASv2 04 G12A 30.0 20.051 POS 20.766 POS PASS
KRASv2 09 G12A 30.0 23.027 POS 23.364 POS PASS
KRASv2 23 G12D 30.0 22.397 POS 22.518 POS PASS
KRASv2 24 WT 30.0 22.274 POS 22.722 POS PASS
NTC 0.0 42.475 (POS) NEG PASS Background only
KRASv2 15 WT 30.0 19.570 POS 20.002 POS PASS
KRASv2 16 WT 30.0 22.902 POS 23.126 POS PASS
KRASv2 17 WT 30.0 25.109 POS 25.616 POS PASS
KRASv2 18 G12D 30.0 21.159 POS 21.649 POS PASS
KRASv2 19 G13D 30.0 20.057 POS 20.478 POS PASS
KRASv2 20 WT 30.0 21.121 POS 21.487 POS PASS
KRASv2 22 WT 30.0 22.000 POS 22.320 POS PASS
KRASv2 25 WT 30.0 20.091 POS 20.770 POS PASS
KRASv2 26 WT 30.0 20.094 POS 20.458 POS PASS
NTC 0.0 NEG NEG PASS
KRASv2 27 G12V 32.6 22.915 POS 23.288 POS PASS
KRASv2 28 G13D 27.0 19.814 POS 19.874 POS PASS
KRASv2 29 G12D 21.0 23.844 POS 26.716 POS PASS
KRASv2 30 G12V 31.4 19.237 POS 19.761 POS PASS
NTC 0.0 NEG NEG PASS
KRASv2 31 G13D 25.0 20.602 POS 21.184 POS PASS
KRASv2 32 G12V 29.0 19.315 POS 19.675 POS PASS
KRASv2 33 G12D 33.2 18.982 POS 19.587 POS PASS
KRASv2 34 EGFR WT 37.4 22.163 POS 22.992 POS PASS
KRASv2 35 EGFR WT 25.9 21.970 POS 23.954 POS PASS
KRASv2 36 EGFR WT 23.0 23.384 POS 22.559 POS PASS
KRASv2 37 EGFR WT 31.4 22.010 POS 22.468 POS PASS
NTC NEG NEG PASS
KRASv2 38 WT 30.0 22.286 POS 21.822 POS PASS
NTC NEG 49.202 NEG PASS
KRASv2 39 G12V 31.4 18.809 POS 19.139 POS PASS
KRASv2 40 G12V 3.0 22.299 POS 21.545 POS PASS
KRASv2 41 G12V 1.5 22.521 POS 21.796 POS PASS
KRASv2 42 G12V 0.6 22.859 POS 21.996 POS PASS
NTC NEG NEG PASS
KRASv2 43 G13D 27.0 19.115 POS 18.774 POS PASS
KRASv2 44 G13D 3.0 20.086 POS 21.341 POS PASS
KRASv2 45 G13D 1.5 21.555 POS 21.447 POS PASS
KRASv2 46 G13D 0.6 21.879 POS 21.890 POS PASS
KRASv2 01 WT 30.0 35.910 POS 23.447 POS PASS
KRASv2 03 G12A 30.0 N/A 22.047 POS PASS
KRASv2 05 G12D 15.0 N/A 22.088 POS PASS
KRASv2 06 G12C 30.0 22.431 POS N/A PASS
KRASv2 08 G12A 30.0 24.163 POS N/A PASS
KRASv2 10 G12V 30.0 21.439 POS N/A PASS
PCR Pass: 49
PCR Fail: 0
Failure rate: 0%
ROX A ROX B
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Table 2.3.7.3 shows the results of the ROX endogenous control assay for the samples and 
controls tested using version 2 of the GF KRAS PCR. In five case (cells highlighted with a black 
border) the samples could only be loaded in one of the two reactions, therefore these 
reactions were not expected to generate a ROX signal. In all 49 samples and controls tested, 
all gave the correct result in the endogenous control assay. This is a significant improvement 
on the performance from version 1. 
 
 
2.3.8 GF KRAS Assay Version 3 
 
GeneFirst KRAS PCR version 3 improved on the performance of version 2, here achieving 
78.9% concordance with the original results, with a discrepancy level of 21.1% (see tables 
2.3.8.1 and 2.3.8.2). Again 100% of the wild-type samples matched with the original results. 
All the discrepant samples came from false positives or false negatives within the mutant 
positive samples. 
 
Similarly to the GeneFirst EGFR assay, problems with the endogenous control appeared in 
version 3 of the KRAS assay. On several occasions the No Template Control (NTC) negative 
control samples started giving a positive signal for the endogenous control (ROX channel). 
Like the equivalent problem in the EGFR assay, this was initially considered to be accidental 
user contamination; however successive repeats and reactions prepared with only master 
mix (i.e. reagents only, no DNA or nuclease free water) continued to produce this 
endogenous control positive signal. The data from these experiments is shown in the Chapter 
two appendix tables A2.2.6 and figures A2.2 and A2.3. The source of this signal was later 
discovered to also be a contamination in the manufacturing process at GeneFirst, so it was 
not an incident that could be avoided in the UHCW Pathology laboratory. 
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Table 2.3.8.2: Summary table showing the concordance % and discrepancy % of the GeneFirst KRAS PCR assay 
version 3. WT = Wild-type. 
 
 
 
Table 2.3.8.3 shows the ROX endogenous control results from the samples and controls 
tested with the GF KRAS assay version 3. All DNA samples gave a positive ROX signal as 
expected, however both NTC samples also gave strong (Ct ~15) positive ROX signals. Overall 
failure rate was 2/19 (9.5%). These results suggest contamination of the PCR reagents. 
 
 
 
 
 
 
 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 8 4 12 66.7
WT 7 0 7 100.0
Totals 15 4 19
Concordance % 78.9
Discrepancy % 21.1T
o
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GeneFirst KRAS v3 Sample Concordance %
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Table 2.3.8.3 Endogenous control results from samples tested using the KRAS assay version 3. Samples not 
numbered sequentially due to some samples being excluded for technical reasons. ROX A = ROX reporter signal 
in master mix A, ROX B = ROX reporter signal in master mix B, NTC = No template control, WT = Wild-type. 
 
 
 
2.3.9 GF KRAS Assay Version 4 
 
Only a single run was performed using the version 4 KRAS kit. The samples used all gave very 
different results to those obtained using castPCR, data shown in table 2.3.9.1. Concordance 
with castPCR results was low, with only 4 of 15 samples (26.7%) matching. This reduction in 
assay performance represents a 52.28% fall in concordance from version 3 to version 4 of 
the KRAS assay. Table 2.3.9.2 shows the overall performance of the assay. In this version of 
the KRAS assay the wild-type samples performed particularly poorly, with only 1 sample of 9 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
KRASv3 01 G12A 6.84 10.135 POS 12.806 POS PASS
KRASv3 02 G12D 2.14 11.603 POS 13.953 POS PASS
KRASv3 03 G12C 4.32 10.555 POS 13.087 POS PASS
KRASv3 04 G12A 4.52 12.065 POS 14.707 POS PASS
NTC 15.311 POS 17.936 POS FAIL
KRASv3 06 G12D 2.36 12.458 POS 14.942 POS PASS
KRASv3 07 G13D 20.80 9.522 POS 12.213 POS PASS
KRASv3 08 G12D 18.70 10.265 POS 15.089 POS PASS
KRASv3 09 G12V 21.00 7.844 POS 11.144 POS PASS
KRASv3 15 G12D 15.00 9.211 POS 12.138 POS PASS
KRASv3 16 G12V 15.00 12.021 POS 14.485 POS PASS
KRASv3 17 WT 15.00 11.133 POS 13.686 POS PASS
KRASv3 18 G13D 15.00 11.002 POS 13.741 POS PASS
KRASv3 19 WT 15.00 13.768 POS 15.608 POS PASS
KRASv3 20 WT 15.00 11.811 POS 14.386 POS PASS
KRASv3 21 WT 15.00 11.942 POS 14.597 POS PASS
KRASv3 22 WT 15.00 13.513 POS 15.749 POS PASS
KRASv3 23 WT 15.00 10.268 POS 12.935 POS PASS
KRASv3 24 G12V 15.00 9.330 POS 12.365 POS PASS
KRASv3 25 WT 15.00 11.085 POS 13.898 POS PASS
NTC 15.353 POS 17.697 POS FAIL
PCR pass: 19
PCR fail: 2
Failure rate: 9.5%
ROX A ROX B
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(11%) matching previous results using the castPCR assay. Only 6 mutant samples were 
available at this phase of the project. 3 of the 6 (50%) mutant samples matched previous 
results.  
 
 
Table 2.3.9.2: Summary table showing the concordance % and discrepancy % of the GeneFirst KRAS PCR assay 
version 4. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
 
 
 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 3 3 6 50.0
WT 1 8 9 11.1
Totals 4 11 15
Concordance % 26.7
Discrepancy % 73.3T
o
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Table 2.3.9.3 Endogenous control results from samples tested using the KRAS assay version 4. ROX A = ROX 
reporter signal in master mix A, ROX B = ROX reporter signal in master mix B, NTC = No template control, WT = 
Wild-type. 
 
 
 
Table 2.3.9.3 shows the performance of the ROX endogenous control assay from GF KRAS 
PCR version 4. For master mix A all samples and controls performed as expected. In master 
mix B however four samples gave a negative result in the ROX channel. This could potentially 
be due to low DNA input, as the quantity of DNA loaded for these reactions ranged from only 
0.4- 5.4 ng, below the guideline concentration of 30 ng per reaction. Conversely two of three 
NTC samples gave a positive ROX signal in master mix B, however the Ct values were high 
(39.728 and 39.401) suggesting a weak signal. 
 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
KRASv4 01 G12D 24.4 20.956 POS 28.177 POS PASS
KRASv4 02 WT 5.4 23.838 POS NEG FAIL
KRASv4 03 WT 10.1 22.562 POS 30.567 POS PASS
KRASv4 04 WT 9.3 21.173 POS 28.425 POS PASS
KRASv4 05 WT 5.6 23.301 POS 33.565 POS PASS
KRASv4 06 WT 0.7 25.277 POS NEG FAIL
KRASv4 07 WT 11.4 20.985 POS 29.964 POS PASS
KRASv4 08 G12A 8.7 20.577 POS 28.669 POS PASS
KRASv4 09 G12C 7.2 21.123 POS 28.908 POS PASS
KRASv4 10 G12V 16.0 20.556 POS 28.847 POS PASS
KRASv4 11 WT 0.4 26.185 POS NEG FAIL
KRASv4 12 WT 1.0 29.678 POS NEG FAIL
KRASv4 13 WT 3.3 21.809 POS 29.809 POS PASS
KRASv4 14 G12V 4.2 22.114 POS 30.511 POS PASS
KRASv4 15 G12D 4.2 23.548 POS 30.737 POS PASS
NTC NEG NEG PASS
NTC NEG 39.728 POS FAIL
NTC NEG 39.401 POS FAIL
PCR Pass: 12
PCR Fail: 6
Failure rate: 33.3%
ROX A ROX B
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2.3.10 GF KRAS Assay Version 5 
 
18 samples were tested using the final version of the GeneFirst KRAS assay. Table 2.3.10.1 
shows a summary of the results for all samples tested. A major improvement in concordance 
observed compared to version 4: 66.7% in version 5 compared to 26.7% in version 4. Table 
2.3.10.2 shows the overall performance of the assay. The assay performed equally well with 
wild-type and mutant samples, where 66.7% of both sample types matched the results from 
the castPCR assay. 
 
 
Table 2.3.10.1: Summary table showing the concordance % and discrepancy % of the GeneFirst KRAS PCR assay 
version 5. WT = Wild-type. 
 
 
 
To determine the exact sensitivity and specificity of the KRAS version 5 assay, all the PCR data 
was analysed, including the results from the individual master mixes. The KRAS version 5 
assay utilised two master mixes, each with two reporters (VIC and FAM) so therefore it was 
possible to generate up to four signals per sample. The results are shown in table 2.3.10.2. 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 8 4 12 66.7
WT 4 2 6 66.7
Totals 12 6 18
Concordance % 66.7
Discrepancy % 33.3T
o
ta
l
GeneFirst KRAS v5 Sample Concordance %
C
A
ST
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In all cases, the discrepant results were false positives i.e. one or more master mixes gave a 
signal that corresponded to a mutation that had not been previously been detected by the 
castPCR assay. This phenomena affected both master mixes equally, with six false positive 
results in master mix A, and five false positive results in master mix B. 
 
 
Table 2.3.10.2: Complete analysis of PCR results from all GF KRASv5 master mixes. Designations ‘True Positive’, 
‘True Negative’, ‘False Positive’ and ‘False Negative’ are assigned based on the original castPCR results. WT = 
Wild-type. 
 
 
 
The analysis from table 2.3.10.2 was used calculate the sensitivity and specificity of the GF 
KRAS version 5 assay. The results are shown in table 3.3.10.3. The assay achieved 100% 
sensitivity, but only 54.2% specificity. 
 
 
A B
True 
Pos
True 
Neg
False 
Pos
False 
Neg
KRASv5 01 WT TRUE NEG TRUE NEG 0 2 0 0
KRASv5 02 WT TRUE NEG TRUE NEG 0 2 0 0
KRASv5 03 G12V TRUE POS TRUE NEG 1 1 0 0
KRASv5 04 G12C TRUE POS TRUE NEG 1 1 0 0
KRASv5 05 G12C TRUE POS TRUE NEG 1 1 0 0
KRASv5 06 G12D FALSE POS FALSE POS 0 0 2 0
KRASv5 07 G12D TRUE POS TRUE POS 2 0 0 0
KRASv5 08 G12A FALSE POS TRUE POS 1 0 1 0
KRASv5 09 WT FALSE POS FALSE POS 0 0 2 0
KRASv5 10 WT TRUE NEG TRUE NEG 0 2 0 0
KRASv5 11 WT TRUE NEG TRUE NEG 0 2 0 0
KRASv5 12 G12V FALSE POS FALSE POS 0 0 2 0
KRASv5 13 G12C TRUE POS TRUE NEG 1 1 0 0
KRASv5 14 G12C TRUE POS TRUE NEG 1 1 0 0
KRASv5 15 G12D TRUE POS TRUE POS 2 0 0 0
KRASv5 16 G12D TRUE POS TRUE POS 2 0 0 0
KRASv5 17 G12A FALSE POS FALSE POS 0 0 2 0
KRASv5 18 WT FALSE POS FALSE POS 0 0 2 0
TRUE 12 13
FALSE 6 5
Study ID
Mutation 
type
GF KRASv5 PCR Master Mix Result
Totals: 12 13 11 0
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Table 2.3.10.3 Endogenous control results from samples tested using the KRAS assay version 5. ROX A = ROX 
reporter signal in master mix A, ROX B = ROX reporter signal in master mix B, NTC = No template control, WT = 
Wild-type. 
 
 
 
Table 2.3.10.3 shows the performance of the ROX endogenous control in GF KRAS version 5 
assay. Two of the 20 samples failed, resulting in a 10% failure rate. Both the NTCs gave no 
signal in the ROX channel which was the expected result. This is an improvement on version 
4 of the assay, where overall 33% of samples failed the endogenous control assay, including 
2/3 of the NTCs.  
 
 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
KRASv5 01 WT 30.0 NEG 29.629 POS FAIL
KRASv5 02 WT 30.0 26.220 POS 26.285 POS PASS
KRASv5 03 G12V 30.0 20.440 POS 21.520 POS PASS
KRASv5 04 G12C 30.0 22.532 POS 23.735 POS PASS
KRASv5 05 G12C 30.0 29.616 POS NEG FAIL
KRASv5 06 G12D 30.0 22.093 POS 21.418 POS PASS
KRASv5 07 G12D 30.0 24.379 POS 24.644 POS PASS
KRASv5 08 G12A 30.0 21.755 POS 20.911 POS PASS
KRASv5 09 WT 30.0 28.380 POS 25.461 POS PASS
NTC 0.0 NEG NEG PASS
KRASv5 10 WT 15.0 29.965 POS 26.412 POS PASS
KRASv5 11 WT 15.0 25.939 POS 25.528 POS PASS
KRASv5 12 G12V 15.0 21.510 POS 22.580 POS PASS
KRASv5 13 G12C 15.0 21.921 POS 22.611 POS PASS
KRASv5 14 G12C 15.0 27.893 POS 27.188 POS PASS
KRASv5 15 G12D 15.0 22.266 POS 22.074 POS PASS
KRASv5 16 G12D 15.0 25.269 POS 24.932 POS PASS
KRASv5 17 G12A 15.0 22.067 POS 21.438 POS PASS
KRASv5 18 WT 15.0 26.925 POS 25.510 POS PASS
NTC 0.0 NEG NEG PASS
PCR Pass: 18
PCR Fail: 2
Failure rate: 10.0%
ROX A ROX B
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Table 2.3.10.4: Summary of GF KRAS version 5 data. 
 
 
 
In total 112 samples were tested using the five different versions of the GF KRAS assay. The 
data concordance is shown in table 2.3.10.5. Overall 77 of the 112 (68.8%) samples tested 
matched the original castPCR results. The assays performed slightly better with wild-type 
samples, as 74.4% of wild-type samples matched the original castPCR results, compared to 
65.8% of matching mutant samples. 
 
 
 
 
 
 
 
Gene First KRAS Assay version 5
Test Mutant Present Mutant absent
Positive True Positive 12 False Positive 11
Negative False Negative 0 True Negative 13
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
100.0%
54.2%
52.2%
100.0%
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Table 2.3.10.5: Summary table showing the overall concordance % and discrepancy % of the GeneFirst KRAS PCR 
assay versions 1-5. WT = Wild-type. 
 
 
 
 
Figure 2.3.10.1 Summary graph of EGFR and KRAS Endogenous Control performance across all tested versions. 
Data from the EGFR assay is coloured red, data from the KRAS assay is coloured blue. 
 
 
Figure 2.3.10.1 shows the frequency of endogenous control failure across several versions of 
both prototype assays. From the graph it can be clearly seen that failure rate varied greatly. 
Match Discrepant Totals
Mutant 
Samples
WT samples
Mutant 48 25 73 65.8
WT 29 10 39 74.4
Totals 77 35 112
Concordance % 68.8
Discrepancy % 31.3T
o
ta
l
Gene First KRAS v1-5 Sample Concordance %
C
A
ST
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For EGFR the failure rate ranged from 33.3% (version 3) to 0% (version 2). For KRAS the failure 
rate ranged from 33.3% (version 4) to 0% (version 2). Interestingly version 2 of both assays 
had a 0% failure rate for endogenous control, but unfortunately this performance could not 
be replicated for future versions. 
 
 
2.3.11 Confirmatory Testing using Next Generation Sequencing 
 
Due to the significant number of discrepant samples identified by the validation of the 
GeneFirst assays using previously tested Pathology samples, Next Generation Sequencing 
(NGS) was utilised to establish the exact genotype of a selection of the discrepant samples. 
 
The samples that were selected for NGS analysis were selected based on the fact they had 
been tested and did not match the results determined by either Therascreen or castPCR, and 
also had a sufficient remaining volume of DNA extract for analysis. The samples were all DNA 
samples extracted from tissue. 
 
A total of nine samples were sequenced over three runs using the Ion Torrent PGM platform. 
Amplified DNA libraries were prepared from the DNA extracts using the primer pool from 
the 22-gene panel (later incorporated into the Oncomine Solid Tumour DNA kit), as described 
in the Methods (section 2.2.8.3). 
 
The hotspot mutations detected in EGFR and KRAS are shown in table 2.3.11.1. In total nine 
EGFR or KRAS hotspot mutations were detected in seven of the nine samples: three in EGFR; 
six in KRAS. Two samples (EGFRv2 46 and EGFRv3 06) were wild-type for EGFR and KRAS. Of 
the nine hotspots detected, there were two (EGFR p.P741L and EGFR p.A871T) that the 
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GeneFirst EGFR assay was not designed to detect, therefore I would not expect these 
mutations to give a positive result in the GeneFirst EGFR assay. 
 
Table 2.3.11.1: Hotspot mutations detected in samples from the GeneFirst EGFR and KRAS assays. 
 
 
 
The NGS results were compared to corresponding data generated by the Therascreen, 
castPCR and GeneFirst assays. The results are shown in table 2.3.11.2.  
 
 
Table 2.3.11.2 Mutation detection results from five assays: Therascreen, GeneFirst EGFR PCR, castPCR, GeneFirst 
KRAS PCR and Ion Torrent NGS. WT = Wild-type. 
 
 
Study ID Frequency Quality Gene ID Allele Name AA change Coverage Allele Cov Strand Bias
EGFRv2 04 88.6 12667.50 EGFR COSM6224 p.L858R 1996 1768 0.5073
EGFRv2 43 2.8 12.52 EGFR COSM17570 p.P741L 177 5 0.5527
EGFRv2 43 41.3 774.99 KRAS COSM522 p.G12A 213 88 0.5634
EGFRv2 44 2.3 8.55 EGFR COSM28605 p.A871T 133 3 0.5617
EGFRv2 44 25.8 401.81 KRAS COSM516 p.G12C 229 59 0.5199
EGFRv2 46 No EGFR or KRAS Hotspot Mutations Detected
EGFRv3 06 No EGFR or KRAS Hotspot Mutations Detected
KRASv2 03 40.3 7238.55 KRAS COSM522 p.G12A 2000 806 0.5094
KRASv2 05 3.5 9.21 KRAS COSM521 p.G12D 260 9 0.7188
KRASv2 07 48 4827.25 KRAS COSM516 p.G12C 1019 489 0.5117
KRASv3 08 50.3 7922.22 KRAS COSM521 p.G12D 1546 777 0.5096
Study ID
Therascreen 
Result (EGFR)
GF EGFR Result
CastPCR Result 
(KRAS)
GF KRAS Result NGS Result Comments
EGFRv2 04 L858R
T790M, L858R, 
Exon 19 Del
N/A N/A EGFR p.L858R GF does not match NGS
EGFRv2 43 WT T790M N/A G12A KRAS p.G12A
GF matched NGS KRAS 
result but not EGFR
EGFRv2 44 WT T790M N/A G12C KRAS p.G12C
GF matched NGS KRAS 
result but not EGFR
EGFRv2 46 WT WT N/A WT WT All tests match
EGFRv3 06 WT WT N/A N/A WT All tests match
KRASv2 03 N/A N/A G12A G13D KRAS p.G12A GF does not match NGS
KRASv2 05 N/A N/A G12D G13D KRAS p.G12D GF does not match NGS
KRASv2 07 N/A N/A G12C WT KRAS p.G12C GF does not match NGS
KRASv3 08 N/A N/A G12D G12D and G12A/C/V KRAS p.G12D GF does not match NGS
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In all cases, the NGS sequencing results agreed with the original Qiagen Therascreen EGFR 
RGQ PCR and the Life Technologies KRAS castPCR assays. In total 7 false positive mutation 
results were identified amongst six samples tested on the GeneFirst assays. In one sample 
the GeneFirst KRAS PCR identified it as WT, but the presence of a G12C mutation was 
confirmed by NGS. Therefore that sample was a false negative according the GeneFirst KRAS 
PCR result.  
 
There were two additional KRAS mutations detected by the GeneFirst assays that were 
confirmed by the NGS analysis (see samples EGFRv2 43 and EGFRv2 44). Two wild-type 
samples were also sequenced to act as negative controls (EGFRv2 46 and EGFRv4 06). The 
NGS results for these two samples matched the negative results from Therascreen, no EGFR 
(or KRAS) mutations were detected. 
 
EGFR samples 43, 44 and 46 were also tested using the GF KRAS assay, two of which gave 
positive signals for KRAS mutations. Interestingly NGS analysis confirmed all three of these 
results. This could suggest that the GF KRAS assay actually performed slightly better than the 
GF EGFR assay. However this observation cannot be confirmed with such a limited number 
of samples analysed by NGS. 
 
In addition, a wide range of additional mutations and novel variants were identified in the 
samples which would not have been detectable by the PCR methods. The full range of 
hotspots identified are given in the chapter two appendix, table A2.3. 
 
Unfortunately due to DNA samples being depleted during the various PCR testing phases, no 
further samples could be analysed by NGS. Therefore the results from versions 4 and 5 of the 
GeneFirst EGFR and KRAS assays could not be confirmed using the Ion Torrent platform. 
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2.3.12 GF EGFR/ KRAS Assays and cfDNA 
 
To observe the performance of the GeneFirst PCR assays with cfDNA, 5 cfDNA samples were 
analysed using the GF EGFR (version 3) and GF KRAS (version 3) assays. For details of the 
cfDNA samples and their preparation, see chapter four Methods (sections 4.2.3.1- 3). Due to 
the highly variable DNA concentrations in the cfDNA samples, they could not all be loaded 
into the PCR reactions at the same concentration. Table 2.3.12.3 shows the PCR and 
corresponding NGS results for the 5 cfDNA samples. 
 
Table 2.3.12.1 Endogenous control results from plasma samples tested on EGFR assay version 3. ROX A = ROX 
reporter signal in master mix A, ROX B = ROX reporter signal in master mix B, ROX C = ROX reporter signal in 
master mix C, ROX D = ROX reporter signal in master mix D, NTC = No template control, WT = Wild-type. 
 
 
 
Table 2.3.12.2 Endogenous control results from plasma samples tested on KRAS assay version 3. ROX A = ROX 
reporter signal in master mix A, ROX B = ROX reporter signal in master mix B, NTC = No template control, WT = 
Wild-type. 
 
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay PASS/ 
FAIL
PL001 WT 7.4 23.746 POS 23.808 POS 21.317 POS 22.635 POS PASS
PL002 WT 2.2 25.205 POS 25.517 POS 24.012 POS 25.109 POS PASS
PL005 WT 1.0 28.722 POS 28.463 POS 28.731 POS 31.450 POS PASS
PL003 WT 1.1 29.372 POS 28.886 POS 26.553 POS 27.793 POS PASS
PL004 WT 0.9 30.003 POS 29.576 POS 27.554 POS 27.533 POS PASS
NTC 0.0 31.221 POS 30.389 POS 28.150 POS NEG FAIL
PCR Pass: 5
PCR Fail: 1
Failure rate: 33.3%
ROX A ROX B ROX C ROX D
Study ID
Mutation 
type
DNA (ng, 
total)
Ct Mean
Control 
Pos/ Neg
Ct Mean
Control 
Pos/ Neg
Assay Pass/ 
Fail
PL001 WT 7.4 11.604 POS 13.660 POS PASS
PL002 WT 2.2 12.733 POS 15.285 POS PASS
PL005 WT 1.0 15.944 POS 18.192 POS PASS
PL003 WT 1.1 15.917 POS 17.990 POS PASS
PL004 WT 0.9 16.471 POS 18.405 POS PASS
NTC 0.0 14.987 POS 17.489 POS FAIL
PCR Pass: 5
PCR Fail: 1
Failure rate: 33.3%
ROX A ROX B
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Table 2.3.12.3 cfDNA samples analysed with GF PCR and NGS. 
 
 
 
Analysing the cfDNA samples by EGFR PCR has detected T790M mutations in two samples. 
However these mutations were not detected in the same samples using NGS. The PCR results 
from the KRAS assay agreed with the NGS results, both assays found the cfDNA samples to 
be negative for KRAS mutations. 
 
  
EGFR KRAS Variants Hotspots EGFR KRAS
PL001 T790M POS NEG 24 0 Discrepant Match
PL002 NEG NEG 37 0 Match Match
PL003 NEG NEG 41 0 Match Match
PL004 NEG NEG 42 0 Match Match
PL005 T790M POS NEG 48 0 Discrepant Match
Plasma 
Sample 
No.
GeneFirst PCR Results NGS Results Concordance
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2.3 DISCUSSION 
 
2.3.1 GeneFirst EGFR PCR assay development using Tissue 
 
Five versions of the GeneFirst EGFR PCR assay were tested over the course of this phase of 
the project (Sept 2013- December 2014). In the final version, the assay achieved an overall 
concordance of 49.3% (see table 2.3.5.1) compared to the original Pathology Department 
results using Qiagen Therascreen EGFR assay. These results are clearly not suitable for use 
as a clinical diagnostic assay. An earlier version of the assay (version 2) did achieve 1- 2.5% 
LoD and was able to perform analysis on very low gDNA input (<1 ng in some cases). The 
decision was made not to perform any further LoD experiments until the issue of frequent 
false positives was resolved in the assay, hence only version 2 was used for LoD experiments. 
 
The most significant issue was the frequent occurrence of false positives. In some cases these 
false positives may have been due to DNA cross-linking due to DNA fixation with formalin or 
probe degradation, however the level of discrepancy (>50%) is too high to be explained just 
by formalin DNA changes and PCR artefacts. This problem needed to be overcome in further 
developmental steps in assay design, but the technology has now been abandoned by 
GeneFirst.  
 
In addition to the false positive error rate encountered with all versions of the assays, there 
was also an incidence of reagent contamination at the manufacturing stage. The reagents 
for version 3 of the EGFR assay produced results where all reactions (including non-template 
negative controls) gave positive results for the control assay. The source of this signal was 
later discovered to be a contamination in the manufacturing process at GeneFirst. 
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Under normal circumstances, data generated from runs with failed controls would be 
excluded from a validation dataset. However in the case of this series of experiments, the 
general performance of the assay was such that including this sub-optimal data did not have 
a huge impact on the overall quality of the dataset. 
 
Version 4 of the assay gave a minor improvement in overall assay concordance (46.7%) with 
the original results, compared to version 3 (39.1%). 100% Wild-type samples matched 
original results, however there were only 2 wild-type samples tested, so this result is too 
underpowered to be considered a positive reflection of assay performance. 
 
Unfortunately with the following version 5, assay performance again showed very low 
concordance with previous results (26.7%). This could have been partially due to a number 
of very low DNA concentration samples being used, however a majority of these low DNA 
concentration samples were previously identified as wild-type, and thus I would not expect 
them to give a positive signal for any mutants. Performance with mutant samples was the 
worst of all assay versions (10.5% concordance). A major weakness of the assay was shown 
to be PCR master mix D (designed to detect exon 19 deletions and the L858R mutation) which 
had the most frequent occurrence of false positives, almost as many as the other three 
master mixes- 19 false positives in master mix D alone, compared to 21 in master mixes A, B 
and C combined. Without knowing the exact technical specifications of the design of the 
primer and probes used in this master mix it is impossible to state exactly why this problem 
occurred so frequently, however it was most likely due to low specificity of the assay for its 
intended mutant targets. Alternatively it could have been due to changes in the assay 
chemistry, or poor sample quality, or a combination of both factors. Analysis of the results 
was also very cumbersome due to the varying thresholds and multiple reporters used in the 
four PCR master mixes. 
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Similar to the variable performance of the mutant target assays, the endogenous control 
assay included in the GF EGFR PCR regularly failed during the testing phases. The best results 
for this assay component were seen in version two, were the endogenous control performed 
correctly for all samples. All other versions however suffered some degree of failure, with 
the worse performance being in version three where the assays failed in 33.3% of the 
samples. This unreliable performance of the endogenous control assay further shows that 
these prototype assays are not suitable for diagnostic use. In a number of cases, the failure 
of many samples and controls in the endogenous control assay may have been due to 
contamination of the reagents at the manufacturing stage (explained earlier). This is the 
most likely explanation of the frequent phenomena of non-template controls giving positive 
ROX signals. Beyond this however analysis of the endogenous control performance is difficult 
as no technical details of the endogenous control assay (primer design etc.) were provided 
by the manufacturer. Analysis of the PCR products using gel electrophoresis (see figure 2.3.3) 
did not show any evidence of primer dimers or amplicons (specific or non-specific), however 
this isn’t necessarily a definitive answer as the PCR products may have contained fragments 
at a concentration below that which can be visualised by the gel. 
 
 
2.3.2 GeneFirst KRAS PCR assay development using Tissue 
 
Five versions of the GeneFirst KRAS PCR assay were tested over the course of the project. 
Generally this assay performed better than the EGFR assay, achieving a concordance of 
68.8% across all versions of the assay (see table 2.3.10.5), compared to 49.3% for the EGFR 
assay overall (see table 2.3.5.5). Version 2 of the assay achieved a good LoD at 1% in the LoD 
experiments, and was able to perform valid analysis using low inputs of gDNA (7.5 ng). The 
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advantage for the KRAS testing was that the original Pathology Department samples were 
extracted using punched sections from tissue blocks, rather than the scraped sides used for 
the EGFR assay, so that much higher gDNA yields and sample volumes were available. 
 
Similarly to the EGFR assay, the most significant source of error was the occurrence of false 
positives amongst mutation positive samples. Most often the false positive result was caused 
by anomalous signals in the FAM channel in one of the master mixes, which in combination 
with a similar signal in the VIC channel gave a positive result for a specific mutation 
(Gly13Asp). This false positive occurred frequently in version 2 of the assay (see NGS data 
table 2.3.11.2 and appendix table A2.2.2) and is most likely a feature of sub-optimal PCR 
conditions, rather than DNA cross linking or probe degradation, as described in the previous 
paragraph. Despite these issues, the KRAS assay performed better than the EGFR assay. 
 
In addition to the high false positive rate, the other major problem was the manufacturing 
contamination incident detected in version 3 of both kits. Although this does not represent 
an innate problem with the assay, more an unfortunate incident during manufacture, it did 
however invalidate the testing done on version 3 and represent a considerable amount of 
time lost. 
 
Versions 4 of the KRAS assays saw considerable reductions in performance. Version 4 
achieved an overall concordance of only 26.7%, compared to 79% in the previous version 
(version 3, although these reagents were contaminated at source so the results are not 
reliable). 
 
Version 5 achieved an improvement over version 4 (66.7% compared to 26.7%) however 
there was still very high incidence of false positive results, although with the limited number 
157 
 
of samples available it was not possible to identify if this was an issue associated with either 
of the master mixes. One major improvement in version 5 saw the assay generate no false 
negatives, resulting in a sensitivity of 100% for this version of the assay. Specificity 
unfortunately was low at 54.2% due the frequent occurrences of false positives. Like the 
EGFR assay, it is impossible to know the exact cause of these issues without technical 
information about the assay design. This could have been due to changes in the assay 
chemistry or poor sample quality. 
 
Another issue that arose with version 5 was the introduction of a very complex and confusing 
analysis algorithm in the kit SOP (see Methods figure 2.8.2). Not only was the analysis flow 
diagram difficult to interpret, but it also gave imprecise thresholds for determining ΔCt cut 
offs for separating positive and negative results. In a number of cases, symbols such as << 
and >> (without associated value ranges) were given as criteria for determining the PCR 
results instead of discreet thresholds, so therefore some interpretation and subjectivity was 
employed by the operator. This process was variable and cumbersome, and far too prone to 
human error to be suitable for a diagnostic assay. 
 
Endogenous control performance across all five versions of the GF KRAS assay was highly 
variable. The best results for this assay component were seen in version two, were the 
endogenous control performed correctly for all samples. All other versions however suffered 
some degree of failure, with the worse performance being in version four where the assays 
failed in 33.3% of the samples. This unreliable performance of the endogenous control assay 
further shows that these prototype assays are not suitable for diagnostic use. Similar to the 
mutant target assays, no technical information regarding the endogenous control assay was 
supplied by GeneFirst, therefore it is difficult to explain exactly why this assay gave such 
variable results.  
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2.3.3 NGS application 
 
Next Generation Sequencing was used in a limited capacity to perform confirmatory testing 
on discrepant samples from the GeneFirst EGFR and KRAS PCR assays. This technology 
provides a “gold standard” in terms of accuracy, sensitivity and depth of coverage for genetic 
analysis. However due to significantly higher cost of equipment and reagents, and the more 
time consuming and labour intensive workflow, it was not at the time a suitable method for 
large scale testing in patient samples within pathology. 
 
NGS confirmatory sequencing showed that only one of the five EGFR mutations identified by 
the EGFR PCR assay were correct, whilst the other 4 were not detected by Qiagen 
Therascreen (tested by Pathology Department) or by NGS. This strongly suggests that the 
additional mutations identified by the EGFR assay were false positives. 
 
Seven of the nine NGS analysed samples were analysed using the GeneFirst KRAS assay, 
identifying six mutations in total. The NGS data agreed with three of the six mutations found. 
Interestingly the NGS analysis identified two KRAS mutations in two samples that had been 
previously only analysed for EGFR mutations. This finding makes a strong case for wider 
genetic analysis of tumour tissue samples, the mutations identified would have clinical 
implications and thus this would a useful tool for patient management. 
 
In addition to confirming the presence or absence of mutations identified by PCR, the NGS 
technology also identified a considerable number of other mutations and novel variants 
present in the samples (see appendix table A2.3). The significance of these additional 
mutants and variants need to be investigated using various online genetic reference libraries. 
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The detection of such a range of genetic features further demonstrated the power of the 
NGS technologies over the PCR format assays. 
 
 
2.3.4 Conclusion 
 
The GeneFirst EGFR and KRAS PCR assays demonstrated good levels of sensitivity at certain 
points during the investigation, although this varied greatly as the assay versions changed. 
The best examples are the LoD experiments, and the final version of the KRAS assay 
demonstrated 100% sensitivity. However the specificity of this technical approach needs to 
be significantly improved before it can be considered for diagnostic use. Manufacturing 
issues were apparent, although these may have been isolated incidences. Another barrier to 
the diagnostic use of these assays (assuming the specificity issue were corrected) is the 
complexity of the analysis process. The equations for calculating ΔCt were straightforward 
and could most likely be automated, however the extremely confusing and complicated flow 
diagram for determining the final results (introduced in KRAS version 5) made the analysis 
very cumbersome and extremely prone to misinterpretation. If this format of assay were to 
ever be considered for diagnostic use then a more user friendly analysis algorithm would 
have to be designed. With all the above observations considered, both GeneFirst assays were 
shown to not be fit for purpose. 
 
The Ion Torrent NGS technology showed itself to be powerful, and proved to be an extremely 
useful tool for genetic analysis on a selected number of samples during this phase of the 
project. Unfortunately it was not possible to analyse all discrepant samples identified by the 
GeneFirst PCR assays by NGS. There were two reasons for this: firstly, the cost of NGS 
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reagents meant only small number of chips could be allocated to this section of the project; 
and secondly, small volume of sample DNA available often meant repeats were not possible. 
 
The major limitation of the NGS technology was cost and as a result it saw only limited use 
here. It will be employed more in following chapters. PCR technologies are very efficient in 
terms of cost and as a result it is preferable to develop PCR based diagnostic tools rather 
than NGS based. Assays like the GeneFirst prototype EGFR and KRAS assays could be 
appropriate for diagnostic use but only after very extensive development to increase the 
specificity and to streamline the analysis process. 
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A2 CHAPTER TWO APPENDIX 
 
A2.1 GeneFirst EGFR raw data versions 1-5 
 
Table A2.1.1: Anonymised Pathology samples tested using the GeneFirst EGFR PCR assay version 1. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
Study ID Mutations
DNA Loading 
(ng)
Concordance with 
Therascreen
EGFRv1 17 Exon 19 Del 52.56 Match
EGFRv1 14 WT 34.60 Discrepant
EGFRv1 16 T790M 34.02 Match
EGFRv1 08 T790M 33.40 Match
EGFRv1 18 T790M 26.18 Discrepant
EGFRv1 05 L858R 25.60 Discrepant
EGFRv1 12 WT 25.20 Match
EGFRv1 09 T790M 18.40 Match
EGFRv1 03 Exon 19 Del 16.80 Match
EGFRv1 07 L858R 16.80 Match
EGFRv1 15 T790M & L858R 16.80 Match
EGFRv1 02 Exon 19 Del 16.00 Match
EGFRv1 06 L858R 15.80 Discrepant
EGFRv1 21 S768I 13.48 Match
EGFRv1 10 WT 12.00 Discrepant
EGFRv1 04 Exon 19 Del 11.20 Match
EGFRv1 11 WT 9.00 Match
EGFRv1 01 Exon 19 Del 7.80 Match
EGFRv1 13 WT 6.00 Match
EGFRv1 20 Exon 19 Del 2.50 Discrepant
EGFRv1 19 L861Q 1.64 Discrepant
Match: 19.82 Concordance
Discrepant: 16.90 66.67%
Mean PCR DNA 
input (ng)
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Table A2.1.2: Anonymised Pathology samples tested using the GeneFirst EGFR PCR assay version 2. Positive 
concordance percentage shown in the bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
 
 
Study ID Mutations
DNA 
Loading 
(ng)
Concordance with 
Therascreen
Study ID Mutations
DNA 
Loading 
(ng)
Concordance with 
Therascreen
EGFRv2 13 T790M 80.00 Discrepant EGFRv2 03 Exon 19 Del 8.40 Match
EGFRv2 32 WT 73.92 Match EGFRv2 05 L858R 8.40 Discrepant
EGFRv2 17 Exon 19 Del 56.96 Discrepant EGFRv2 02 Exon 19 Del 8.00 Match
EGFRv2 11 T790M 39.27 Discrepant EGFRv2 08 WT 4.50 Match
EGFRv2 29 WT 39.20 Match EGFRv2 34 WT 4.14 Match
EGFRv2 43 WT 37.40 Discrepant EGFRv2 53 T790M 3.00 Match
EGFRv2 19 WT 34.60 Discrepant EGFRv2 28 WT 2.90 Match
EGFRv2 46 WT 31.40 Match EGFRv2 30 WT 2.88 Match
EGFRv2 47 WT 30.00 Match EGFRv2 48 L858R 2.80 Discrepant
EGFRv2 52 T790M 30.00 Discrepant EGFRv2 40 WT 2.34 Match
EGFRv2 44 WT 25.90 Discrepant EGFRv2 38 Exon 19 Del 1.64 Discrepant
EGFRv2 15 L858R 25.60 Discrepant EGFRv2 49 L858R 1.50 Discrepant
EGFRv2 45 WT 23.00 Discrepant EGFRv2 54 T790M 1.50 Match
EGFRv2 33 WT 22.56 Match EGFRv2 42 WT 1.39 Discrepant
EGFRv2 14 T790M 18.40 Discrepant EGFRv2 39 E18 G719X 1.06 Match
EGFRv2 27 WT 18.00 Discrepant EGFRv2 50 L858R 1.00 Discrepant
EGFRv2 41 WT 17.68 Match EGFRv2 12 L861Q 0.82 Match
EGFRv2 16 L858R 16.80 Match EGFRv2 55 T790M 0.60 Match
EGFRv2 01 Exon 19 Del 16.00 Match EGFRv2 31 WT 0.52 Match
EGFRv2 20 L858R 15.80 Match EGFRv2 51 L858R 0.50 Match
EGFRv2 25 WT 15.32 Match EGFRv2 22 WT 0.48 Match
EGFRv2 18 S768I 13.80 Match EGFRv2 37 Exon 19 Del 0.43 Discrepant
EGFRv2 10 T790M 13.09 Discrepant EGFRv2 23 WT 0.40 Match
EGFRv2 04 L858R 12.80 Discrepant EGFRv2 24 WT 0.40 Match
EGFRv2 09 WT 12.60 Match EGFRv2 36 WT 0.36 Match
EGFRv2 21 WT 12.00 Match EGFRv2 26 WT 0.32 Discrepant
EGFRv2 35 WT 9.86 Match Match: 15.07 Concordance
EGFRv2 06 T790M 9.20 Discrepant Discrepant: 14.71
EGFRv2 07 T790M 9.20 Discrepant
Mean PCR 
DNA Input 
(ng)
60.38%
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Table A2.1.3: Anonymised Pathology samples tested using the GeneFirst EGFR PCR assay version 3. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
Study ID Mutations
DNA Loading 
(ng)
Concordance with 
Therascreen
EGFRv3 11 WT 207.20 Match
EGFRv3 06 T790M 160.00 Discrepant
EGFRv3 08 WT 149.60 Discrepant
EGFRv3 05 Exon 19 Del 113.92 Discrepant
EGFRv3 09 WT 74.80 Discrepant
EGFRv3 14 WT 69.20 Match
EGFRv3 23 L861Q 60.80 Discrepant
EGFRv3 27 L861Q 60.80 Match
EGFRv3 01 T790M 60.00 Match
EGFRv3 12 WT 51.80 Match
EGFRv3 02 T790M 36.80 Match
EGFRv3 07 T790M 26.18 Discrepant
EGFRv3 03 T790M 18.40 Discrepant
EGFRv3 26 Exon 19 Del 18.24 Discrepant
EGFRv3 15 L858R 16.80 Discrepant
EGFRv3 24 L858R 16.24 Discrepant
EGFRv3 10 WT 10.00 Discrepant
EGFRv3 04 L858R 5.60 Discrepant
EGFRv3 22 Exon 19 Del 1.74 Match
EGFRv3 25 L861Q 0.94 Discrepant
EGFRv3 28 L861Q 0.94 Match
EGFRv3 13 Exon 19 Del 0.86 Discrepant
EGFRv3 16 WT 0.64 Match
Match: 54.35 Concordance
Discrepant: 48.03 39.13%
Mean PCR DNA 
input (ng)
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Table A2.1.4: Anonymised Pathology samples tested using the GeneFirst EGFR PCR assay version 4. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID Mutations DNA Loading (ng)
Concordance with 
Therascreen
EGFRv4 02 T790M 78.54 Discrepant
EGFRv4 14 Exon 19 Del 56.96 Discrepant
EGFRv4 04 WT 35.60 Match
EGFRv4 06 L858R 33.60 Discrepant
EGFRv4 10 Exon 19 Del 32.21 Match
EGFRv4 13 L858R 31.60 Discrepant
EGFRv4 15 WT 30.60 Match
EGFRv4 05 T790M 17.46 Discrepant
EGFRv4 12 Exon 19 Del 16.80 Match
EGFRv4 01 Exon 19 Del 13.40 Discrepant
EGFRv4 11 Exon 19 Del 11.20 Discrepant
EGFRv4 07 L858R 2.56 Match
EGFRv4 03 Exon 19 Del 1.73 Discrepant
EGFRv4 08 L858R 1.28 Match
EGFRv4 09 L858R 0.51 Match
Match: 17.17 Concordance
Discrepant: 30.48 46.67%
Mean PCR DNA 
input (ng)
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Table A2.1.5 Anonymised Pathology samples tested using the GeneFirst EGFR PCR assay version 5. Positive 
concordance value (%) shown in bottom right cell. 12 samples contained DNA at a concentration below the lower 
threshold of the Qubit instrument, indicated with “Unknown (low)” in the DNA loading field. WT = Wild-type. 
 
 
 
 
 
Study ID Mutations DNA loading (ng)
Concordance with 
Therascreen
EGFRv5 09 Exon 19 Del 30.00 Match
EGFRv5 01 Exon 20 Ins 30.00 Discrepant
EGFRv5 02 L861Q and G719X 30.00 Discrepant
EGFRv5 03 Exon 19 Del 30.00 Discrepant
EGFRv5 04 T790M 30.00 Discrepant
EGFRv5 05 L861Q 30.00 Discrepant
EGFRv5 06 L858R 30.00 Discrepant
EGFRv5 07 T790M 30.00 Discrepant
EGFRv5 08 S768I 30.00 Discrepant
EGFRv5 18 Exon 19 Del 15.00 Match
EGFRv5 10 Exon 20 Ins 15.00 Discrepant
EGFRv5 11 L861Q and G719X 15.00 Discrepant
EGFRv5 12 Exon 19 Del 15.00 Discrepant
EGFRv5 13 T790M 15.00 Discrepant
EGFRv5 14 L861Q 15.00 Discrepant
EGFRv5 15 L858R 15.00 Discrepant
EGFRv5 16 T790M 15.00 Discrepant
EGFRv5 17 S768I 15.00 Discrepant
EGFRv5 21 WT Unknown (low) Match
EGFRv5 22 WT Unknown (low) Match
EGFRv5 23 WT Unknown (low) Match
EGFRv5 24 WT Unknown (low) Match
EGFRv5 29 WT Unknown (low) Match
EGFRv5 30 WT Unknown (low) Match
EGFRv5 19 WT Unknown (low) Discrepant
EGFRv5 20 Del Unknown (low) Discrepant
EGFRv5 25 WT Unknown (low) Discrepant
EGFRv5 26 WT Unknown (low) Discrepant
EGFRv5 27 WT Unknown (low) Discrepant
EGFRv5 28 WT Unknown (low) Discrepant
Match: 22.50 Concordance
Discrepant: 22.50 26.67%
Mean PCR DNA 
input (ng)
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Table A2.1.6 Experiments running no template controls in the GF EGFR assay version 3. Control designations: ‘NF 
H2O’ = Nuclease Free water control, tested in master mix A, B, C or D. ‘MM only’ = master mix only, (no H2O 
added) master mix A, B, C or D. All no template controls (H2O) gave a signal in the ROX channel. The only reaction 
to not give a ROX signal was one of the ‘MM only’ controls in master mix D. No signals were detected in the VIC 
and FAM channels.  
 
 
 
 
Figure A2.1 Amplification plot showing the ROX channel from the no template control experiment with GF EGFR 
assay version 3 (sample data shown in table A2.1.6). The plot shows a number of fluorescence signals being 
generated by no template controls. No signals were detected in the VIC and FAM channels. 
Sample 
Name
PCR Master 
Mix
Ct Ct Mean
Control Pos/ 
Neg
Assay Pass/ 
Fail
Comments
NF H20 A 30.762 31.899 POS FAIL ROX positive
NF H20 A 33.036 31.899 POS FAIL ROX positive
MM only A 28.562 28.583 POS FAIL ROX positive
MM only A 28.605 28.583 POS FAIL ROX positive
NF H20 B 30.157 29.957 POS FAIL ROX positive
NF H20 B 29.756 29.957 POS FAIL ROX positive
MM only B 29.436 29.213 POS FAIL ROX positive
MM only B 28.991 29.213 POS FAIL ROX positive
NF H20 C 27.731 27.441 POS FAIL ROX positive
NF H20 C 27.150 27.441 POS FAIL ROX positive
MM only C 29.833 28.146 POS FAIL ROX positive
MM only C 26.459 28.146 POS FAIL ROX positive
NF H20 D 30.425 29.721 POS FAIL ROX positive
NF H20 D 29.016 29.721 POS FAIL ROX positive
MM only D Undetermined 27.518 NEG PASS
MM only D 27.518 27.518 POS FAIL ROX positive
PCR VALIDATIONROX
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A2.2 GeneFirst KRAS raw data versions 1-5 
 
Table A2.2.1: Anonymised Pathology samples tested using the GeneFirst KRAS PCR assay version 1. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
Study ID Mutations DNA Loading (ng)
Concordance 
with CAST
KRASv1 01 G12A 30.00 Match
KRASv1 02 G12D 30.00 Match
KRASv1 03 WT 30.00 Match
KRASv1 04 G12A 30.00 Match
KRASv1 05 WT 30.00 Match
KRASv1 06 G12C 30.00 Match
KRASv1 07 G12V 30.00 Discrepant
KRASv1 08 G12A 15.00 Discrepant
KRASv1 09 G12D 15.00 Match
KRASv1 10 G12A 15.00 Match
KRASv1 11 WT 15.00 Match
KRASv1 16 G12C 15.00 Match
KRASv1 17 G12V 15.00 Match
KRASv1 18 WT 15.00 Match
KRASv1 12 G12A 7.50 Match
KRASv1 13 G12D 7.50 Match
KRASv1 14 G12A 7.50 Match
KRASv1 15 WT 7.50 Match
KRASv1 19 G12C 7.50 Match
KRASv1 20 G12V 7.50 Match
KRASv1 21 WT 7.50 Match
Match: 16.97 Concordance
Discrepant: 22.50 90.48%
Mean PCR DNA 
input (ng)
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Table A2.2.2: Anonymised Pathology samples tested using the GeneFirst KRAS PCR assay version 2. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
Study ID Mutations DNA Loading (ng)
Concordance 
with CAST
KRASv2 06 G12C 185.20 Match
KRASv2 07 G12C 185.20 Discrepant
KRASv2 10 G12V 111.31 Match
KRASv2 11 G12V 111.31 Match
KRASv2 08 G12A 86.53 Discrepant
KRASv2 09 G12A 86.53 Match
KRASv2 25 WT 85.93 Match
KRASv2 26 WT 84.33 Match
KRASv2 17 WT 63.62 Match
KRASv2 22 WT 61.97 Match
KRASv2 01 WT 61.41 Match
KRASv2 02 WT 61.41 Match
KRASv2 20 WT 59.72 Match
KRASv2 24 WT 52.89 Match
KRASv2 03 G12A 52.33 Discrepant
KRASv2 04 G12A 52.33 Discrepant
KRASv2 18 G12D 50.78 Discrepant
KRASv2 16 WT 47.31 Match
KRASv2 15 WT 35.72 Match
KRASv2 23 G12D 35.14 Discrepant
KRASv2 33 G12D 33.20 Discrepant
KRASv2 27 G12V 32.60 Match
KRASv2 30 G12V 31.42 Match
KRASv2 39 G12V 31.40 Match
KRASv2 38 WT 30.00 Match
KRASv2 32 G12V 29.04 Match
KRASv2 28 G12D 27.00 Discrepant
KRASv2 43 G12D 27.00 Match
KRASv2 31 G12D 25.00 Match
KRASv2 19 G12D 22.15 Match
KRASv2 21 G12V 21.90 Discrepant
KRASv2 29 G12D 21.00 Discrepant
KRASv2 05 G12D 8.18 Discrepant
KRASv2 40 G12V 3.00 Match
KRASv2 44 G12D 3.00 Match
KRASv2 41 G12V 1.50 Discrepant
KRASv2 45 G12D 1.50 Match
KRASv2 42 G12V 0.60 Match
KRASv2 46 G12D 0.60 Match
Match: 49.85 Concordance
Discrepant: 47.92 69.23%
Mean PCR DNA 
input (ng)
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Table A2.2.3 Anonymised Pathology samples tested using the GeneFirst KRAS PCR assay version 3. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
 
Study ID Mutations
DNA Loading 
(ng)
Concordance with 
CAST
KRASv3 09 G12V 21.00 Match
KRASv3 07 G13D 20.80 Match
KRASv3 08 G12D 18.70 Discrepant
KRASv3 15 G12D 15.00 Discrepant
KRASv3 16 G12V 15.00 Match
KRASv3 17 WT 15.00 Match
KRASv3 18 G13D 15.00 Match
KRASv3 19 WT 15.00 Match
KRASv3 20 WT 15.00 Match
KRASv3 21 WT 15.00 Match
KRASv3 22 WT 15.00 Match
KRASv3 23 WT 15.00 Match
KRASv3 24 G12V 15.00 Match
KRASv3 25 WT 15.00 Match
KRASv3 01 G12A 6.84 Match
KRASv3 04 G12A 4.52 Match
KRASv3 03 G12C 4.32 Match
KRASv3 06 G12D 2.36 Discrepant
KRASv3 02 G12D 2.14 Discrepant
Match: 13.83 Concordance
Discrepant: 9.55 78.95%
Mean PCR DNA 
input (ng)
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Table A2.2.4 Anonymised Pathology samples tested using the GeneFirst KRAS PCR assay version 4. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID Mutations DNA Loading (ng)
Concordance with 
CAST
KRASv4 01 G12D 24.40 Discrepant
KRASv4 10 G12V 16.00 Match
KRASv4 07 WT 11.44 Discrepant
KRASv4 03 WT 10.12 Discrepant
KRASv4 04 WT 9.32 Discrepant
KRASv4 08 G12A 8.72 Discrepant
KRASv4 09 G12C 7.16 Match
KRASv4 05 WT 5.56 Discrepant
KRASv4 02 WT 5.44 Discrepant
KRASv4 14 G12V 4.24 Match
KRASv4 15 G12D 4.16 Discrepant
KRASv4 13 WT 3.26 Discrepant
KRASv4 12 WT 1.00 Match
KRASv4 06 WT 0.71 Discrepant
KRASv4 11 WT 0.39 Discrepant
Match: 7.10 Concordance
Discrepant: 7.59 26.67%
Mean PCR DNA 
input (ng)
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Table A2.2.5 Anonymised Pathology samples tested using the GeneFirst KRAS PCR assay version 5. Positive 
concordance value (%) shown in bottom right cell. WT = Wild-type. 
 
 
Table A2.2.6 Experiments running no template controls in the GF KRAS assay version 3. Control designations: ‘NF 
H2O’ = Nuclease Free water control, tested in master mix A or B. ‘MM only’ = master mix only, (no H2O added) 
master mix A or B. All controls (H2O and MM only) gave a signal in the ROX channel. Additionally the MM only 
control in master mix B gave a signal in the FAM channel.  
 
 
 
Study ID Mutations DNA Loading (ng)
Concordance with 
CAST
KRASv5 01 WT 30.00 Match
KRASv5 02 WT 30.00 Match
KRASv5 03 G12V 30.00 Match
KRASv5 04 G12C 30.00 Match
KRASv5 05 G12C 30.00 Match
KRASv5 06 G12D 30.00 Discrepant
KRASv5 07 G12D 30.00 Match
KRASv5 08 G12A 30.00 Discrepant
KRASv5 09 WT 30.00 Discrepant
KRASv5 10 WT 15.00 Match
KRASv5 11 WT 15.00 Match
KRASv5 12 G12V 15.00 Discrepant
KRASv5 13 G12C 15.00 Match
KRASv5 14 G12C 15.00 Match
KRASv5 15 G12D 15.00 Match
KRASv5 16 G12D 15.00 Match
KRASv5 17 G12A 15.00 Discrepant
KRASv5 18 WT 15.00 Discrepant
Match: 22.50 Concordance
Discrepant: 22.50 66.67%
Mean PCR DNA 
input (ng)
Sample 
Name
PCR Master 
Mix
Ct Ct Mean Ct Ct Mean
Control 
Pos/ Neg
Assay 
Pass/ Fail
Comments
NF H20 A Undetermined 15.374 15.345 POS FAIL ROX positive
NF H20 A Undetermined 15.316 15.345 POS FAIL ROX positive
MM only A Undetermined 14.606 14.730 POS FAIL ROX positive
MM only A Undetermined 14.854 14.730 POS FAIL ROX positive
NF H20 B Undetermined 17.624 17.790 POS FAIL ROX positive
NF H20 B Undetermined 17.956 17.790 POS FAIL ROX positive
MM only B 24.285 24.697 17.450 17.476 POS FAIL ROX positive
MM only B 25.108 24.697 17.502 17.476 POS FAIL ROX positive
PCR VALIDATIONFAM ROX
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Figure A2.2.1 Amplification plot showing the ROX channel from the no template control experiment with GF 
KRAS assay version 3 (sample data shown in table A2.2.6). The plot shows a number of fluorescence signals 
being generated by no template controls. No signals were detected in the VIC channel.  
 
 
 
Figure A2.2.2 Amplification plot showing the FAM channel from the no template control experiment with GF KRAS 
assay version 3 (sample data shown in table A2.2.6). The plot shows the two fluorescence signals generated by 
the master mix only control in reaction B. No signals were detected in the VIC channel. 
 
173 
 
A2.3 NGS Supplemental Data 
 
Table A2.3 All NGS hotspot data detected in tissue DNA samples that were tested using the GeneFirst EGFR or 
KRAS assays. Rows containing EGFR and KRAS hotspots are highlighted in blue. SNP = Single Nucleotide 
Polymorphism. 
 
  
Study ID Frequency Quality Type Allele Name AA change Gene ID Coverage
Allele 
Coverage
Strand 
Bias
EGFRv2 43 2 7.28 SNP COSM232263 p.R612Q ERBB4 152 3 0.6714
EGFRv2 43 66.7 1974.18 SNP COSM125370 p.E545K PIK3CA 255 170 0.5217
EGFRv2 43 66.7 1974.18 SNP COSM763 p.E545K PIK3CA 255 170 0.5217
EGFRv2 43 3.6 7.92 SNP COSM22973 p.R393* FBXW7 56 2 0.5884
EGFRv2 43 2.8 12.52 SNP COSM17570 p.P741L EGFR 177 5 0.5527
EGFRv2 43 2 7.48 SNP COSM33729 p.R603* BRAF 252 5 0.7722
EGFRv2 43 41.3 774.99 SNP COSM522 p.G12A KRAS 213 88 0.5634
EGFRv2 43 3.4 7.40 SNP COSM11183 p.R267W TP53 119 4 0.684
EGFRv2 43 3.4 7.40 SNP COSM179804 p.R267W TP53 119 4 0.684
EGFRv2 43 1.9 6.39 SNP COSM6932 p.G245S TP53 312 6 0.6191
EGFRv2 43 1.9 6.39 SNP COSM121037 p.G152S TP53 312 6 0.6191
EGFRv2 43 1.9 6.39 SNP COSM121036 p.G245S TP53 312 6 0.6191
EGFRv2 43 1.9 6.39 SNP COSM121035 p.G245S TP53 312 6 0.6191
EGFRv2 43 2.9 10.97 SNP COSM43939 p.T211I TP53 139 4 0.5394
EGFRv2 43 2.3 8.60 SNP COSM45440 p.A189A TP53 133 3 0.7497
EGFRv2 43 2.6 11.23 SNP COSM45627 p.I162I TP53 229 6 0.5239
EGFRv2 43 5.5 13.23 SNP COSM44492 p.W91* TP53 55 3 0.5331
EGFRv2 44 2.8 12.34 SNP COSM232263 p.R612Q ERBB4 179 5 0.8275
EGFRv2 44 2.3 8.55 SNP COSM28605 p.A871T EGFR 133 3 0.5617
EGFRv2 44 6.7 9.81 DEL COSM13047 p.V1578delV NOTCH1 30 2 0.533
EGFRv2 44 25.8 401.81 SNP COSM516 p.G12C KRAS 229 59 0.5199
EGFRv2 44 2.9 11.86 SNP COSM44737 p.E287G TP53 140 4 0.7434
EGFRv2 44 16.8 122.24 SNP COSM10859 p.V272L TP53 137 23 0.5399
EGFRv2 44 21.8 388.92 SNP COSM11517 p.Y126C TP53 289 63 0.5352
EGFRv2 44 36.7 193.51 DEL COSM20871 p.P281fs*6 STK11 139 51 0.5651
EGFRv2 44 36.7 193.51 DEL COSM12924 p.P281fs*6 STK11 139 51 0.5651
EGFRv2 46 2.4 8.37 DEL COSM13047 p.V1578delV NOTCH1 82 2 0.5604
EGFRv2 46 1.7 6.62 DEL COSM5823 p.T321fs*23 PTEN 287 5 0.6341
EGFRv2 46 1.7 6.62 DEL COSM5801 p.N323fs*21 PTEN 287 5 0.6341
EGFRv2 46 3 11.83 SNP COSM44194 p.A84V TP53 135 4 0.5037
EGFRv2 46 2.1 9.06 SNP COSM14065 p.V842I ERBB2 328 7 0.526
EGFRv2 04 88.6 12667.50 SNP COSM6224 p.L858R EGFR 1996 1768 0.5073
EGFRv2 04 52.6 4657.79 SNP COSM710 no record MET 855 450 0.5017
KRASv2 05 1.9 6.16 SNP COSM449 p.G464E BRAF 215 4 0.7641
KRASv2 05 2.4 9.40 SNP COSM13042 p.L1593P NOTCH1 123 3 0.6971
KRASv2 05 1.8 6.60 SNP COSM12772 p.L1574P NOTCH1 114 2 0.5347
KRASv2 05 1.8 6.60 SNP COSM24673 no record NOTCH1 114 2 0.5347
KRASv2 05 3.5 9.21 SNP COSM521 p.G12D KRAS 260 9 0.7188
KRASv3 08 50.3 7922.22 SNP COSM521 p.G12D KRAS 1546 777 0.5096
KRASv2 03 33.7 5434.23 SNP COSM760 p.E542K PIK3CA 1999 674 0.5038
KRASv2 03 40.3 7238.55 SNP COSM522 p.G12A KRAS 2000 806 0.5094
KRASv2 07 39 6870.49 SNP COSM760 p.E542K PIK3CA 2000 780 0.5222
KRASv2 07 48 4827.25 SNP COSM516 p.G12C KRAS 1019 489 0.5117
KRASv2 07 78.2 1989.65 SNP COSM10660 p.R273H TP53 193 151 0.5143
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Chapter Three – Optimisation 
and Validation of Cancer Gene 
Mutation Detection in tissue 
using TaqMan Array 
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3.1 INTRODUCTION 
 
The advancement of molecular biology over recent decades has revolutionised diagnostic 
medicine by allowing rapid, accurate and cost effective analysis of genetic aspects of human 
disease pathology. Current developments in personalised medicine for the treatment of 
cancer would not be possible without both the expansion of our knowledge of actionable 
mutations and recent developments in molecular technology. Diagnosis rates for many 
cancers are also improving dramatically, resulting in many more patients being diagnosed 
and managed at an earlier stage. 
 
However, the expansion of our knowledge and increased diagnosis rate has put both 
additional strain on the NHS pathology services and an increased demand for analysis of 
molecular targets. Molecular diagnostic laboratories are under increasing pressure to offer 
a broader range of molecular assays with a fast turnaround time. In order to meet this 
demand, NHS pathology services must continuously assess their current assays and 
investigate new technology that can maximise staff time efficiency, maintain standards of 
accuracy and precision, and potentially broaden the range of services the department can 
offer to their clinical colleagues. 
 
In order to meet these requirements of a rapidly developing field, many current molecular 
assays have become increasingly complex and labour intensive to perform. Increasing 
complexity of assays leaves them vulnerable to human error and contamination, resulting in 
potential mistakes or misdiagnosis, and also resulting in assays needing to be repeated and 
thus a knock on affect to turnaround time and cost. 
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In the UHCW Pathology Department EGFR, KRAS and BRAF testing are performed on separate 
assays (Qiagen Therascreen for EGFR, an in-house Life Technologies castPCR for KRAS and 
BRAF). Technical details of these assays are described in the Methods section. These assays 
have both been clinically validated for diagnostic use, however they both require the use of 
multiple master mixes and a considerable amount of staff hands-on-time due to multiple 
replicates required per sample, and a high degree of manual dexterity due to the small 
RotaGene™ tubes (Therascreen) or microtiter plate wells (CastPCR) used to run the reactions. 
 
The TaqMan Array (TA) is a PCR platform technology developed by Life Technologies 
(ThermoFisher). The array comes uses a 384 well plate format, with each set of 48 wells 
separated into 8 micro-fluidic channels. Each of the 48 wells in the channels contains a set of 
lyophilised primers and probes for one specific molecular target dispensed during 
manufacture of the array. Each well has a reaction volume of just 1 microlitre. A mixture of 
sample and master mix reagents are dispensed into a loading port at one end of the plate, 
which is then centrifuged to distribute the sample-reagent mixture across all 48 wells in that 
channel. The chemistry for these individual well assays is the same as castPCR (described 
previously). 48 specific molecular targets can be analysed per sample per run. This is a 
considerable improvement on other assays as in this case every target has its own well, 
whereas other assays often detect multiple mutants in the same well, but cannot distinguish 
between them (e.g. GeneFirst). 
 
Once the sample and reagents are centrifuged into the TA wells, the plate can be sealed and 
run on a ViiA7 Thermocycler fitted with a compatible heating block and lid. As the plate is 
separated into channels of 48 wells, therefore 8 samples (typically 7 samples and 1 negative 
control) can be analysed on one plate, and the entire plate can be loaded in only 8 pipetting 
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actions. This dramatically reduces operator hands on time and the chances of contamination 
error. 
 
Beyond potential diagnostic applications, TA format assays are widely used in a number of 
research settings, most notably for the analysis of microRNA (miRNA) samples. In the field of 
cancer there are a number of recent studies using TA to analyse miRNA samples to 
investigate a range of different cancers, including: esophageal cancer (Warnecke-Eberz et al., 
2016), gastric cancer (Qiu et al., 2016; Zhu et al., 2014), hepatocellular carcinoma (Zhuang et 
al., 2015) and ovarian cancer (Zheng et al., 2013). Outside cancer TA assays are utilised in a 
number of other disciplines including a range of microbiology applications (Muhammad et 
al., 2015; Joshi & Arankalle, 2015; Aqil et al., 2014), cardiology (Sepramaniam et al., 2014) 
and psychiatry/ neurology (Wei et al., 2015). The diversity of fields in which the TA has been 
applied strongly suggests this format of molecular assay is both robust and adaptable, so 
should mean it is well suited to the detection of EGFR and KRAS mutations in our clinical 
setting. 
  
178 
 
3.1.1 Aims 
 
The Taqman Array assay has a number of considerable advantages over the two currently 
used assays in UHCW Pathology.  It has the potential to combine several gene mutation 
assays in one plate, with reduced hands-on time and equivalent sensitivity.  The aim of the 
study was to replace the current Qiagen Therascreen EGFR assay and KRAS castPCR assays 
with a single array, producing savings for the department in staff time and resources while 
providing patients with an improved molecular diagnostic service.  The combined RAS, EGFR 
and BRAF assay is known as the REB array. 
 
 To optimise the sample loading specifications for analysis of EGFR, KRAS, NRAS and 
BRAF from extracted FFPE tissue samples. 
 
 To validate the performance of the REB array assay against the currently used 
Qiagen Therascreen EGFR assay and the Life Technologies castPCR assay. Results to 
be verified by Ion Torrent NGS analysis. 
 
 If the TA assay gives comparable or improved results over currently used assays: 
the TA will be implemented by UHCW Pathology as their new service method for 
detection of EGFR, KRAS, NRAS and BRAF mutations. 
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3.2 METHODS 
 
3.2.1 Equipment 
 
Bench top centrifuge compatible with 1.5ml micro-centrifuge tubes (up to 15500g) 
Bench top centrifuge compatible with 96 well PCR plates (up to 1600g) and Taqman arrays 
Bench top centrifuge compatible with Ion Torrent sequencing chips (314, 316 and 318) 
Heat block capable of heating 1.5ml tubes to 70C 
Promega Maxwell Automated Extraction Instrument 
Laminar Flow safety cabinet with UV decontamination feature 
Qubit 2.0 Nucleic Acid Analyser 
Life Technologies ViiA 7 Dx Real Time PCR instrument with Fast 96 well block 
Life Technologies ViiA 7 384 well block 
Life Technologies TaqMan Array card staker (for TA card sealing) 
Life Technologies Ion Chef instrument (see figure 2.2.8.3.2) 
Life Technologies Ion Torrent PGM instrument (see figure 2.2.8.3.2) 
Millipore water purification system 
 
3.2.2 Kits and Reagents 
 
Qubit dsDNA High Sensitivity reagent kit 
Promega Maxwell FFPE DNA Kit 
Promega Maxwell Circulating DNA Kit (prototype) 
Nuclease free DEPC-treated water 
TaqMan Universal PCR Master Mix 
Life Technologies Ion AmpliSeq™ Colon and Lung Panel 
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Life Technologies Ion Express Barcode 1-16 Kit 
Life Technologies Ion Express Barcode 17- 32 Kit 
Life Technologies Ion Torrent PGM Sequencing 200 Kit 
Life Technologies Ion AmpliSeq™ Library Kit 2.0 
Life Technologies Ion PGM IC 200 Kit 
Life Technologies Oncomine™ Solid Tumour DNA Kit 
 
 
3.2.3 Design of REB Arrays 
 
The plate design is shown in table 3.2.3. In discussion with my supervisor Prof Cree, the 
COSMIC database was interrogated to identify mutations that were most commonly 
reported, and the resultant list was used to compile the plate playout. CastPCR assays for 
each of these were identified from the Life technologies website 
(http://www.lifetechnologies.com/it/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/taqman-mutation-detection-assays/somatic-mutation-real-time-pcr.html) and 
used to populate a spreadsheet which was used to manufacture the array cards. TaqMan® 
Mutation Detection Assays for the detection of mutant alleles must be run in parallel with 
corresponding wild-type allele assays.  This acts as a positive control for the wild-type DNA. 
For each gene, a reference assay was therefore required. 
 
 
 
 
 
 
181 
 
Table 3.2.3 Reference (suffix _rf) and Mutant (suffix _mu) assays included in the TA assay plate lay out. 
 
 
 
Each well on the 384 well REB Array contains a separate assay, allowing detection of a large 
number of targets, without multiplexing. The card is divided along the rows into 8 separate 
channels, each containing 48 wells housing separate castPCR assays (four reference wild-
type assays, 44 mutant assays) into which a single sample is loaded with a single pipetting 
step. This elimination of individual well pipetting dramatically reduces the risk of 
contamination or operator error. As each port uses 48 wells, and the individual assays are 
very reliable (CoV < 2% in previous studies (Glaysher et al., 2009)), a single well is sufficient 
for each assay. It is however, good practice to run control plates at regular intervals, 
particularly with new plate or reagent batches. If duplicates or triplicates for individual 
samples or controls are required, two or three ports respectively must be used. 
 
 
TA Ref HGVS TA Ref HGVS
1 A EGFR_rf - B KRAS_522_mu KRAS c.35G>C p.Gly12Ala
2 A EGFR_ex19dels_mu EGFR c.2238_2252del15 
p.L747_T751delLREAT B KRAS_518_mu KRAS c.34G>C p.Gly12Arg
3 A EGFR_6224_mu
EGFR c.2573T>G p.Leu858Arg; EGFR 
c.2572_2573CT>AG p.Leu858Arg
B KRAS_19404_mu KRAS c.436G>A p.Ala146Thr
4 A EGFR_6240_mu EGFR c.2369C>T p.Thr790Met B KRAS_527_mu KRAS c.37G>T p.Gly13Cys
5 A EGFR_6213_mu EGFR c.2582T>A p.Leu861Gln B KRAS_554_mu KRAS c.183A>C p.Gln61H
6 A EGFR_6241_mu c.2303G>T p.Ser768Ile B KRAS_553_mu KRAS c.182A>T p.Gln61Leu
7 A EGFR_6239_mu EGFR c.2156G>C Gly719Ala B KRAS_529_mu KRAS c.37G>C p.Gly13Arg
8 A EGFR_6252_mu EGFR c.2155G>A p.Gly719Ser B NRAS_rf -
9 A EGFR_6253_mu EGFR c.2155G>T P.Gly719Cys B NRAS_569_mu NRAS c.37G>C p.Gly13Arg
10 A EGFR_12988_mu EGFR c.2125G>A p.Glu709Lys B NRAS_562_mu NRAS c.34G>T p.Gly12Cys
11 A EGFR_13427_mu EGFR c.2126A>C p.Glu709Ala B NRAS_563_mu NRAS c.34G>A p.Gly12Ser
12 A EGFR_13428_mu EGFR c.2311_2312insGCGTGGACA B NRAS_573_mu NRAS c.38G>A p.Gly13Asp
13 A EGFR_12381_mu EGFR c.2319_2320ins9 B NRAS_583_mu
1 2A>T p.Gln61Leu; 
NRAS c.181_182CA>TT 
14 A BRAF_rf - B NRAS_564_mu NRAS c.35G>A p.Gly12Asp
15 A BRAF_476_mu BRAF c.1799T>A p.Val600Glu B NRAS_580_mu NRAS c.181C>A p.Gln61Lys
16 A BRAF_475_mu BRAF c.1798_1799GT>AA p.Val600Glu B NRAS_584_mu
2A G Arg; 
NRAS c.181_182CA>AG 
17 A BRAF_474_mu BRAF c.1798_1799GT>AG p.Val600Arg B NRAS_574_mu NRAS c.38G>T p.Gly13Val
18 A BRAF_473_mu BRAF c.1799_1800TG>AT p.Val600Asp B NRAS_566_mu NRAS c.35G>T p.Gly12Val
19 A KRAS_rf - B NRAS_585_mu NRAS c.183A>T p.Gln61His
20 A KRAS_521_mu KRAS c.35G>A p.Gly12Asp B NRAS_586_mu NRAS c.183A>C p.Gln61His
21 A KRAS_520_mu KRAS c.35G>T p.Gly12Val B NRAS_565_mu NRAS c.35G>C p.Gly12Ala
22 A KRAS_532_mu KRAS c.38G>A p.Gly13Asp B NRAS_570_mu NRAS c.37G>T p.Gly13Cys
23 A KRAS_516_mu KRAS c.34G>T p.Gly12Cys B NRAS_571_mu NRAS c.37G>A p.Gly13Ser
24 A KRAS_517_mu KRAS c.34G>A p.Gly12Ser B NRAS_575_mu NRAS c.38G>C p.Gly13Ala
RowColumn Row
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3.2.4 Patients and Samples 
 
96 patients were retrospectively identified with known mutational status. Samples were 
either extracted DNA from remaining formalin-fixed, paraffin-embedded FFPE blocks, or 
used stored DNA from the previous diagnostic PCR assays to validate the Taqman/ REB array, 
the characteristics according to the BRISQ (Biospecimen reporting for improved study 
quality) guidance (Moore et al., 2011). Due to its retrospective nature for laboratory 
developed test validation, UK Health Research Authority Ethics Committee approval was not 
required. 
 
FFPE blocks were identified for a series of patients with NSCLC (n = 42), colorectal cancer (n 
= 26), and melanoma (n = 28) for which mutational analysis previously been performed using 
Therascreen or castPCR.  It should be noted that these were not consecutive or randomly 
selected patients, but were instead chosen reflect the range of mutations seen in our 
laboratory, for the purpose of clinical validation of the REB array from samples with sufficient 
remaining tissue surplus to diagnostic requirements. Where it was necessary to obtain 
further DNA, the same block was used when this could be identified from the pathology 
report.   
 
 
3.2.5 DNA Extraction 
 
Areas of high cellularity for neoplastic cells within the tumour were identified by a 
histopathologist and marked on a slide. These were matched with the corresponding block 
and case.  Samples from the areas marked were punched out using a 1 mm diameter skin 
punch, as previously described (Bolton et al., 2015).  The samples were then placed in the 
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vial of a Maxwell DNA extraction robot (Promega, Southampton, UK) and DNA extracted 
according to the manufacturer’s instructions.  Stored or newly extracted DNA was checked 
for content and quality using a Nanodrop or Qubit instrument (both from Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 
 
 
3.2.6 TaqMan Arrays 
 
Individual samples were diluted with MM and dH2O to give a volume of 100 µL. The reaction 
mixtures were prepared at varying DNA concentrations, depending on which phase of the 
validation was being performed (see Results). After mixing, 100 µL of each sample extract 
was added to each port of a REB array.  The array plates were sealed, spun and placed in a 
previously calibrated ViiA7 PCR machine (ThermoFisher). Standard PCR conditions were used 
as follows: 50oC for 2 min, followed by 95oC for 1 min, then 40 cycles of 95oC for 15 sec, and 
60oC for 1 min. Each run took 118 minutes to complete.  
 
For efficient use of the REB arrays, samples must be grouped into batches of 7 (to fill the 8 
channel card, 7 samples + 1 negative control). Smaller batch sizes require empty channels to 
be loaded with master mix before running, to avoid inaccurate data analysis by the ViiA7 
software.  
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Figure 3.2.6 Diagram of the TaqMan Array card, from kit handbook (Thermofisher). 48 well channels are loaded 
using one of the eight fill reservoirs located in the fill strip at the open end of the card. The fill strip is removed 
after the card is sealed.  
 
 
3.2.7 Data Analysis 
 
The ViiA7 software produces a spreadsheet of Ct values for each well, clearly identified by 
sample number.  The results from the spreadsheets were then collected into a further 
summary spreadsheet in Excel (Microsoft).  The following exclusions were applied: 
 
 Samples with insufficient DNA content (<50 ng total card input) were excluded from the 
analysis. 
 Samples where one or more controls failed were excluded from the analysis as failed 
samples. 
 Samples giving positive Ct values for targets on genes not present in the comparator 
assays were excluded from analysis as the significance of these results could not be 
determined. 
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Cases with discrepant results were sequenced on the Ion Torrent PGM using the 
OncoNetwork 22 gene panel (Tops et al., 2015).  Descriptive statistics, including sensitivity 
and specificity were produced using Excel. 
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3.3 RESULTS 
 
3.3.1 Setting Analysis Thresholds 
 
The first priority of the optimisation process was to determine the cycle thresholds for 
classifying samples as positive or negative. The manufacturer’s guidance suggested a cut off 
Ct of 32 for positive PCR signals, however I considered it important to assess the performance 
of the assay with our sample type and select cut offs appropriate to our setting. 
 
36 samples previously analysed FFPE DNA samples were obtained from the Pathology 
Department. The samples were loaded and run on the TaqMan Array cards at a range of DNA 
concentrations in order to assess the performance of the assay. Samples with high DNA 
concentrations or large remaining volumes were loaded at higher DNA inputs (where 
possible). Samples with low DNA concentrations or low remaining volumes were not diluted.  
 
Table 3.2.1.1 shows the performance of the TaqMan Array control assays with the panel of 
36 samples at varying concentrations. Ct values within these data varied greatly from 25.76 
to 39.58. Using the manufacturer’s suggested cut off resulted in 28/ 36 (77.8%) failing to 
generate a ‘positive Ct’ in all control assays. This suggested that the manufacturer’s guidance 
was not necessarily suited to our sample types. 
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Table 3.3.1.1 TaqMan Array control assay performance with a selection of samples at varying DNA concentrations. 
Ranked and colour scaled in order of gDNA input, lowest to highest. Ct values considered positive are below 32, 
highlighted in green/ blue. Assays failing for generate a Ct are represented as ‘Undetermined’ (highlighted red/ 
pink). 
 
 
 
Study Sample 
No
gDNA input 
(ng, total)
EGFR_Rf Ct KRAS_Rf Ct NRAS_Rf Ct BRAF_Rf Ct
1 18.0 31.55 29.99 31.06 31.22
8 30.0 34.85 32.51 32.80 33.35
32 31.3 28.66 28.73 30.59 30.11
3 47.8 33.36 29.88 31.28 31.12
5 60.0 34.82 38.67 37.70 Undetermined
31 62.5 27.64 27.47 29.58 27.64
28 75.0 33.29 30.82 33.70 32.30
36 100.0 33.65 30.73 31.17 32.03
4 100.2 32.63 29.81 31.36 30.96
30 125.0 28.92 27.70 29.83 29.21
27 150.0 33.43 29.14 31.15 30.54
35 239.0 33.40 27.32 30.80 31.86
29 250.0 28.64 25.76 28.87 27.94
10 250.0 31.57 28.97 30.70 31.12
7 250.0 32.41 31.27 32.51 32.51
19 250.0 33.60 33.08 30.34 31.59
25 250.0 34.68 36.43 31.65 32.68
24 250.0 34.92 36.94 30.65 33.79
15 250.0 35.02 37.59 31.80 33.15
16 250.0 35.11 37.66 31.71 32.69
23 250.0 35.27 Undetermined 31.11 33.55
22 250.0 35.33 38.31 30.85 32.74
17 250.0 36.03 Undetermined 31.66 33.77
21 250.0 36.80 Undetermined 32.27 33.84
12 250.0 37.08 Undetermined 31.59 34.99
18 250.0 38.50 39.58 33.23 37.17
14 250.0 39.45 Undetermined 33.17 37.76
13 250.0 Undetermined Undetermined 35.50 Undetermined
20 250.0 Undetermined Undetermined Undetermined Undetermined
33 300.0 33.69 28.68 30.31 30.63
34 300.0 Undetermined 31.94 33.21 33.45
2 302.8 36.63 33.24 32.96 32.35
26 450.0 30.77 27.22 28.64 29.97
9 500.0 29.18 27.35 29.01 29.06
11 500.0 32.11 28.99 31.12 31.66
6 500.0 33.08 29.72 32.17 31.58
188 
 
The performance of the mutant target assays is shown in table 3.2.1.2. In total 31 mutant 
assays gave a detectable signal. Using the manufacturer’s guidance cut off value of Ct32 for 
positive results, only 2/ 31 (6.5%) were determined as positive. Again this suggests the 
guidance values are not suited to our sample type. 
 
The results from this initial data set were reanalysed using higher cut off values. Table 3.3.1.3 
shows the reanalysed data from the control assays using a higher cut off of Ct35. This 
adjusted parameter resulted in a reduction in failure rate to 16/ 36 (44.4%), and reduction 
of 33.4% over the first analysis.  
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Table 3.3.1.2 TaqMan Array mutant target assay performance with a selection of samples at varying DNA 
concentrations. Ranked and colour scaled in order of gDNA input, lowest to highest. Ct values considered positive 
are below 32, highlighted in green/ blue. 
 
 
 
 
 
Sample 
No
DNA input (ng, 
total)
Target Name Ct Mean
1 18.0 BRAF_475_mu 37.00
1 18.0 BRAF_476_mu 38.23
1 18.0 NRAS_564_mu 38.10
9 30.0 BRAF_477_mu 33.99
32 31.3 NRAS_573_mu 39.86
3 47.8 NRAS_584_mu 34.24
8 60.0 BRAF_476_mu 36.18
31 62.5 BRAF_476_mu 39.48
31 62.5 EGFR_6240_mu 39.32
28 75.0 KRAS_19404_mu 35.31
36 100.0 KRAS_553_mu 31.44
4 100.2 KRAS_553_mu 32.87
27 150.0 KRAS_19404_mu 34.08
35 239.0 NRAS_584_mu 33.42
7 250.0 BRAF_476_mu 35.53
10 250.0 KRAS_520_mu 34.62
12 250.0 NRAS_580_mu 31.93
14 250.0 EGFR_6240_mu 39.17
16 250.0 BRAF_474_mu 32.58
16 250.0 NRAS_564_mu 32.56
19 250.0 BRAF_476_mu 34.66
20 250.0 EGFR_6253_mu 36.26
20 250.0 NRAS_565_mu 37.77
21 250.0 BRAF_476_mu 36.25
24 250.0 BRAF_476_mu 37.32
33 300.0 BRAF_476_mu 36.38
2 302.8 NRAS_583_mu 38.95
26 450.0 KRAS_19404_mu 32.99
6 500.0 BRAF_476_mu 34.02
11 500.0 EGFR_6240_mu 36.99
11 500.0 KRAS_520_mu 32.99
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Table 3.3.1.3 TaqMan Array control assay performance with a selection of samples at varying DNA concentrations. 
Ranked and colour scaled in order of gDNA input, lowest to highest. Ct values considered positive are below 35, 
highlighted in green/ blue. Assays failing for generate a Ct are represented as ‘Undetermined’ (highlighted red/ 
pink). 
 
 
 
 
Study Sample 
No
gDNA input 
(ng, total)
EGFR_Rf Ct KRAS_Rf Ct NRAS_Rf Ct BRAF_Rf Ct
1 18.0 31.55 29.99 31.06 31.22
8 30.0 34.85 32.51 32.80 33.35
32 31.3 28.66 28.73 30.59 30.11
3 47.8 33.36 29.88 31.28 31.12
5 60.0 34.82 38.67 37.70 Undetermined
31 62.5 27.64 27.47 29.58 27.64
28 75.0 33.29 30.82 33.70 32.30
36 100.0 33.65 30.73 31.17 32.03
4 100.2 32.63 29.81 31.36 30.96
30 125.0 28.92 27.70 29.83 29.21
27 150.0 33.43 29.14 31.15 30.54
35 239.0 33.40 27.32 30.80 31.86
29 250.0 28.64 25.76 28.87 27.94
10 250.0 31.57 28.97 30.70 31.12
7 250.0 32.41 31.27 32.51 32.51
19 250.0 33.60 33.08 30.34 31.59
25 250.0 34.68 36.43 31.65 32.68
24 250.0 34.92 36.94 30.65 33.79
15 250.0 35.02 37.59 31.80 33.15
16 250.0 35.11 37.66 31.71 32.69
23 250.0 35.27 Undetermined 31.11 33.55
22 250.0 35.33 38.31 30.85 32.74
17 250.0 36.03 Undetermined 31.66 33.77
21 250.0 36.80 Undetermined 32.27 33.84
12 250.0 37.08 Undetermined 31.59 34.99
18 250.0 38.50 39.58 33.23 37.17
14 250.0 39.45 Undetermined 33.17 37.76
13 250.0 Undetermined Undetermined 35.50 Undetermined
20 250.0 Undetermined Undetermined Undetermined Undetermined
33 300.0 33.69 28.68 30.31 30.63
34 300.0 Undetermined 31.94 33.21 33.45
2 302.8 36.63 33.24 32.96 32.35
26 450.0 30.77 27.22 28.64 29.97
9 500.0 29.18 27.35 29.01 29.06
11 500.0 32.11 28.99 31.12 31.66
6 500.0 33.08 29.72 32.17 31.58
191 
 
Table 3.3.1.4 shows the reanalysed data for the mutant target assays, using a higher cut off 
of Ct36.5. Using this higher cut off resulted in 20/ 31 (64.5%) signals being designated as 
positive, an increase of 58.0% over the previous analysis. 
 
Based on these preliminary observations, the decision was made to continue with these 
adjusted cut off values into the next phase of analysis. 
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Table 3.3.1.4 TaqMan Array control assay performance with a selection of samples at varying DNA concentrations. 
Ranked and colour scaled in order of gDNA input, lowest to highest. Ct values considered positive are below 36.5, 
highlighted in green/ blue. Assays failing for generate a Ct are represented as ‘Undetermined’ (highlighted red/ 
pink). 
 
 
 
 
Sample 
No
DNA input (ng, 
total)
Target Name Ct Mean
1 18.0 BRAF_475_mu 37.00
1 18.0 BRAF_476_mu 38.23
1 18.0 NRAS_564_mu 38.10
9 30.0 BRAF_477_mu 33.99
32 31.3 NRAS_573_mu 39.86
3 47.8 NRAS_584_mu 34.24
8 60.0 BRAF_476_mu 36.18
31 62.5 BRAF_476_mu 39.48
31 62.5 EGFR_6240_mu 39.32
28 75.0 KRAS_19404_mu 35.31
36 100.0 KRAS_553_mu 31.44
4 100.2 KRAS_553_mu 32.87
27 150.0 KRAS_19404_mu 34.08
35 239.0 NRAS_584_mu 33.42
7 250.0 BRAF_476_mu 35.53
10 250.0 KRAS_520_mu 34.62
12 250.0 NRAS_580_mu 31.93
14 250.0 EGFR_6240_mu 39.17
16 250.0 BRAF_474_mu 32.58
16 250.0 NRAS_564_mu 32.56
19 250.0 BRAF_476_mu 34.66
20 250.0 EGFR_6253_mu 36.26
20 250.0 NRAS_565_mu 37.77
21 250.0 BRAF_476_mu 36.25
24 250.0 BRAF_476_mu 37.32
33 300.0 BRAF_476_mu 36.38
2 302.8 NRAS_583_mu 38.95
26 450.0 KRAS_19404_mu 32.99
6 500.0 BRAF_476_mu 34.02
11 500.0 EGFR_6240_mu 36.99
11 500.0 KRAS_520_mu 32.99
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3.3.2 Optimisation of sample loading  
 
The second priority of the optimisation process was to establish the optimal DNA loading 
conditions for analysing FFPE DNA samples using the TaqMan Array. The previous stage 
(described in 3.2.1) gave some indication of the relative performance of the TaqMan Array 
at varying DNA concentrations, however this next phase would aim to determine the optimal 
DNA input amount. 
 
28 previously analysed samples were obtained from the UHCW Pathology Tissue Bank, DNA 
extracted using the Promega Maxwell, quantified by Qubit then analysed the TaqMan Array 
assay at varying concentrations, ranging from 250 ng to 1000 ng. Manufacturer’s guidance 
suggested a DNA input range of 10- 1000 ng gDNA, however for diagnostic use I believed 
determining an optimal DNA input was an essential step. When working with clinical 
samples, material is often limited, meaning it may not always be possible to input a high 
amount of DNA.  
 
The data from these samples is shown in table 3.3.2.1 and figure 3.3.2.1. It is clear from the 
control and target Ct values and the amplification plots that increasing gDNA input beyond a 
certain threshold has an inhibitory effect on assay performance. 
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Figure 3.3.2.1 Amplification plots from TaqMan Array runs at varying gDNA concentrations. Increasing gDNA input 
seems to inhibit assay performance. 
 
 
As a result of the data above, the next step was to perform serial dilutions at lower 
concentrations. Seven samples were serially diluted and analysed on the TaqMan Array. The 
samples were run at concentrations of 150, 100 and 50 ng of gDNA input. If assay 
performance was acceptable at these DNA inputs, then this would be very advantageous in 
the diagnostic setting due to the frequently low yield of DNA from certain specimens. The 
data from these serial dilutions is shown in figures 3.3.2.2- 5. 
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Figure 3.3.2.2 Amplification plots from TaqMan Array runs at varying gDNA concentrations. Decreasing gDNA 
input below 150 ng does not appear to inhibit assay performance. 
  
Figure 3.3.2.3 Performance of TA control assays (_rf) at varying DNA inputs. Series name have been removed 
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Figure 3.3.2.4 Summary chart of mean Ct from all control assays (_rf) at varying DNA inputs 
 
 
 
Figure 3.3.2.5 Performance of TA mutant target assays (_mu) at varying DNA inputs.  
 
 
Figures 3.3.2.2- 5 show the performance of the 7 serially diluted samples from 50- 150 ng. 
The increase in Ct as DNA input increases can be easily seen in the amplification plots shown 
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in figure 3.3.2.2. This suggests a slight inhibitory effect with increased DNA loading. Figure 
3.3.2.3 shows the Ct values of the control assays in more detail. Whilst many signal remain 
stable from 50- 150 ng of DNA input, there are a number of samples where Ct increases, and 
one example where the assay failed at 150 ng DNA input. The average Ct values for all the 
control assays generated by each sample was calculated and plotted in figure 3.3.2.4. This 
figure clearly shows the trend of increasing Ct with increased DNA input. 
 
With the mutant target assays the relationship between DNA input and assay performance 
was not as clear. The data is shown in figure 3.3.2.5. In some cases increasing DNA input 
lower Ct (sample EGFR 01) which reflects improved assay performance. However in other 
cases (KRAS 03, KRAS 04 and KRAS 05) increasing DNA input resulted in higher Ct, suggesting 
reduced assay performance. 
 
Due to the limitations in terms of the number of samples available, and the often low DNA 
concentrations experienced with clinical samples, the final analysis parameters were decided 
based on the observations described in sections 3.3.1 and 3.3.2.  
 
 
Final Analysis Thresholds: 
 
Sample loading: 50 ng total gDNA input. 
Control assays: Ct<=35 for positive. 
Mutant Target assays: Ct<=36.5 for positive. 
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3.3.3 Parallel testing of Pathology Department Diagnostic Samples 
 
Once optimal DNA loading and analysis cut offs had been determined, the next phase of this 
validation was to retest a panel of previously analysed samples using the TaqMan Array.   
 
 
3.3.4 Parallel testing: EGFR 
 
42 FFPE tissue samples from NSCLC patients were obtained from UHCW Pathology, DNA was 
extracted from micro dissected sections and the DNA analysed using the TaqMan Array. 
Table 3.2.4.1 shows the data from the NSCLC samples, including the original Therascreen 
results and the new results generated by the TaqMan Array.  
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Table 3.3.4.1 Results of NSCLC validation samples, including Therascreen and TaqMan Array results. WT = Wild-
type. 
 
 
 
39/42 samples matched the original Therascreen results, demonstrating a high level of 
concordance (92.86%). All samples gave strong Ct values for the control assays (<35), 
indicating well optimised control robust reactions with good tolerance for FFPE DNA which 
can be variable in quality from sample to sample. 
 
Sample ID
PCR PASS/ 
FAIL
Positive EGFR Targets Ct TA Result
Therascreen 
Result
Concordance
EGFR 01 PASS EGFR_6241_mu 32.905 S768I S768I MATCH
EGFR 02 PASS EGFR_ex19dels_mu 28.986 Exon 19 Del Exon 19 Del MATCH
EGFR 03 PASS EGFR_6224_mu 31.630 L858R L858R MATCH
EGFR 04 PASS EGFR_ex19dels_mu 36.119 Exon 19 Del Exon 19 Del MATCH
EGFR 05 PASS None WT WT MATCH
EGFR 06 PASS None WT WT MATCH
EGFR 07 PASS None WT WT MATCH
EGFR 08 PASS EGFR_ex19dels_mu 32.152 Exon 19 Del Exon 19 Del MATCH
EGFR 09 PASS EGFR_ex19dels_mu 30.311 Exon 19 Del Exon 19 Del MATCH
EGFR 10 PASS
EGFR_6213_mu; 
EGFR_6252_mu
33.492; 33.841
L861Q and 
G719X
L861Q and 
G719X
MATCH
EGFR 11 PASS EGFR_ex19dels_mu 31.994 Exon 19 Del Exon 19 Del MATCH
EGFR 12 PASS None WT WT MATCH
EGFR 13 PASS EGFR_6213_mu 31.691 L861Q L861Q MATCH
EGFR 14 PASS EGFR_ex19dels_mu 30.878 Exon 19 Del Exon 19 Del MATCH
EGFR 15 PASS EGFR_ex19dels_mu 31.060 Exon 19 Del Exon 19 Del MATCH
EGFR 16 PASS WT WT MATCH
EGFR 17 PASS WT WT MATCH
EGFR 18 PASS EGFR_ex19dels_mu 30.501 Exon 19 Del Exon 19 Del MATCH
EGFR 19 PASS None WT WT MATCH
EGFR 20 PASS None WT WT MATCH
EGFR 24 PASS None WT WT MATCH
EGFR 25 PASS None WT WT MATCH
EGFR 26 PASS None WT WT MATCH
EGFR 27 PASS None WT WT MATCH
EGFR 28 PASS None WT WT MATCH
EGFR 29 PASS None WT WT MATCH
EGFR 30 PASS None WT WT MATCH
EGFR 31 PASS None WT WT MATCH
EGFR 32 PASS EGFR_ex19dels_mu 34.947 Exon 19 Del Exon 19 Del MATCH
EGFR 33 PASS None WT WT MATCH
EGFR 34 PASS None WT WT MATCH
EGFR 35 PASS None WT WT MATCH
EGFR 36 PASS None WT WT MATCH
EGFR 37 PASS None WT WT MATCH
EGFR 38 PASS None WT WT MATCH
EGFR 39 PASS None WT WT MATCH
EGFR 40 PASS None WT WT MATCH
EGFR 41 PASS None WT WT MATCH
EGFR 42 PASS None WT WT MATCH
EGFR 21 PASS None WT S768I DISCREPANT
EGFR 22 PASS None WT Exon 20 Ins DISCREPANT
EGFR 23 PASS None WT T790M DISCREPANT
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There were 3 discrepancies: all were detected as wild-type by TaqMan Array but were 
previously positive on Therascreen. To confirm the mutation status of these samples they 
were analysed using the Ion Torrent NGS platform. The results are given in table 3.3.4.2. In 
two cases (EGFR 21 and 23) the NGS analysis confirmed the TaqMan results, so these were 
not true discrepancies, and the Therascreen results were incorrect. In the final discrepant 
sample (EGFR 22) NGS analysis confirmed the presence of an exon 21 insertion, however this 
was not a true discrepancy as the panel of mutations included in our TaqMan Array plate 
design did not include this exact mutation, therefore I would not expect the TaqMan Array 
to be able to detect it. NGS Analytics show the exon 20 insertion to have been at high 
frequency (56.7%) but relatively low coverage (216 reads) so this mutation may not have 
constituted a large proportion of the original sample. This discrepancy occurred due to 
differences in design between the two assays, and not due to an issue to sensitivity or 
specificity. So after confirmation by NGS, the adjusted concordance between Therascreen 
and TaqMan Array was 41/42 (97.62%). 
 
 
Table 3.3.4.2 NSCLC samples giving discrepant results (Therascreen vs TaqMan Array) and associated NGS results. 
WT = Wild-type. 
 
 
3.3.5 Parallel testing: KRAS/ NRAS 
 
26 FFPE tissue samples from NSCLC patients were obtained from UHCW Pathology, DNA was 
extracted from macrodissected sections and the DNA analysed using the TaqMan Array. 
TA Therascreen Concordance NGS Result Coverage Frequency
EGFR 21 WT S768I DISCREPANT WT - - True Negative
EGFR 22 WT Exon 20 Ins DISCREPANT Exon 20 Ins 216 56.7 False Negative
EGFR 23 WT T790M DISCREPANT WT - - True Negative
NGS Data
Sample ID
PCR Results
Designation
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Table 3.3.5.1 shows the samples where the original castPCR results matched the new results 
generated by the TaqMan Array. 7 samples had to be excluded from the analysis due to poor 
sample quality, therefore only 19 were included in the KRAS/ NRAS validation. 
 
Table 3.3.5.1 Results of colorectal validation samples, including castPCR and TaqMan Array results. WT = Wild-
type. 
 
 
 
The TA assay shows a high degree of concordance with CastPCR results, 18/19 (94.74%). 
There was one discrepant sample (KRAS 08) which was determined to be wild-type by TA but 
was determined to contain a G12D mutation by the original castPCR assay. This sample was 
sequenced using the Ion Torrent NGS system and the G12D mutation was detected. 
Therefore this was a true discrepancy, where the mutation was not detected by TA but 
successfully detected by castPCR and NGS. 
 
 
Sample ID
PCR PASS/ 
FAIL
Positive Targets Ct TA Result CAST Result Concordance
KRAS 01 PASS None WT WT MATCH
KRAS 02 PASS None WT WT MATCH
KRAS 03 PASS KRAS_520_mu 33.321 G12V G12V MATCH
KRAS 04 PASS KRAS_516_mu 34.060 G12C G12C MATCH
KRAS 05 PASS KRAS_521_mu 35.893 G12D G12D MATCH
KRAS 06 PASS KRAS_532_mu 31.412 G12D G12D MATCH
KRAS 07 PASS KRAS_532_mu 35.956 G12D G12D MATCH
KRAS 09 PASS NRAS_580_mu 31.751 Q61L Q61L MATCH
KRAS 10 PASS KRAS_522_mu 34.899 G12A G12A MATCH
KRAS 11 PASS KRAS_521_mu 33.179 G12D G12D MATCH
KRAS 12 PASS NRAS_564_mu 33.023 G12D G12D MATCH
KRAS 13 PASS KRAS_522_mu 35.350 G12A G12A MATCH
KRAS 14 PASS KRAS_521_mu 34.220 G12D G12D MATCH
KRAS 15 PASS KRAS_521_mu 35.144 G12D G12D MATCH
KRAS 16 PASS None WT WT MATCH
KRAS 17 PASS None WT WT MATCH
KRAS 18 PASS None WT WT MATCH
KRAS 19 PASS None WT WT MATCH
KRAS 08 PASS None WT G12D DISCREPANT
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Table 3.3.5.2 Colorectal samples giving discrepant results (castPCR vs TaqMan Array) and associated NGS 
results. WT = Wild-type.
 
 
 
3.3.6 Parallel testing: BRAF 
 
28 FFPE tissue samples from melanoma patients were obtained from UHCW Pathology, DNA 
was extracted from micro dissected sections and the DNA analysed using the TaqMan Array 
and Ion Torrent NGS. Table 3.3.6 shows the results of these tests. The TaqMan Array results 
from 27 of the 28 samples matched the results generated by NGS. There was one discrepant 
sample (MLM 27) where the TaqMan Array detected a V600E mutant which was not detected 
by NGS. This was determined to be a true discrepancy. 
  
Sample ID TA Result CAST Result TA vs CAST NGS Result Designation
KRAS 08 WT G13D DISCREPANT G14D Detected False Negative
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Table 3.3.6.1 Results of Melanoma validation samples, including TaqMan Array and NGS results. WT = Wild-
type. 
 
 
 
Table 3.3.6.2 Colorectal samples giving discrepant results (castPCR vs TaqMan Array) and associated NGS 
results. WT = Wild-type. 
 
  
Study ID
PCR PASS/ 
FAIL
Positive Targets Ct TA RESULT NGS Concordance
MLM 01 PASS NRAS_580_mu 31.714 Q61K Q61K MATCH
MLM 02 PASS BRAF_476_mu 32.078 V600E V600E MATCH
MLM 03 PASS WT WT MATCH
MLM 04 PASS BRAF_476_mu 35.811 V600E V600E MATCH
MLM 05 PASS BRAF_476_mu 33.455 V600E V600E MATCH
MLM 06 PASS NRAS_584_mu 34.406 Q61R Q61R MATCH
MLM 07 PASS NRAS_584_mu 34.056 Q61R Q61R MATCH
MLM 08 PASS WT WT MATCH
MLM 09 PASS NRAS_584_mu 35.556 Q61R Q61R MATCH
MLM 10 PASS WT WT MATCH
MLM 11 PASS WT WT MATCH
MLM 12 PASS WT WT MATCH
MLM 13 PASS NRAS_584_mu 35.592 Q61R Q61R MATCH
MLM 14 PASS BRAF_476_mu 32.146 V600E V600E MATCH
MLM 15 PASS NRAS_584_mu 36.232 Q61R Q61R MATCH
MLM 16 PASS BRAF_476_mu 33.090 V600E V600E MATCH
MLM 17 PASS BRAF_476_mu 31.873 V600E V600E MATCH
MLM 18 PASS WT WT MATCH
MLM 19 PASS BRAF_476_mu 33.260 V600E V600E MATCH
MLM 20 PASS WT WT MATCH
MLM 21 PASS BRAF_476_mu 36.159 V600E V600E MATCH
MLM 22 PASS BRAF_476_mu 32.099 V600E V600E MATCH
MLM 23 PASS BRAF_476_mu 36.474 V600E V600E MATCH
MLM 24 PASS WT WT MATCH
MLM 25 PASS BRAF_476_mu 34.339 V600E V600E MATCH
MLM 26 PASS NRAS_569_mu 35.205 G13R G13R MATCH
MLM 28 PASS NRAS_584_mu 35.093 Q61R Q61R MATCH
MLM 27 PASS BRAF_475_mu 31.447 V600E WT DISCREPANT
Study ID TA Result NGS Result TA vs NGS Designation
MLM 27 V600E WT DISCREPANT False Positive
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3.3.7 Sensitivity and Specificity 
 
The TaqMan array assay performed well with a majority of the lung, colorectal and 
melanoma samples used for validation. A summary of the data and associated statistics for 
sample set are shown in tables 3.3.7.1- 3. A summary of the overall data is shown in table 
3.3.7.4. Overall the assay demonstrated a sensitivity of 95.7% and a specificity of 97.8%. 
 
Table 3.3.7.1 Validation summary of lung samples tested using the TaqMan Array assay. 
 
  
TA Validation: Lung
Test Mutant Present Mutant absent
Positive True Positive 13 False Positive 0
Negative False Negative 1 True Negative 28
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
92.9%
100.0%
100.0%
96.6%
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Table 3.3.7.2 Validation summary of colorectal samples tested using the TaqMan Array assay. 
 
 
 
Table 3.3.7.3 Validation summary of melanoma samples tested using the TaqMan Array assay. 
 
 
 
 
TA Validation: Colorectal
Test Mutant Present Mutant absent
Positive True Positive 12 False Positive 0
Negative False Negative 1 True Negative 6
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
92.3%
100.0%
100.0%
85.7%
TA Validation: Melanoma
Test Mutant Present Mutant absent
Positive True Positive 19 False Positive 1
Negative False Negative 0 True Negative 10
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
100.0%
90.9%
95.0%
100.0%
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Table 3.3.7.4 Validation summary of Melanoma samples tested using the TaqMan Array assay. 
 
 
 
3.3.8 Prospective testing of plasma cfDNA 
 
After the validation of the TA using DNA extracted from lung, colorectal and melanoma tissue 
samples (sections 3.3.4, 3.3.5 and 3.3.6), the TA assay was implemented as the diagnostic 
assay for cancer gene mutations detection in EGFR, KRAS, NRAS and BRAF in the UHCW 
Pathology Department. Shortly after implementation I began prospectively testing plasma 
cfDNA samples submitted for testing by clinical staff. Plasma cfDNA samples were prepared 
as described in methods and loaded into the TA cards to the same specifications as tissue 
(up to 50 ng DNA total load per channel). To date 16 cfDNA samples have been tested using 
the TA. The results from these runs are shown in table 3.2.8. 
 
 
TA Validation: All Sample types
Test Mutant Present Mutant absent
Positive True Positive 44 False Positive 1
Negative False Negative 2 True Negative 44
Statistic Value
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
95.7%
97.8%
97.8%
95.7%
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Table 3.3.8 TA results for control and mutant assays using prospective cfDNA samples. Control assays giving a Ct 
below 35 are highlighted in blue/green. DNA loading concentrations below 50 ng are highlighted in red. WT = 
Wild-type. 
 
 
 
Due to the characteristics of cfDNA only five of 16 samples could be loaded at 50 ng per 
channel. The samples varied greatly in their DNA concentrations and how much DNA could 
subsequently be loaded into the TA card. Two samples (TA Plasma 009 and 016) were at such 
low concentration that they could not be quantified by the Qubit instrument, so as a result 
the exact amount of DNA loaded for those samples is not known.  
 
Despite these low DNA concentrations, the cfDNA samples all gave strong positive signals for 
all the control assays, there were no failures (Ct>35). The control assay Ct ranged from 27.28 
to 32.57, all a comfortable margin below the cut off of 35. No mutant assays gave a signal 
STUDY ID
DNA loading 
(ng)
EGFR 
Ref Ct
EGFR
BRAF 
Ref Ct
BRAF
KRAS 
Ref Ct
KRAS
NRAS 
Ref Ct
NRAS
TA Plasma 001 50.0 27.74 WT 27.64 WT 27.44 WT 28.37 WT
TA Plasma 002 50.0 27.86 WT 27.48 WT 27.73 WT 28.28 WT
TA Plasma 003 11.2 30.58 WT 30.43 WT 30.78 WT 31.29 WT
TA Plasma 004 14.3 31.10 WT 30.15 WT 30.45 WT 30.70 WT
TA Plasma 005 50.0 27.98 WT 27.94 WT 27.89 WT 28.04 WT
TA Plasma 006 13.3 30.06 WT 29.66 WT 29.93 WT 29.98 WT
TA Plasma 007 9.1 30.97 WT 30.29 WT 31.11 WT 31.24 WT
TA Plasma 008 26.6 30.04 WT 29.47 WT 29.52 WT 30.27 WT
TA Plasma 009 <50.0 32.37 WT 31.27 WT 32.36 WT 32.57 WT
TA Plasma 010 44.7 27.70 WT 28.11 WT 27.97 WT 28.20 WT
TA Plasma 011 50.0 28.02 WT 27.66 WT 27.68 WT 28.03 WT
TA Plasma 012 13.2 30.02 WT 29.56 WT 30.59 WT 30.13 WT
TA Plasma 013 50.0 27.66
E709K 
Ct=37.907 
27.28 WT 27.65 WT 27.91 WT
TA Plasma 014 7.5 30.90 WT 30.97 WT 32.11 WT 30.84
G13S; 
c.37G>A 
Ct=36.884
TA Plasma 015 5.4 31.48 WT 31.05 WT 31.88 WT 31.53 WT
TA Plasma 016 <50.0 31.95 WT 31.91 WT 31.83 WT 32.46 WT
Median 30.05 29.61 30.19 30.20
Min 27.66 27.28 27.44 27.91
Max 32.37 31.91 32.36 32.57
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below our current cut off (Ct<36.5), however two mutant assays (EGFR E709K and NRAS 
G13S) gave Cts with two samples (TA Plasma 013 and 014). Unfortunately the Ct values were 
above our threshold for positive samples (Ct37.907 and Ct36.884) but it suggests there is 
potential for cfDNA to be a suitable analyte for use with the TA format of assay. 
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3.4 DISCUSSION 
 
In general there was very good concordance between the TA, Therascreen, castPCR and NGS. 
88 of the 91 (96.7%) samples tested agreed with the original results. There were only three 
true discrepancies (one false negative in EGFR and BRAF, one false positive in KRAS). Whilst 
it is unfortunate that these discrepancies occurred, some discrepancies would be expected 
when compared different techniques due to the individual characteristics and analysis 
parameters of the various assays. The presence of two false negatives may suggest that the 
TA assay has slightly lower sensitivity than some of the other assays, however the impact of 
this does not seem to be significant. 
 
NGS proved to be an invaluable tool for this validation process, giving very accurate and 
sensitive results for confirming the mutation status of discrepant samples. However it is 
expensive and time consuming, and therefore a PCR based method offers good sensitivity 
and specificity as well as being rapid and cost effective. The minor compromise in this case 
is some loss of sensitivity or specificity compared to NGS, however these differences can be 
partially compensated for by quality control measures at the DNA extraction and 
quantification phase i.e. maximising sample quality prior to analysis on the TA. 
 
An advantage of the TA is the very low DNA input requirement. During the optimisation 
phase it was found that the TA control and mutant target assays worked consistently well 
with only 50 ng of DNA. Given the clinical context, in particular with EGFR samples which are 
often extracted from FFPE slides, then having a robust assay with very low DNA input 
requirements is a considerable advantage. The Therascreen assay manufacturer guidelines 
do not specify an exact DNA input requirement, however the assay does require eight 
separate reactions to be run which uses a large volume of the extracted DNA sample. The 
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castPCR assay for KRAS requires 50 ng DNA per reaction, and therefore 800 ng DNA in total. 
The low DNA requirement of TA assay is a major advantage as it not only means dilute 
samples can be analysed (which otherwise might not be possible with the other assays) but 
also repeat analysis may also be possible of there is remaining material. Again with reference 
to the clinic, this means the TA may allow results to be obtained for samples which would 
otherwise fail, and thus the genetic information would not be available for the management 
of the patient. 
 
The TA assay had another major advantage over the other assays in terms of the number of 
pipetting steps and the hands on time. After sample preparation (diluting sample DNA with 
water and TaqMan PCR Master Mix), the entire card can be loaded with just one pipetting 
action per channel (therefore a maximum of eight actions). This gives a great advantage in 
terms of staff time but also reduces the chances of accidently contamination by operator 
error. Subsequently this will have a positive effect of the failure rate of runs, and thus 
improvements in service turnaround time and reagent costs. 
 
Following this validation study, the Pathology Department at UHCW has implemented the 
TA assay (designed and validated here) as their diagnostic test for EGFR, KRAS, NRAS and 
BRAF mutation detection of NSCLC, CRC and melanoma samples. It has been a great success, 
readily adopted by the Molecular Laboratory, and is routinely run approximately twice a 
week. The combining of two assays into one has generated a saving in staff time. 
 
Alongside the routine tissue testing using the TA assay, there has also been prospective pilot 
testing of plasma cfDNA using the TA. The results from these tests have shown that although 
no positive mutants were detected (within our analysis parameters) the control assays 
performed well within a consistent range, which strongly suggests that cfDNA has potential 
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as a suitable source of DNA for testing in the TA. It is particularly impressive that the control 
assays gave strong results even with very low DNA inputs (<10 ng in a number of cases). The 
weakness of this approach is that the tumour DNA (containing the target mutations) is at 
very low concentrations and very highly diluted in wild-type genomic DNA, so the assay in its 
current format is not able to detect those mutations consistently. The low DNA 
concentrations in the samples also meant it was not possible to confirm the mutation status 
of the samples by NGS. 
 
A frequent challenge with cfDNA is the low concentration of DNA in the plasma, which then 
has an impact on the amount of DNA which can be loaded into the TA card. It may be possible 
to partially overcome this technical challenge by extracting a large volume of EDTA blood, 
but this is dependent on clinical and logistical factors associated with the blood collection. In 
terms of future validation, assuming there is a good source of plasma samples, it may be 
beneficial to optimise the DNA loading of cfDNA samples on TA. Increasing the DNA 
concentration may increases the abundance of the tumour DNA in the sample, potentially 
allowing them to be detected by the TA chemistry. However increasing the DNA loading of 
cfDNA samples may have a similar inhibitor effect on the PCR (as seen this FFPE DNA in this 
chapter), but this can only be established experimentally. 
 
A practical consideration for diagnostic assays is cost. In order to introduce the TA assay into 
routine use in the UHCW Pathology Department a business case was submitted to the Trust, 
which included a financial assessment of the projected cost of running the assay based on 
predicted numbers of samples. According to this analysis, assuming 450 tests per year, the 
TA assay was projected to cost £183 per test, compared to £233 per test for Therascreen, a 
saving of £50 per test. A summary of these costings can be found in the chapter 3 appendix. 
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This chapter has shown the TA assay to be a robust and reliable approach for the detection 
of cancer gene mutations from extracted FFPE tissue DNA. It is also rapid and user friendly 
to set up, and its relatively broad range of targets (by PCR standards) makes it an efficient 
and cost effective solution for the service demands of a molecular diagnostic laboratory. 
 
There are a number of ways this technology can be developed in the future. Firstly, the 
molecular laboratory (UHCW) continues to run a number of molecular assays on a number 
of different platforms (Qiagen Rotorgene®, Life Technologies ViiA7®, Abbott M2000 RT®, 
Cepheid SmartCycler® and Roche LightCycler®). Running and maintaining a suite of different 
PCR instruments is costly and requires a large amount of bench space, and also requires the 
staff to be familiar with numerous assays that are essentially very similar. If custom TaqMan 
Array plates could be designed and validated it would greatly increase efficiency within the 
molecular laboratory, and reduce the bench space required to house multiple PCR 
instruments. 
 
Secondly, more specific to cancer mutation detection, the TA technology could be utilised to 
design more custom plates for detecting targets in other cancers e.g. ovarian, pancreatic, 
breast etc. This would greatly increase the services the Pathology department could offer 
without a significant logistical impact as no new equipment would be required, only a supply 
for the TA cards. 
 
In terms of the plasma testing, this remains a significant challenge for molecular diagnostics. 
One approach could be to experiment with higher DNA concentrations (described earlier). 
Another could be the development of a pre-amplification step of the extracted DNA before 
loading into the TA i.e. a multiplex PCR to amplify the target genes. This would of course add 
214 
 
additional time and cost to the assay, however it would most likely still be cheaper than using 
an NGS approach. 
 
The limitations of this work are associated with the format of the technology that is being 
utilising and the logistics of working in a pathology laboratory. The TA, whilst robust and 
reliable, can only detect 44 targets per channel, and whilst this is an improvement on many 
other assays, it inevitably means not all targets can be covered, although the most common 
are included in the panel. In terms of the samples used, ideally more samples would have 
been used in the validation stage, although 91 was sufficient. This is not an issue that could 
be controlled by our research group. Finally, more plasma samples and a large volume of 
each sample would have been very beneficial to the prospective plasma testing phase, 
although this again is an issue that was controlled by external factors. 
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A3 CHAPTER THREE APPENDIX 
 
 
Table A3: Costings estimate for new TaqMan Array assay (referred to here as ‘REB Array’) compared to the 
currently in use test (Qiagen Therascreen). Adapted from UHCW Pathology Department TaqMan Array business 
case. 
 
 
  
Summary Unit cost Number Total 
REB Array (New test)
Cost of consumables per test 54.14 450 24,363
External quality assurance 3.00 836 2,509
Equipment rental and maintenance 1.00 15,710 15,710
Training 49.48 5 247
Staff costs 1.00 18,151 18,151
Overheads @ 35% 1 21,343
Total 82,324
Cost per patient 183
Current Test (450 tests)
Cost of consumables per test 150.00 450 67,500
External quality assurance 3.00 1,931 5,793
Equipment rental and maintenance 1.00 3,388 3,388
Training 150.00 5 750
Staff costs 1.00 27,260 27,260
Overheads @ 35% 1 36,642
Total 104,691
Cost per patient* 233
*Only one gene per cancer - in many cases 2-3 will be needed
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Chapter Four – Automated 
isolation of circulating cell 
free DNA from blood 
plasma in lung cancer 
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4.1 INTRODUCTION 
 
Circulating Free DNA (cfDNA) is described as non-cell associated DNA found in various bodily 
fluids (lymph, plasma, semen, saliva). It is generated by natural and disease associated 
cellular degradation; as cells are lysed by apoptosis, autophagy, or necrosis, their nucleic 
acids will be released from the nucleus and cytoplasm to enter the surrounding environment 
(Qin et al., 2016).  Exosomes are also known to be a source of cfDNA (Hyun et al., 2016). 
Upon entering the surrounding environment, the blood plasma for example, the cfDNA has 
a number of fates. Firstly it can be degraded by natural DNase enzymes circulating in the 
plasma. Secondly, it can be removed from the blood stream by the liver, spleen or kidneys 
(Volik et al., 2016). Elimination of cfDNA is part of host natural immune system and as a result 
elimination of cfDNA is efficiently performed, resulting in the half-life of cfDNA in plasma 
being very short, as low as 16 min reported in one study (Lo et al., 1999). Other studies have 
found the clearance kinetics of cfDNA to be slightly longer at around 13 hours (Yu et al., 
2013), however it is certain that cfDNA turnover in vivo is a relatively rapid process.  More 
research in this area is needed to ensure that cfDNA assays for diagnostic use are clinically 
reliable.  
 
cfDNA was first identified in the 1940s (Mandel & Metais, 1948) and also described in the 
1970s (Leon et al., 1977), however it is only recently that interest has grown in utilising cfDNA 
as a potential diagnostic tool (Johnson & Lo, 2002). A number of studies have described 
elevated cfDNA in disease sufferers compared to healthy controls (Mead et al., 2011; 
Szpechcinski et al., 2012; Szpechcinski et al., 2015) so some researchers suggested that crude 
cfDNA levels alone can be used as diagnostic disease biomarker, however other studies have 
found cfDNA levels to be highly variable both between individuals and between malignant 
218 
 
and benign conditions. As a result cfDNA levels alone cannot be used as a confirmation of 
malignant disease (Shaw et al., 2012) until our understanding is more complete. 
 
A major challenge in lung cancer is to obtain tissue samples suitable for molecular analysis, 
as the anatomy of the lung often means tumours cannot be biopsied until a fairly advanced 
stage, at which point patient outcomes become more unfavourable and therapy becomes 
less effective. In this context, mutation detection using cfDNA potentially offers considerable 
advantage over tissue in terms of how early oncogenic mutations can be identified, and 
subsequently at what stage the patient begins treatment. 
 
A number of recent studies have investigated the potential use of cfDNA for cancer mutation 
detection. A study by Shaw et al. (Shaw et al., 2012) examined the use of cfDNA to detect 
gene copy number variation (CNV) in breast cancer patients using Affymetrix SNP (Single 
Nucleotide Polymorphism) arrays. The study showed that CNV in specific genes could be 
detected in cfDNA, and that genetic analysis of cfDNA could distinguish cancer patients from 
healthy controls. Certain disease markers were found to be present in the cfDNA even after 
successful treatment or surgery, which implies cfDNA could be potentially used as a means 
of monitoring disease dormancy. 
 
There have been a number of studies specifically investigating the use of cfDNA for mutant 
detection in lung cancer patients. Typically concordance between tumour DNA and cfDNA 
has been found to be encouragingly high. The study by Ishii et al. (Ishii et al., 2015) compared 
the detection of four types of lung cancer mutants in cfDNA and tissue using digital PCR. The 
findings were that the overall concordance between cfDNA and tissue was 83.3%, and that 
cfDNA had potential as a means of detecting genetic changes contributing to TKI resistance 
in patients receiving therapy. Another study by Mok et al. (Mok et al., 2015) analysed cfDNA 
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as part of a phase III clinical trial of erlotinib with platinum based chemotherapy. Blood 
samples were collected before, during and after the treatment phases, and molecular 
analysis of the isolated cfDNA gave both an insight into the concordance between blood and 
tissue DNA, and gave an indication of the dynamics of the genetic changes occurring as a 
result of treatment. Multiple studies are consistently proposing a strong case for the use of 
cfDNA in cancer diagnostics and disease monitoring.   
 
Biotechnology companies are starting to appreciate the potential clinical utility of cfDNA, 
and as a result a number of kits have become available for cfDNA isolation, either by 
adaptation of an existing kit or specific new kits have been designed and manufactured. 
Manual and automated solutions are available. A number of recent studies have evaluated 
manual methods (Sherwood et al., 2016; Yuan et al., 2012), however recent guidance advises 
that automated methodologies are far more suited to the routine diagnostic setting (Cree et 
al., 2014). Another equipment issue related to cfDNA are the type of tubes used to collect 
the whole blood from the patient. A recent study investigated specifically designed blood 
collection tubes for the stabilization of cfDNA before plasma separation (Toro et al., 2015). 
Toro et al. compared Cell-free DNA BCT tubes (Streck, NE) and PAXgene DNA blood tubes 
(Qiagen). They concluded the Streck tubes were effective at stabilizing cell free DNA in 
plasma for up to a week at room temperature. Whilst using specifically designed blood tubes 
would be ideal, introducing a new tube type into the UHCW phlebotomy department simply 
would not be practical. Performing this investigation in the diagnostic Pathology laboratory 
setting presents a number of limitations on sample types and equipment available. 
 
I aimed to perform a side-by-side comparison of two leading platforms for automated cfDNA 
extraction from plasma: the commonly available Qiagen EZ1 instrument used frequently to 
isolate circulating viral DNA in plasma, running the DSP Virus Kit 2.0 (Qiagen), and the 
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Promega Maxwell instrument running the prototype Circulating DNA Kit (Promega). It is 
important to state clearly that the Qiagen DSP Virus Kit is not specifically designed for cfDNA 
isolation from plasma, however there was no suitable alternative prototype or retail kit 
available from Qiagen at the time of this study. The kit chemistry is designed to isolate viral 
DNA from plasma, so it should in theory be able to isolate cfDNA from plasma also. The 
Qiagen and Promega extraction platforms were selected for this study as they were routinely 
used for DNA extraction in the investigating laboratory. 
 
 
4.1.1 Aims 
 
There are three aims for this study: 
 
 To determine if cfDNA can be isolated from standard EDTA blood samples, using 
existing equipment used in the diagnostic laboratory. 
 
 To establish which of the available standard extraction platforms is most efficient at 
extracting cfDNA, and which yields the best quality DNA for downstream 
applications. 
 
 To evaluate if cfDNA obtained from these samples and extraction platforms can be 
used to detect cancer mutations, using pre-designed NGS assays designed for use 
with tissue. 
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4.2 METHODS 
 
4.2.1 Equipment 
 
Bench top centrifuge compatible with 4ml EDTA Blood tubes (up to 1600g) 
Bench top centrifuge compatible with 1.5ml micro-centrifuge tubes (up to 15500g) 
Bench top centrifuge compatible with 96 well PCR plates (up to 1600g) and Taqman arrays 
Bench top centrifuge compatible with 0.2 ml PCR strip tubes 
Bench top centrifuge compatible with Ion Torrent sequencing chips (314, 316 and 318) 
Heat block capable of heating 1.5ml tubes to 70C 
Qiagen EZ1 automated extraction instrument (see figure. 2.3) 
Promega Maxwell Automated Extraction Instrument (see figure. 2.3) 
Laminar Flow safety cabinet with UV decontamination feature 
Nanodrop spectrophotometer (see figure 4.2.1.2) 
Qubit 2.0 Nucleic Acid Analyser (see figure 2.2.7) 
Life Technologies ViiA 7 Dx Real Time PCR instrument with Fast 96 well block 
Life Technologies ViiA 7 384 well block 
Life Technologies Ion Chef instrument (see figure 2.2.8.3.2) 
Life Technologies Ion Torrent PGM instrument (see figure 2.2.8.3.2) 
Millipore water purification system 
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Figure 4.2.1.1 (Left) Promega Maxwell DNA Extraction Instrument. (Right) Qiagen EZ1 DNA Extraction 
Instrument. 
 
 
Figure 4.2.1.2 Nanodrop spectrophotometer instrument for DNA quantification. 
 
 
4.2.2 Kits 
 
Qiagen EZ1 Blood Virus Kit (48 isolations) 
Qubit dsDNA High Sensitivity reagent kit 
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Promega Maxwell Circulating DNA Kit (prototype) 
Life Technologies Ion AmpliSeq™ Colon and Lung Panel 
Life Technologies Ion Express Barcode 1-16 Kit 
Life Technologies Ion Express Barcode 17- 32 Kit 
Life Technologies Ion Torrent PGM Sequencing 200 Kit 
Life Technologies Ion AmpliSeq™ Library Kit 2.0 
Life Technologies Ion PGM IC 200 Kit 
Life Technologies Oncomine™ Solid Tumour DNA Kit 
 
 
4.2.3 Cell Free DNA Analysis 
 
Summary: Patient EDTA blood samples were obtained from the Blood Sciences laboratory 
and analysed in parallel using both available automated extraction platforms, the Qiagen EZ1 
and Promega Maxwell. The former is used routinely for extraction of viral DNA from blood, 
and the Maxwell was initially designed for FFPE samples.  The amount and purity of the 
cfDNA obtained was then assessed by two quantification methods (Nanodrop and Qubit).  
Ion Torrent next generation sequencing (NGS) was used to further assess sample DNA quality 
for NGS library preparation and to determine the mutations present. Finally, cfDNA samples 
were analysed using TaqMan Array cards to assess the suitability of cfDNA for routine 
analysis by PCR. 
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4.2.3.1 Patients and Samples 
 
A series of patients attending the UHCW lung clinic (see table 4.2.3.1) had blood taken as 
part of their standard clinical investigation. Each patient gave written informed consent for 
research use of tissue and blood not required for diagnosis.  Ethics approval for this was 
granted to the Arden Tissue Bank by the NRES Committee South Central Ethics Committee 
(12/SC/0526 – ATBMC-00002).  Residual plasma from EDTA samples was obtained from the 
routine blood samples, the plasma was separated (method below), divided into 1 ml aliquots, 
and stored at -20C until extraction.  Prior to extraction, samples were thawed at room 
temperature and then processed according to the manufacturer’s instructions, as described 
in a later section. 
 
 
4.2.3.2 Plasma Separation 
 
EDTA anti-coagulated blood samples were centrifuged at 1600 x g for 15 mins to separate 
the plasma from the cellular component. The supernatant was collected and the cellular 
fraction discarded. The supernatant was centrifuged again at high speed (15,500 x g for 4 
minutes) to remove platelets and cellular components such as exosomes. The supernatant 
was collected and the pellet discarded. If the samples were not to be extracted immediately, 
the samples were stored at -20 C until ready to be extracted. 
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Table 4.2.3.1: Samples and clinical details, n= 40. N.B. PL012 and PL017 excluded due to technical reasons. 
Unfortunately complete data was not available for all samples. NA = Not applicable. 
 
 
 
4.2.3.3 DNA Extraction from Plasma 
 
Twice centrifuged EDTA plasma samples (procedure described above) were extracted using 
two different automated extraction platforms: the Qiagen EZ1 instrument (using the Qiagen 
EZ1 DSP Virus 2.0 Kit) and the Promega Maxwell instrument (using the prototype Promega 
Plasma 
Sample No.
Sample type Age Tissue diagnosis Radiological diagnosis
Site of primary 
tumour
Staging Clinical comments
PL001 EDTA Blood 61
PL002 EDTA Blood 59 Clear cell renal cell carcinoma metastatic disease kidney metastatic disease
PL003 EDTA Blood Unknown
PL004 EDTA Blood 52
PL005 EDTA Blood 42
PL006 EDTA Blood 63 Metastatic lung adenocarcinoma
PL007 EDTA Blood 72 NA RUL, RLL masses
PMH: breast carcinoma - Rx 
Arimidex. Severe 
emphysema, lung biopsy not 
possible
PL008 EDTA Blood 69
PL009 EDTA Blood 61 NA benign pleural plaque NA NA
PL010 EDTA Blood 78 Squamous cell carcinoma lung T3 N3 M1b
PL011 EDTA Blood 59
Malignant NET-atypical spindled 
morphology, IHC in keeping with 
lung primary
lung T4 N3 M1b
PL013 EDTA Blood 59
Malignant NET-atypical spindled 
morphology, IHC in keeping with 
lung primary
lung T4 N3 M1b
PL014 EDTA Blood 66 Amyloidosis no tumour no tumour PMH: SLE
PL015 EDTA Blood 72
PL016 EDTA Blood 77 NA NA NA
PL018 Serum 59 Non-small cell carcinoma LUL mass lung T4 N2 M1b previous lymphoma
PL019 EDTA Blood 73 adenocarcinoma lung T1 N0 M1 Bone marrow metastasis
PL020 EDTA Blood 73 adenocarcinoma lung T1 N0 M0 Bone marrow metastasis
PL021 EDTA Blood 70 no evidence of malignancy NA Cerebral metastases cerebral metastases
PL022 EDTA Blood 72 Metastatic adenocarcinoma right lung perihilar mass lung T4 N3 M1b
PL023 EDTA Blood 60 Metastatic small cell carcinoma Bilateral consolidation lung T4 N3 M1b
PL024 EDTA Blood 60 Metastatic small cell carcinoma Bilateral consolidation lung T4 N3 M1b
PL025 EDTA Blood 75
Non-small cell carcinoma, favour 
adenocarcinoma
LLL mass lung T4 N2
Initial diagnosis 2011 - Rx 
carboplatin/alimta and high 
dose radiotherapy
PL026 EDTA Blood 74 NA No malignancy - COPD NA NA
PL027 EDTA Blood 76 adenocarcinoma lung T4 N2
PL028 EDTA Blood 86 NA RUL mass lung T2 N0 M0
PL029 EDTA Blood 76 adenocarcinoma RUL/RLL consolidation lung T4 N2
PL030 EDTA Blood 76 adenocarcinoma RUL/RLL consolidation lung T4 N3
PL031 EDTA Blood 70 adenocarcinoma LUL mass lung pT3 pN0
patient had separate tumour 
<1cm in same lobe
PL032 EDTA Blood 82 NA LLL mass lung T4 N1 M1a
PL033 EDTA Blood 81 NA RLL opacity --> resolved NA NA
previous Hodgkin lymphoma, 
breast cancer and 
tuberculosis
PL034 EDTA Blood 84 NA Fibrosis NA NA
PL035 EDTA Blood 79 Squamous cell carcinoma LLL mass lung T3 N2 M0
PL036 EDTA Blood 87 Metastatic squamous cell carcinoma RUL mass lung T3 N2 M1b
PL037 EDTA Blood 75 adenocarcinoma LLL mass lung pTa N0 M0
PL038 EDTA Blood 79 adenocarcinoma RUL mass lung pT1a N0 M0
PL039 EDTA Blood 59 adenocarcinoma (mucinous) right lung mass lung pT4 N0 Mx
PL040 EDTA Blood 70 Metastatic adenocarcinoma RUL mass lung Not staged previous Hodgkin lymphoma
PL041 EDTA Blood 78 Metastatic small cell carcinoma RUL mass lung T2a N2 M0
PL042 EDTA Blood 50 adenocarcinoma LLL mass lung T4 N3 M1b
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Maxwell Circulating DNA Kit). DNA samples were eluted in 60 µl elution volumes for both 
instruments and stored at -20C until ready for molecular analysis. 
 
 
4.2.4 DNA quantification  
 
The quantity of the extracted nucleic acid obtained from EDTA blood was assessed by two 
methods, listed below: 
 
1. Quantification by Nanodrop spectrophotometer platform. 
2. Quantification by the Qubit platform (for method, see section 2.2.7) 
 
Nanodrop procedure: before beginning measurements of samples, the instrument pedestal 
as cleaned with 1.5 µl dH2O and a lint free tissue. Two blank measurements were then made 
with 1.5 µl extraction kit elution buffer to normalise the instrument sensor for background 
absorbance. To measure the DNA concentration of the extracted DNA samples, a 1.5 µl 
volume was dispensed onto the Nanodrop instrument pedestal, and the absorbance 
measured at 260/280 nm. The measurement result is outputted as a value in ng/ml. The 
instrument was re-blanked with extraction kit elution buffer every five sample 
measurements, and after all samples had been measured the instrument pedestal was 
cleaned with dH2O. 
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4.2.5 Ion Torrent Next Generation Sequencing of Plasma DNA 
 
Sequencing was performed as previously described (Tops et al., 2015), with the following 
changes to accommodate Ion Chef loading of the Ion Torrent 318 chips.  Stored or newly 
extracted DNA was checked for content and quality using a Qubit 2.0 Fluorometer. 10 ng of 
gDNA from each of the samples chosen for NGS analysis was combined with the Ampliseq™ 
reagents and primer pool for the OncoNetwork 22 gene panel (Tops et al., 2015) and 
amplified for 30 cycles. After initial amplification the amplified products were partially 
digested before Ion Express Adapters and Barcode sequences are ligated to the library 
fragments. Following barcoding the libraries were cleaned up using a magnetic bead method. 
The cleaned up products were then quantified by the AmpliSeq™ Q-PCR method. Once the 
libraries had been successfully quantified they were combined and diluted to 50 pM. For Ion 
Torrent 318 chips, 20 libraries were combined per chip. These library pools were then loaded 
into the Ion Chef instrument for further library preparation and chip loading. The loaded 318 
chips were then run on the Ion Torrent PGM instrument according to manufacturer’s 
instructions. 
 
The Variant Caller plugin (including in the provided Ion Suite software) was used to analyse 
the aligned sequence data for the identification of hotspot mutations and novel variants. The 
variant data was filtered using ‘High Stringency’ parameters to reduce the incidence of false 
positives (key filters: minimum variant frequency: 3%; minimum quality score: 10; Minimum 
coverage: 20 reads). 
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4.2.6 TaqMan Array PCR Assay 
 
As a limited scale pilot study, hotspot positive cfDNA samples were also analysed using a 
TaqMan Array PCR assay. This assay had been previously validated for detection of 44 
common somatic mutations in lung and colorectal FFPE tissue samples (Kikuchi H., 2016). 
Extracted cfDNA samples were loaded at 50 ng per channel and run according to 
manufacturers' instructions. 
 
For direct comparison, if a patient sample was found to be positive for a hotspot by NGS on 
either extract (EZ1/ Maxwell), then both extracts were analysed by the TaqMan array, 
regardless of whether the other extract had been previously been found to be negative by 
NGS. In accordance with the previously published validation study, mutant targets producing 
a Ct below 36.5 were considered positive, any signals coming up later than this were 
considered negative. 
 
 
4.2.7 Statistical Analysis 
 
Statistical tests were carried out using R (RC, 2015). Where appropriate, t tests were paired 
and two sided, with significance level α = 0.05.  Variances were not assumed to be equal.  
Pearson correlation coefficients were calculated using rcorr from the package Hmisc. 
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4.3 RESULTS 
 
4.3.1 DNA quantity  
 
The overall DNA recovery from separated plasma samples extracted in parallel both on the 
Qiagen EZ1 and Promega Maxwell platform is shown in figure 4.3.1.1. The extracts were 
measured using both Nanodrop and Qubit to determine the isolated DNA concentration. 
Using the Nanodrop spectrometer method, the Qiagen EZ1 extracts appear to have a 
significantly higher DNA concentration (mean 41.68 ng/µl) compared to the Maxwell (mean 
4.26 ng/µl). This difference is statistically significant (P<0.01). 
 
However, when measurements were repeated using the Qubit method, the extracts from 
Maxwell contained a higher concentration of DNA (mean 2.10 ng/µl) compared to EZ1 (mean 
1.04 ng/µl), data shown in figure. 4.3.1.2, although the difference is only marginally above 
the threshold for statistical significance (P=0.053). This suggests that the EZ1 extracts 
contained a higher level of protein contamination, giving a falsely high reading at the 260/ 
280 absorbance frequency. The Maxwell extracts also gave a higher DNA concentration 
result when measured by Nanodrop (compared to Qubit), however the difference between 
the results from the two instruments was not as dramatic compared to the EZ1 extracts. This 
may suggest the Maxwell extracts contained purer DNA samples than the equivalent EZ1 
extracts, and that Qubit gives more accurate measurements of DNA content. 
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Figure 4.3.1.1: DNA isolation from plasma, using platforms Qiagen EZ1 and Promega Maxwell. Measurements by 
Nanodrop. Mean values of data group are shown as thick black lines, outlying data points represented as circles. 
 
 
 
Figure 4.3.1.2: DNA isolation from plasma, using platforms Qiagen EZ1 and Promega Maxwell. Measurements by 
Qubit. Mean values of data group are shown as thick black lines, outlying data points represented as circles. 
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The mean cfDNA recovery from the separated plasma samples (measured by Qubit), using 
both automated extraction platforms is shown in figure 4.3.1.3. The samples are grouped 
based on the storage time of the original unseparated EDTA blood samples (24, 48 and 72 
hours). In all groups, the Promega Maxwell isolated higher cfDNA concentrations than the 
same samples extracted using the Qiagen EZ1. The highest cfDNA concentrations were found 
in the 48 hour storage time group. However it is important to point out that none of the 
these samples were sequentially extracted on concurrent days, and therefore these data do 
not necessarily reflect DNA degradation over time within the same sample, rather it simply 
illustrates the high degree of variation of cfDNA levels found in clinical samples. 
 
 
 
Figure 4.3.1.3: Graph showing the cfDNA recovery from plasma separated at varying storage times. 
Measurements from Qubit instrument. Black connecting lines indicate paired extracts from the same original 
plasma sample. 
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Figure 4.3.1.4: Graph showing the cfDNA recovery from plasma separated at varying storage times. EZ1 platform 
only. Measurements from Qubit instrument. 
 
 
 
Figure 4.3.1.5: Graph showing the cfDNA recovery from plasma separated at varying storage times. Maxwell 
platform only. Measurements from Qubit instrument. 
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Interestingly when the data is separated by EDTA blood storage time, there is no statistical 
significance between which extraction platform was use or the storage time. The graph 
illustrating this analysis are shown in figures 4.3.1.4 (EZ1) and 4.3.1.5 (Maxwell).  
 
 
4.3.2 NGS Library quality: Quantitation EZ1 vs Maxwell 
 
NGS library preparation involved a library quantification step using Q-PCR, using the Ion 
Torrent Library Quantitation Kit (Thermo Fisher). After completing the quantification step 
each library had a precise quantification value in pM/ µl, which gives an indication of how 
efficiently the library preparation process has occurred and reflects the quality of the original 
template DNA used to create the library. Figure 4.3.2 shows a side by side plot of all the 
libraries generated using the extracted cfDNA from both platforms. Libraries generated from 
samples extracted on both platforms are arranged together. The paired samples are plotted 
in ascending order based on library quantification values derived from the Promega Maxwell 
extract. The data clearly shows that in a majority of cases the extract from the Promega 
Maxwell generated a far higher library quantification value (i.e. higher quality library) 
compared to the equivalent EZ1 extract. There are only four incidences where the EZ1 library 
has a higher quantification value than the Maxwell library.  
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Figure 4.3.2: Graph showing NGS library quantification values, arranged in ascending order from Maxwell 
extracts. Quantification values from parallel extracted samples are arranged adjacently. 
 
 
4.3.3 NGS Data Quality 
 
Following the Ion Library Quantitation step all cfDNA libraries were diluted and pooled to 50 
pM (where possible) and were processed on the Ion Chef platform for library enrichment 
and chip loading onto 316v2 or 318v2 chips (Thermo Fisher). The samples on the chips were 
sequenced using the Ion Torrent PGM instrument according to manufacturer’s guidelines. 
The resulting data was used to analyse both the sequencing success of cfDNA starting 
material and to compare the relative quality of the extraction methods used to isolate the 
DNA samples. 
 
Figure 4.3.3.1 shows the original DNA samples grouped by their EDTA storage time, 
separated by extraction platform, and plots the mean read length of sequencing reads 
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achieved by these samples. In this case, the data shows that the choice of extraction platform 
has a statistically significant influence on the mean read length of the NGS results (P<0.01).  
In all groups, the read lengths achieved by Maxwell extracted DNA samples are longer than 
those extracted on the EZ1 platform, suggesting that the length of DNA fragments was 
greater in the Maxwell extracts. 
 
 
 
Figure 4.3.3.1: Graph showing EDTA blood storage time against mean read length from NGS analysis. Samples 
are grouped by storage time and separated by extraction method. Black connecting lines indicate data from 
paired extracts from the same original plasma sample. 
 
 
The mean read length data for the individual extraction platforms are shown in figures 
4.3.3.2 (EZ1) and 4.3.3.3 (Maxwell). The data appears to show that EDTA storage time (from 
24 to 72 hours) does not have a significant influence on the mean read length. Mean read 
length results are consistent across all samples groups (based on storage time). 
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Figure 4.3.3.2: Graph showing EDTA blood storage time against mean read length from NGS analysis. EZ1 
platform only. 
 
 
Figure 4.3.3.3: Graph showing EDTA blood storage time against mean read length from NGS analysis. Maxwell 
platform only. 
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Figure 4.3.3.4 shows the DNA samples grouped by their EDTA storage time, separated by 
extraction platform, and plots the mean number of sequencing reads achieved by these 
samples. This plot shows that in the 24 and 72 hour groups, the choice of extraction platform 
has a statistically significant difference on the number of sequencing reads generated. At 48 
hours there is no significant difference between the extraction platforms. 
 
Libraries from Maxwell extracted samples show increasing variability of read number as 
EDTA storage time increases, with the lowest and most variable number of reads occurring 
in the 72 hour group (range 61176- 563406 reads), suggesting increased fragmentation at 
that point. The EZ1 extracted samples demonstrated a high degree of variability, and mean 
read numbers were not consistent across the storage time groups, indicating a lack of 
consistency in the quality of cfDNA isolated by this platform. The data from figure 4.3.3.4 
appears very similar to the cfDNA recovery data from figure 4.3.1.3, so this logically suggests 
initial cfDNA concentration has an influence on NGS read numbers when sequenced. 
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Figure 4.3.3.4: Graph showing EDTA blood storage time against mean number of reads from NGS analysis. 
Samples are grouped by storage time and separated by extraction method. Black connecting lines indicate data 
from paired extracts from the same original plasma sample. 
 
 
When the read numbers data is separated by extraction platform, the data again shows that 
EDTA storage time does not have a significant effect on this aspect of the NGS results. See 
figures 4.3.3.5 (EZ1) and 4.3.3.6 (Maxwell). 
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Figure 4.3.3.5: Graph showing EDTA blood storage time against mean number of reads from NGS analysis. EZ1 
Platform only. 
 
 
Figure 4.3.3.6: Graph showing EDTA blood storage time against mean number of reads from NGS analysis. 
Maxwell Platform only. 
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Figure 4.3.3.7 shows the correlation between read length and coverage achieved by the two 
sets of libraries (Maxwell and EZ1 extracted). Libraries that failed sequence analysis (i.e. data 
was of insufficient quality to perform coverage or variant caller analysis) were removed. With 
the exception for four outliers, the Maxwell libraries demonstrate a consistent grouping of 
read length and coverage. By contrast EZ1 libraries are much less consistent, with read length 
generally being much lower and associated coverage highly variable. Centroid markers for 
the two datasets show that the Maxwell extracts have generally higher read length, whereas 
the two groups are equivalent in terms of coverage (number of reads per amplicon). 
 
 
 
Figure 4.3.3.7: Graph correlating read length against coverage from NGS analysis. Samples are grouped by 
extraction method. 
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4.3.4 NGS Variant Detection 
 
Library samples sequenced on the Ion Torrent PGM instrument (that generated data of a 
suitable quality) were analysed by the Variant Caller plugin included in the Torrent Suite 
server software. Sample data was analysed using the pre-set 'High Stringency' analysis 
parameters to filter out low quality data and low frequency variants to reduce the likelihood 
of false positives in our dataset (filters described in Methods section 4.2.5).  
 
Variant Caller analysis identified a wide range of novel variants and hotspot mutations 
detected in our cfDNA samples. Figure 4.3.4 shows the number of variants (novel and 
hotspots) detected in all the paired samples extracted on the two extraction platforms. In all 
but four samples, more variants are detected in the libraries from Maxwell extracts than the 
equivalent samples from the EZ1 platform. This suggests that the Maxwell extracts contained 
higher quality (higher purity and less fragmented) DNA which has had a direct influence on 
the quality of the NGS data generated downstream. 
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Figure 4.3.4: Graph showing the number of variants detected in each cfDNA sample, arranged in ascending 
order (based on Maxwell extract variant detection). Samples are grouped with paired EZ1 extracts. 
 
 
4.3.5 NGS Hotspot Detection 
 
The high stringency analysis parameters used by the Variant Caller plugin produced data 
which is likely to be free of false positives, so the assumption was made that any hotspots 
remaining after this filtering can be confidently called positive. Figure 4.3.5 shows the 
numbers of hotspot mutations identified in our cfDNA samples. In total eight extracts tested 
positive for a total of 12 hotspot mutations. These eight positive extracts were derived from 
six original clinical samples. Of the 12 hotspot mutations identified, a total of nine were 
identified in the Maxwell extracted samples, whereas only three were detected in the EZ1 
extracted samples. 
 
243 
 
 
  
Figure 4.3.5: Graph of hotspot mutations detected in cfDNA libraries. Libraries that could not be analysed are 
designed with a coloured dot in the NA (not applicable) column. 
 
 
There was very little concordance between the results from different extraction platforms. 
Of the six clinical samples that tested positive for hotspot mutations, the results from the 
Maxwell and EZ1 instruments only agreed in one case (PL042). In three of the other cases 
(PL027, PL039 and PL041), hotspots were detected in the Maxwell extracts whereas none 
were detected in the corresponding EZ1 extracts. In another case (PL021), two hotspots were 
detected in the Maxwell extract whereas only one was detected in the EZ1 extract; and finally 
in one case (PL008) a single mutation was detected in the EZ1 extract whilst the 
corresponding Maxwell extract was negative for hotspots. 
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Table 4.3.5: Hotspots detected from cfDNA samples. Hotspots detected in EZ1 extracts are highlighted in blue. 
SNP =  Single Nucleotide Polymorphism, DEL = Deletion. 
 
 
 
Table 4.3.5 shows a detailed overview of the hotspot mutations detected in our sample set. 
Quality scores and coverage were highly variable amongst the hotspots identified, which is 
most likely related to individual properties of the template DNA (concentration, 
fragmentation). However all these hotspots were retained after high stringency filtering by 
the Variant Caller plugin in the Torrent Suite software, and therefore these are likely to be 
genuine mutations from the clinical samples. Of most interest is the detection of the 
actionable KRAS activating mutation (COSM516, KRAS c.34G>T p.Gly12Cys) detected in 
sample PL021, and this mutation was detected using both the Maxwell and EZ1 extracted 
DNA, although the quality score and coverage are far higher for the Maxwell sample. 
 
 
4.3.6 Performance of cfDNA in TaqMan Array Assay 
 
Six sets of paired samples (which tested positive for hotspot mutations by NGS) were 
analysed in parallel by TaqMan array. The results are shown in table 4.3.6.The samples were 
analysed in sets of six over two runs. Unfortunately the second run failed so the final six 
samples could not be analysed (data not shown). For the six extracts that could be analysed, 
Sample 
Name
Platform Frequency Quality Type Allele Name Gene ID Mutation Details Coverage
Allele 
Cov
Strand 
Bias
PL021 MAXWELL 21.7 2145.53 SNP COSM516 KRAS p.G12C 1659 360 0.50
PL021 EZ1 22.9 122.64 SNP COSM516 KRAS p.G12C 83 19 0.57
PL021 MAXWELL 17.1 1417.11 SNP COSM20957 STK11 p.D194V 1651 283 0.55
PL008 EZ1 7 50.75 SNP p.Gly774Glu DDR2 p.Gly774Glu 316 22 0.95
PL039 MAXWELL 10.2 37.68 SNP COSM10645 TP53 p.C176F 88 9 0.56
PL039 MAXWELL 5.9 9 DEL COSM20871 STK11 p.P281fs*6 118 7 0.58
PL039 MAXWELL 5.9 9 DEL COSM12924 STK11 p.P281fs*6 118 7 0.58
PL041 MAXWELL 50.8 1293.7 SNP COSM706 MET p.E168D 246 125 0.50
PL041 MAXWELL 48.5 148.14 SNP COSM710 MET No COSMIC record 33 16 0.55
PL042 MAXWELL 40.2 873.28 SNP COSM775 PIK3CA p.H1047R 241 97 0.57
PL042 EZ1 43.4 407.39 SNP COSM775 PIK3CA p.H1047R 106 46 0.60
PL027 MAXWELL 52.5 10867.4 SNP COSM706 MET p.E168D 1986 1042 0.51
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the TaqMan Array assay gave 100% concordance with the NGS results. Clinical data was only 
available for two of the samples analysed. Samples 1 and 3 (01 MXW/ 01EZ1 and 03 MXW/ 
03 EZ1) were metastatic adenocarcinomas. Staging information was only available for sample 
1, which was staged at T4 N3 M1b. Considering the advanced stage of the disease, the 
presence of a detectable hotspot mutation is not surprising. No clinical data was available 
for sample 2 (02 MXW/ 02 EZ1). 
 
 
Table 4.3.6: Results from TaqMan Array (TA) analysis of paired CFDNA samples (positive for mutations on NGS). 
 
 
 
4.3.7 Disease Stage versus cfDNA Levels in Plasma 
 
Clinical background information was available for a majority of the plasma samples used in 
this study. Where staging information was available, the cfDNA concentrated from the 
corresponding plasma has been recorded. Figure 4.3.7 shows the cfDNA levels extracted 
from plasma against the staging information for that patient. 
 
 
Sample no.
DNA input 
(ng)
PCR PASS/ 
FAIL
Positive 
Targets
CT TA vs NGS Disease type Disease Stage
01 MXW 50.00 PASS KRAS G12C 31.458 MATCH
Metastatic 
adenocarcinoma
T4 N3 M1b
01 EZ1 50.00 PASS KRAS G12C 33.042 MATCH
Metastatic 
adenocarcinoma
T4 N3 M1b
02 MXW 4.10 PASS None detected MATCH Not available Not available
02 EZ1 29.47 PASS None detected MATCH Not available Not available
03 MXW 11.22 PASS None detected MATCH
Metastatic 
adenocarcinoma
Not staged
03 EZ1 7.07 PASS None detected MATCH
Metastatic 
adenocarcinoma
Not staged
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Figure 4.3.7: Graph showing cfDNA concentrated against patient disease stage. Trend line shows a majority of 
samples in stage 4. ND = No Diagnosis. 
 
 
From this dataset, there is no significance between the cfDNA levels at different stages. A 
basic observation from the figure shows that there is a broader range of cfDNA levels at stage 
IV, but a majority of samples are at the lower end of the DNA concentration scale. 
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4.4 DISCUSSION 
 
In this investigation I have found clear evidence that both the extraction platforms involved 
in this study are able to isolate cell free DNA from plasma, although clearly one platform 
produced better quality DNA than the other. 
 
The first research question in this study was: can cfDNA be extracted from standard EDTA 
blood samples, using standard equipment used in the diagnostic laboratory? Our data has 
shown that standard EDTA blood samples, obtained through the routine blood sciences 
services, can be used to obtain cfDNA samples using routine equipment. Whilst these EDTA 
blood samples were sub-optimally stored (according to other literature) it was reassuring to 
discover that cfDNA can still be recovered from EDTA blood that has been stored at 4C for 
72 hours after collection. In crude terms mutation detection in this context simply requires 
a positive or negative result, so therefore sub-optimally stored samples are sufficient for 
giving this sort of data output. Of course the ideal conditions would use optimally stored 
cfDNA, however the results here suggest there is some robustness in the methods I have 
employed. 
 
The discrepancy between the DNA concentration values obtained on Nanodrop and Qubit 
suggest that the EZ1 extracts contained a significant level of protein contamination, giving a 
falsely high reading at the 260 nm absorbance frequency. This phenomenon has been 
described in other studies (Kapp et al., 2015; Simbolo et al., 2013). The Maxwell extracts 
were more consistent when measured by the different quantification methods. This may 
suggest the Maxwell extracts contained purer DNA samples than the equivalent EZ1 extracts. 
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This slight increase is cfDNA in the 48 hour group may be due to the shedding of DNA from 
lysing exosomes and white blood cells in the blood whilst being stored. This could therefore 
imply that EDTA blood samples stored for longer than 24 hours have an increased risk of 
contamination of the plasma by non-cell free DNA being shed during storage. 
 
The data appears to show that EDTA storage time (from 24 to 72 hours) does not have a 
significant influence on the mean read length or the number of reads (coverage). This seems 
contrary to other publications where cfDNA is described as rapidly degrading and that the 
results of downstream analysis would be negatively affected by extended periods of EDTA 
storage before plasma separation. It is important to state however that whilst read length 
and number of reads are crucial factors effecting NGS data quality, they are not the only 
factors to consider. It seems that cfDNA (whilst rapidly metabolised in the body) seems fairly 
stable at 4˚C in EDTA blood (at least up to 72 hours). The data from figure 4.3.3.6 (storage 
time vs. number of NGS reads) appears very similar to the cfDNA recovery data from figure 
4.3.1.5, so this suggests cfDNA concentration has a significant influence on NGS coverage 
when sequenced. 
 
It was unfortunate that staging information was not available for more patients. Typically, 
cfDNA concentration would theoretically be expected to increase with disease progression, 
but as a majority the samples in our dataset were in stage IV (or unknown stage) then 
definitive conclusions cannot be drawn from the data. 
 
The second research question in this study was: of the available standard extraction 
platforms, which is most efficient at extracting cfDNA, and which yields the best quality 
DNA for downstream applications? The Promega Maxwell instrument using the prototype 
cell free DNA extraction kit was the superior platform in this study. In the majority of cases, 
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DNA from this instrument was of higher yield and quality, and gave consistently better results 
when used for NGS analysis. In terms of efficiency, it is important to remember that the 
sample input volume for the EZ1 platform was only 400 µl, compared to 1 ml for the Maxwell. 
Given that the Maxwell can accept 2.5 times the plasma volume of the EZ1, it would be logical 
to expect that the cfDNA yield from the Maxwell would be approximately 2.5 times higher 
than that of the EZ1. As the average Maxwell extract was less than 2.5 times the EZ1 average, 
this might suggest that the Maxwell is slightly less efficient than the EZ1. The key difference 
however is clearly the DNA quality. In crude terms the EZ1 elutes more DNA per µl of plasma 
input, but the quality is inferior, shown by the Qubit quantification results, and the NGS 
analytics. This suggests the Maxwell extraction procedure excludes contaminants and highly 
fragmented DNA molecules. 
 
Probably the clearest demonstration of the effect of extraction platform on NGS data quality 
is shown in figure 4.3.3.1 and figure 4.3.3.4. In these figures there is a clear statistically 
significant difference between the relative performances of the extraction platforms, with 
the only exception being coverage at the 48 hour storage time (figure 4.3.3.4). In all other 
cases, the libraries generated from Maxwell extracts have longer read length and coverage 
than the equivalent EZ1 extracts (see figure 4.3.3.7). This is again most likely related to the 
purity and fragmentation of the eluted DNA samples produced by these instruments. 
Another consideration in this data is contamination of the extracted plasma DNA by genomic 
DNA from lysed white blood cells. Due to the extending storage times, it is likely this may 
have occurred in a proportion of the samples, and may account for some of the longer read 
length amplicons shown in the NGS data. Unfortunately given the limitations of our sample 
collection and laboratory set up it was not possible to control/ mitigate this process. 
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The Taqman array results, whilst limited, give an insight into the relative quality of the DNA 
samples isolated from the original plasma. Whilst there are a number of NGS analytics 
showing the Maxwell extracts the be superior, all DNA samples analysed here have given 
positive results in the TaqMan Array control assays, in some cases with very low DNA input 
(table 4.3.6). This is most likely a combination of the robustness of the TaqMan Array assay 
and the quality of the DNA samples. This data is limited however as the number of samples 
tested is low. It is encouraging however that all the TaqMan Array results matched those 
determined by NGS, albeit a small number.  
 
 
The final research question in this study was: Can cfDNA be used to detect cancer mutations, 
using pre-designed NGS assays? Our data shows that cfDNA is a suitable analyte for the Ion 
Torrent AmpliSeq™ NGS assay designed for use with FFPE tissue, assuming the DNA is 
isolated using a platform and kit specifically designed for cfDNA.  The Ion Torrent AmpliSeq™ 
kits are of course designed for use with fragmented DNA derived from FFPE tissue blocks, 
and are robust enough for this use. Others have examined clinical series and find similar 
results (Garrigou et al., 2016; Caen et al., 2015; Vanni et al., 2015). Library samples generated 
from cfDNA samples generally gave good results at all quality control steps and generated 
good quality sequence data.  
 
Under the conditions used, the Maxwell appears to have greater consistency than the EZ1 
which may reflect their kit and equipment design. As previous emphasised, the Qiagen Virus 
Kit is not designed for isolation of cfDNA from plasma, so this needs to be taken into 
consideration when judging the results. Despite this, it was still possible to isolate cfDNA with 
potential diagnostic utility from plasma using the EZ1 and use the extracted DNA for 
molecular methods (PCR and NGS) however the consistency and quality of data was inferior 
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to that of the extracts from the Maxwell platform. It is important to note that other 
manufactures (e.g. Siemens, Perkin-Elmer and others) have instruments of their own with 
varying throughput, plasma volumes etc. for the isolation of cfDNA.  To our knowledge, no 
other comparisons between these systems have been done, and this is an omission making 
it difficult for diagnostic laboratories to invest in new equipment for cfDNA analysis.   Qiagen 
currently offers a circulating nucleic acid kit for manual extraction, but they have yet to 
develop a similar kit for their automated platforms.  
 
Results obtained using the Ion Torrent PGM instrument with cfDNA are encouraging as a 
wide range of novel variants and hotspot mutations were successfully identified, and the 
data was generally of high quality (see table 4.3.5). This data suggest that cfDNA can be used 
for detection of actionable cancer mutations. 
 
The limited number of samples tested using the relatively new TaqMan Array technology 
were very encouraging, as this suggests cfDNA can be used in this far cheaper assay for 
mutation screening, without the need to perform the full NGS procedure for all cases. The 
NGS workflow is expensive and time consuming, so the TaqMan Array assay offers a far more 
rapid and economical testing format. The main limitations of the TaqMan Array assay were 
the relatively small range of mutations it can detect (44 mutations across EGFR, KRAS, NRAS 
and BRAF) compared to the NGS, and it's relatively high DNA requirement (50 ng for TaqMan 
Array, 10 ng for NGS). It was impressive to observe however that even with a very low DNA 
input (4- 11 ng) the TaqMan Array control assays still gave a positive signal, demonstrating 
that this assay has a high tolerance for low DNA input below the recommended amount. This 
limitation could be negated by improved cfDNA isolation systems, or the ability to extract 
cfDNA from larger volumes of plasma, therefore increasing yield for downstream 
applications. 
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It is important to take into consideration the limitations of this study when considering the 
potential for future work. The technical limitations (non-equivalent extraction kits) have 
been explicitly described, and therefore the performance of the EZ1 platform cannot be 
expected to be comparable to the Maxwell instrument. This however does illustrate the 
point that it is important to use appropriate kits for specific applications, especially for work 
with clinical / diagnostic implications. Whilst a manual extraction kit is available from Qiagen, 
these sorts of kits are difficult adopt in the diagnostic setting, therefore this study has 
focused only on automated methods. Automated methods are rapid, consistent and have 
reduced hands on time compared to manual methods, and therefore they are far better 
suited to the diagnostic setting. 
 
Another major limitation was access to samples and the associated sub-optimal EDTA 
storage time, most likely resulting in a potential reduction in sample quality at the time of 
plasma separation. It was surprising to observe that cfDNA derived from EDTA stored for 72 
hours before separation could still be used for NGS analysis, however it is likely data quality 
would have been improved had the sample been available earlier. 
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Chapter Five – Discussion 
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5.1 INTRODUCTION 
 
This project aimed to research, develop and validate new approaches to detecting clinically 
actionable oncogenic mutations in patient tumour DNA, with the aim of identifying potential 
clinically useful methods to improve early diagnosis and companion diagnostics. The current 
status of EGFR and KRAS mutation detection methods was reviewed in Chapter One, showing 
that at the beginning of the study (c.2013/14) this process is almost entirely reliant on FFPE 
tissue and PCR based testing methods, and this is largely still the case at time of submission 
(c.2017). There was however a considerable interest in exploring new sources of tumour 
DNA, most notable cfDNA and ctDNA, although work on these analytes was in its early stages 
at the beginning of the project. In order to follow this area of research, and number of 
different approaches were adopted in this study. 
 
 
5.2 SINGLE GENE TESTING 
 
The first approach was to follow the established method of single gene testing with a 
molecular assay. This involved assisting in the development of the prototype PNA PCR assay 
(GeneFirst MMD EGFR PCR and MMD KRAS PCR kits), described in Chapter Two. There was 
a lot of supporting evidence from the literature that this was a logical approach due to the 
numerous PCR-based assays in use diagnostically (High Resolution Melt assays, Qiagen 
Therascreen, Life Technologies castPCR for KRAS, Roche Diagnostics COBAS test for BRAF) 
and a number of other PCR techniques in development/ validation (digital PCR, SNaPshot). 
PCR had the cost advantage over the more expensive and time consuming NGS assays. 
Unfortunately the prototype GeneFirst PNA PCR assays displayed a very low level of 
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specificity resulting in very frequent false positive results, along with a certain degree of 
assays failure on the controls. With any assay development, a certain level of discrepancy or 
variations in reliability are to be expected at early stages, however the fundamental 
problems in the assays continued throughout all five successive versions. This eventually led 
to this approach to be discontinued in early 2015, and further development work by 
GeneFirst was subsequently abandoned. 
 
Beyond the highly variable sensitivity, specificity and reliability issues, the assay was also 
time consuming and complicated to set up due to its multiple master mixes (and multiple 
replicates required per sample). It is worth noting however that this is not specific to the 
GeneFirst assays, as many other diagnostic PCR assays also employ multiple master mixes 
and require multiple replicates per sample to establish a reliable average signal (Ct) for 
mutation calling. The consequence of these assays using multiple master mixes and 
replicates resulted in a very high sample volume and DNA requirement, which for some 
sample types (in particular small cytology samples) resulted in very low DNA input for the 
individual reactions, thus creating the possibility of assay failure or false negative results due 
to the lack of template. The complicated set up also meant the GeneFirst assays offered no 
advantage over other assays in terms of easy-of-use or hands-on-time. 
 
The GeneFirst assays were tested to a very limited extent with cfDNA (see section 2.3.12) 
and the results were consistent with the variable results found when using tissue. The assays 
were designed with the intention to apply them to cfDNA testing, however the results 
showed them to be unsuitable for both testing tissue and cfDNA.  
 
Whilst PNA PCR has been shown to be successful at detecting low concentration targets in a 
number of other settings, for example the CE-IVD marked PNAClamp™ EGFR Mutation 
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Detection kit (Panagene, Daejeon, Korea) in this case unfortunately the assays could not be 
validated for clinical use. The findings of this phase of the study do not eliminate PNA PCR 
based methods as a suitable methods for detecting oncogenic mutations, but it does 
highlight the difficulties involved in assay development. This work demonstrates that assays 
designed for diagnostic use need to be well designed in order ensure both set up and result 
interpretation are efficient and as simple as possible. 
 
The clinical implications of false positive and false negative results in NSCLC or CRC are 
severe, and as a result high sensitivity and specificity are essential for any diagnostic assay 
that effect clinical decisions. In NSCLC, the presence of activating EGFR mutations is an 
indicator that a patient is suitable for anti-EGFR antibody therapy. A false positive result 
would result in the patient being given drugs that would be of no therapeutic benefit instead 
of a more appropriate treatment. A false negative would result in an activating mutation not 
being detected, resulting in the patient not receiving the anti-EGFR therapy, and most likely 
receiving an alternative which is both ineffective and likely to be toxic. In the case of CRC, 
the situation is different. The presence of activating KRAS mutations indicates that anti-EGFR 
therapy will be ineffective, therefore in the case of a KRAS positive CRC sample then the 
patient will be given an alternative treatment to anti-EGFR therapy. 
 
The final issue related to this approach is that single gene testing is not the optimal method 
for routine testing of clinical samples. Clinically actionable mutations in lung and colorectal 
cancer (and many other cancers) often occur in multiple genes, and therefore it is logical to 
perform genetic analysis on multiple genes when analysing a clinical sample. Performing 
separate assays for mutations in a single gene has limited usefulness and is very inefficient 
in terms of staff time, and also demands a larger amount of genetic material for analysis, the 
availability of which can be very varied in certain contexts. 
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5.3 MULTIPLE GENE TESTING 
 
After the unsuccessful development of the GeneFirst PNA PCR and the single gene testing 
approach, the second phase of the project was to move to multiple gene testing. This 
involved the use of an alternative PCR format- TaqMan Array, covered in Chapter Three. The 
layout of this plate was devised by searching the most common oncogenic mutations on 
COSMIC. A series of lung, colorectal and melanoma samples were extracted and analysed 
using the TaqMan Array assay. The assay performed extremely well, matching all the 
previously obtained results (from the Therascreen, castPCR or COBAS assays) except in a 
small number of cases. These discrepancies were analysed by NGS (if not already done so) in 
order to ascertain the true genotype. 
 
The dramatically superior performance of this assay compared to the GeneFirst assays was 
due to a number of factors. Firstly, the TaqMan Array assays are based around the already 
well proven castPCR technology, which has been shown to be both robust and reliable 
(Bolton et al., 2015) and a version of this was previously used in UHCW Pathology for its 
routine cancer gene mutation detection for colorectal samples. Reformatting the castPCR 
assays from a 96 well format (20 µl per reaction) to an enclosed 384 well format (1 µl per 
reaction) allowed the reaction chemistry to remain the same whilst the reaction volume, and 
therefore the required DNA input, to be greatly reduced i.e. the TaqMan Array assays 
running efficiently with only 50 ng DNA per 48 well channel (therefore approximately 1 ng 
DNA per reaction). This reduces the chance of assay failure due to too little DNA, while 
increasing the coverage of actionable mutations. 
 
The second factor was the far superior discrimination/ identification power of the TaqMan 
Array plates. As each well on the plate only contains one assay i.e. the primers and probes 
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for one target, therefore the assay results are a very clear present or not present outcome 
(based on the presence or absence of a signal below our established threshold). Because of 
this there was a much lower occurrence of false positive or false negative results. This 
characteristic also means that interpretation of the results is far simpler than the equivalent 
process with the GeneFirst assays. The GeneFirst assays employed a very complicated system 
of ΔCt thresholds which were different depending on the targets and the master mixes. In 
particular, the GeneFirst KRAS version 5 assay introduced a new flow diagram for interpreting 
the ΔCt results from the two master mixes which was extremely difficult to interpret (see 
Methods sections 2.2.8 and figure 2.2.8.2). This type of analysis would be completely 
unsuitable for routine diagnostic use as the flow diagram was so ambiguous different 
operators may come to different interpretations of the assay results. By contrast the analysis 
of the TaqMan Array assay results were simple and could also be easily automated, removing 
the potential for operator error in the analysis step. 
 
The final factor contributing to the TaqMan Array’s superiority over the GeneFirst system is 
the user friendly enclosed 384 well plate format. With the plate separated into eight separate 
channels (48 wells per channel) the entire plate could be loaded in only eight pipetting 
actions maximum. This dramatically reduces hands on time, and most importantly greatly 
reduces the chances of accidental contamination by the operator or other operator errors. 
These three factors together resulted in excellent performance by the TaqMan Array with 
high sensitivity, specificity and reproducibility. 
 
In addition to testing a large series of FFPE DNA samples from lung, colorectal and melanoma 
patients, the TA was also tested prospectively using a series of cfDNA samples from patient 
plasma. The results from this testing gave strong results (Ct<35) for all the TA control assays, 
which indicated the castPCR assays within the TA plate were robust and had a high tolerance 
259 
 
for potentially highly fragmented and low concentration DNA. Unfortunately there were no 
mutant targets that gave a signal below our threshold for positive results (Ct<36.5). There 
were two signals detected for EGFR and NRAS, however they were Ct37.9 and Ct36.9 and 
thus above the positive cut off set during validation. However examination of the 
amplification plots revealed the signals possessed genuine sigmoidal amplification profiles 
and thus there may be a case for adjusting the analysis thresholds for cfDNA samples. 
 
 
5.4 CELL FREE DNA 
 
The third approach employed in this project was to investigate if analysis of cfDNA could be 
practically and efficiently adopted by a diagnostic laboratory, by looking at the stability of 
cfDNA whilst stored in EDTA, by comparing extraction systems for isolating cfDNA, and finally 
to investigate if the cfDNA obtained in the routine laboratory could be used to detect 
oncogenic mutations with the Ion Torrent PGM platform.  
 
The results from the evaluation of the extraction platforms was very helpful in terms of the 
very significant influence of extraction platform (and selection of an appropriate kit 
chemistry) on results. In a vast majority of cases throughout this evaluation, DNA extracts 
from the Promega Maxwell instrument produced superior results than those extracted by 
the Qiagen EZ1 platform. At initially DNA quantification, the Promega Maxwell extracted 
samples had consistently higher DNA concentrations, as measured by Qubit. When the 
samples were analysed by Ion Torrent NGS, the results generated by the Maxwell extracts 
were consistently superior in terms of the NGS analytics (read length, number of reads, 
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higher quality scores, higher coverage and more even strand bias). This is clear evidence that 
the DNA eluted from Maxwell was consistently of higher quality than that eluted by the EZ1. 
 
In the broader context, this project shows that the quality of starting material is critical to 
successful of downstream molecular techniques, which is an important consideration when 
analysing the results from novel sources of DNA. This also highlights the point that if cfDNA 
were to be used diagnostically, the storage and separation procedures would be have to be 
as equally stringent as the measures taken when running the diagnostic assays, as otherwise 
the results generated may not accurately reflect the biological reality. 
 
The issues related to processing methods of cfDNA highlighted by this project are analogous 
to the issues around the processing and storage of FFPE tissue, which is still the primary 
source of genetic material for molecular diagnostic analysis. Formalin has a number of 
irreversible effects on treated tissue, it dramatically slows autolysis and putrefaction by cross 
linking and denaturing proteins, and by fragmentation, cross linking and methylation of DNA 
(Hamazaki et al., 1993; Koshiba et al., 1993). Of particular concern in terms of molecular 
analysis is the artefact that formalin causes cross linking between cytosine molecules in the 
DNA, which in turn can cause DNA polymerases to fail to recognise the cytosine base and 
instead incorporate an adenosine or guanosine base, creating artificial mutations (Williams 
et al., 1999). A number of studies of performed investigations into the effect of formalin 
fixation on downstream applications (Ferrer et al., 2007; Miething et al., 2006; Zsikla et al., 
2004) which universally conclude that formalin fixation does have an effect on molecular 
assays and that fixation procedures must be optimised to the specific sample type in order 
to balance preservation with good quality DNA for analysis. The issue of tissue fixation shows 
that no biological DNA source is ideal and that processing methods must be well optimised 
and efficiently performed to achieve the most accurate results in downstream tests. 
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Another important finding from this investigation was the importance of the choice of 
quantification method for DNA concentration in the DNA extracts. Spectrophotometry (used 
in the Nanodrop) is routinely used for DNA quantification in many diagnostic and routine 
settings, however the data from our investigation has showed this method to be very 
vulnerable to giving falsely high readings, most likely caused by samples with a high degree 
of contaminants (Kapp et al., 2015). This suggests that in laboratories where Nanodrop is the 
primary or only method used to quantify DNA before molecular analysis, then there is a high 
likelihood that samples are not being loaded at the optimal concentration, leading to 
increased failure rates. Whilst the DNA may be sufficient to pass control assays, the low 
concentration of target template i.e. mutated tumour DNA, may be too low to generate a 
positive signal, resulting in a false negative result. The data from this section of the study 
supports the idea that molecular laboratories should use fluorescence based quantification 
methods (e.g. Qubit) rather than spectrophotometry based methods. 
 
The most significant finding from the cfDNA investigation was that an actionable oncogenic 
mutation was identified from cfDNA using both the NGS platform and the TaqMan Array. The 
mutation was a KRAS p.G12C substitution which is a well-known hotspot mutation in 
colorectal cancer, and to a lesser extent in lung cancer. This finding shows that cfDNA does 
have the potential to be used to detect oncogenic mutations in clinical plasma samples, by 
not only NGS but also by TaqMan Array.  
 
One clear finding from this investigation is that NGS is absolutely superior to PCR in terms of 
the depth of analysis, and can also provide more information about individual variants or 
mutations identified e.g. the frequency at which the mutant was detected as a proportion of 
all the reads from that amplicon. The disadvantage of NGS is that it is expensive and time 
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consuming, and thus is better suited to smaller throughput runs such as specialist testing. 
PCR on the other hand is rapid and relatively cheap. The disadvantage of PCR is that the 
number of targets it can detect is limited to the exact targets the test is designed for, and 
there is a relatively low upper limit (compared to NGS) of how many targets can be efficiently 
detected per run. This suggests that the ideal system in a pathology laboratory would be to 
test a majority of samples via a PCR array method, then use NGS to confirm a small number 
of samples that are of insufficient quality/ concentration for PCR analysis, or samples in 
which a driver mutation is not identified. 
 
 
5.5 OUTCOMES FROM WORK PERFORMED IN THIS PROJECT 
 
The major outcome from this project is the adoption of the validated TaqMan Array assay as 
the new diagnostic technique for the detection of activating EGFR, KRAS, NRAS and BRAF 
mutations in lung, colorectal and melanoma samples in the UHCW Pathology department, 
replacing the previously used Qiagen Therascreen assay (for EGFR) and the in-house castPCR 
assay (for KRAS). The new TA assay has combined both assays into one test, whilst adding 
additional capabilities in terms of detecting NRAS mutations and more BRAF mutations.  
 
In addition to tissue, cfDNA is being trialled on the TaqMan Array as a prospective study 
(initial results to date shown in chapter four). Whilst this is in the early stages, in time this 
study will give an interesting insight into the potential for cfDNA to be used in TaqMan Array 
format assay. If this is successful then it may become possible to utilise cfDNA with PCR based 
methods rather than the more complex NGS techniques. 
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Beyond routine service, the validated TaqMan Array has been used for development of other 
diagnostic tools in the Pathology Department. The TaqMan Array (alongside NGS) was used 
as a comparator method for BRAF mutation detection against Qiagen Therascreen® and 
Roche Cobas® in order to validate a melanoma NGS panel. The study was subsequently 
published (Reiman et al., 2017). 
 
The final outcome from the project is the intention for UHCW Pathology to expand its 
services in order to include NGS analysis. A business case for this development, and to 
employ a new member of staff who will oversee/ perform this work has been accepted. This 
represents a considerable investment in terms of time and resources by UHCW Pathology, 
however adoption of NGS technology will dramatically update their molecular repertoire and 
significantly expand their molecular capabilities not just in terms of oncology but also 
potentially in microbiology, genetics and prenatal screening. 
 
 
5.6 LIMTATIONS OF THE PROJECT 
 
Whilst there were a number of positive outcomes from this investigation, there were also a 
number of limitations that had an impact on its overall success. 
 
5.6.1 GeneFirst Assays 
 
During the testing of the prototype GeneFirst PNA PCR assays, there was no guidance or 
feedback from the company regarding what aspects had been changed in the assays 
between each version of the assay. Recommended DNA inputs were guides rather than 
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optimised parameters, and this may have contributed to some of the assays failures or false 
results that were experienced during this phase of the project. Considering the highly 
variable nature of the assay performance, it may have been better to have used DNA 
extracted from cell lines to test these assays, rather than surplus clinical material. Although 
using surplus clinical FFPE samples was appropriate to the purpose the assays were designed 
for, in retrospect these samples would have been better used at a later stage when the assays 
were more reliable. Cell lines would also have been useful as this would allow the same lines 
to be re-tested with multiple versions of the assays, and therefore giving another means of 
analysing assay consistency. However unfortunately this was not a practical approach for the 
diagnostic laboratory due to limited culture facilities, and the need to keep human cell lines 
separate from microbial cultures. Using the surplus FFPE samples typically resulted in each 
sample only being analysed once, whereas being able to observe assay consistency over 
multiple runs would have been beneficial. 
 
 
5.6.2 TaqMan Array 
 
By contrast, there were few limitations to the validation of the TaqMan Array assay. The key 
limitation was the number of samples available to create the validation panels. Under ideal 
circumstances there would have been a higher number of lung, colorectal and melanoma 
samples tested during the validation. Thankfully there were enough to demonstrate the 
sensitivity and specificity of the assay and to complete the validation. Another issue with the 
validation was cost of the plates and the manufacturing time. As the plates are a custom 
layout, they need to be ordered and manufactured for the user each time, resulting in a 
delivery time of approximately six weeks for every order. In the event of any incident relating 
to optimal storage of the plates e.g. power failure to refrigeration equipment, a six week 
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replacement time would mean result in a considerable disruption to the service. To mitigate 
the possibility of service disruption and alternative method (Biocartis Idylla™) has now been 
brought into ensure continuity of service. 
 
The final limitation of TA assay is limited by number of samples that can be run per plate. 
Only seven can be analysed at once. This is similar to the preceding assays (eight samples per 
run for Qiagen Therascreen) and at present suits the workload of the molecular laboratory, 
if demand for these services increases in the future then only being able to analyse seven 
samples at once may have an impact on turnaround time, although this is partially negated 
by the speed of the assay set up, meaning multiple runs could be performed per day with 
relative ease. 
 
 
5.6.3 Plasma Samples 
 
The greatest limitation in this entire project was undoubtedly the very limited access to 
patient plasma samples, which unfortunately was entirely out of the research group’s 
control. In total over the course of three years only 40 samples were obtained, which 
represents an extremely small proportion of all the potential patients attending the UHCW 
lung clinic over the same period. There are several reasons for this. Firstly, limited support 
from clinical staff for the research work resulted in all the plasma samples coming from only 
two sources (the lung nursing team and one medic). Secondly, an inconsistent level of 
support from staff in the UHCW Pathology Blood Sciences laboratory meant on the rare 
occasions samples were sent up to our group, I was often not informed by Blood Sciences 
that the sample(s) had arrived, if I was informed at all. As a result, the number of plasma 
samples which were separated on day of receipt i.e. separated in 24 hours or less, was very 
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low. Many of the plasma samples which were separate from EDTA whole blood at 48 or 72 
hours were due to us not being informed about the arrival of samples. So these two issues 
(i.e. low support from clinical staff and lack of support from Blood Sciences) exacerbated 
each other, resulting in low numbers of plasma samples received and sub-optimal storage of 
those that were received. A number of samples had to be discarded as they had been stored 
at room temperature for extended periods and haemolysed. 
 
Another limitation with the cfDNA analysis was that no matched patient tissue samples were 
available for any of the plasma samples. Whilst this may be consistent with the frequent 
problem in lung cancer that tissue is difficult to obtain (especially at early stage), it would be 
have very interesting/ informative to have been able to sequence matching tissue and 
plasma samples from the same patients, as done in a number of other studies (Xu et al., 
2012). 
 
 
5.7 DEVELOPMENTS IN THIS FIELD 
 
Since the commencement of this investigation in 2013, the field of cfDNA analysis has grown 
dramatically. What was initially a novel approach is now on the verge of being used clinically. 
An online search of literature using ‘cfDNA’ as a key word yields 29 articles from January 
2017 alone. Examination of these papers gives an interesting insight into the breadth of work 
being performed in this field. Amongst the 29 papers identified 20 of them are related to 
cancer, illustrating that cancer diagnostics are a key focus of cfDNA research. Within the 20 
cancer papers, the articles were distributed amongst the following themes: lung (Cargnin et 
al., 2017; Chen et al., 2017; Lysov et al., 2017; Malapelle et al., 2017; Wu et al., 2017); breast 
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(Page et al., 2017; Shaw et al., 2017); colorectal (Nagai et al., 2017; Spindler, 2017), 
pancreatic (Allenson et al., 2017; Woo et al., 2017); other cancers (Kumari et al., 2017; Rossi 
et al., 2017; Sandulache et al., 2017); general cancer or technical investigations (Fujii et al., 
2017; Kockan et al., 2017; Ma et al., 2017; Sorber et al., 2017; Wang et al., 2017); and one 
article on veterinary cancer (Beffagna et al., 2017). 
 
The articles of greatest relevance to this project were those related to lung and colorectal 
cancer. Of the five articles related to lung cancer, three focused on EGFR mutation detection 
with cfDNA utilising either RT-PCR (Malapelle et al., 2017; Wu et al., 2017) or NGS (Chen et 
al., 2017). Malapelle et al (Malapelle et al., 2017) evaluated the use of the Roche COBAS® 
EGFR mutation test v2 using cfDNA. They concluding that the test was a reliable and accurate 
test for use with both tissue and cfDNA. Wu et al (Wu et al., 2017) analysed the serum, 
plasma and paired tissue samples from EGFR positive adenocarcinoma patients who were 
participating in a phase III clinical trial. The Qiagen Therascreen EGFR assay was used for 
mutation detection. The study reported that mutations were detected in 28.6% of serum and 
60.5% of plasma, which supports the findings of other studies that favour plasma for cfDNA 
analysis. Chen et al (Chen et al., 2017) used cfDNA to detect rare resistance mutations to 
osimertinib. CfDNA was isolated from plasma and from pleural effusion, and analysed using 
NGS. Comparison of mutation results from pre-treatment tissue revealed that resistance 
mutations were acquired after treatment. This article demonstrates the usefulness of cfDNA 
not only for diagnostics but for disease monitoring during treatment. 
 
The other two articles related to lung cancer focused more of properties of cfDNA rather 
than its use for mutation detection. Cargnin et al (Cargnin et al., 2017) performed a 
systematic review and meta-analysis of the impact of baseline cfDNA levels on survival 
outcomes in lung cancer patients. Whilst there was no statistically significant association 
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between baseline cfDNA level and progression free survival, the analysis of overall survival 
did reveal an increased risk of death with higher baseline cfDNA levels p <0.001 (Cargnin et 
al., 2017). The study by Lysov et al (Lysov et al., 2017) investigated the effect of platinum 
based chemotherapy on cfDNA levels, using non-tumour bearing murine control and a 
murine xenograph model. Comparisons of cfDNA levels in response to chemotherapy 
revealed that chemotherapy increased cfDNA in both healthy and in tumour-bearing mice.  
 
The two papers related to colorectal cancer were a review by Spindler et al (Spindler, 2017) 
and a quantitative study of LINE-1 hypomethylation in cfDNA by Nagai et al (Nagai et al., 
2017). The review by Spindler et al concluded that studies using cfDNA in CRC are very 
heterogeneous but cfDNA is a very promising tool for diagnosis and prognosis of CRC. In the 
study by Nagai et al the group used cfDNA to determine the level of LINE-1 hypomethylation 
in 114 CRC patients. Their results showed that later stage patients had significantly higher 
LINE-1 hypomethylation levels compared to early stage, and that LINE-1 hypomethylation is 
higher in CRC patients compared to health controls (Nagai et al., 2017). This article suggests 
LINE-1 hypomethylation (detected by cfDNA) could be a new biomarker for CRC. 
 
Beyond lung and colorectal cancer there were 12 other publications related to cancer: two 
on breast cancer; two on pancreatic cancer; three on other cancers (gall bladder; B-cell 
lymphoma and anaplastic thyroid carcinoma) and five additional papers that did not focus 
on one type of cancer specifically. The two articles on breast cancer focused on investigating 
breast cancer genetic heterogeneity by NGS (Page et al., 2017) and on comparing the genetic 
profiles of CTCs and cfDNA (Shaw et al., 2017). The two articles on pancreatic cancer 
investigated exosome-derived DNA (Allenson et al., 2017) and on the effect of chemotherapy 
on cfDNA in terms of concentration and mutations detectable (Woo et al., 2017). The 
publication on gall bladder cancer quantified serum cfDNA levels in patients as potential 
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diagnostic marker (Kumari et al., 2017). The study on B-cell lymphoma used NGS to genotype 
diffuse large B-cell lymphoma (DLBCL) from plasma cfDNA (Rossi et al., 2017). Finally the 
paper on anaplastic thyroid carcinoma (ATC) compared the performance of two NGS assays 
for the genetic analysis of cfDNA from ATC patients (Sandulache et al., 2017). 
 
Outside the field of cancer, there were six articles on trisomy detection and three articles on 
other non-cancer cfDNA topics including: trauma care (Gogenur et al., 2017); hepatic 
inflammation (Patrick et al., 2017); and interstitial lung disease in dermatomyositis patients 
(Zhang et al., 2017). Of the six articles related to trisomy detection, four were original studies 
of various aspects and methods for trisomy detection using cfDNA (Colosi et al., 2017; 
Gerundino et al., 2017; Hu et al., 2017; Palomaki et al., 2017), one was a review and meta-
analysis of best practice for screening (Iwarsson et al., 2017), and one article was the 
recommendations from the Society for Maternal-Fetal Medicine on use of ultra-sound with 
cfDNA testing (Norton et al., 2017). 
 
This brief summary of literature published in the first month of 2017 shows very clearly that 
there is a very high level of interest in the clinical utility of cfDNA, largely in cancer but 
followed closely by maternal-fetal medicine. The range of articles published on this subject 
also show that cfDNA has a very broad spectrum of applications, far beyond just cancer. 
 
 
5.8 FUTURE WORK AND CONCLUSION 
 
The relatively new field of Liquid Biopsy is an expanding area and interest in this field 
continues to grow. As a result there are a number of directions this work could follow. 
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In terms of technical approaches, there a number of ways the laboratory processes may be 
developed to expand or enhance the current capabilities. With reference to the TA assay, it 
has demonstrated robustness and efficiency in terms of the strong signals generated by the 
control assays when analysing cfDNA. The mutant assays did not perform as well, so one 
approach could involve pre-amplification of the template DNA to enrich the sample for the 
tumour DNA component. Whilst this may enhance the tumour derived DNA signal, there is a 
risk that pre-amplification could introduce non-specific products or amplification errors into 
the template DNA, so development of any technique such as this will have to be stringently 
monitored and quality assured to ensure test accuracy is maintained. 
 
Activating and resistance to treatment mutations make up a majority of oncogenic changes 
in EGFR, however they are not the only considerations. EGFR amplification is another 
frequent occurrence in lung (Liang et al., 2010) and colorectal cancer (Shen et al., 2014), and 
detection of this phenomena should also be developed, both in terms of detection from 
tissue but also from plasma cfDNA.  
 
Beyond EGFR, ALK fusions are another key concern for lung cancer diagnostics (Hainsworth 
& Anthony Greco, 2016). There are currently NGS panels designed to detect this phenomena 
in tissue, including a version of the Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel 
which is currently in development by Thermo Fisher, which was tested in the UHCW 
Pathology laboratory. Research has been conducted into detecting ALK fusions from cfDNA 
with promising results (Cui et al., 2017; Dietz et al., 2016). 
 
The primary aim of future work would be to continue to develop the current methods for 
optimal detection of oncogenic mutations in cfDNA. This would not only involve lab based 
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optimisation, but also promoting the work to clinical staff to obtain more samples on a more 
regular basis, and to establish a more efficient system of obtaining samples through Blood 
Sciences, which caused a significant impact during this project. 
 
The next aim would be to perform cfDNA monitoring on patients currently being treated at 
UHCW. Plasma could be used to monitor cfDNA levels and the tumour mutation profile of a 
patient at key monitoring points e.g. at investigation, during treatment, before and after 
surgery, and during recovery (where appropriate). Expansion of the role of cfDNA in this 
manner would give extremely important insight into the molecular/ genetic dynamics 
occurring during cancer treatment, and may also guide patient management and treatment 
decisions to produce the most favourable outcome. 
 
Beyond the clinic, cfDNA may be useful as a screening tool. Analysing a population of high 
risk individuals (e.g. for lung cancer: chosen by age and smoking history) for mutations in 
cfDNA may have a benefit in terms of early diagnosis, potentially improving the patient 
outcomes and maximising treatment effectiveness. There may also be a saving to the health 
services in terms of more effective and cheaper early treatment compared to expensive and 
relatively ineffective therapy of more advanced disease. 
 
The work presented in this thesis has a range of potentially useful clinical applications and 
should be developed further. Despite the multiple limitations present, the effectiveness and 
benefits of both high throughput diagnostic PCR platforms (TaqMan Array) and analysis of 
cfDNA have been demonstrated, with key findings being published in a peer reviewed 
journal. The TaqMan Array assay has introduced as the primary diagnostic test for detection 
of EGFR, KRAS, NRAS and BRAF mutations in the UHCW Pathology department. Also a 
business case has been submitted by UHCW Pathology and accepted by the Trust for the 
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introduction of Next Generation Sequencing as a diagnostic service in the department. Both 
these changes in UHCW Pathology have occurred due to work performed during this 
investigation. In the future liquid biopsy, in conjunction with sensitive and accurate 
molecular techniques, may provide a superior alternative to tissue biopsy for management 
of cancer patients, resulting in earlier diagnosis, more effective treatment and improved 
outcomes for patients. 
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